Molecular and Imaging Biomarkers of Radioresistance in Head and Neck Squamous Cell Carcinoma by Suh, Yae-Eun
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 






















Molecular and Imaging 
Biomarkers of Radioresistance in 







A thesis presented for the degree of Doctor of 





Molecular Oncology, Clinical Oncology and Imaging Sciences 
Department of Mucosal & Salivary Biology 
King’s College London 
2016
  2 
Abstract 
 
The development of individualised treatments in head and neck squamous cell carcinoma 
(HNSCC) requires understanding of the molecular biology of cancer and the ability to 
translate this into therapy. Due to the heterogeneity of HNSCCs biomarkers are needed to 
identify the mechanisms of tumourigenesis and treatment resistance to improve outcome. 
Radioresistance is a major cause of treatment failure and early identification is key to the 
development of treatment strategies to overcome resistance and improve disease control. 
 
MicroRNAs are small endogenous non-coding RNAs that regulate gene expression at the 
post-transcriptional level, and are a potential source of biomarkers. Altered expression has 
been reported in almost all types of cancer and directly implicated in tumourigenesis. We 
found miR-196a to be upregulated in a group of patients with HNSCC with recurrent 
disease after radical treatment. In HNSCC cell lines miR-196a exerted an oncogenic 
phenotype through targeting the protein annexin A1. In addition miR-196a overexpression 
resulted in resistance to irradiation, suggesting that it may represent both a prognostic and 
predictive biomarker in HNSCC. 
 
Hypoxia is a well established biomarker of radioresistance in HNSCC and the association 
with poor outcome is well known. Many therapeutic strategies to overcome hypoxia have 
been developed, but accurately detecting tumour hypoxia has limited the translation of 
hypoxia modification strategies into routine practice. 64Cu-ATSM PET is currently a 
research tool used to image hypoxia, and in combination with gene expression profiling of 
diagnostic biopsy samples, could provide early identification as well as the quantification 
and spatial distribution of hypoxia. We performed a pilot study in 15 patients with locally 
advanced oropharyngeal squamous cell carcinoma and demonstrated that increasing 
hypoxic volume defined by 64Cu-ATSM PET was significantly associated with published 
hypoxia gene signatures in corresponding biopsy samples. We developed a 64Cu-ATSM 
hypoxic volume specific gene signature, which can be applied prospectively to future 
samples and correlated with long term follow up to investigate its role as a biomarker. In 
addition, circulating miR-196a levels in patient plasma samples correlated with increasing 
tumour volume. 
 
In conclusion, miR-196a may represent a biomarker of aggressive and radioresistant 
disease, partly through targeting annexin A1. 64Cu-ATSM-defined hypoxic volume 
correlates with published hypoxia gene signatures, and in conjuction with gene signatures 
from biopsy samples, may represent a method for early identification of patients with 
radioresistant disease at a stage when management could be altered to improve outcome. 
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18F-FAZA 18Fluorine-fluoroazomycin arabinofuranoside 
18F-FDG  18Fluorine-fluorodeoxyglucose 
18F-FLT 18fluorine-fluorothymidine 
18F-FMISO 18Fluorine-fluoromisonidazole 
FFPE Formalin fixed paraffin embedded  
FIH Factor-inhibiting hypoxia-inducible factor 
FITC Fluorescein isothiocyanate 
FOX Forkhead box 
5-FU 5-fluorouracil 
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GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GBM Glioblastoma 
GFP Green fluorescent protein 
GLUT Glucose transporters 
GTP Guanosine triphosphate 
GTV Gross tumour volume 
Gy Gray 
Hb Haemoglobin 
HEBS HEPES-buffered saline 
HEPES 1-(2-hydroxyethyl)-1-piperanzineethanesulfonic acid 
HF Hypoxic fraction 
HIF Hypoxia-inducible factor 
HMGA2 High mobility group AT-hook 2 
HNSCC Head and neck squamous cell carcinoma 
HOX Homeobox 
HOX Homeobox 
HPV Human papillomavirus 
HRE Hypoxia-responsive elements 
HRP Horseradish peroxide 
HV Hypoxic volume 
IgG Immunoglobulin G 
IHC Immunohistochemistry 
IMRT Intensity modulated radiotherapy 
ING5 Inhibitor of growth 5 
IκBα Inhibitor of kappa B 
JAK Janus kinases 
KD Knockdown 
KT5 Keratin 5 
LB Luria-Bertani 
LDH Lactate dehydrogenase 
LRC Locoregional control 
LRC Locoregional control 
LSB Lamelli sample buffer 
LSB Lamelli sample buffer 
MAPK Mitogen-activated protein kinase 
MDM2 Mouse double minute 2 homolog 
MDR Multidrug resistance 
MEK Mitogen-activated protein kinase kinase 
MET Mesenchymal epithelial transition factor 
miRNA MicroRNA 
MRI Magnetic resonance imaging 
mRNA Messenger RNA 
mTORC Mammalian target of rapamycin complex  
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NAD Nicotinamide adenine dinucleotide 
NADH Nicotinamide adenine dinucleotide hydrogen 
NF-κB Nuclear factor kappa B 
NPC Nasopharyngeal cancer 
NSCLC Non-small cell lung cancer 
OPN Osteopontin 
OPSCC Oropharyngeal squamous cell carcinoma 
OS Overall survival 
PAGE Polyacrylamide gel electrophoresis 
PARP Poly ADP ribose polymerase 
PBS Phosphate-buffered saline 
PDGF Platelet-derived growth factor 
PDH Pyruvate dehydrogenase 
PDK Pyruvate dehydrogenase kinase 
PE Plating efficiency 
PERK Protein kinase R-like endoplastic reticulum kinase 
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PET Positron emission tomography 
PFA Paraformaldehyde 
PHD Propyl hydroxylase 
PI3K Phosphatidylinositol 3-kinase 
PIK3CA Phosphatidylinositol-4,5-bisphosphate 3-kinase 
PMSF Phenylmethylsulfonyl fluoride 
pO2 Oxygen partial pressure 
PTEN Phosphatase and tensin homolog 
qRT-PCR Quantitative real time polymerase chain reaction 
Rb Retinoblastoma 
RFP Red fluorescent protein 
RFS Recurrence free survival 
RISC RNA-induced silencing complex 
ROS Reactive oxygen species 
ROI Region of interest 
RT Radiotherapy 
RT-PCR Reverse transcription polymerase chain reaction 
S100A9 S100 calcium-binding protein A9 
SCC Squamous cell carcinoma 
SDS Sodium docecyl sulphate 
SF Survival fraction 
shRNA Small hairpin RNA 
SNP Single nucleotide polymorphism 
SPRR2C Small proline-rich protein 2C 
STAT Signal transducer and activator of transcription 
SUV Standardised uptake value 
SUVmax Maximum standardised uptake value 
SUVmean Mean standardised uptake value 
SUVpeak Peak standardised uptake value 
SV40 Simian virus 40 
TBR Tumour to background ratio 
TBS Tris-buffered saline 
TBS-T Tris-buffered saline-Tween 
TCA Tricarboxylic acid 
TE Tris-EDTA 
TEMED Tetramethylethylenediamine 
TGF-β Transforming growth factor β 
TK1 Thymidine kinase 1 
TLR8 Toll-like receptor 8 
TMR Tumour to muscle ratio 
TPZ Tirapazamine 
TRAIL Tumour necrosis factor-related apoptosis inducing ligand 
Tris Tris(hydroxymethyl)aminomethane 
TSC Tuberous sclerosis 
TSG Tumour suppressor gene 
UPR Unfolded protein response 
UTR Untranslated region 
VEGF Vascular endothelial growth factor 
VHL Von Hippel Lindau 
VOI Volume of interest 
VSV-G Glycoprotein G of the vesicular stomatitis virus 
w/v Weight/volume 
ZEB Zinc finger E-box binding homeobox  
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 Introduction 1.1
There is an urgent need for biomarkers in head and neck cancer to improve the 
management and outcome of this patient population. The first half of the thesis (chapter 2) 
explores the early stages of molecular biomarker discovery in vitro in head and neck 
cancer, specifically microRNA-196a. The second half (chapter 3) focuses on hypoxia, a 
well known biomarker of radioresistance and poor outcome in head and neck cancer, and 
investigates the combination of molecular and novel imaging biomarkers to improve 
detection and translation into clinical practice. This first chapter summarises the current 
management of head and neck squamous cell carcinomas (HNSCC) and the need for 
biomarkers in this group of patients. Established and important molecular and imaging 
biomarkers under investigation will be reviewed followed by a review of microRNAs, 
hypoxia and 64Cu-ATSM, the imaging biomarker investigated in the thesis. 
 
 
 Clinical background 1.2
Head and neck cancers encompass a heterogeneous group of tumours which, in general, 
are biologically aggressive in nature. They include the following subsites: oral cavity, 
oropharynx, hypopharynx, larynx, paranasal sinuses, nasal cavity, nasopharynx and 
salivary glands. Over 90% are squamous cell carcinomas arising from the epithelial cells 
that line the mucosal surfaces of the head and neck.1 These cancers remain difficult to treat 
as they are often situated near critical anatomical structures that are sensitive to treatment-
induced damage. Both tumour and treatment can cause severe, long-term and permanent 
adverse effects.  
 
For patients who do not achieve locoregional control by surgery and/or 
(chemo)radiotherapy, there are few effective treatment options. Targeted therapies and 
predictive biomarkers are needed in order to improve the management and minimise the 
treatment toxicity, and to allow the selection of patients who are likely to benefit from 
conventional or novel therapies. 
 
 Incidence and risk factors 1.2.1
There were an estimated 686000 new cases of head and neck cancers worldwide in 2012, 
accounting for 4.8% of all malignancies, and an estimated 376000 deaths, equating to 
4.6% of all cancer mortality.2 In the UK in 2012 there were 9127 new cases and 2903 
deaths of oral (lip, tongue, mouth, oropharynx, piriform sinus, hypopharynx) and larynx 
cancers.3 
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More than 75% of cases of head and neck squamous cell carcinomas are attributable to 
tobacco smoking and alcohol consumption. Smoking increases the risk by approximately 
10-fold compared with never smokers, and heavy alcohol intake is an independent risk 
factor.4 The combined effect of tobacco and alcohol causes a greater than multiplicative 
risk.5 Public health measures have been successful in reducing the use of tobacco, and 
therefore the incidence of HNSCC overall has been decreasing over the last 30 years in 
developed countries. However, there has been a dramatic increase in the incidence rates 
of oropharyngeal (tonsil and base of tongue) cancers, predominantly in developed 
countries and at younger ages, due to infection with high-risk human papillomavirus 
(HPV).6-8 Other cultural and habitual risk factors include chewing tobacco or Betel nut in 
South East Asia and drinking mate in South America.9  A high incidence of aggressive 
HNSCC at a young age is seen in Fanconi’s anaemia, a rare autosomal recessive disorder 
associated with chromosomal instability.10 
 
 Stage and treatment 1.2.2
The subsite and stage at presentation are predictive of survival and guides management. 
The treatment of an individual cancer is typically determined in a multidisciplinary setting, 
with additional tumour information, such as the histological subtype, and patient 
characteristics, such as fitness, baseline swallow and airway function, guiding optimal 
treatment strategies.  
 
 Early stage disease 1.2.2.1
Approximately one third of patients present with early stage (stage I and II) disease and in 
general have small primary tumours with no cervical nodal involvement. These patients are 
treated with either surgery and postoperative radiotherapy (RT) or primary radiotherapy 
depending on the primary tumour site, patient factors and patient choice, with cure rates of 
70-90%.11  
 
 Locally advanced disease 1.2.2.2
The majority of patients present with locally advanced (stage III and IV) disease. Radical 
treatment in this situation requires multimodality therapy with surgery, commonly followed 
by postoperative RT or chemoradiotherapy (chemoRT), or organ preserving primary RT 
with or without concomitant chemotherapy with reduced cosmetic compromise.12 
Multimodality treatments are intensive and associated with severe acute toxicity, such as 
mucositis, dermatitis, and dysphagia, and long-term sequelae, for example sensorineural 
hearing loss, permanent xerostomia and altered swallowing function. The choice of 
treatment again depends on many factors and is determined on a case-by-case basis.  
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Resectable disease describes tumours that can be removed without causing unacceptable 
cosmetic and functional morbidity. Postoperative RT is standard treatment for patients with 
locally advanced tumours as they are at high risk of locoregional failure after surgery. 
Aggressive features of high risk of relapse include tumours with microscopically positive 
resection margins and extracapsular nodal disease.13,14 Multiple involved nodes, close 
resection margins, T stage 3/4 disease, perineural and lymphovascular invasion are also 
factors that are be taken into consideration. In 2004, two mulit-centre randomised studies 
demonstrated that the addition of cisplatin chemotherapy to postoperative radiotherapy in 
high risk groups significantly improved outcomes and therefore postoperative chemoRT 
became the standard of care for patients with high risk pathological features.13,15 
 
Locally advanced resectable and unresectable HNSCC can be treated with primary RT 
using doses of 70 Gy (2 Gy per fraction) to the primary tumour and involved nodes, and 44 
to 50 Gy (2 Gy per fraction) to low/intermediate risk sites.16 The addition of cisplatin 
chemotherapy to RT to increase the efficacy of RT has improved the survival in HNSCC 
and is currently the standard of care. A meta-analysis of 87 trials showed that the addition 
of chemotherapy improved survival, whether given as adjuvant, induction or concomitant, 
with an absolute benefit of 4.5% at 5 years. Concomitant chemoRT yielded the greatest 
absolute benefit of 6.5% at 5 years,12 and platinum-based regimes were more effective17 
but with increased mucositis18 and late toxicity.19 Cetuximab is a monoclonal antibody 
against epidermal growth factor receptor (EGFR), which is overexpressed in HNSCC and 
associated with poor outcome.20 Radiation increases the expression of EGFR in cancer 
cells and blocking the EGFR signalling pathway with cetuximab has been shown to 
enhance the effects of RT.21 Cetuximab concomitant with RT is superior to RT alone in 
patients with locally advanced HNSCC,22 and is an alternative option to platinum 
chemotherapy in patients medically unfit for chemoRT.  
 
Altered fractionation schemes have been investigated to overcome accelerated 
repopulation. As tumours reduce in size during a course of RT the clonogenic surviving 
cells compensate by dividing rapidly. An estimated dose increment of 0.6 Gy per day 
approximately 28 days after the start of RT is required to compensate for this repopulation 
in HNSCC.23 Accelerated RT delivers the total dose of radiation over a shorter period of 
time, decreasing the chance for tumour cells to regenerate during treatment. 
Hyperfractionation delivers more than one fraction of RT a day in smaller doses per 
fraction, given over the same period of time as standard RT, allowing the increased total 
dose delivery as late responding normal tissues are less sensitive to smaller doses per 
fraction. These strategies have been shown in randomised trials to significantly increased 
locoregional control (LRC) but with increased toxicity,24,25 and a meta-analysis from 15 
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randomised trials of altered fractionation in HNSCC demonstrated an absolute survival 
benefit of 3.4% at 5 years.26 The benefit was significantly higher with hyperfractionated RT 
(8% benefit at 5 years). The use of chemotherapy with altered fractionation has been 
shown to be more efficacious than altered fractionation alone without increased toxicity,27 
but has not shown a benefit over concomitant chemotherapy with standard RT.28 
 
Radioresistance is a major cause of treatment failure and is influenced by many factors 
including accelerated repopulation, intrinsic radiosensitivity and tumour hypoxia. Despite 
recent advances in both surgical and radiotherapy delivery techniques up to 50% of locally 
advanced tumours relapse, usually within the first 2 years after treatment. There are limited 
options for salvage surgery or re-irradiation, which are associated with high risk of 
complications.12  
 
 Metastatic disease 1.2.2.3
The outcome of patients with recurrent of metastatic disease with conventional treatments 
is very poor, and options are often limited by the performance status of patients who 
frequently have morbidity due to previous therapy.  
 
Several chemotherapy agents can be used for inoperable recurrences or metastatic 
disease, with response rates of only 10-35% and median survival of 6-12 months.29 The 
commonly used chemotherapy combination is cisplatin or carboplatin with 5-fluorouracil (5-
FU), which has been shown to produce higher response rates and better quality of life than 
single agent treatment such as methotrexate, but with no difference in OS.30 Cetuximab 
has been investigated in the palliative setting and has a response rate of 13% as a single 
agent after previous platinum therapy.31 An improved response rate of 26% was seen in 
combination with cisplatin compared with a response rate of 10% with cisplatin alone,32 and 
a phase III trial demonstrated significantly improve median survival when cetuximab was 
combined with cisplatin/5-FU versus cisplatin/5-FU (10.1 versus 7.4 months), with response 
rates of 36% and 20% respectively.33  
 
 
 Biomarkers in HNSCC  1.3
Locally advanced disease in HNSCC represents tumours with multiple genetic aberrations 
that have allowed the tumour to proliferate, grow and locally metastasise. They have an 
aggressive phenotype and are characterised by complex molecular changes that lead to 
RT resistance. Despite the progress in improving current treatments and developing novel 
targeted therapies, there have only been modest improvements in the outcome for this 
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group of patients over the last 30 years. Therefore, there is an urgent clinical need to 
understand the mechanisms of treatment resistance and identify those at risk of treatment 
failure. As HNSCC is such a heterogeneous disease improved patient stratification and 
selection to develop more individualised treatment strategies would improve the therapeutic 
ratio and achieve better disease control. 
 
Biomarkers, which include molecular and imaging markers of biological processes, are 
increasingly being evaluated to aid diagnosis, prognosis and prediction of treatment 
response. Prognostic biomarkers are associated with outcomes independent of a given 
treatment, whereas predictive biomarkers are associated with outcomes to a specific 
treatment. Predictive biomarkers are in clinical use, such as the identification of EGFR 
mutation in lung cancer to determine response to erlotinib34 and BRAF mutation in 
melanoma to predict response to vemurafenib.35 Genetic and molecular advances in 
HNSCC have revealed new genes and pathways involved in tumourigenesis, creating 
opportunities to explore novel therapeutic targets. In addition, imaging technologies are 
continually in development, providing further strategies to classify patients into prognostic 
groups. In HNSCC established prognostic biomarkers include HPV in oropharyngeal 
squamous cell carcinoma (OPSCC) and 18Fluorine-flourodeoxyglucose positron emission 
tomography.  
 
 Established prognostic biomarkers in HNSCC 1.3.1
 Human Papillomavirus (HPV) 1.3.1.1
HPV infection in OPSCC is now recognised as an aetiological agent, responsible for the 
significant increase in incidence in Western countries.7,8 An estimated 60 to 70% of newly 
diagnosed oropharyngeal cancers in the US and Western Europe are associated with 
HPV.6 These cancers represent a distinct subgroup characterised by specific biological and 
clinical profiles. Patients with HPV-associated OPSCC tend to be white males, on average 
5 years younger than HPV-negative patients, have higher socioeconomic status and are 
less likely to smoke or drink alcohol.6 HPV is detected in other subsites such as larynx and 
nasopharynx but no causal relationship or association with outcome has been established, 
and the significance in non-oropharyngeal head and neck tumours is unclear.36  
 
HPVs are small, non-enveloped, double stranded DNA viruses. The genome encodes for 
early genes (E1-7) and late structural genes (L1, L2). E1 and 2 encode regulatory proteins 
and E5-7 encode oncoproteins. HPVs enter the host via wounds or abrasions in the 
mucosa and infect basal epithelial cells, where the host cell DNA replication machinery is 
used for viral replication.37 The E6 protein interacts with E6-associated protein (E6-AP) 
resulting in a rapid degradation of tumour suppressor p53 via the ubiquitin-proteosome 
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pathway. This leads to inhibition of the proapoptotic functions of p53 and bypassing of the 
p53-mediated checkpoints.38 The E7 protein competes with E2F1 transcription factor for 
binding to the pRb tumour suppressor, displacing E2F1. E2F1 activates genes responsible 
for cell cycle progression through the G1 to S phase, promoting cellular proliferation and 
transformation.39 pRb is a negative regulator of the cyclin-dependent kinase inhibitor 
p16INK4A, and therefore inactivation of pRb results in p16INK4A upregulation. This can be 
detected using immunohistochemistry in HPV-associated tumour samples and represents a 
biologically significant surrogate marker for HPV oncoprotein expression.40  
 
Locally advanced OPSCC is treated with concomitant chemoRT and at present, treatment 
is the same regardless of HPV status outside the context of a clinical trial. HPV-associated 
OPSCC has a favourable prognosis, with a 60-80% reduction in the risk of death compared 
with HPV-negative OPSCC after standard therapy,41,42 highlighting the need for different 
treatment strategies to reduce the morbidity associated with current treatment. Locally 
advanced HPV-negative OPSCC continues to have a poor prognosis and a significant 
proportion of these patients develop recurrent disease. Therefore HPV-negative OPSCC 
patients would benefit from markers predictive of response from current treatment, as well 
as the development of treatment intensification strategies and novel targeted agents. The 
research into HPV as a biomarker in OPSCC has translated into several phase III studies 
currently recruiting to investigate the replacement of standard cisplatin in concomitant 
chemoRT with cetuximab, or assessing de-escalating treatment strategies such as using 
induction chemotherapy followed by reduced dose radiation.43 HPV vaccines are under 
development, as both preventative and therapeutic applications. Gardasil and Cervarix are 
HPV vaccines in use for the prevention of cervical cancer, but could afford protection 
against oral HPV16/18 infection. Reduced prevalence of oral HPV infection was found in 
women recruited to investigate the efficacy of HPV vaccination against cervical cancer.44 
These vaccines may also cause induction of cell mediated immunity against HPV positive 
tumours and phase I studies are ongoing investigating the ability to deliver HPV16 E7 
antigen using recombinant listeria-based vaccine or a DNA-based vector.45 Tumour 
infiltrating lymphocytes in HPV-positive OPSCC express high levels of programmed cell 
death protein 1 (PD-1) receptor and its ligand PD-L1. The interaction of PD-L1 with PD-1 
receptor results in negative T cell regulation and immune inhibition, and in normal tissues 
this is a mechanism to protect against excessive tissue destruction. Localised expression 
of PD-L1 has been demonstrated in the deep crypts of normal tonsils where initial HPV 
infection takes place, suggesting a protected site where the virus can evade immune 
recognition.46 PD-L1 has been shown to be induced by the activation of the PI3K/AKT 
pathway through the loss of PTEN,47 which is a common mutation in HPV-positive but not 
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HPV-negative SCC.48,49 Anti-PD-1 and anti-PD-L1 phase I studies have been carried out in 
solid tumours with objective responses.50,51  
 
 18Fluorine-fluorodeoxyglucose positron emission tomography 1.3.1.2
Positron emission tomography (PET) is a molecular imaging technique that can visualise 
and quantify tumours and their microenvironment. Different biological tumour 
characteristics can be imaged depending on the radiotracer used, including those relevant 
to radioresistance such as increased metabolism, accelerated repopulation or proliferation, 
and hypoxia. As it is non-invasive and visualises whole tumours and metastatic lesions 
simultaneously, patients can potentially receive serial imaging to monitor response to 
treatment, with the patient serving as their own control, and therefore has important roles in 
treatment selection and possible treatment adaptation.  
 
The most commonly used radiotracer is 18Fluorine (18F) labelled fluorodeoxyglucose (FDG), 
which is a glucose analogue that is taken up by cells with increased glucose metabolism. 
18F-FDG enters cells via glucose transporters and is phosphorylated by hexokinase to 18F-
fluoro-2-deoxyglucose-6-phosphate, which becomes trapped within the cell. 18F undergoes 
radioactive decay and emits positrons. These positrons interact with electrons in an 
annihilation reaction to emit two 511 KeV photons in opposite directions, which are 
detected by scintillation crystals of the PET scanner, converted to light and a 3D image is 
reconstructed. PET is combined with a computed tomography (CT) imaging in a single 
scanner to provide both quantitative functional and anatomical information.  
 
18F-FDG PET in HNSCC is used for improved diagnosis and staging, tumour volume 
assessment to aid RT planning, and response assessment. High uptake has been 
correlated with more advanced tumour stage, poorer differentiation and perineural and 
extracapsular invasion,52 and has been shown to have prognostic value. Two meta-
analyses have demonstrated that the semi-quantitative measure of the normalised 
concentration of radioactivity in a tumour SUVmax (maximum standardised uptake value) 
before treatment is associated with outcome.53,54 Low pre-treatment SUVmax of primary 
tumours were associated with reduced risk of progression, recurrence and death, although 
the definition of low/high SUVmax was variable. Post-treatment 18F-FDG PET is used 
routinely for response assessment after primary (chemo)RT, to guide whether further 
surgical management is required.55 A meta-analysis of PET in the post-treatment setting 
demonstrated high negative predictive value for the primary tumour and neck metastases.56 
It can be used to avoid post-treatment neck dissection but the positive predictive value can 
be as low as 38% due to inflammation related uptake after RT.57  
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Mid-treatment 18F-FDG PET has also been investigated in small studies and shown 
potential for early treatment response assessment, either after induction chemotherapy58 or 
1-2 weeks after the start of chemoRT,59 with a SUVmax reduction of > 50% associated with 
complete clinical response and better OS. Mid-treatment 18F-FDG PET therefore has the 
potential to identify patients who may benefit from treatment modification. Integration of 18F-
FDG PET into RT planning is currently an active area of research. 18F-FDG PET can be 
used as an aid to tumour volume definition for RT as it can potentially define tumours more 
accurately compared with CT or MRI,60 and has demonstrated frequent tumour extension 
outside CT-based tumour volumes.61 In addition a significant proportion of recurrences 
after treatment have been shown to occur in the pre-treatment 18F-FDG PET region and 
therefore coverage of this region in the high dose RT volume is essential.62 However the 
direct PET-based RT planning is not carried out outside of clinical trials mainly due to the 
uncertainties regarding optimal tumour segmentation. Preclinical autoradiography studies 
have been found discrepancies between PET images and microregional distributions of 
18F-FDG due to the finite resolution of PET,63 and the discrimination of uptake from 
background tissues remain unclear. 
 
 Biomarkers under investigation in HNSCC 1.3.2
Gene expression profiling using microarray based assays has allowed the evaluation of the 
expression of tens of thousands of genes at once, enabling lists of genes, or signatures 
that are over- or underexpressed to be assessed. Next-generation sequencing now 
provides the platform to carry out the evaluation of the whole exome, genome, 
transcriptome and copy number variations to provide a comprehensive assessment of the 
genetic alterations underlying HNSCC, which can potentially provide information that can 
be used to change patient management. 
 
Genomic data from 3 large genome-wide sequencing studies have demonstrated that the 
majority of HNSCC tumours have loss of function mutations in tumour suppressor genes 
(TSGs) and only a few functionally activating gene mutations (Table 1.1).48,49,64 
Unfortunately targeting TSGs or their pathways to restore or reactivate their function is 
difficult compared with targeting oncogenes with specific inhibitors. Therefore elucidating 
the genetic basis of tumours, as well as exploring other novel biomarkers, such as 
microRNAs, and further developing established biomarkers, such as hypoxia, are important 
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Table 1.1 Mutation rates of genes found to be commonly mutated in 3 gene 
sequencing studies in HNSCC. Adapted from Sun et al.65 
 
Gene Type of gene Cancer Genome Atlas64 (n=279) 
Agrawal et al48 
(n=120) 
Stransky et al49 
(n=74) 
TP53 TSG 72% 47% 62% 
CDKN2A TSG 22% 9% 12% 
NOTCH1 Both 19% 15% 14% 
PIK3CA Oncogene 21% 6% 8% 
FBXW7 TSG 5% 5% 5% 
HRAS Oncogene 4% 4% 5% 
 
 
 p53/Retinoblastoma (pRb)  1.3.2.1
Tumour suppressor protein p53 plays a key role in the regulation of genes involved in cell 
cycle and growth arrest, DNA repair or apoptosis, thereby maintaining genomic stability.66 
In response to DNA damage p53 can arrest the cell cycle and activate repair or initiate 
apoptosis. The level of p53 is regulated by Mouse double minute 2 homolog (MDM2), an 
E3 ubiquitin-protein ligase, which binds to p53 and causes its degradation. MDM2 is 
inhibited by p14ARF, which is encoded by the gene CDKN2A, protecting p53 from 
degradation. Tumour suppressor protein pRb controls the expression of genes involved in 
cell cycle progression through the G1 restriction point. pRb binds and inhibits E2F1 
transcription factors, which induce expression of S phase genes and cell proliferation. 
Mitogenic signals activate cyclin D1/CDK4/CDK6 complexes, which phosphorylate pRb 
resulting in the release of E2F1. The cyclin D1-CDK4/6 complexes are inhibited by 
p16INK4A, encoded by the gene CDKN2A, and p21 (cyclin-dependent kinase inhibitor 
1/CDKN1).67 Mutations in p53 and pRb pathways result in limitless replicative potential and 
immortalisation. 
 
Mutation of the TP53 tumour suppressor gene is one of the earliest and most frequently 
detectable genetic alterations in HNSCC, reported in 50-80% of cases.48,68 In p53 wild type 
tumours, p53 function may be inactivated by other mechanisms, such as HPV infection, 
overexpression or amplification of MDM2 and deletion of the p14ARF gene.66 pRb is 
targeted early carcinogenesis through inactivation of the tumour suppressive CDKN2A 
gene, with mutations seen in 9-22% and copy number losses in a further 20-30% of 
cases.48,49,64 The CCND1 gene, which encodes cyclin D1, has been found to be amplified 
or overexpressed in over 80% of HNSCC.69 In addition E2F1 activating mutations were 
observed in 20% of The Cancer Genome Atlas tumours, particularly in HPV-positive 
samples. TP53 mutation, loss of p16INK4A and overexpression of cyclin D1 are all 
associated with reduced survival.68 TP53 mutation is predictive of poor response to 
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chemotherapy and locoregional recurrence following radiotherapy,70 and cyclin D1 
deregulation has been associated with EGFR-inhibitor resistance.71  
 
Restoring or modulating p53 as targeted therapy, for example with gene therapy, has been 
an area of intensive research for decades, with limited success. A phase I study of dendritic 
cell p53 peptide vaccine therapy recently reported the feasibility and safety in the adjuvant 
setting.72 p53-reactivating small molecules are currently under investigation in HNSCC cell 
lines,73 and other strategies include targeting CDKN2A to reactivate p16INK4A and CDK 
inhibitors.  
 
 Epidermal growth factor receptor  1.3.2.2
EGFR (ErbB1) is a member of the ErbB/HER2 family of transmembrane receptor tyrosine 
kinases, which play a major role in cell proliferation, differentiation, survival and migration. 
EGFR is activated by a number of ligands such as EGF, resulting in downstream signal 
transduction cascades including the Ras/Raf/mitogen-activated protein kinase (MAPK), 
phosphoinositide 3-kinase (PI3K)/AKT and Janus kinases (JAK)/signal transducers and 
activators of transcription 3 (STAT3) pathways (Figure 1.1).74 EGF-bound EGFR can also 
translocate to the nucleus to function as a transcription factor. One of the nuclear targets is 
CCND1, which encodes cyclin D1 protein involved in cell cycle progression.75  
 
EGFR is overexpressed in 80-90% of HNSCC76 and in dysplasic lesions,77 indicating that 
EGFR is an early event in HNSCC carcinogenesis. EGFR overexpression is mainly at the 
transcriptional level as there are few EGFR activating mutations in HNSCC.64,76 The 
intensity of expression, as assessed by immunohistochemistry, and increased gene copy 
number has been shown to indicate poor outcome.20,78 However, variations in EGFR 
antibody staining protocols and interpretation, and the lack of association with the efficacy 
of EGFR-directed therapy has limited its clinical utility.79 EGFR can be targeted either by 
inhibition of the extracellular ligand binding using monoclonal antibodies, such as 
cetuximab, or by inhibition of the tyrosine kinase domain with a small molecule (TKIs), such 
as gefitinib and erlotinib, but despite the high expression, EGFR inhibition has only a 
modest effect. Gefitinib and erlotinib inhibit only EGFR and have shown disappointing 
results in HNSCC.80,81 Afatinib irreversibly blocks EGFR, HER2 and ErbB4 and is under 
investigation in HNSCC. 
 




Figure 1.1 RTK signalling cascade.  
Activation of RTKs result in the signalling of a number of pathways involved in cell survival. 
 
 
 NOTCH  1.3.2.3
NOTCH1 signalling is involved in a number of biological functions, including regulation of 
self-renewal capacity, survival, and promoting terminal differentiation. The NOTCH 
pathways consists of four receptors bound to the cell membrane, NOTCH 1-4, and two 
families of ligands, Delta-like (1, 3, and 4) and Jagged (JAG1 and 2). Ligand binding leads 
to two cleavages of NOTCH1 by TNFα-converting enzyme (TACE) and γ-secretase 
resulting in release of the NOTCH1 intracellular domain (NCID). NCID translocates to the 
nucleus and interacts with nuclear co-activating MAML proteins to promote transcription of 
its target genes. NOTCH1 is regulated partly by ubiquitination and degradation, which 
involves FBXW7.82  
 
NOTCH1 and FBXW7 mutations in HNSCC were novel findings in whole-exome 
sequencing studies.48,49 Chromosomal aberrations in JAG1, JAG2 and MAML1 have also 
been reported.69 The majority of NOTCH1 mutations were nonsense mutations, predicted 
to result in truncated NOTCH1 proteins lacking the transcriptional activation domains, 
therefore suggesting a tumour suppressor role for this pathway in HNSCC. However recent 
reports have suggested a subset of HNSCC with activating NOTCH1 mutation,83 supported 
by in vitro functional studies in HNSCC cell lines.84 The role of NOTCH1 in HNSCC 
tumourigenesis needs to be further investigated, but could potentially represent another 
therapeutic target. Both NOTCH1 pathway inhibitors, such as γ-secretase inhibitors,85 and 
NOTCH1 pathway activators, via inhibition of histone deacetylase, are currently in clinical 
development. 
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 PI3K/AKT/mTOR  1.3.2.4
PI3Ks are a family of enzymes that have important roles in promoting cell growth, 
differentiation and survival. PI3Ks are heterodimers and composed of a 110 kDa catalytic 
subunit and an 85 kDa regulatory subunit. Activation by RTKs results in the 
phosphorylation of phosphatidylinositol1,4-bisphosphate (PIP2) by the catalytic subunit to 
form phosphatidylinositol1,4,5-triphosphate (PIP3). PIP3 recruits AKT to the plasma 
membrane resulting in phosphorylation and activation of AKT by mammalian target of 
rapamycin complex 2 (mTORC2). Activated AKT phosphorylates proteins involved in cell 
growth and survival, including MDM2, NF-κB via IκB kinase, and inactivation of the pro-
apoptotic protein BAD. AKT also stimulates cell proliferation by inactivating p21 and 
stabilising cyclin D1. The tumour suppressor phosphatase and tensin homology (PTEN) 
mediates the conversion of PIP3 to PIP2, counteracting the activation of AKT.86 Mammalian 
target of rapamycin (mTOR) is a protein kinase that acts downstream of PI3K and AKT and 
plays an important role in cell growth, survival, protein synthesis and autophagy. mTORC1 
activates ribosomal protein S6 kinase 1 (S6K1) and inactivates eukaryotic translation 
initiation factor 4E-binding protein 1 (4E-BP1), resulting in protein translation and cell 
growth.  
 
Genetic aberrations of the PI3K pathway are common in HNSCC. The 110 kDa catalytic 
subunit, p110α, is encoded by the PIK3CA gene, which is mutated in 6-30% of HNSCC, 
resulting in constitutive activation of the pathway.48,49,87 It has been found to be particularly 
common in HPV-positive HNSCC cases, where the mutation is in the helical domain of the 
PIK3CA gene. HPV-negative tumours have mutations throughout the gene, but 
demonstrate specific mutations, such as H1047R in exon 20 in the kinase domain, which 
may predict higher response rates to treatment with PI3K pathway inhibitors.88 In addition, 
PTEN mutations have been reported in 7% of HNSCC, and the mTOR pathway is 
frequently activated, independent from activation of EGFR or the presence of mutant p53, 
particularly in HPV positive tumours.49,89,90 The PI3K pathway is an important therapeutic 
target for cancers and the activation has been implicated in radioresistance.91 HNSCC 
xenografts with PIK3CA mutation demonstrated selective sensitivity to mTOR/PI3K 
inhibition compared with wild type tumours87 and differential sensitivity to PI3K inhibition 
over AKT inhibition in HPV-positive tumours.92 The mTOR inhibitors everolimus and 
temsirolimus are in clinical use in different tumour types, and have been investigated in 
HNSCC in phase I and II trials in combination with chemotherapy and EGFR inhibition.93 
PI3K and AKT inhibitor early phase studies are ongoing. Bortezomib is a protease inhibitor 
which also inhibits the activation of NF-κB and induces PTEN expression. A phase I study 
in combination with chemoRT in locally advanced or recurrent HNSCC, demonstrated a 
median survival of 24.7 months.94  
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 RAS 1.3.2.5
Ras is a guanosine nucleotide binding protein localised on the plasma membrane. There 
are three Ras genes: HRAS, KRAS and NRAS. In the inactivated state Ras is bound to 
guanosine diphosphate (GDP). Activation converts Ras to the guanosine triphosphate 
(GTP) bound form, which binds to and activates Raf-1. The targets for phosphorylation of 
Raf-1 include the kinases MEK1 and MEK2, which in turn activate the MAP kinases ERK1 
and ERK2. These translocate to the nucleus and target genes involved in cell growth, 
proliferation and survival. Ras can also activate the PI3K signalling cascade.95 Activating 
HRAS mutations have been found in 4-5% of HNSCC cases.48,49 KRAS in colorectal 
cancers are predictive of poor response to EGFR inhibitors,96 but the predictive value in 
HNSCC remains unclear. Sorafenib is a tyrosine kinase inhibitor, which has multiple targets 
including Raf and VEGF (vascular endothelial growth factor receptor) and in combination 
with chemotherapy has shown a response rate of 55% and median overall survival of 22.6 
months in one phase II trial in HNSCC.97 The MEK inhibitor trametinib has recently been 
approved for use in metastatic melanoma and is under investigation in combination with 
AKT inhibition in solid tumours including HNSCC. 
 
 MET  1.3.2.6
The proto-oncogene c-MET encodes mesenchymal epithelial transition factor (MET), which 
is an RTK activated by hepatocyte growth factor (HGF). Ligand binging activates signalling 
cascades resulting in cell morphogenesis, motility, growth and survival. MET and HGF 
have been found to be overexpressed in over 80% of HNSCC and increased MET copy 
numbers in 13% of HNSCC tumour samples.98,99 MET expression has been suggested to 
be a prognostic biomarker in HPV-negative HNSCC with overexpression correlating with 
reduced disease-free and overall survival.100 It has also been implicated in resistance to 
radiation, cisplatin and cetuximab.101-103 Foretinib is a multi-tyrosine kinase inhibitor that 
binds to the ATP pocket of the MET receptor. It has been tested in a phase II study in 
recurrent/metastatic HNSCC which showed disease stabilisation.104  
 
 JAK/STAT 1.3.2.7
The Janus kinases (JAKs) are part of a family of non-receptor tyrosine kinases that 
phosphorylate signal transducer and activator of transcription (STAT) and promote cell 
growth and survival, angiogenesis and suppression of immune surveillance.105 STAT 
proteins are important in mediating EGFR signalling and STAT3 is overexpressed in 
HNSCC.106 In HNSCC tumour models inhibition of STAT3 resulted in increased 
apoptosis,106 and STAT3 knockdown HNSCC cells demonstrated increased radiosensitivity 
and cetuximab sensitivity.107 Direct targets of STAT3 include members of the Bcl-2 family, 
genes involved in cancer inflammation such as interleukin-6, matrix metalloproteinases, 
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hypoxia-regulated factor-1 (HIF-1) and vascular endothelial growth factor (VEGF).108 
Ruxolitinib is a JAK inhibitor being investigated in phase I studies in combination with 
chemotherapy in advanced solid tumours. A phase 0 trial of a STAT decoy oligonucleotide 
injected into HNSCC tumours before surgery demonstrated downregulation of STAT3 
target gene expression warranting further investigation of this target in HNSCC.109 
 
 Gene expression profiling 1.3.2.8
Gene expression profiling using microarrays have been investigated to predict outcome. 
Using samples from patients with clinical data, supervised analysis can identify genes that 
are most strongly associated with clinical outcomes. Signatures to predict with 
recurrence,110 lymph node metastases,111 hypoxia112 and outcome after chemoRT113 have 
been described using both fresh frozen and formalin fixed paraffin embedded (FFPE) 
samples. More recently a meta-analysis of 9 microarray gene expression datasets of 
HNSCC demonstrated a 172 gene signature highly prognostic of risk of relapse, 
independent from HPV status, and was validated in 6 independent datasets.114  
 
Gene expression profiling has also demonstrated that HNSCC can be characterised based 
on their gene expression profile. Chung et al115 assayed 60 HNSCC samples and found 
that the gene expression patterns allowed categorisation into 4 distinct subtypes, which 
showed significant differences in recurrence free survival. In addition they identified a 
signature from the primary tumour diagnostic biopsy sample that could predict the 
presence of lymph node metastases. The subtypes were validated by Walter et al using 
integrated genomic analysis,116 and classified as basal, mesenchymal, atypical and 
classical, and confirmed more recently by The Cancer Genome Atlas Network.64 For 
example, the atypical subtype was characterised by lack of chromosome 7p amplifications, 
which contains EGFR, and enrichment of HPV-positive tumours with activating mutations in 
the PIK3CA helical domain. The classical subtype included TP53 mutations, loss of 
chromosome 9p containing CDKN2A and a heavy smoking history. Studies have also 
identified clear differences between HPV-negative and positive tumours. HPV-negative 
tumours harbor TP53 loss in almost all cases and high rates of CDK2NA loss, altering the 
pRB pathway. They also demonstrated amplification of EGFR and CCND1, and deletions 
in NOTCH1. HPV-positive tumours have infrequent TP53 and CDKN2A mutations and 
more frequent PIK3CA activating mutations.87,117  
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 Other PET biomarkers 1.3.2.9
Other PET-based imaging biomarkers of radioresistance are under investigation, including 
radiotracers to detect proliferation and hypoxia. Hypoxia imaging is further discussed in 
section 1.5.4. 
 
Compensatory enhanced proliferation during RT is a recognised mechanism for resistance 
and treatment failure in HNSCC.118 18F-fluorothymidine (FLT) is a PET tracer that is taken 
up into cells by nucleoside transporters, phosphorylated and trapped by the cytosolic 
enzyme thymidine kinase 1 (TK1), the activity of which increased nearly 10-fold during DNA 
synthesis. 18F-FLT retention is therefore a measure of cellular TK1, which is closely related 
to cellular proliferation.119 In HNSCC pre-treatment high uptake has been shown to be 
predictive of poor outcome, and patients with high SUVmax treated with chemoRT had better 
outcome compared with RT alone.120 Serial PET before and during RT has demonstrated a 
decrease in proliferative activity during therapy,121 with greater decline indicative of better 
long-term outcome.120,122 18F-FLT PET therefore has the potential to identify patients who 
are not responding adequately to treatment at a stage when there is a possibility for 
treatment intensification. 
 
Another imaging target in HNSCC is EGFR, which could monitor and predict EGFR-
targeted treatment response. Cetuximab has been labelled with several radionuclides and 
investigated in animal models, for example 89Zr and 64Cu.123 Uptake in tumours have been 
correlated with EGFR expression assessed by IHC.124 In addition 111In-cetuximab has been 
shown to visualise EGFR accessibility and radiation-induced changes in EGFR HNSCC 




 MicroRNAs as biomarkers 1.4
MicroRNAs (miRNAs) are endogenous, small, non-coding RNAs, 18 to 25 nucleotides in 
length. They are evolutionarily highly conserved in eukaryotic organisms and regulate and 
refine gene expression at the post-transcriptional level.126 Over 2500 mature miRNAs have 
been identified to date (miRBase.org), with each miRNA influencing the expression of 
hundreds of genes and a single messenger RNA (mRNA) being targeted by multiple 
miRNAs. It is estimated that over one third of human genes are conserved targets of 
miRNAs.127 They are involved in a wide variety of critical biological processes including cell 
cycle regulation, differentiation, development, metabolism and death.128 MiRNAs have 
been described as micromanagers of protein output within a complex interactive network, 
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fine-tuning the expression of many genes, with alteration of a single miRNA likely to result 
in subtle phenotypic consequences.129 MiRNAs were first discovered in 1993 by Ambros et 
al.130 During their study of the nematode Caenorhabditis elegans gene lin-4, they found that 
this gene did not encode a protein but produced a small RNA. This small RNA repressed 
the expression of its target LIN-14 through base pairing with the 3’-untranslated region (3’-
UTR) of the lin-14 mRNA. However the significance of this discovery was only realised 
when the second miRNA, let-7, was characterised in 2000,131 and subsequently found to 
be conserved in many species. Since the discovery of miRNAs there has been huge 
interest in their role in tumourigenesis, and their potential as biomarkers and possible 
therapeutic targets.   
 
 Biogenesis 1.4.1
Thirty percent of miRNA genes are located in intergenic regions, or in their own 
transcription units, and therefore transcribed as independent units.132 The rest are located 
within the introns or exons of non-coding or protein-coding genes.133 These miRNAs are 
usually expressed with the transcription of the host gene, suggesting that they may be 
regulated together and derive from a common transcript.134 MiRNAs can be organised as 
individual genes or located close to each other and transcribed as clusters, with common 
function and sequence.135 
 
MiRNAs are transcribed by RNA polymerase II into an initial miRNA precursor called pri-
miRNA, which are several kilobases in length and fold into hairpin structures containing 
imperfectly base-paired stems. The pri-miRNA is processed in the nucleus by the 
ribonucleases Drosha and DiGeorge syndrome critical region 8 (DGCR8), which forms the 
microprocessor complex, to become a precursor of about 70 to 100 nucleotides, called pre-
miRNA. Pre-miRNA is exported to the cytoplasm by exportin 5,136 where it undergoes 
further processing by another ribonuclease, Dicer, into a mature 18 to 24 nucleotide double 
strand miRNA. Only one strand (the ‘guide’ strand) is incorporated into a large protein 
complex called RNA-induced silencing complex (RISC), which is constituted by Argonaute 
family protein members, whilst the other strand (the ‘passenger’ strand or miRNA*) is 
removed and degraded. The mature miRNA will recognise the complementary sequences 
in the target mRNA and guide the miRNA-RISC complex to cleave the mRNA or inhibit 








Figure 1.2 MiRNA biogenesis. 
a) MiRNA transcription by RNA polymerase II into pri-miRNA, which is cleaved by the 
enzyme Drosha to form a hairpin precursor pre-miRNA. b) Pre-miRNA is exported to the 
cytoplasm by exportin 5. c) Pre-miRNA is processed in the cytoplasm by the enzyme Dicer 
to form a transient miRNA duplex. One strand is incorporated into the protein complex RISC. 
d) The mature miRNA leads the RISC to degrade the mRNA or induce translational 
repression, depending on the degree of complementarity between the miRNA and mRNA 
target. Adapted from Garzon et al 2009.137 
 
 
The main function of miRNAs is to inhibit protein synthesis, either by inhibition of translation 
or mRNA degradation by base pairing with their mRNA targets. The specificity depends on 
the degree of base pairing between the nucleotide positions 2 to 8 of the 5’-UTR of the 
mature miRNA, which is known as the seed region, with the 3’-UTR of the target mRNA.127 
MiRNAs with the same 2 to 8 nucleotide sequences belong to the same family.138 In plants 
most miRNAs base pair to mRNA with nearly perfect complementarity, resulting in mRNA 
degradation.139 This is rare in animals, where imperfect miRNA-mRNA base pairing leads 
to post-translational inhibition,140 including inhibition of translation initiation or post-initiation, 
mRNA destabilisation and decay, or co-translational protein degradation.  
 
 
MiRNA biogenesis and function in animals are complex and do not always follow this 
pathway. They have been reported to target the 5’-UTR and coding regions of target 
mRNAs, with association of miRNAs with 5’-UTR target sites sometimes resulting in 
activation rather than repression of translation.141 Some miRNAs mature by mRNA splicing 
with or without exonuclease trimming of strands, independent of the enzymes Drosha and 
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have been reported to also have decoy activity that interferes with the function of regulatory 
proteins, acting as molecular decoys for RNA-binding proteins.143 
 
 MicroRNAs in cancer 1.4.2
The first report of the role of miRNAs in cancer was published in 2002, when it was 
demonstrated that in more than 65% of cases of chronic lymphocytic leukaemia, a small 
region in chromosome 13q14 was deleted. This region did not contain a protein-coding 
tumour suppressor gene but two microRNAs, miR-15 and miR-16.144 Since then altered 
miRNA expression has been reported in almost all types of cancer.145 MiRNA deregulation 
can be caused by a variety of mechanisms, including genomic deletion, mutation or 
amplification,146 single nucleotide polymorphisms,147 and epigenetic instability such as 
promoter hypermethylation and histone deacetylation.148 Transcription factors, known to be 
deregulated in cancer, can also influence the regulation of miRNA transcription. For 
example MYC, a well established oncogenic transcription factor, has been shown to 
promote the transcription of the miR-17-92 cluster of oncogenic miRNAs.149 In addition, 
miRNA expression is under tight regulatory control and alterations to the enzymes in their 
biogenesis pathway can also affect tumorigenesis.150  
 
MiRNAs are directly implicated in the tumorigenesis of cancer by acting as oncogenes or 
tumour suppressor genes (TSGs). They have been found to be involved in a variety of 
pathways in cancer development and progression, such as proliferation, apoptosis,151 
angiogenesis,152 maintenance of the cancer stem cell and metastasis.153 In some cases the 
same miRNA can act as an oncogene in one cell type and a TSG in other, by acting on 
different targets or by functioning under differing transcriptional regulation.  For example, 
miR-7 in head and neck cancer cell lines was shown to regulate EGFR expression and 
AKT activity and therefore has a tumour suppressor function. On the other hand miR-7, 
along with miR-21, has been associated with keratinisation of oral tumours and poor 
prognosis, suggesting a possible oncogenic role.154  
 
Improved understanding of the role of miRNAs in both physiological and pathological 
processes has revealed their huge clinical potential, especially as they have been found to 
be are stable even after many years in FFPE samples and in body fluids.155,156 The 
biogenesis of miRNAs is tightly regulated and very sensitive to endogenous and 
exogenous stimuli, resulting in differing expression profiles between cell types and cell 
conditions. Global miRNA gene profiling of normal and tumour tissues has been carried out 
to assess whether miRNA signatures could be used as clinical biomarkers of diagnosis, 
classification, prognosis, and treatment response prediction. For example, miRNA 
expression profiling can differentiate between normal and diseased tissue and identify 
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tissues of origin accurately.145 They have also been shown to be able to discriminate 
different subtypes of a particular cancer, such as basal and luminal breast cancer 
subtypes.157 MiRNA profiling has revealed patterns of expression associated with disease 
outcome, such as miR-155 overexpression and let-7a downregulation in lung cancer, which 
predicts for poor disease outcome,158 supporting the potential of miRNAs as prognostic 
biomarkers. A more important potential role for miRNA signatures is the ability to predict 
the response to specific drugs or radiotherapy. For example, high miR-21 expression has 
been shown to predict poor response to adjuvant chemotherapy in pancreatic and colon 
cancer,159 and radioresistance in lung cancer.160  
 
MiRNAs represent potential therapeutic targets for the diseases in which they are 
deregulated. MiRNAs that are overexpressed can be targeted using a class of anti-miRNA 
antisense oligonucleotides called antagomirs. In tumours where miRNAs are 
downregulated and function as TSGs, miRNAs can be replaced using synthetic miRNAs, 
which mimic the expression of the protective miRNAs, or genes coding for downregulated 
miRNAs could be inserted into viral constructs. However, their development has the 
challenges of delivery and retention, safety and potential off target effects.161 MicroRNAs 
are increasingly being integrated into clinical trials but these are mainly looking at the 
expression signatures as biomarkers for diagnosis, prognosis or treatment response. 
However there are currently two clinical studies, one phase 2 trial of miravirsen, a miR-122 
inhibitor for hepatitis C infection,162 and one phase one study to assess the safety of a miR-
34 mimic in patients with primary liver cancer or liver metastases.163 
 
 MicroRNAs in head and neck cancer 1.4.3
Several mechanisms for miRNA deregulation have been identified in the pathogenesis of 
HNSCC. For example, single nucleotide polymorphism (SNP) in miR-885-5p164 and in the 
3’-UTR of Dicer, affecting the binding of miRNAs to Dicer,150 have been associated with 
HNSCC susceptibility. In addition, miR-137 and miR-193a tumour suppressor miRNAs 
have been found to be epigenetically silenced during oral carcinogenesis.165  
 
Expression profiling of miRNAs has been performed in head and neck, but with variable 
results due to differences in the HNSCC subtype investigated, condition of samples used 
and their processing, as well as data analysis methods. However there are some 
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Table 1.2 Examples of consistently altered miRNAs in HNSCC. 
 
MicroRNA Targets Reference 
Upregulated 
  miR-21 
  miR-31   
  miR-106b-25  













  let-7 
  miR-125a/b 
  miR-133a/b 












Upregulation of miR-21 is one of the commonest findings in human cancers, where it is 
implicated in cell proliferation, invasion and metastases, and is consistently upregulated in 
head and neck cancer.168,178 MiR-21 upregulation in HNSCC is associated with poor 
prognosis and correlated with tumour suppressor targets such as PTEN and the 
programmed cell death 4 (PDCD4) gene.166 MiR-31 enhances oncogenesis via targeting 
factor-inhibiting hypoxia-inducible factor (FIH), which inhibits the activation of ability of HIF-
1 regulated genes.167 The miR-106b-25 cluster of miRNAs negatively regulates the p21 
CDK inhibitor, can promote cell proliferation by deregulating cell cycle check points,169 with 
knockdown of this cluster resulting in G1 cell cycle arrest.168 MiR-155 promotes proliferation 
and invasion through targeting suppressor of cytokine signalling 1 (SOSC1)-STAT3 
pathway in laryngeal cancers and CDC73 gene,171 which negatively regulates cyclin D1 
and MYC, in oral cancers.170  
 
Consistently downregulated microRNAs include let-7, which negatively regulates KRAS, 
and reduced expression is associated with poor prognosis.172,173 MiR-125a/b is also 
downregulated in independent studies and thought to target the oncogene ERBB2,174 as is 
miR-133a/b which targets pyruvate kinase M2 (PKM2), a key regulator of cancer 
metabolism.175 MiR-133a also directly regulates the actin-related protein complex 5 
(ARPC5) with inhibition of cell migration and invasion when miR-133a is restored or ARPC5 
is repressed.176 Downregulation of the tumour suppressive miR-200a is seen in both saliva 
and tissue samples of HNSCC patients and is known to target ZEB1 and ZEB2, which 
repress the transcription of E-cadherin and mediate epithelial-mesenchymal transition and 
cell migration.177 
 
MicroRNAs have a role in the response to therapy in HNSCC. For example, miR-21 
inhibition was found to induce sensitivity of OSCC cells to cisplatin, with cells transfected 
with PDCD4 siRNA, a known target of miR-21, becoming more resistant to cisplatin. 
Suppression of miR-21 promoted cisplatin-induced apoptosis, whereas PDCD4 
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suppression reduced apoptosis.179 Cisplatin resistant oral cancer cell lines are associated 
with miR-181a downregulation and TWIST1 upregulation, with enhanced epithelial-
mesenchymal transition and metastatic potential. MiR-181a upregulation reversed 
chemoresistance, as did TWIST1 knockdown.180 In addition miR-200b and miR-15b 
downregulation was found in cisplatin-resistant tongue SCCs, and ectopic expression of 
these miRNAs reversed chemoresistance and reduced motility and invasiveness.181 
 
 MicroRNAs and radiotherapy 1.4.4
MiRNAs are implicated in the response of tumours to radiotherapy. Ionising radiation 
induces DNA damage, which triggers the DNA damage response (DDR) pathway. The 
DDR initially responds to radiation by recruiting a large number of proteins to the site of 
DNA damage to form ionising radiation induced foci. Repair pathways include base 
excision repair, single-strand break repair and double-strand break repair, which occur 
through homologous recombination or non-homologous end-joining. Phosphorylation of the 
protein gamma H2AX is an early event, which occurs through the activation of ataxia 
telangiectasia mutated (ATM), DNA-dependent protein kinase catalytic subunit (DNA-PKcs) 
and AT and Rad3-related (ATR) kinases. In double-stranded damage this activation and 
phosphorylation recruits and phosphorylates other proteins, such as sensor proteins 
BRCA1, RAD50, NBS1, which act as signals to activate downstream effectors of the DDR, 
such as XRCC4, Ku70-Ku80, RAD 51/52, and BRACA1/2, resulting in cell cycle arrest 
followed by repair or apoptosis if too much damage has occurred.182  
 
MiRNAs can influence and regulate the proteins involved in the DDR pathway, and DNA 
damage can induce the transcription of specific miRNAs. For example, the miR-34 family is 
induced by DNA damage in a p53-dependent manner, with ectopic miR-34a expression 
inducing cell cycle arrest and promoting apoptosis.183 ATM and ATR have been shown to 
be direct targets of miR-185, with miR-185 overexpression enhancing radiation-induced 
apoptosis via the ATR pathway.184  MiR-421 has also been shown to suppress ATM 
expression and ectopic expression resulted in S-phase cell cycle checkpoint deficiency and 
increased radiosensitivity. In addition, MYC transcription factor overexpression induced 
miR-421 expression, which in turn regulated ATM,185 and miR-24 overexpression 
downregulated histone H2AX resulting in increased sensitivity to irradiation secondary to 
reduced capacity to recruit proteins to repair DNA double strand breaks.186 
 
MiRNA microarrays have been used to show altered miRNA expression profiles before and 
after irradiation, particularly in genes involved in DNA repair, stress response and cell cycle 
control.187 In lung cancer cell lines the let-7 family of miRNAs, which is associated with poor 
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outcome in low levels, has been shown to be downregulated in response to irradiation. 
Overexpression of let-7 resulted in radiosensitivity and decreasing the levels caused 
radioresistance.188 MiR-521 levels were significantly decreased and miR-34c levels 
increased in prostate cancer cells in response to irradiation. MiR-521 overexpression 
sensitised the cells, whereas inhibition caused radioresistance by suppressing the 
expression of Cockayne syndrome protein A, a DNA repair protein.189 MiR-302 has been 
reported to be involved in radioresistance of breast cancer via the modulation of AKT1 and 
RAD52, and enforced expression sensitised resistant breast cancer cells in vitro and in 
vivo.190  
 
In HNSCC miRNA expression has been profiled after irradiation and miR-1284, which 
negatively regulates p53 TSG, has been found to be significantly upregulated.191 In oral 
cancer cell lines miR-1125b transfection resulted in decreased proliferation rate and 
enhanced radiosensitivity to high doses of irradiation.192 Gene expression has been profiled 
in radioresistant versus radiosensitive oral squamous cell carcinoma cell (SCC) lines, with 
different signatures being identified.193 Some of these genes have been shown to be 
downregulated in oral SCC transfected with miR-100, suggesting it is involved in radiation 
response.194 A recent study profiled miRNA expression of a large panel of radioresistant 
and radiosensitive HNSCC cell lines to identify a biomarker for intrinsic radioresistance. 
Low expression of epithelial-mesenchymal transition (EMT) inhibiting miRNAs, especially 
miR-203, were found to be important determinants of radioresistance, and induction of 
EMT reduced radiosensitivity.195 HNSCC samples from the Cancer Genome Atlas 
database was used to validate a five miRNA signature that can could predict radiation 
responsiveness, which correlated with the expression level of ATM.196 MiRNAs therefore 
have the potential to predict radiosensitivity/radioresistance and modulation can alter the 





 Hypoxia as a biomarker 1.5
Tissue hypoxia occurs when the oxygen level in tissues falls below physiological levels 
resulting from the inadequate supply of oxygen to meet demand.197 It arises in tumours due 
to the high metabolic demand of rapidly proliferating cancer cells and also due to disruption 
in the blood supply. Tumours develop aberrant and chaotic microvasculature, which are 
structurally immature and leaky, resulting in ineffective oxygen delivery.198 Fluid 
accumulation and increased tumour interstitial pressure restricts and compresses 
intratumoural blood vessels, further reducing the blood supply. Hypoxia is common in solid 
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tumours and is associated with poor prognosis. Hypoxia leads to increased risk of tumour 
progression, metastases, resistance to anti-cancer therapies and recurrence due of a wide 
range of hypoxia-related consequences, resulting in metabolic and genetic changes that 
promote an aggressive tumour phenotype.199 Hypoxia drives tumour progression by 
selecting clones that can best adapt to the stress of inadequate perfusion and nutrient 
deprivation, which then expand and develop into a more malignant phenotype.  
 
Hypoxia has been extensively investigated in HNSCC and the association with poor 
outcome is well known. However it is difficult to assess as intratumoural hypoxia is 
heterogeneous and dynamic, due to continuing tumour and vessel growth, and constant 
fluctuations in blood flow. Different biological effects are triggered at different levels of 
oxygen partial pressure (pO2) in tissues. There is no consensus for hypoxic thresholds in 
tumours but at pO2 < 25-30 mmHg radiosensitivity progressively decreases,197,200 and at 
pO2 < 10-15 mmHg changes in gene expression under the control of the hypoxia regulated 
transcription factor HIF-1 are demonstrated. At pO2 < 10 mmHg Vaupel et al201 
demonstrated intracellular acidosis and adenosine triphosphate (ATP) depletion in murine 
fibroblasts and this level represents a critical threshold for energy metabolism. There is also 
decreased protein synthesis and oxygen consumption to increase tolerance to hypoxia. At 
pO2 < 1 mmHg there is increased apoptosis, reduced oxidative phosphorylation and cells 
switch to glycolysis to maintain adequate energy levels. Lower levels of pO2 of 0.2-1 mmHg 




Hypoxia can be broadly divided into two basic types: chronic and acute. However there are 
no clear cutoffs between the two types and there are typically mixed heterogeneous 
patterns throughout the tumour. Chronic, or diffusion-limited hypoxia, was first described by 
Thomlinson and Gray in 1955, and is caused by consumption of oxygen by cells close to 
the blood vessels, leaving an inadequate supply of oxygen and nutrients to the cells further 
away from the vessels. A distance of approximately 180 µm from vascularised stroma was 
shown to be the diffusion distance of soluble oxygen.202 It can also be caused by reduced 
oxygen content in the blood, such as in anaemia, which may be caused by tumour-related 
factors as well as anti-cancer therapy or carboxyhaemoglobin formation in heavy smokers, 
and by compromised perfusion of leaky microvessels. Chronic hypoxia usually occurs after 
several hours to days of hypoxia, long enough to induce changes in gene expression.203 
Acute hypoxia, otherwise known as cycling, transient, intermittent, or perfusion-limited 
hypoxia, occurs as a result of fluctuations in the perfusion of tumour vasculature. This 
results in time periods of better or worse oxygenation of tumour areas. This type of hypoxia 
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may be ischaemic due to transient occlusion of blood flow by blood clots or tumour cells, or 
hypoxaemic due to transient reduction in the oxygen content within microvessels.204 Acute 
hypoxia may have greater effects than chronic hypoxia on the development of an invasive 
phenotype with hypoxia-reoxygenation episodes resulting in genomic instability, 
accelerated growth and metastases.205 
 
 
 Biological consequences 1.5.2
Tumour cells exposed to hypoxia activate many signalling pathways, which act in an 
integrated network affecting common downstream pathways and working together to 
ensure adaptation to overcome the lack of oxygen and nutrients. They induce changes 
such as angiogenesis, glycolysis, inhibition of apoptosis and downregulation of cell 
adhesion molecules resulting in tumour cell detachment, all of which lead to the 
development and selection of more aggressive clones of tumour cells.  
 
 Metabolism 1.5.2.1
Glucose is the main source of energy for cells and enters the cell through a family of 
glucose transporters (GLUT1 to 4). Energy in the form of ATP is generated under aerobic 
conditions via glycolysis or the tricarboxylic (TCA) cycle. During glycolysis glucose is 
metabolised to pyruvate in the cytosol to produce 2 ATPs from each molecule of glucose. 
Pyruvate enters the mitochondria and is oxidised by pyruvate dehydrogenase (PDH) to 
produce acetyl coenzyme A (CoA), which enters the TCA cycle. Acetyl CoA is metabolised 
through a series of reactions generating nicotinamide adenine dinucleotide hydrogen 
(NADH), a reducing agent used by the oxidative phosphorylation pathway in mitochondria. 
NADH passes electrons derived from the TCA cycle to the electron transport chain (ETC) in 
mitochondria, and combines with oxygen to produce water and a proton gradient that is 
used to generate 36 ATPs per glucose. In the mitochondria ETC, electrons transfer steps 
are cataylsed at Complex I (NADH dehydrogenase or ubiquinone oxidoreductase) and III 
(coenzyme Q or cytochrome c reductase) and is transferred to O2 at Complex IV 
(cytochrome c oxidase). Each step is coupled with proton translocation across the inner 
mitochondrial membrane, driving ATP synthesis at Complex V. Electrons can escape the 
ETC and be captured by O2, forming reactive oxygen species (ROS) and resulting in 
oxidative stress.206  
 
Under anaerobic conditions the lack of oxygen to act as the final electron acceptor at 
complex IV in the ETC prevents aerobic metabolism from progressing. Pyruvate is not used 
in the TCA cycle, but converted to lactate in the cytosol by lactate dehydrogenase (LDH) to 
regenerate nictotinamide adenine dinucleotide (NAD+) from reduced NADH, which is 
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required by glyceraldehyde-3-phosphate dehydrogenase (GAPDH) for additional cycles of 
glycolysis. PDH is phosphorylated and inactivated by pyruvate dehydrogenase kinase 
(PDK).207 Cancer cells have a high rate of glucose consumption even in the presence of 
oxygen, known as the Warburg effect or aerobic glycolysis.208 ATP production via 
glycolysis is much faster but less efficient and cancer cells avidly consume glucose to meet 
their increased energy and biosynthesis needs. A constant high rate of glycolysis in tumour 
cells uses up the NAD+ pool and glycolysis cannot be sustained unless NAD+ is 
regenerated, which is achieved by increasing lactate production. 
 
 
 Hypoxia-inducible factor-1 signalling pathway  1.5.2.2
Tumour cell responses to hypoxia are initiated through activation of the hypoxia inducible 
factor (HIF) family of transcription factors, the most important of which is HIF-1. HIF-1 is a 
heterodimeric protein consisting of an oxygen-regulated α subunit and a constitutively 
expressed oxygen-independent β subunit. Under conditions of normal oxygen HIF-1α is 
rapidly degraded by the Von Hippel Lindau (VHL) tumour suppressor protein via the 
ubiquitin-proteasome pathway. The α subunits of HIF are hydroxylated at conserved proline 
residues by propyl hydroxylase (PHD), which use oxygen as a co-substrate, resulting in 
recognition and ubiquitination by the VHL E3 ligase, labelling them for degradation by the 
proteasome. HIF-1α accumulation is also prevented under normoxia by factor inhibiting 
HIF-1 (FIH), which hydroxylates the transactivation domain of HIF-1α. This inhibits the 
binding of CREB binding protein (CBP) and p300 transcription co-factors to the HIF-1 
complex (Figure 1.3).209  
 
Hypoxia inhibits hydroxylation of HIF-1α by PHD and FIH, which results in stabilisation and 
accumulation of HIF-1α. HIF-1α translocates to the nucleus where it heterodimerises with 
constitutively expressed HIF-1β, and binds to the hypoxia-responsive elements (HREs) in 
the promotors of target genes. Genes that help overcome hypoxia, such as those involved 
in cell survival under oxidative stress, erythropoiesis, angiogenesis, glucose metabolism 
and pH regulation are upregulated, resulting in the upregulation of more than 100 proteins 
that promote survival and increased aggressiveness of hypoxic tumour cells.209 Vascular 
endothelial growth factor (VEGF) is upregulated by HIF-1α in hypoxia and is the strongest 
inducer of angiogenesis, stimulating the proliferation of endothelial cells and the formation 
of new blood vessels. VEGF also acts as a tumour cell survival factor, inhibiting cell 
apoptosis by inducing the anti-apoptotic protein Bcl-2.210  
 




Figure 1.3 HIF-1 activation pathway. 
 A) Under normoxia HIF-1α is hydroxylated by propyl hydroxylase and is degraded by VHL 
via the ubiquitin-proteosome pathway. B) Under hypoxia propyl hydroxylase and FIH are 
inhibited and HIF-1α is stabilised, allowing heterodimerisation with HIF-1β and subsequent 
binding to the hypoxia-responsive elements in target genes. This results in the upregulation 
of proteins that promote cell survival. HIF-1α can expression can also be upregulatd by 
EGFR and PI3K signaling pathways. Adapted from Rademaker 2008.200 
 
 
Under hypoxia HIF-1α mediates a switch from oxidative to glycolytic metabolism.207 HIF-1α 
activation affects cellular glucose metabolism by inducing the transcription of genes 
involved in increased glucose uptake, such as the glucose transporters GLUT1 and 
GLUT3, and stimulation of glycolytic enzymes that breakdown intracellular glucose. HIF-1α 
induces lactate dehydrogenase A (LDHA), increasing the conversion of pyruvate to lactate. 
In addition, HIF-1α activates pyruvate dehydrogenase kinase (PDK), which inactivates 
pyruvate dehydrogenase (PDH), actively shunting pyruvate away from the mitochondria. 
This reduces flux through the TCA cycle, reducing delivery of NADH to the ETC. 
Mitochondrial function is therefore reduced, decreasing oxygen demand in hypoxic cells. In 
addition HIF-1α induces BCL2/adenovirus E1B 19kDa interacting protein 3 (BNIP3) 
expression, which triggers mitochondrial autophagy, decreasing mitochondrial mass and 
oxygen consumption.206 HIF-1α also diverts pyruvate to be phosphorylated by hexokinase 
to glucose-6-phosphate, which is used in anabolic pathways such as the pentose 
phosphate pathway, by upregulating hexokinase. This pathway generates the precursors of 
nucleotides and amino acids required for the rapid tumour cell growth and proliferation. 
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is released into the cytosol where they inhibit PHDs, resulting in stabilisation of HIF-1α.211 
Glycolytic metabolism results in acidosis of the tumour microenvironment due to increased 
lactate and carbon dioxide levels, which are actively expelled from the tumour cells into the 
extracellular matrix. HIF-1α upregulates monocarboxylate transporter 4 (MCT4), which 
removes lactate from the cell, carbonic anhydrase 9 (CA9), which catalyses the conversion 
of carbon dioxide released during the pentose phosphate pathway to carbonic acid, and 
sodium-hydrogen exchanger (NHE1), which maintains an alkaline intracellular pH and 
acidic extracellular pH. Acidosis induces the secretion of matrix-degrading hyaluronidase 
and metalloproteinases by tumour-associated fibroblasts, creating a tumour 
microenvironment favourable for invasion and migration.212 In addition it reduces anti-
tumour immunity, inhibiting the activity of dendritic cells and T cells, and the efficacy of drug 
uptake by tumours, further driving tumour progression.213  
 
HIF-1α activation has many other downstream effects including the expression of several 
proteins important in epithelial-mesenchymal transition, preparing tumour cells for invasion 
and migration, such as SNAIL, SLUG, TWIST,214 and inhibition of E-cadherin.215 It has also 
been implicated in the regulation of cancer stem cells, through activation of NOTCH1, and 
tumour-mediated immune suppression through attenuation of T cell function.216 HIF-1α is 
also involved in the activation of tumour-associated inflammatory signalling in conjunction 
with nuclear factor-kappa B (NF-κB),217 which activates genes that promote cell 
proliferation and cell survival, and STAT3, which also works with HIF1α to activate 
VEGF.218 In addition miRNAs are also activated, with direct binding of HIF-1α to a HRE on 
the proximal miR-210 promotor.219  
 
Factors other than hypoxia can activate HIF-1α, such as pyruvate and lactate, indicating a 
positive feedback mechanism. HIF-1α expression can also be upregulated under conditions 
of normoxia, such as through activation of the receptors of the tyrosine kinase family 
including EGFR, activation of the PI3K-AKT-mTOR pathway, and genetic mutations 
including VHL inactivation, loss of PTEN and p53 tumour suppressors.220 
 
 
 mTOR signalling  1.5.2.3
mTOR activation results in stimulation of protein synthesis and cell growth. Mild to 
moderate hypoxia levels suppress mTOR through a HIF-1 independent pathway involving 
the activation of tuberous sclerosis protein 1(TSC1)-TSC2 complex via adenosine 
monophosphate-activated protein kinase (AMPK) or via transcriptional regulation of 
REDD1. mTOR is a principle regulator of autophagy under nutrient depleted conditions, 
which is regulated by BNIP3 and AMPK during hypoxia. In addition mTOR interacts with 
HIF-1α, promoting the rate of HIF-1α mRNA translation. In tumour cells hypoxia has been 
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shown to be less effective at inhibiting mTOR through mechanisms such as constitutive 




 The unfolded protein response (UPR) 1.5.2.4
Messenger RNA translation, post-translational modifications and protein folding takes place 
in the endoplasmic reticulum (ER). Under conditions of stress, such as severe hypoxia, 
misfolding of proteins occur which accumulate in the ER, resulting in ER stress. This 
activates the unfolded protein response, which aims to relieve this stress and increase cell 
survival by activating the ER stress sensors such as protein kinase R-like endoplasmic 
reticulum kinase (PERK). PERK activation results in inhibition of global mRNA translation 
and protein synthesis to reduce the load of misfolded proteins and lower energy demands. 
It also upregulates the expression of genes involved in resistance to oxidative stress and 
amino acid metabolism to promote cell survival, and enhances HIF-1α transcriptional 
activity. ER-associated degradation and autophagy occur to remove misfolded proteins, 
further reducing ER stress.222 ER stress also modulates the expression of VEGF, 
stimulating angiogenesis and promoting cell survival of rapidly growing cells. In addition 
VEGF signalling can activate the UPR in endothelial cells in the absence of ER stress via 
mTOR signalling, further promoting angiogenesis.223 The UPR is upregulated in tumours 
and is an important survival response in conditions of prolonged hypoxia, increasing the 
threshold for apoptosis. Tumours cells with abrogated PERK activity show significantly 
reduced clonogenic survival and decreased ability to tolerate moderate to extreme hypoxia, 




Several studies have demonstrated through genome-wide miRNA profiling that miRNA 
expression in tumour cells is altered in response to hypoxia.152,225-229 However due to 
differences in tumour cell lines, variations in exposure to hypoxia severity and duration, as 
well as differences in microarray hybridisation platforms resulting in different ranges of 
miRNAs screened, there has been limited overlap in the patterns of miRNA up- and 
downregulation. Next generation sequencing techniques have revealed a greater number 
of previously not identified miRNAs, highlighting the complexity of miRNA response to 
hypoxia.230 MiR-210, however, has been robustly and consistently induced by hypoxia, in 
both normal and cancer cells. It has also been shown to be overexpressed in a variety of 
solid tumours and patient plasma or serum, including HNSCC, where it is generally 
associated with poor clinical outcome.231,232 Under hypoxic conditions miR-210 is induced 
independently and directly by HIF-1α through interaction with its promotor sequence, and 
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targets genes involved cell cycle regulation, mitochondrial function, apoptosis, 
angiogenesis and metastases. MiR-210 promotes stabilisation of HIF-1α and inhibit PHDs 
preventing the degradation of HIF-1α.233  
 
 
 Clinical consequences in HNSCC 1.5.3
 Clinical studies using Eppendorf polarographic needle electrodes 1.5.3.1
Approximately 50-60% of human tumour contain hypoxic and/or anoxic tissue regions that 
are heterogeneously distributed within the tumour.234 Many clinical studies, mainly in 
HNSCC and cervix cancers, using Eppendorf polarographic needle electrode histography 
have directly demonstrated that tumour hypoxia predicts for decreased local control, 
increased disease recurrence and reduced overall survival. This technique involves 
inserting an electrode into multiple sites in a tumour and measuring the pO2 at several 
points per needle track and data from all tracks form a histogram. In head and neck 
cancers the pO2 measurements between the primary tumour and metastatic lymph nodes 
have shown little difference, and nodal measurements have been used to represent the 
hypoxic status of the patient.235 
 
In head and neck cancer, Gatenby et al236 in 1988 measured the oxygen tension in 31 
lymph node metastases from HNSCC patients, and demonstrated a significant relationship 
between low mean pO2 measurements and poor response to radiotherapy. The volume of 
tumour containing low oxygen levels was also found to be important. Nordsmark et al237 
measured the pretreatment oxygenation status initially in 34 lymph nodes and one primary 
using the Eppendorf polarographic needle electrode histography and evaluated the tumour 
oxygenation status as the percentage of pO2 values ≤ 2.5 mmHg (hypoxic fraction 2.5, 
HF2.5). The median HF2.5 of 15% was used to define hypoxia and these patients had 
significantly poorer locoregional control (LRC). This was confirmed by the same group in a 
further 35 patients.238 Brizel et al239,240 assessed 63 patients for pretreatment tumour 
oxygenation using the primary site or metastatic lymph node. A preliminary study had 
shown significantly worse disease free survival (DFS) at 12 months for patients with a 
median pO2 < 10 mmHg, and this was used to define hypoxic tumours. Whether the 
measurement was taken at the primary or nodal site did not affect the DFS and hypoxic 
tumours had significantly worse 3 year LRC, DFS and overall survival (OS), independent of 
tumour stage. However a small study of 25 patients did not find an association between 
pretreatment oxygen levels and LRC or OS.241  
 
Stadler et al242 identified the importance of the hypoxic subvolume, defined as the 
percentage of pO2 values < 5 mmHg multiplied by the total tumour volume. Fifty-nine 
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HNSCC primaries and nodes were assessed and the median pO2 was 16 mmHg, with no 
difference between the sites. On multivariate analysis the hypoxic subvolume and the HF5 
were significant prognostic factors for survival. This was confirmed in a further 125 patients, 
where hypoxic tumour volume was a strong and independent prognostic factor for 
survival.243 Rudat et al244 evaluated the repeatability and predictive value of pO2 
Eppendorph electrode histography in HNSCC. High variability was seen in patients who 
had 2 repeated independent measurement of the same tumour. In 41 patients with follow 
up data, locally advanced HNSCC the fraction of pO2 ≤ 2.5 mmHg was a significant 
prognostic factor for survival. 
 
A joint analysis of prospectively collected Eppendorf pO2 measurements from multiple 
centres was performed, which consisted of 397 patients with HNSCC.245 Median tumour 
pO2 was 9 mmHg and multivariate analysis demonstrated that HF2.5 greater than 
population median (19%) was associated with poorer OS at 3 years, providing strong 
evidence that tumour hypoxia has a significant role in HNSCC. Table.1.3 summaries the 
clinical data from HNSCC. 
 
Table.1.3 Summary of Eppendorf electrode histography studies in HNSCC. 
 
No. of patients Outcome Ref 
31 Mean pO2 20.6 mmHg in complete responders vs 4.7 mmHg in non-responders to radiotherapy. 
236 
35 Median pO2 14 mmHg.  Median HF2.5 > median (15%) significantly worse LRC. 
237 
31 Median pO2 12 mmHg, median HF2.5 30%. Median HF2.5 > median (15%) significantly worse LRC. 
238 
63 
Median pO2 4.8 mmHg for 24 primary sites.  
Median pO2 4.3 mmHg for 39 nodes. 
Median pO2 < 10 mmHg significantly worse LRC, DFS, OS. 
239,240 
41 Median pO2 10 mmHg. HF2.5 > median (21%) worse OS. 
244 
397 
Joint analysis of prospectively collected data in HNSCC. 
Median tumour pO2 9 mmHg. 
HP2.5 > median (19%) associated with poorer OS. 
245 
25 Mean pO2 20.2 mmHg. No prognostic impact on outcome. 
241 
59 
Median pO2 16mmHg. 
Hypoxic subvolume > 6 cm3, HF5 > median (30%) worse 
overall survival. 
242 




 Resistance to radiotherapy 1.5.3.2
Radiosensitvity rapidly decreases when the pO2 in a tumour is less than 25 to 30 mmHg.197 
In 1953 Gray et al246 determined the radiation dose required to achieve the same biological 
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effect is 2.8 to 3 times higher in the absence of oxygen. When ionising radiation is 
absorbed in tissue, free radicals are produced as a result of ionisations either directly in the 
DNA itself, or indirectly in other molecules such as water. Free radicals break chemical 
bonds and initiate a chain of events that result in DNA damage. Oxygen molecules are able 
to react with the free radicals and create a stable change in the chemical composition of 
the DNA damage. Oxygen therefore enhances the damage by “fixing” or making the 
damage permanent. In the absence of oxygen the target is chemically restored and the 
damage is repaired. In order for oxygen to consolidate radiation-induced damage it needs 
to be present at the time of irradiation or within a few milliseconds.247 Other hypoxia-
induced mechanisms also contribute to radioresistance including glycolytic metabolism and 
lactate accumulation, which act as antioxidants and scavenge free radicals.248,249  
 
The changes in hypoxia heterogeneity during a course of fractionated RT can affect the 
response. During the early stages of treatment cell density decreases as the well-
oxygenated tumour cells are killed. This results in reduced intratumoural pressure and 
increased vascular density leading to tumour reoxygenation.250 This reoxygenation does 
not increase HIF-1α degradation, but the increase in ROS formation stabilises HIF-1α and 
increases the expression in a hypoxia-independent manner.251 This, together with 
accelerated repopulation that occurs at the later stages of RT, means that the entire 
cumulative dose of RT needs to be delivered. 
 
 
 Resistance to chemotherapy 1.5.3.3
Some chemotherapeutic agents, such as etoposide, are dependent on the presence of 
oxygen for maximum cytotoxic effect.252 The disordered and leaky blood vessels in hypoxic 
tumours prevent efficient delivery of chemotherapy drugs. Hypoxic cells are distant from 
blood vessels and therefore not adequately exposed to drugs.253 Alkylating agents, such as 
cisplatin, and anti-metabolites, such as 5-FU, act during DNA synthesis by damaging DNA 
and initiating apoptosis. Cellular proliferation and DNA synthesis decreases as a function of 
distance from blood vessels and hypoxia selects for cells that have lost sensitivity to p53 
mediated apoptosis, reducing the cytotoxic effect. Hypoxia upregulates genes involved in 
drug resistance, such as multidrug resistance 1 (MDR1) leading to the increased 
expression of P-glycoprotein, which is associated with tumour resistance to 
chemotherapeutics.254 The acidic tumour microenvironment creates a pH gradient between 
the tumour cell and extracellular space, inhibiting the accumulation of drugs that are weak 
bases, such as doxorubicin.255 
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 Therapeutic approaches to overcome hypoxia radioresistance in HNSCC 1.5.3.4
Hypoxia represents a potential target for therapy. Various strategies have been used to 
overcome hypoxia in HNSCC, summarised in Table.1.4. A meta-analysis of 32 clinical trials 
of various strategies of hypoxic modification demonstrated a small but significant 
improvement in LRC, disease specific survival (DSS) and OS in HNSCC treated with 
primary RT.256 Hypoxia stratification is required to identify patients at risk of treatment 
failure but also patients with normoxic tumours, who do not gain benefit from additional 
treatment, who can avoid any additional toxicity. 
 




Increasing oxygen availability 
Hyperbaric oxygen 
ARCON 
Blood transfusion, erythropoeitn 
Radiosensitisers Nimorazole 
Hypoxia cytotoxin Tirapazamine 
Increasing radiotherapy dose Dose painting 
Other 





Improving haemoglobin (Hb) levels 
Many studies have demonstrated that low haemoglobin level prior to treatment associated 
with significant reduction in survival and increase in locoregional failure in HNSCC after RT 
or CRT.257,258 Over 1000 patients pooled from 2 studies demonstrated that high Hb was 
significantly associated with higher OS and the administration of blood during therapy 
increased Hb level. However blood transfusions had no impact on LRC, DSS or OS.259 
Exogenous erythropoietin administration to stimulate red blood cell production and correct 
anaemia has been investigated. However this did not improve tumour control or survival as 
demonstrated in 2 meta-analyses, but suggested an increase in mortality.77,260 
 
Increasing oxygen availability 
Hyperbaric oxygen is the administration of 100% oxygen at higher than normal atmospheric 
pressure. This elevated pressure results in increased pO2 in tissues and has been 
delivered in hyperbaric oxygen chambers with RT. This strategy has been shown to 
significantly improve tumour control and mortality, but also causes an increased rate of 
severe radiation tissue injury and chance of oxygen toxic seizures during therapy.261  
 
Carbogen (95% oxygen and 5% carbon dioxide) breathing before RT did not improve 
tumour control,262 but combined with accelerated radiotherapy and nicotinamide (ARCON, 
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accelerated radiotherapy with carbogen and nicotinamide) has been shown to result in high 
LRC in advanced larynx and oropharynx SCC.263 This combination aims to limit clonogenic 
repopulation during therapy by reducing the overall duration of RT by delivering more than 
one fraction a day, decrease diffusion-limited hypoxia with inhalation of carbogen, and 
decrease perfusion-limited hypoxia by administering nicotinamide, a vasoactive vitamin B6 
analogue. A more recent study compared accelerated RT with ARCON in larynx SCC and 
did not demonstrate a benefit. However a subgroup of patients had their hypoxic status 
assessed with pimonidazole IHC, which stains regions of hypoxia, and significant 
improvement in regional control and DFS was found in the high pimonidazole staining 
group treated with ARCON.264 
 
Radiosensitisers 
Cellular sensitivity to RT can be improved by increasing the apparent cellular pO2 levels 
using radiosensitisers. Nitromidazoles are chemical compounds that mimic the 
radiosensitising effect of oxygen by inducing and stabilsing free-radical mediated double-
stranded DNA breaks. The benefit of the addition of a nitroimidazole compound to RT was 
carried out in many studies, without clinical benefit.265,266 However these studies used the 
older generation of the drug which is limited by neurotoxicity. Overgaard et al267 carried out 
a meta-analysis of over 7000 patients treated with nitroimidazole-based radiosensitisers in 
various tumour types of unknown hypoxia status and found an improvement in LRC and 
OS, with the greatest benefit in HNSCC. This was followed by the DAHANCA 5 study which 
randomized over 400 HNSCC patients to receive RT with nimorazole or RT with placebo. 
LRC and DSS were significantly higher with the addition of nimorazole.268 A phase II study 
investigated accelerated RT with nimorazole and cisplatin in 227 patients with locally 
advanced HNSCC and recently reported a high 5-year OS of 75%.269  
 
Hypoxic cytotoxins 
This group of drugs, of which tirapazamine is the most widely investigated, have a direct 
cytotoxic effect on hypoxic cells. Tirapazamine (TPZ) is a prodrug that requires one-
electron reduction to a radical by intracellular reductases. In normoxia the unpaired 
electron in the radical is rapidly transferred to molecular oxygen, forming superoxide and 
regenerating the initial prodrug. In hypoxic conditions the radical accumulates and induces 
DNA damage, in part due to poisoning of topoisomerase II.270 
 
TPZ combined with cisplatin and RT in HNSCC has shown to be well tolerated in phase I 
and II studies.271,272 Rischin et al carried out a phase II randomised trial of this combination 
versus cisplatin and RT and demonstrated a trend towards improved 3-year survival with 
acceptable toxicity.273 However, further studies have not shown a benefit in survival or 
Chapter 1  Hypoxia as a biomarker 
 52 
quality of life from the addition of TPZ.274 Rischin et al also carried out a substudy of 45 
patients who had their tumour hypoxic status assessed by 18F-fluoromisonidazole, a 
hypoxic radiotracer, PET scans. Hypoxic patients performed poorly in the absence of TPZ 
augmentation, whereas the rate of complete response in the hypoxic group receiving TPZ 
was nearly as high as the rate for normoxic chemoRT patient. Patients with hypoxic 
tumours were more likely to develop distant metastatic disease compared with normoxic 
patients.275 
 
Hypoxia image-guided radiotherapy 
Intensity modulated radiotherapy (IMRT) is used in the treatment of HNSCC. The intensity 
of the radiation beam can be modulated to reduce doses to normal structures without 
compromising the doses to the tumour. Tumour recurrence after compete response to 
radiotherapy has been shown to occur predominantly in high radiation dose regions, 
implying that tumours have radioresistant subvolumes, potentially due to hypoxia, within 
this region.276 IMRT dose painting is a method of assigning different dose levels to 
structures within the same treatment fraction, resulting in the potential for higher total doses 
to selected targets.277 Dose painting requires functional imaging such as positron emission 
tomography to direct regions for dose escalation. Intensification of intratumoural 
subvolumes of hypoxia has been investigated as a strategy to improve outcome in RT 
planning studies and radiobiological modelling studies only, as this requires accurate and 
stable identification of hypoxia to guide target volume delineation. 
 
Targeting angiogenesis 
High VEGF expression levels has been associated with worse overall survival in 
HNSCC.278 As tumour vasculature is abnormal, increased VEGF expression and 
microvascular density does not lead to increased blood flow and oxygen delivery. Targeting 
VEGF is a strategy to improve oxygenation by normalising the tumour vasculature and 
thereby increase response to RT. RT can lead to stimulation of angiogenesis through 
upregulation of VEGR and therefore anti-angiogenic therapy has been tested with RT.279 
Bevacizumab is a humanised monoclonal antibody against VEGF approved for use in 
colorectal cancer, and has been investigated in phase II studies concomitant with 
chemoRT in HNSCC with encouraging results.280 It inhibits endothelial cell growth and 
function, disrupting the formation of capillary networks, and has been shown to enhance 
RT response in HNSCC xenograft models.281 Anti-angiogenic agents can improve tumour 
oxygenation by reducing the number of oxygen consuming endothelial and tumour cells, 
and the number of inefficient blood vessels. This also results in less leaky vessels and 
decreased interstitial pressure, improving perfusion.282 
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Targeting HIF-1 
Targeting HIF-1 is an attractive therapeutic strategy to overcome the effects of hypoxia. 
Drugs that inhibit HIF-1 activity are already in clinical use, such as the topoisomerase I 
inhibitor topotecan and mTOR inhibitors which decrease HIF-1 synthesis, the anthracycline 
doxorubicin which suppresses HIF-1 DNA binding, and the proteasome inhibitor 
bortezomib, which reduces HIF-1 transactivation.283 Newer drugs have been developed, 
such as PX-478 that inhibits HIF-1 by inhibiting HIF-1 mRNA translation and HIF-1 
dequbiquitination and is being investigated in a phase I trial. In HNSCC tumour models this 
drug provided significant radiosensitisation of hypoxic cell lines and xenograft tumours.284  
 
 
 Other methods to detect hypoxia in HNSCC 1.5.4
Accurately detecting and quantifying hypoxic tumours is essential in identifying patients 
who have aggressive, treatment resistant disease and has been one of the limiting factors 
for translating hypoxia-modification strategies into routine practice. The use of Eppendorf 
oxygen electrode histography has been crucial to demonstrate the adverse effects of 
hypoxia on outcome in the clinical setting. It has the advantage of directly measuring 
absolute pO2 values and has prognostic potential. However it has not been incorporated 
into routine clinical practice as it is an invasive procedure restricted to accessible tumours. 
It also requires an experiences operator but still exhibits large inter-observer variability,285 
and only provides information on the areas sampled. In addition it cannot differentiate 
between tumour and normal tissues.234 Other methods that have been investigated are 
summarised in Table.1.5. 
 
Table.1.5 Summary of methods used to detect hypoxia. 
 
Method Example 
Direct detection Eppendorf oxygen electrode histography 
Exogenous markers 2-nitroimidazole – pimonidazole, EF5 
Endogenous markers  
     Tumour protein levels 
     Circulating markers 
     Gene expression signatures 
 
HIF-α1, CA9, osteopontin 
Osteopontin, miR-210 
Hypoxia metagene, 15-gene classifier 
 
Non-invasive imaging 
DCE MRI, BOLD MRI 




 Exogenous markers of hypoxia 1.5.4.1
The most commonly used exogenous markers of hypoxia are 2-nitroimidazole compounds 
such as pimonidazole and pentafluorinated etanidazole (EF5).286,287 They are irreversibly 
bioreduced by cellular nitroreductases and bind to thiol-containing proteins in viable 
hypoxic cells, forming stable adducts.288 These adducts can then be detected by IHC 
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staining with specific antibodies. IHC staining can quantify hypoxia by visually or digitally 
estimating the fraction of stained cells and provides hypoxic measurements with high 
spatial resolution. Binding is commonly seen adjacent to regions of necrosis and at a 
distance from blood vessels, in keeping with diffusion-limited hypoxia.286 
 
2-nitroimidazoles bind to tissue at a pO2 level of < 10 mmHg and are more sensitive at 
lower pO2 levels than microelectrodes.289 The amount of bound marker is dependent on 
oxygen, the accumulation rate of individual hypoxic cells and intact nitroreductase enzymes 
in viable hypoxic cells.290 Differences in the activity of the enzymes can affect level 
detected and the accumulation rate of pimonidazole is dependent on pH.291 The main 
disadvantage to exogenous markers of hypoxia is that they have to be administered 
intravenously prior to tissue biopsy or surgical resection, to allow fixation of the adducts 
that form in hypoxic regions. Pimonidazole binding has shown good correlation with 
Eppendorf electrode measurements in mouse models,289 but not in the clinical setting in 
cervix cancers.292 Neither pimonidazole or Eppendorf electrode pO2 were prognostic for 
outcome in 127 cervix cancer patients.293  
 
The prognostic value of 2-nitroimidazoles has been shown in HNSCC. High pimonidazole 
binding in 43 biopsies was significantly associated with LRC and DFS at 2 years. This 
association was lost in the subgroup treated with ARCON, suggesting a predictive role for 
pimonidazole.294 Pretreatment hypoxia using EF5 binding was investigated in 22 HNSCC 
patients and severe hypoxia, defined as maximum 30% EF5 binding which approximated to 
a pO2 of 0.76 mmHg, was associated with shorter event free survival at 3 years.295  
 
 
 Endogenous markers of hypoxia 1.5.4.2
Endogenous markers are genes or gene products that are specifically upregulated under 
hypoxic conditions and can be measured in tumour specimens. HIF-1α, GLUT1 and 3, CA9 
and osteopontin are detected by immunohistochemistry and can be assessed on formalin 
fixed paraffin embedded (FFPE) archival material, allowing correlation with outcomes. 
However the techniques of tissue processing and staining analysis have not been validated 
between different laboratories, limiting comparisons and clinical applications. Samples are 
usually from small biopsy specimens and therefore not representative of the hypoxia 
heterogeneity of entire tumour. In addition their expression may be affected by the type of 
hypoxia, for example HIF-1α is induced and repressed rapidly and reflect acute changes in 
hypoxia, whereas CA9 is slow to accumulate.296 In general, studies using these markers 
show conflicting results, and the association between these markers and oxygen status of 
tissue is weak. 
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HIF-1α 
HIF-1α is overexpressed in a wide variety of tumours. In HNSCC many studies have 
demonstrated an association with poor survival and poor response to chemoRT,297,298 and 
has been found to be an independent prognostic factor in HNSCC. However there are also 
studies that show no association with prognosis,299,300 and in one study in a surgically 
resected cohort of HNSCCs, HIF-1α expression was associated with significantly better 
DFS and OS.301  
 
Glucose transporters (GLUT) 
These glucose transporters are present in normal tissue but upregulated in tumours due to 
increased glucose requirements in anaerobic glycolysis.302 In HNSCC GLUT-1 has been 
associated with poor treatment outcome in multiple retrospective series.303,304 In 58 patients 
treated with ARCON GLUT-1 was associated with an increased rate of distant metastasis 
and worse OS but GLUT-3 was associated with better LRC.305 Co-expression of HIF-1α 
and GLTU-1 significantly correlated with an increased risk of tumour-related death.306 
 
Carbonic anhydrase 9 (CA9) 
CA9 is a transmembrane enzyme and a downstream target of HIF-1. It catalyses the 
reversible hydration of carbon dioxide to carbonic acid and is involved in pH regulation. 
Elevated expression has been demonstrated at pO2 < 20 mmHg.307  Overexpression of 
CA9 has been found in different types of cancer including HNSCC but shows conflicting 
results as a prognostic marker. Strong CA9 expression was found to be related to poor 
complete response rate after treatment with chemoRT,308 but positivity was associated with 
better LRC and freedom from distant metastases in 58 patients treated with ARCON,305 or 
no association with LRC.309 In the DAHANCA 5 study patients 320 samples were available 
for CA9 staining and the expression of CA9 did not correlate with any of the tumour or 
patient characteristics, was not a prognostic marker and did not correlate with nimorazole 
treatment.310  
 
Osteopontin (OPN) in tissue and plasma 
OPN is an extracellular matrix-associated integrin-binding glycoprotein induced by hypoxia, 
initially identified in non-collagenous bone matrix. Binding of OPN to cell surface receptors 
on tumour cells activates integrins and matrix metalloprotein signalling pathways, 
increasing the risk of tumour invasion and migration.311 It is also involved in angiogenesis, 
promotes cell survival through PI3K/AKT and JAK/STAS3 signalling and regulation of NF-
κB. It is upregulated through AKT activation, independent of HIF-1 under hypoxia.312 High 
OPN levels in both tissue and plasma have been correlated with low tumour pO2 in HNSCC 
and outcome.309 A retrospective study of the DAHANCA 5 trial patients demonstrated that 
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high OPN plasma levels was associated with higher locoregional tumour failure and 
disease specific mortality.313 Patients with high OPN levels who received nimorazole had 
better outcomes compared with patients with high OPN levels who did not receive 
nimorazole, whereas no effect was seen in the low/intermediate OPN group. Lim et al314 
investigated the predictive potential of OPN in patients who received tirapazamine but did 
not find that high levels were associated with poor prognosis and found no interaction 
between OPN and treatment. The difference in results compared with the DAHANCA study 
may be due to differences in treatment protocols, but also lack of standardisation for OPN 
thresholds between the studies. 
 
Gene expression signatures of hypoxia  
As hypoxia influences many biological pathways, a single marker is incapable of 
adequately describing this complex heterogeneous response. To improve hypoxia 
specificity combining several markers in gene expression signatures of hypoxia has been 
investigated. Different methods have been used to derive clinically applicable hypoxic gene 
signatures and are summarised in Table 1.6. 
 
In vitro derived gene sets have been described by culturing tumour cell lines under 
normoxic and hypoxic conditions, then assessing the differences in gene expression. 
Koong et al315 used FaDu HNSCC and SiHa cervical SCC cell lines to identify 9 genes 
exhibiting greater than 3-fold induction under hypoxic conditions when using the expression 
of VEGF as a cut off point for assessing hypoxia-induced genes. An 84 upregulated gene 
signature was generated by culturing normal and transformed keratinocytes at various 
different oxygen levels, which could be grouped into 6 functional groups, including as 
metabolism/transport, angiogenesis, tissue remodelling, apoptosis, 
proliferation/differentiation and gene expression.316  
 
Chi et al317 evaluated the gene expression in response to hypoxia in several primary cell 
lines in vitro using cDNA microarrays and found a wide variation in the response between 
cell and tissue types. However a 253 gene signature was identified which were concordant 
with gene expression data from a distinct subset of renal tumours, allowing classification by 
hierarchical clustering into 2 groups with high or low expression of the hypoxia response 
genes. The high expression group consisted of clear cell renal carcinomas, which typically 
have loss of function al VHL proteins, and the low group were other histological subtypes or 
normal samples. Similar classification grouped breast cancers in to ductal 
adenocarcinomas (high expression) and fibroadenomas or normal samples (low 
expression). In addition the gene signature was a strong predictor of clinical outcome in 
independent breast and ovarian cancer datasets.  
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Table 1.6 Summary of hypoxia gene expression signatures. 
 
Source of signature No. of genes in signature Prognostic validation Ref 
FaDu, SiHa cell lines in vitro under 
hypoxia and normoxia 
 
9  No  315 
Normal cervical and dermal 
keratinocytes, normal stromal 
fibroblasts, SiHa, C33a, FaDu cells 
 
84 No 316 
Mammary and renal tubular epithelial 
cell lines under hypoxia or normoxia 
for 12 hours 
253 
2 breast cancer, 1 ovarian cancer 
datasets – prognostic for OS and RFS 
on univariate analysis; breast dataset - 




Mammary epithelial cell line under 




Early signature prognostic for DSS in 
breast cancer dataset on univariate 




59 HNSCC biopsy specimens 




Independent prognostic factor in head 
and neck for RFS and breast for OS 
and metastasis free survival 
 
112 
In silico generation of hypoxia co-
expression networks using 3 head 





Prognostic in breast, 2 lung, head and 
neck datasets 
319 
FaDu, UTSCC5, UTSCC 14, 
UTSCC15 cell lines under hypoxia 
and either normal or acidic pH 
 
27 No 320 
UTSCC33 , FaDu and SiHa tumour 
xenografts - hypoxic regions identified 
using FAZA hypoxia tracer; 58 
HNSCC fresh frozen biopsies with 
oxygen electrode measurements 
 
15 
FFPE samples from DAHANCA5 trial – 
independent prognostic factor; more 
hypoxic tumours treated with 
nimorazole had reduced incidence of 
locoregional failure. 
321 
DU145, HT29, MCF7 cell lines 
exposed to normoxia and different 
times of severe hypoxia 
 
7 temporal and 
2 general 
signatures 
Not prognostic in breast cancer dataset 322  
 
 
Human mammary epithelial cells were cultured under hypoxic conditions at early and late 
time points to assess the time dependency of hypoxia-regulated gene expression.318 The 
early response gene signature was characterised by genes related to growth, apoptosis, 
insulin and oestrogen receptor signalling, whereas the late response was characterised by 
genes involved in angiogenesis, glucose transport, proliferation, metastasis and apoptosis, 
and were similar to the genes identified by Chi et al. The early but not late signature was 
prognostic in univariate analysis, but not maintained in multivariate analysis in a breast 
cancer dataset. Sorensen et al320 exposed 4 head and neck cell lines to different oxygen 
concentrations at normal or low pH, and analysed the gene expression to identify genes 
upregulated by hypoxia, independent of pH. Hypoxia induced pH independent genes were 
selected if they were common in 3 of the 4 head and neck cell lines, resulting in a 27 gene 
signature. 
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Winter et al112 developed a hypoxia metagene from 59 HNSCC fresh frozen samples by 
clustering around the mRNA expression of 10 well-known hypoxia-regulated genes, such 
as CA9, GLUT1 and VEGF. Strongly correlated upregulated genes appearing in > 50% of 
clusters defined a signature comprising of 99 genes, which was found to be an 
independent prognostic factor for recurrence free survival (RFS) in an independent head 
and neck cancer and breast cancer dataset. The same group derived a common hypoxia 
metagene consisting of 51 genes by selecting genes that were consistently co-expressed 
with previously validated hypoxia-regulated genes.319 By applying more training sets and 
co-expression networks a reduced metagene had prognostic significance in 4 independent 
datasets of breast, lung and head and neck cancers, and outperformed larger published 
signatures. The top 26 genes from this signature were retrospectively assessed in FFPE 
samples from laryngeal and bladder cancer patients treated with ARCON or CON 
(carbogen and nicotinamide) respectively.323 Tumours were categorised into high and low 
hypoxia groups, and laryngeal tumours in the high hypoxia group showed greater benefit 
from ARCON than the low hypoxia group. The hypoxia signature did not predict benefit 
from CON in bladder cancer.  
 
In contrast to previous studies on hypoxia gene expression, Toustrup et al321 developed a 
classifier based on the hypoxic status of tumours. The hypoxia induced pH independent 
gene profile developed by Sorensen et al was validated in vivo in a xenograft study using 
18F-FAZA as an exogenous hypoxia radiotracer in autoradiographic studies. Hypoxic, non-
hypoxic and mixed heterogeneous tumour areas defined by 18F-FAZA positive and 
negative regions were demarcated and dissected. All the genes investigated were 
significantly upregulated in hypoxic tumour areas compared with non-hypoxic areas, and all 
but 3 were upregulated in samples from mixed heterogenous versus non-hypoxic areas. To 
identify the most informative genes, a training set of 58 hypoxia-evaluated HNSCC FFPE 
biopsies were analysed for gene expression. The oxygenation status of these tumours had 
previously been evaluated in accordance to the relative number of oxygen electrode 
measurements less than 2.5 mmHg in their metastatic cervical lymph nodes. A 15-gene 
expression classifier was generated containing 15 of the in vitro identified hypoxia-
responsive genes, which could best discriminate between ‘more’ and ‘less’ hypoxic human 
HNSCCs. This was evaluated in an independent data set, where patients with HNSCC 
were randomised to receive either hypoxic modification with nimorazole or placebo 
concomitant with radiotherapy. Patients with ‘more’ hypoxic tumours defined by the 
classifier had significantly higher cumulative incidence of locoregional failure at 5 years 
compared with those with less hypoxic tumours. Within the ‘more’ hypoxic group, patients 
treated with nimorazole had significantly reduced incidence of failure compared with 
placebo, whereas in the ‘less’ hypoxic group there was no significant difference in outcome, 
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suggesting the classifier potentially has predictive value. Further subgroup analysis 
demonstrated that this benefit was only found in HPV-negative ‘more’ hypoxic tumours and 
not HPV-positive, whose outcome was unaffected by hypoxic modification.324 The same 
frequencies of ‘more’ and ‘less’ hypoxic tumours were in HPV-negative and positive groups 
as assessed by the classifier. More recently the classifier was used to assess 55 patients 
recruited in a randomised trial of accelerated RT with or without nimorazole.325 RT alone in 
16 patients with ‘more’ hypoxic tumours was associated with higher locoregional tumour 
failure. 
 
Further investigation into the time dependent gene expression changes in response to 
hypoxia has been carried out using prostate, colon and breast cancer cell lines exposed to 
hypoxia at 8 different time points between 0 and 24 hours.322 Seven different signatures 
consisting of induced genes with distinct temporal profiles and 2 general hypoxia 
signatures were generated, but none were prognostic in a large breast cancer cohort. In 
contrast previously published in vivo derived signatures showed clear prognostic power, 
suggesting the importance of the tumour microenvironment in the response to hypoxia.  
 
Classification of hypoxia gene expression has the potential to represent prognostic and 
predictive markers in cancer and has been demonstrated retrospectively to be applicable to 
unselected FFPE biopsy samples, and therefore translatable into clinical practice. However 
the 2 smaller gene signatures (15 and 26 gene signatures) which have demonstrated 
predictive value, have only 4 genes that overlap, suggesting that this method alone may 
not identify all hypoxic tumours. Prospective validation in clinical studies is required before 
further conclusions can be made. 
 
 
 Magnetic resonance imaging (MRI) 1.5.4.3
 
Dynamic contrast-enhanced MRI (DCE MRI) 
In this technique fast repeated images are acquired before, during and after the rapid 
administration of a small hydrophilic gadolinium-based contrast agent, which diffuses 
through blood vessel walls and distributes into the extracellular space. The change in 
signal intensity reflects tumour perfusion, vessel permeability and the volume of 
extracellular space.326 It does not correlate directly with tissue pO2 levels but a small study 
in HNSCC found positive correlation between imaging parameters of poor perfusion and 
pimonidazole staining,327 and with hypoxia defined by 18F-fluoromisonidazole PET uptake 
in nodal metastases.328 
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Blood oxygen level-dependent MRI (BOLD MRI)  
This is an indirect measure of visualising pO2 in blood vessels and surrounding tissue 
based on the paramagnetic properties of deoxyhaemoglobin, which is related to tissue 
oxygenation. It does not provide quantitative information on oxygen concentration and the 
signal can be influenced by many factors such as blood flow and pH. However studies 
have shown correlation between this technique and polargraphic electrode pO2 
measurements and pimonidazole staining in prostate cancer, suggesting BOLD MRI may 
provide complementary information related to tissue oxygenation.329  
 
 
 Positron emission tomography (PET)  1.5.4.4
Several hypoxia-specific PET radiotracers have been developed and extensively 
investigated as it is a potentially useful non-invasive technique for identification, 
quantification of hypoxia and repeated measurements after intervention. The metabolic 
activity demonstrated by 18F-FDG uptake is indirectly related to the proliferative activity and 
oxygenation status of tumours, but cannot reliably distinguish hypoxic tumours. A good 
hypoxia tracer should be able to detect pO2 levels that are clinically relevant to therapy, and 
be able to distinguish between normoxia, hypoxia, anoxia and necrosis. The molecule 
should be small and lipophilic making it highly membrane permeable leading to rapid 
uptake into cells and rapid clearance from normoxic cells to allow a high tumour to 
background contrast. It should also have a good dosimetry profile with simple radiolabelling 
and production, and low radiation dose to the patient. Two main classes of hypoxia imaging 
radiotracers are in available in the clinical trial setting: one based on the nitroimidazole 
compounds and one based on a complex of copper with diacetyl-bis(N4-
methylsemicarbazone) (ATSM) ligands (section 1.6). A meta-analysis of published hypoxia 
imaging studies, which included PET and other imaging modalities of hypoxia, showed a 
uniform tendency for poor response to radiotherapy in tumours showing a higher uptake 
despite the heterogeneity of the image acquisition, data analysis and treatments.330  
 
2-Nitroimidazole-based hypoxia tracers 
18 F-fluoromisonidazole (18F-FMISO) 
18F-FMISO is a derivative of the nitroimidazole group of compounds and is the most widely 
studied hypoxic radiotracer. It is moderately lipophilic and enters cells by passive diffusion 
across the cell membrane. The nitro group of the imidazole ring structure (R-NO2) is 
reduced by intracellular reductases to R-NO2-, which is reoxidised in the presence of 
oxygen and the tracer can flow back into the extracellular compartment. In conditions of 
hypoxia R-NO2- can be further reduced with progressive production of R-NH2 compounds 
that bind covalently to intracellular molecules and the tracer becomes trapped. This occurs 
at pO2 < 10 mmHg and therefore 18F-FMISO detects clinically relevant hypoxia. The 
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process requires viable cells with functional nitroreductases and the tracer does not 
accumulate in necrotic cells.331 The bioreductants involved in the mechanism is not clear 
but cytochrome P450, NADPH and xanthine oxidoreductase are implicated.332,333  
 
18F-FMISO distributes nearly equally between lipophilic tissues and hydrophilic blood and 
normoxic tissues show a tissue to blood ratio of almost 1.0. The optimal quantification of 
hypoxia is at 2-4 hours post-injection of tracer when normal tissues have equilibrated with 
plasma and hypoxic tissue continues to have selective retention. However even after this 
long uptake period tracer accumulation is still low with tumour to blood ratios of 1.2-1.4 
indicative of hypoxia.334,335 The tumour to blood ratio calculation increases the image 
contrast, compared with tumour to background muscle ratios, but requires a venous blood 
sample in the middle of the scan. The optimal timing is not entirely clear as a recent study 
in a preclinical tumour model demonstrated the tumour to blood ratio continued to increase 
up to 6 hours post-injection.336 18F-FMISO is metabolised by the liver and excreted through 
the kidney and bladder and results in low radiation exposure compared with other 
radiopharmaceuticals.337   
 
Clinical studies of 18F-FMISO in HNSCC 
Direct pO2 measurements with polarographic electrodes in HNSCC patients showed 
greater 18F-FMISO retention in hypoxic tumours, with a strong correlation between uptake 
and pO2 ≤ 5 mmHg338 or HF2.5 and HF5,339 but not with 18F-FDG.  However no correlation 
in HNSCC has also been reported340 Rajendran et al341 reported the largest study 18F-
FMISO, which involved 73 patients with HNSCC. Uptake was seen in 85% of patients and 
tumour to blood ratio and hypoxic volume showed a trend to be an independent prognostic 
measure. Rischin et al275 demonstrated that pretreatment 18F-FMISO was effective in 
determining hypoxic regions and tirapazamine was effective in patients with hypoxic 
tumours as assessed by 18F-FMISO. Another group found that an SUV > 2 and tumour to 
muscle ratio (TMR) > 1.6 at 4 hours after injection were associated with disease recurrence 
after RT.342 The same group also investigated the changes in 18F-FMISO uptake during RT 
by performing a scan pretreatment and repeating at 30 Gy. The mean SUV and TMR 
significantly decreased during RT, indicating RT-induced reoxygenation. Lee et al343 also 
performed a baseline and midtreatment scan and found 90% of 20 patients had hypoxia 
before treatment and only 2 had detectable hypoxia on their midtreatment scan, which did 
not correlate with outcome. Zips et al344 carried out a baseline scan and 3 further scans 
during RT. The imaging parameters from scans at week 1 and 2 of RT strongly correlated 
with progression free survival, suggesting the prognostic value of imaging hypoxia at the 
start of RT rather than at baseline. Smaller studies have showed variable results, with 18F-
FMISO showing borderline significance for stratifying patients into treatment outcome 
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groups in 12 patients, and high SUVmax but not TMR correlating with poor DSS after RT or 
surgery in 17 patients.345  
 
18F-FMISO imaging has been used to assess the feasibility of hypoxia image-guided dose 
escalation. An additional 10 Gy to the hypoxic subvolume in HNSCC was estimated to 
increase the tumour control probability by 17% with acceptable increases in normal tissue 
complication probability in RT planning study.276 Lee et al334 also demonstrated the 
feasibility of this approach without compromising the dose to normal tissues, but the 
intratumoural distribution of hypoxia varied considerably and the hypoxic tumour volume 
delineated was not reproducible between 2 scans performed 3 days apart.335 RT plans 
generated using the first scan were applied to the second scan which resulted in 
compromised coverage of the hypoxic tumour volumes.346 However Okamoto et al347 
reported high reproducibility between 18F-FMISO scans performed at 2 days apart in 11 
patients, with 4 hour uptake parameters showing no significant difference in 10 of the 11 
patients, concluding that 18F-FMISO is promising for accurate RT planning. A further recent 
study again demonstrated high percentage tumour reoxygenation during RT shown by a 
reduction in uptake after 20 Gy, suggesting that dose escalation to hypoxic volumes may 
be inappropriate, but hypoxia imaging may be more useful in adaptive RT.348
 
18F-FMISO is not a universal hypoxia tracer in cancer. It has shown minimal activity in 
pancreatic cancer patients349 and high background uptake in the normal rectum in patients 
with colorectal cancer, as well as tracer diffusion through the bowel wall, making images 
difficult to interpret.350 The low uptake of 18F-FMISO in target tissue and slow clearance of 
unbound 18F-FMISO from normoxic areas results in images of poor contrast. The relatively 
short half life of 110 minutes hampers late imaging that could enhance contrast between 
hypoxic and normoxic tissues. This has led to the development of other tracers with 
improved pharmacokinetics.  
 
18F-fluoroazomycin arabinofuranoside (18F-FAZA) 
This second generation 2-nitroimidazole is more hydrophilic than 18F-FMISO and therefore 
has faster clearance from normal tissues and higher tumour to background ratios. 
Souvatzoglou et al351 carried out an 11 patient pilot study in HNSCC and reported a higher 
contrast with non-target tissues compared to 18F-FMISO, with an average TMR of 2.0 at 2 
hours post injection. Mortensen et al352 performed static 18F-FAZA imaging in 40 
oropharynx SCC patients. A hypoxic volume could be identified in 25 patients, with a 
median TMR of 1.5. The distribution of hypoxia among HPV positive and negative tumours 
was not significantly different and there was a significant difference in DFS in patients with
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non-hypoxic tumours compared with hypoxic tumours. Tumours were ranked according to 
the expression of genes included in a 15-gene hypoxia classifier but no correlation was 
found between the hypoxic status as assessed by the classifier and 18F-FAZA imaging, 





 Copper bis(thiosemicarbazone) complexes 1.6
In the 1960s dithiosemicarbazones were found to have anti-tumour properties that were 
enhanced when complexed with Cu(II).353 The simplicity of the chemistry of the ligand and 
the availability of several positron emitting copper isotopes led to the further development 
of these complexes. Copper(II)-pyruvaldehyde-bis(N4-methylthio-semicabazone) (Cu-
PTSM) was initially developed as a perfusion tracer.354 This complex rapidly diffuses into 
cells and becomes non-selectively bioreduced resulting in an unstable Cu(I) complex, from 
which the ligand dissociates, releasing the copper which is trapped within the cell. 
Manipulating the ligand backbone of the complexes altered their reduction potential, 
releasing/trapping Cu under specific intracellular conditions. Dearling et al355,356 
demonstrated that increasing the number of alkyl groups on the diketone backbone of 
bis(thiosemicarbazone) resulted in hypoxia selectivity by lowering the redox potential in 
vitro in EMT6 tumour cells. Several copper radionuclides are available for both PET and 
targeted radiotherapy, highlighting the versatility of this radiotracer (Table 1.7). 64Cu is a 
good compromise as it has sufficiently long half-life, allowing the tracers to be produced 
and transported to over greater distances, with better intrinsic image resolution, and good 
production yield.357 In addition 64Cu emits Auger electrons as a result of electron capture, 
which have high linear energy transfer and short range, and can be potentially used for 
internal radiotherapy.358  
 
Table 1.7 Properties of positron-emitting isotopes of copper. 
 
Isotope Half-life  Radioactivity 
 
Range in tissue Production 
60Cu 0.38 hours β+ 93% 





61Cu 3.32 hours β+ 62% 
Electron capture 38% 
 
2.6 mm Cyclotron 
62Cu 0.16 hours β+ 89% 
Electron capture 2% 
 
6.6 mm 62Zn/62Cu 
generator 
64Cu 12.7 hours β+ 19% 
Electron capture 41% 






66Cu 0.09 hours β- 100% 
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 Copper(II)-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) 1.6.1
Cu-ATSM was found to be a hypoxia selective complex.356 Alkyl groups at the R1 and R2 
positions of bis(thiosemicarbazone) determined the hypoxia selectivity and alkylation at the 
terminal amino R3 and R4 positions increased lipophilicity (Figure 1.4).   
 
 
         
 
Figure 1.4 Structure of copper bis(thiosemicarbazone)s (left) and Cu-ATSM 
(right). 
 
Cu-ATSM was developed to overcome some of the limitations of 18F-FMISO imaging. It is 
an uncharged lipophilic molecule of low molecular weight and high membrane permeability. 
It has fast tumour uptake and clearance form normoxic tissues, allowing rapid imaging after 
injection and higher hypoxic-to-normoxic contrast. It is also simpler to synthesise and 
radiolabel compared with 18F-FMISO, but the longer half-life results in a higher radiation 
dose to patients.359 Radiation dosimetry calculated from rat biodistriution data and human 
imaging using 480 MBq 60Cu-ATSM demonstrated that the liver is the dose-limiting organ 
and 64Cu would remain in the liver for 8.25 ± 0.17 hours after injection.360 
 
 Mechanism 1.6.2
Several mechanisms for the hypoxia selectivity of Cu-ATSM have been suggested, all 
based on the bioreduction of Cu(II) to Cu(I). However the precise cellular retention 
mechanism is still unclear. The first mechanism was proposed by Fujibayashi et al;361 
Cu(II)-ATSM is reduced to Cu(I)-ATSM only within hypoxic cells due to the abnormally 
reduced state of their mitochondria, caused by the lack of oxygen as the final electron 
acceptor, and becomes irreversibly trapped following dissociation of Cu(I) from ATSM 
ligand. Using the Langendorff isolated rat ischaemic heart model, where the oxygen 
concentration can be controlled without changing blood flow, 62Cu-ATSM showed low 
retention and rapid washout from normally perfused hearts, with a 3.5-fold increase in 
retention under hypoxic conditions within 15 minutes of tracer administration. They 
demonstrated that Cu-ATSM accumulation involved NADH-dependent enzymes of the 
mitochondrial ETC. Reduction only occurred in hypoxic cells and involved electron transfer 
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from hyper-reduced Complex I using NADH as a two-electron donor. The addition of 
NADH, which is known to increase in hypoxic tissues, increased Cu-ATSM reduction.361 
Obata et al362 demonstrated that in tumour cells reduction was dependent on the presence 
of electron donors such as NADH and NADPH, and inhibition of the microsomal enzymes 
NADH-dependent cytochrome b5 reductase and NADPH-dependent cytochrome P450 
reductase caused a 25-50% decrease in Cu(II)-ATSM reduction. This indicated that the 
retention may not entirely be dependent on oxygen concentration but also on the relative 
concentrations of intracellular reductants. 
 
Dearling et al356 observed that trapping of hypoxia selective complexes, such as Cu-ATSM, 
within the hypoxic cells was partially reversible, whereas trapping of the non-selective 
complexes, such as Cu-PTSM, was irreversible. They suggested that the reduction of 
Cu(II)-ATSM to Cu(I)-ATSM occurs in both normoxic and hypoxic cells, generating unstable 
anionic Cu(I)-ATSM. Cu(I) slowly dissociates from the ATSM ligand in cells with low oxygen 
concentration, becoming irreversibly trapped within the cell. In the presence of oxygen 
Cu(I)-ATSM oxidised back to neutral Cu(II)-ATSM and diffuses out of the cell. Cu(II)-PTSM 
is also reduced to Cu(I)-PTSM in all cells but is not readily oxidised back by oxygen due to 
its relatively high redox potential. It dissociates to become irreversibly trapped even if 
oxygen is available. The hypoxia selectivity therefore is a competition between dissociation 
and reoxidation of the reduced copper complexes, which is dependent on the oxygen 
concentration.356,363  
 
Burgman et al364 demonstrated efflux and reduction in the level of 64Cu-ATSM in anoxic 
and hypoxic rodent prostate tumour cells after 30 minutes in vitro incubation, contradicting 
the models that suggest irreversibly trapping in conditions of low oxygen concentration. 
They proposed that following dissociation of Cu(I) and ATSM, Cu(I) is not trapped but 
absorbed into the intracellular Cu pool and is subject to cellular Cu metabolism. Cu is a co-
factor in redox reactions of enzymes that carry out many normal physiological processes 
and its metabolism is tightly regulated. Cu uptake into cells is mediated by a plasma 
membrane protein CTR1, and ATP7A (Menkes protein) and ATP7B (Wilson protein) are 
Cu-transporting ATPases which export Cu to maintain intracellular levels. The uptake and 
efflux of Cu(I) from cells are suggested to be a result of active transport. The level of 
expression of these transporters vary in different cell types and regulation is cell specific,365  
which may explain the variations in Cu-ATSM retention. 
 
Yoshii et al366 observed that 64Cu-ATSM accumulates in cells with over-reduced states 
caused by mitochondrial dysfunction, regardless of oxygen levels. Cell lines with 
mitochondrial DNA depletion or mutated mitochondria showed higher uptake compared 
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with control human osteosarcoma cells under normoxia, which did not increase under 
hypoxic conditions. 64Cu-ATSM accumulation correlated with levels of the biological 
reductants NADH and NADPH, rather than increasing hypoxia. They suggested that 64Cu-
ATSM uptake reflects an over-reduced intracellular state, as indicated by the levels of 
NADH and NADPH, and would be a potential marker of disorders such as mitochondrial 
encephalomyopathies and Parkinson’s disease, in which impairment of the respiratory 
chain generates excess electrons resulting in over-reduction and oxidative stress.367,368 
Similar results were demonstrated using cells with impaired mitochondrial ETC function, 
which accumulate NADH.369 These cells showed increased Cu-ATSM retention, and the 
uptake did increase under hypoxic conditions. Hypoxia leading to NADH accumulation 
provides the cellular reduction potential to reduce Cu(II) to Cu(I) and dissociate from the 
ligand, resulting in increased retention.369 Therefore the primary mechanism that drives 
cellular retention of Cu-ATSM may be the accumulation of NADH due to impaired activity of 
the mitochondrial ETC, resulting from conditions such as hypoxic tumours, myocardial 
ischaemia, mitochondrial encephalomyopathies, Parkinson’s disease and other disorders 
that involve mitochondrial dysfunction. 
 
Cu-ATSM uptake and retention has been associated with a number of other factors. 
Multidrug resistance protein 1 (MDR1) is a member of the ATP-binding cassette 
superfamily of membrane transport proteins and is involved in the mechanism of resistance 
to several chemotherapeutic drugs. Higher MDR1 expression is associated with poorer 
outcome after treatment and the expression varies in different tumours.370 Liu et al371 
showed that cellular and tumoural retention of 64Cu-PTSM and 64Cu-ATSM were influenced 
by MDR1 expression, and knockdown of MDR1 resulted in increased cellular retention and 
decreased efflux. 64Cu-ATSM has also been shown to be associated with CD133+ cells. 
CD133 is used as a marker for cancer stem cells, which have been shown to increase in 
proportion when cancer cells are cultured under hypoxia compared with cell under 
normoxia.372 64Cu-ATSM accumulation localised preferentially in regions with a high density 
of CD133+ cells in mouse colon carcinoma cell lines, and when the proportion of CD133+ 
cells was expanded by culturing under glucose starvation and hypoxia uptake was 
increased in these conditions. 
 
Recent studies have reported that Cu itself plays a significant role in Cu-ATSM 
entrapment.373 The in vitro and in vivo distribution of 64Cu-ATSM and 64Cu-acetate in EMT6 
and CaNT mouse tumour models were compared, where 64Cu-acetate, with no hypoxia 
selectivity, was used as a marker of cellular Cu processing. They demonstrated similar 
tumour uptake kinetics and biodistribution at 2 and 16 hours, both of which correlated with 
EF5 IHC at 16 hours only. Increasing inspired oxygen of anaethetised mice reduced the 
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uptake of both 64Cu-ATSM and 64Cu-acetate, and serum analysis indicated that 64Cu-ATSM 
was partly metabolised to yield circulating, protein-bound 64Cu in vivo. This suggests that 
the retention of the tracers may be significantly influenced by cellular Cu metabolism and 
processing. Multiple clinical studies demonstrate a clear correlation between high tumour 
uptake and poor prognosis in a range of tumour sites. However, Cu metabolism itself is 
altered in cancers, with elevated levels in tissue and serum associated with tumour 
recurrence and metastasis,374 and how tumour hypoxia affects Cu metabolism is unknown. 
Therefore the redox trapping pathway may not fully explain the observed hypoxia selectivity 
of Cu-ATSM. 
 
 Preclinical models 1.6.3
The first report of Cu-ATSM as a hypoxia selective agent was described by Fujibayashi et 
al in 1997 in myocardial tissue as described above.361 Lewis et al375 investigated Cu-ATSM 
uptake in different canine myocardial ischaemia models, supporting Cu-ATSM as an 
effective tracer in the detection of global hypoxia. They also demonstrated that Cu-ATSM 
was not retained in necrotic tissue, and therefore able to distinguish between hypoxic 
viable and non-functional dead myocardial tissue.  
 
Cu-ATSM uptake in many different tumour models have been studied (Table 1.8). Lewis et 
al376 in 1999 showed 64Cu-ATSM to be selectively trapped in vitro in the EMT6 murine 
mammary carcinoma cell line under hypoxic conditions and in vivo in EMT6 tumour-bearing 
mice. In vitro kinetics was compared with 18F-MISO after exposure to different 
concentrations of oxygen. 64Cu-ATSM demonstrated oxygen concentration dependent 
uptake at 1 hour and 18F-MISO at 2 hours, but the uptake of 18F-MISO was only 
approximately 10% of the uptake of 64Cu-ATSM. The biodistribution compared with 60Cu-
PTSM in mice bearing EMT6 tumours showed that the optimal uptake was after only 10 
minutes post injection, suggesting rapid uptake and trapping of 64Cu-ATSM in solid 
tumours. Ex vivo autoradiography displayed uniform uptake of 60Cu-PTSM compared with 
heterogeneous uptake of 64Cu-ATSM, consistent with selective trapping into hypoxic cells 
of the tumour. The same group confirmed in vivo the pO2 dependent selective uptake of 
Cu-ATSM in rat 9L gliosarcoma tumours.359 They demonstrated a good correlation 
between low tumour pO2 and high Cu-ATSM accumulation measured using needle oxygen 
electrodes, PET and autoradiography, and confirmed for the first time that Cu-ATSM 
uptake in vivo in tumour tissues was related to tissue pO2. In addition, they compared 64Cu-
ATSM uptake with 18F-FDG uptake and found distinctly different uptake regions, which was 
also observed in rabbits transplanted with VX2 carcinoma377 and in mice with tumours of 
different origins.378 High 64Cu-ATSM uptake regions were found to be hypovascular and 
consisted of cells arrested in the cell cycle on immunohistochemical (IHC) staining, 
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whereas high 18F-FDG uptake areas were hypervascular and cells were actively 
proliferating. This suggests that 18F-FDG regions may respond well to conventional 
treatments but regions of high 64Cu-ATSM consist of viable but hypoxic and resistant cells, 
requiring more aggressive treatment.378 Similarly Oh et al379 compared 64Cu-ATSM and 18F-
FDG distributions using the Lewis lung carcinoma (LLC1) model. They also found 64Cu-
ATSM mainly accumulated at the edge of tumours, whilst 18F-FDG distributed inside the 
tumour and inside the 64Cu-ATSM uptake regions. Pimonidazole staining correlated with 
high 18F-FDG uptake regions but not 64Cu-ATSM. 18F-FDG can accumulate in normoxic 
proliferating cells as well as hypoxic non-proliferating cells, as these cells have high 
demand for energy for anaerobic glycolysis. Ki67 and BrdU IHC suggested that cells in 
high 64Cu-ATSM regions were quiescent but continued DNA synthesis. The colony forming 
ability of cells obtained from high 64Cu-ATSM uptake regions was significantly higher 
compared with cells from intermediate or low accumulation areas. The authors concluded 
that 64Cu-ATSM regions indicate quiescent but clonogenic tumour cells that continue DNA 
synthesis, which is induced by mild hypoxia, and these regions may represent areas in 
extremely reductive conditions rather than in severe hypoxia. 
 
O’Donoghue et al380 compared the intratumoral distribution of 64Cu-ATSM with 18F-MISO in 
rats bearing the R3327-AT anaplastic rat prostate tumour and nude rats bearing xenografts 
from the human SCC cell line FaDu using direct pO2 measurements, autoradiography and 
immunofluorescent microscopy. There was poor correlation in R3327-AT tumours at 2 
hours post-injection, but when tumours were imaged and sacrificed at 16-20 hours post-
injection there was significant correlation in the distribution between the 2 tracers, indicating 
temporal evolution of the distribution of 64Cu-ATSM. In the FaDu tumour model early and 
late 64Cu-ATSM images were similar and in concordance with the 18F-MISO scans. This 
study suggested a tumour specific dependence of Cu-ATSM uptake and retention and 
raised concerns about the use of Cu-ATSM at early imaging times. This group also studied 
the uptake in vitro in 4 different human and 2 rodent tumour cell lines and observed 64Cu-
ATSM uptake and retention to be rapid during the first 30 to 60 minutes of incubation, but 
after this initial period the accumulation varied depending on the cell line and oxygenation 
conditions.364 A steady state was achieved after approximately 2 hours, with uptake in 
normoxic cells anywhere between 2 to 9 times lower than hypoxic cells. R3327-AT prostate 
cancer cells, however, again showed different uptake characteristics. After the initial uptake 
period in hypoxic/anoxic cells there was rapid efflux of 64Cu and therefore no hypoxia 
selectivity was demonstrated. 64Cu-ATSM was shown to be metabolised rapidly depending 
on the oxygenation and cell line, and the 64Cu level was attributable to 64Cu-ATSM uptake 
only for a limited time. This data suggested hypoxia selectivity is highest at 30 to 60 
minutes of incubation, and early imaging may actually provide the most reliable hypoxia 
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imaging. At late imaging times, cellular levels of 64Cu may reflect the active transport of 
64Cu metabolites rather than the uptake of 64Cu-ATSM.  
 
To further assess the difference in uptake seen in prostate cancer cells Vavere et al381 
investigated whether the fatty acid synthesis pathway in these cells may be involved in Cu-
ATSM hypoxia selectivity. This pathway is overexpressed and utilised in prostate cancers 
for improving redox balance, consuming reducing equivalents, such as NADPH, that are 
required by the Cu-ATSM retention mechanism. They found that inhibition of fatty acid 
synthase resulted in significantly increased 64Cu-ATSM retention in prostate tumour cells 
under hypoxia, and this pathway may therefore affect Cu-ATSM metabolism. Yuan et al382 
compared autoradiographic distributions of 64Cu-ATSM with EF5 IHC, as a hypoxia marker, 
in rodent R3230 mammary adenocarcinoma (R3230Ac), fibrosarcoma (FSA) and 9L glioma 
tumour models. After 1 hour post-injection close spatial correlation was seen in R3230Ac 
and 9L glioma, but not in FSA tumours, confirming that 64Cu-ATSM is a valid hypoxia 
marker only in some tumour types, and may not represent a universal PET hypoxia marker.  
 
Matsumoto et al383 used mouse SCCVII tumours and different inspired oxygen mixtures to 
modulate tumour hypoxia to compare the uptake of 64Cu-ATSM and 18F-FMISO. Changes 
in oxygen levels, assessed by pimonidazole staining, did not result in altered 64Cu-ATSM 
tumour uptake, whereas 18F-FMISO showed a positive trend towards uptake as a function 
of changing hypoxia levels, raising concerns regarding the mechanism of hypoxia 
selectivity of Cu-ATSM. Further tracer comparison studies were carried out by Dence et 
al.384 The 9L gliosarcoma rat model was used to compare the distributions of 18F-FMISO 2 
hours post-injection, 64Cu-ATSM 10 minutes and 24 hours post-injection, 18F-FDG and 18F-
FLT. In contrast to Matsumto et al they found strong correlations between the regional 
distributions of both early and late 64Cu-ATSM and 18F-FMISO, and with 18F-FLT, but a 
poor correlation between 64Cu-ATSM and 18F-FDG. 64Cu-ATSM has also been compared 
with other nitoimidazole-based radiotracers, confirming the cell-dependent distribution and 
retention kinetics of 64Cu-ATSM.385,386 The distribution at 2 and 24 hours was compared 
with 18F-FAZA in EMT6, PC3 and FaDu xenograft tumour models in vivo and ex vivo.385 
The FaDu model demonstrated overlapping radioactivity distributions of the 2 tracers at all 
time points of 64Cu-ATSM acquisition, which matched CA9 staining, but in the EMT6 and 
PC3 models there was little similarity between the 2 tracers and between early and late in 
64Cu-ATSM imaging. Carlin et al386 compared 18F-MISO, 18F-HX4, 18F-FAZA and 64Cu-
ATSM in SQ20b human HCSCC cell line xenograft 80-90 minutes after tracer 
administration. Autoradiographic distribution was compared with the exogenous hypoxia 
marker pimonidazole and the endogenous hypoxia marker CA9, as well as the vascular 
perfusion marker Hoechst 33342. The nitroimidazoles showed uptake increasing with 
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pimonidazole and CA9 staining, but 64Cu-ATSM showed the opposite pattern with the 
highest uptake in regions with lowest pimonidazole and CA9 staining. An inverse pattern of 
staining was observed with Hoechst 33342, suggesting correlation between tracer uptake 
and vascular delivery.  
 
Dynamic PET imaging and kinetic analysis were performed in the FaDu head and neck 
tumour model in rats to further investigate the extent to which 64Cu-ATSM distribution is 
determined by vascular delivery and perfusion or pO2.387 Cu-ATSM was rapidly taken up by 
tumours, resulting in a 4-fold higher 64Cu-ATSM uptake than muscle. Tumour to muscle 
ratios (TMRs) continued to increase over the course of imaging of 18 hours. At 1 hour post-
injection 64Cu-ATSM showed no correlation with pimonidazole staining but strong 
correlation with Hoechst-33342, indicating highly perfused regions, and at 18 hours there 
was no correlation with Hoechst-33342 nor with pimonidazole, suggesting Cu-ATSM is 
related to perfusion rather than pO2.  
 
There have also been a number of studies in cats and dogs. Hansen et al388 compared 
64Cu-ATSM and 18F-FDG uptake in 9 dogs with spontaneous soft tissue sarcomas or 
carcinomas. 64Cu-ATSM imaging at 3 and 24 hours demonstrated moderate correlation but 
temporal changes were observed, especially in hypoperfused regions, attributed to cycling 
hypoxic changes, regional differences in uptake kinetics, or reversibility of 64Cu-ATSM. The 
hypoperfused regions displayed delayed uptake, possibly limited by perfusion, and slower 
washout. Cu-ATSM scans at 3 hours after injection showed a strong positive correlation 
with pimonidazole uptake in the most heterogeneous tumour regions.389 In a further study 
22 dogs with sinonasal carcinomas and sarcomas imaged with 61Cu-ATSM before and mid-
treatment with radiotherapy showed stable spatiotemporal distribution, with carcinomas 
demonstrating significant decreased uptake mid-treatment.390,391 Canine tumours have also 
been used to demonstrate the feasibility of dose escalating radiotherapy dose to 64Cu-
ATSM or 18F-FDG or overlapping uptake regions.392,393   
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EMT6 cell line Incubation with tracer and different 
concentrations of dissolved oxygen; 
64Cu activity assessed using γ counter 
 
64Cu-ATSM more efficient uptake and washout kinetics. 376 
64Cu-ATSM  
60Cu-PTSM  




67Cu-ATSM 9L gliosarcoma in 
rats 
Hydralazine administration; 100% oxygen 
administration; needle oxygen electrode; 
dynamic PET imaging over 25 minutes; 
autoradiography 
Hydralazine decreased tumour pO2, increased relative uptake of 67Cu-ATSM by 
37% compared with control animals. 
100% oxygen increased tumour pO2, decreased relative 67Cu-ATSM uptake by 







9L gliosarcoma in 
rats 
Autoradiography to compare distribution Regions of uptake at 60 minutes post 18F-FDG administration and 10 minutes 
post 64Cu-ATSM administration distinctly different. 
 
359 
64Cu-ATSM   
18F-FDG 
VX2 in white 
rabbits 
Autoradiography  64Cu-ATSM uptake around outer rim of tumour, 18F-FDG uptake widely 
distributed with highest levels in inner regions of tumour. 
 
377 
64Cu-ATSM   
18F-FDG 
LLC1, Meth-A, 
B16, colon26 in 
mice 
Autoradiography; Ki67, CD34 (blood 
vessel marker) IHC 
64Cu-ATSM accumulation at edge of tumours, not in centre where cells necrotic. 
18F-FDG accumulation inner adjacent to 64Cu-ATSM.  




64Cu-ATSM   
18F-MISO 
R3327-AT prostate 
and human FaDu 
xenografts in rats 
PET imaging at 0.5 to 2 hours (early) and 
16 to 20 hours (late) post-injection; 
oxygen probe measurements; 
autoradiography; pimonidazole IHC 
R3327-AT tumours – correlation of tracers at late PET imaging but not early. 
Oxygen probe measurements consistent with late 64Cu-ATSM and 18F-MISO 
images. Pimonidazole IHC correlated with late 64Cu-ATSM distribution only. 




64Cu-ATSM Human MDA468, 
MCF7, DU145, 
FaDu and rodent 
R3327-AT, FSaII 
cell lines 
Incubation with 64Cu-ATSM for different 
times under normoxic, hypoxic or anoxic 
conditions; 64Cu activity assessed using γ 
counter 
Most cell lines – accumulation rapid during first 0.5-1 hour of incubation followed 
by steady state level after 2 hours. Uptake in normoxic cells 2-9 times lower, 
depending on cell line and incubation time.  
R3327-AT cell line – no hypoxia selectivity demonstrated after 1 hour. 
364 
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64Cu-ATSM R3230Ac, FSA, 9L 
glioma in rats 
Dynamic PET imaging over 60 minutes; 
EF5, pimonidazole, CA9, Hoechst 33342 
IHC; carbogen breathing (95% pO2) in 
FSA 
Significantly higher TMR and SUV in FSA compared with R3230Ac and 9L. 
R3230Ac and 9L - correlation between 64Cu-ATSM uptake and EF5 IHC. 
FSA – no correlation between 64Cu-ATSM and EF5, pimonidazole, CA9. 
Carbogen in FSA – reduced EF5 but no change in 64Cu-ATSM uptake. 
 
382 
64Cu-ATSM   
18F-FMISO 
SCCVII in mice Dynamic PET imaging after inspired air, 
10% oxygen or carbogen; pimonidazole 
IHC 
Significant changes in pimonidazole staining but no change in 64Cu-ATSM 








9L gliosarcoma in 
rats 
PET imaging at 10 minutes (early) and 24 
hours (late); autoradiography 
Distribution of 64Cu-ATSM at early and late time points correlated with 18F-
FMISO. 
Poor correlation between 64Cu-ATSM and 18F-FDG. 
Good correlation between 64Cu-ATSM and 18F-FLT. 
 
384 
64Cu-ATSM   
18F-FDG 
LLC1 in mice Autoradiography; Ki67, BrdU, 
pimonidazole IHC; colony formation 
64Cu-ATSM accumulation at edge of tumours, none in necrotic tumour centre. 
18F-FDG accumulation inside 64Cu-ATSM region. 
64Cu-ATSM negative correlation with Ki67, positive with BrdU. 
Cells from high 64Cu-ATSM regions greater colony forming ability. 
 
379 
64Cu-ATSM FaDu in rats Dynamic PET imaging for min 1 hour 
(early) and at 18 hours (late); 
autoradiography; pimonidazole, Hoechst 
33342 IHC 
 
Rapid tumour uptake and retention, uptake continued to rise at 18 hours. 
Early – no correlation with pimonidazole, positive correlation with Hoechst 33342. 
Late – no correlation with pimonidazole or Hoechst 33342. 
 
387 
64Cu-ATSM   
18F-FAZA 
Human PC3, 
FaDu and EMT6 
in mice 
PET imaging at 2 hours (early) and 24 
hours (late); autoradiography; CA9, CTR1 
and ATP7B IHC 
Higher TMR with 64Cu-ATSM in all 3 models.  
FaDu – early and late 64Cu-ATSM distribution matched 18F-FAZA and CA9. 
EMT6 and PC3 – no correlation. 













PET imaging after 80-90 minutes; 
autoradiography; pimonidazole, CA9, 
Hoechst 33342 IHC 
 
 
TMR significantly greater with Cu compared with nitoimidazole tracers. 
64Cu-ATSM uptake corresponded to low pimonidazole, low CA9 staining, high 
Hoechst 33342 staining. 















Dynamic PET imaging early and late; 
autoradiography; EF5 IHC; 60% and 100% 
inspired oxygen 
 
64Cu-ATSM and 64Cu-acetate uptake and biodistribution similar at 2 & 16 hrs. 
EF5 correlated with imaging at 16 hrs and with 18F-MISO at 2 hrs. 
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 Clinical studies 1.6.4
The first published study using Cu-ATSM in patients was in 2000. Takahashi et al394 used 
62Cu-ATSM in 4 normal subjects and 6 patients with lung cancer and to evaluate the 
characteristics in humans. 62Cu-ATSM was rapidly cleared from the blood with little lung 
uptake in normal subjects and intense uptake in the liver. Patients with lung cancer had 
intense tumour uptake, which did not correlate with 18F-FDG uptake. 15O-water PET scans 
were performed in 4 patients to compare blood flow and 62Cu-ATSM uptake, and a 
negative correlation was found suggesting that 62Cu-ATSM is retained in poorly perfused 
regions. Takahashi also investigated 62Cu-ATSM in 7 patients with coronary heart disease 
and found increased myocardial uptake in one patient with unstable angina, whereas 




Further work in lung cancer was carried out by Dehdashti et al396 to compare the 
pretreatment uptake of 60Cu-ATSM in non-small cell lung cancers with tumour response to 
therapy. The primary lesion and bilateral back muscle groups were defined by delineating 
regions of interest (ROIs) in multiple planes, guided by CT and 18F-FDG PET. The overall 
tumour uptake was assessed semi-quantitatively on the 30-60 minute summed images by 
determining the TMR using the maximum pixel value for the tumour and average value for 
the muscle. In 14 out of 19 patients with response evaluation the mean TMR of non-
responders was significantly higher that responders. An arbitrarily selected TMR threshold 
of < 3.0 was a cut-off value for distinguishing responders and non-responders. The 
maximum standardised uptake value (SUVmax) of either 60Cu-ATSM or 18F-FDG were not 
significantly different between the 2 groups. Cu-ATSM has been investigated as a 
diagnostic imaging biomarker in lung tumours. Two patients with lung nodules suspicious 
for malignancy received 62Cu-ATSM, 62Cu-PTSM and 18F-FDG PET imaging prior to 
surgery, one lesion was subsequently identified on histology as adenocarcinoma and the 
other granuloma.397 SUVs were compared and 62Cu-ATSM was the only radiotracer that 
could potentially distinguish benign from malignant disease. Lolith et al398 compared 62Cu-
ATSM and 18F-FDG uptake in patients with histologically different types of lung cancer and 




Dehdashti et al have also investigated the use of 60CuATSM in cervix cancer. 60Cu-ATSM 
scans were carried out initially in a group of 14 patients,399 followed by a larger series of 
38.400 A dynamic scan over 60 minutes was performed and ROIs were drawn in multiple 
planes on the summed images obtained at 30-60 minutes, guided by CT or FDG-PET. 
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Volumes of interest (VOIs) were then created of the primary cancers and bilateral gluteal 
muscles and the TMR calculated. They found that a TMR threshold of 3.5 distinguished 
patients who did and did not develop recurrent disease, with a significantly improved 
progression-free and cause-specific survival in patients with a TMR of ≤ 3.5. There was no 
difference between the 2 groups in frequency of lymph node involvement, total radiation 
dose or overall treatment time, and there was no correlation between disease stage and 
60Cu-ATSM uptake. The patients also received an 18F-FDG PET in this study and again no 
correlation was seen between 18F-FDG SUVmax and 60Cu-ATSM uptake. Paraffin blocks 
from the initial diagnostic biopsy of 15 patients were analysed for hypoxia-related molecular 
markers. 60Cu-ATSM hypoxia correlated with overexpression of VEGF, COX-2, CA9 and 
EGFR by immunohistochemistry and an increase in apoptosis.401 Lewis et al402 compared 
PET image quality and tumour uptake of 60CuATSM and 64CuATSM in 10 patients with 
cervix cancer. 64CuATSM provided better image quality, allowing clearer delineation of 
tumours. The uptake pattern and TMRs of the 2 tracers were similar in studies carried out 





Similar analysis has been performed on 19 patients with cancer of the rectum who received 
a dynamic 60Cu-ATSM PET scan prior to treatment with neoadjuvant chemoradiation 
followed by surgery.403 ROIs were drawn around the primary rectal cancer and bilateral 
gluteal muscle groups in multiple planes to calculate the TMR. The median TMR value of 
2.6 was used to define hypoxia. The mean TMR for downstaged tumours was significantly 
lower than tumours not downstaged, and after a median follow up of 4.1 years none of the 
patients with TMR < 2.6 had developed recurrent disease or died from their cancer, 
compared with a progression-free survival and overall survival at 3 years of 50% and 63% 
respectively in the hypoxic group. There was no correlation between tumour size or stage 




More recently 62Cu-ATSM PET has been used in 22 newly diagnosed and recurrent glioma 
patients to investigate the ability to predict tumour grade and HIF1α expression.404 ROIs 
were outlined within areas of increased tracer uptake on each section. SUVmax, SUVmean 
and tumour to background ratio (TBR; tumour uptake relative to uptake in contralateral 
normal brain) were significantly higher in grade 4 compared with grade 3 tumours, and at a 
TBR cut off threshold of 1.8 62Cu-ATSM uptake predicted HIF1α positivity on 
immunohistochemical staining of the tumour specimens. MRI correlation revealed 62Cu-
ATSM uptake only within MRI enhanced regions and not in necrotic tissue identified on 
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MRI. The same group studied a further 23 patients and compared the uptake to 18F-FDG 
and L-methyl-11C-methionine (11C-MET) uptake.405 The mean 62Cu-ATSM TBR and SUVmax 
were significantly higher in glioblastomas (GBM) compared with non-glioblastomas. 
Receiver operating characteristic analysis showed a TBR cut off of 1.9 was most predictive 
of GBM, which had better sensitivity than 11C-MET, whilst 18F-FDG had no predictive value.  
 
Head and neck cancer 
 
In 2001 Chao et al406 used 60Cu-ATSM in a radiotherapy planning study to demonstrate the 
feasibility of Cu-ATSM-guided IMRT to overcome hypoxia tumour resistance. TMR ≥ 2 was 
defined as hypoxia as at this threshold no normal tissue in the contralateral neck displayed 
60Cu-ATSM activity. The region of 60Cu-ATSM uptake within the gross tumour volume 
(GTV) was targeted to deliver 85 Gy in 35 fractions, with the remaining GTV receiving 70 
Gy in 35 fractions, and a plan without compromising normal tissue sparing was achieved. 
Minagawa et al407 assessed 62Cu-ATSM as a predictor of response in 17 patients. ROIs 
were manually drawn around the primary tumour, with the tumour volume defined as the 
sum of ROIs on CT. Tumour uptake was assessed semi-quantitatively by determining the 
SUVmax and TMR. The muscle uptake was determined by drawing 2 muscular ROIs on the 
bilateral posterior cervical muscles and the uptake determined by the mean of each 
SUVmean. After 2 years of follow up SUVmax but not TMR was significantly different in 
patients with or without residual/recurrent tumour, and a SUVmax > 5 was a possible cut off 
threshold for poor outcome. There was no significant difference in 18F-FDG between 
patients with and without residual/recurrence tumour. Sato et al408 also evaluated the 
prognostic potential of 62Cu-ATSM in 25 patients with head and neck cancer. Time activity 
curves from dynamic PET acquisition over 20 minutes showed that all tumours had stable 
tracer retention at approximately 10 minutes, and therefore an average image of the last 
10-minute frame was used to evaluate hypoxia. VOIs were drawn on the primary tumour 
and bilateral sternocleidomastoid muscles and the overall uptake assessed semi-
quantitatively by determining SUVmax and TMR, using the SUVmax for the tumour and mean 
SUVmax for the muscles. 62Cu-ATSM SUVmax > 3.6 was associated significantly worse 
progression free survival (PFS), and a TMR > 3.2 was associated with significantly worse 
progression free survival and cause specific survival (CSS). 18F-FDG uptake parameters 
did not distinguish patients with good and poor outcome. 
 
Studies comparing different tracers have been conducted. The distribution of 62Cu-ATSM 
and 18F-FDG uptake was compared in 30 patients with any subtype of head and neck 
cancer, including paranasal sinus and parotid carcinomas.409 The scans were analysed by 
drawing multiple small circular ROIs of 8mm in diameter on each tumour lesion, with at 
least 10 in total placed on the soft tissue density area inside the tumour, excluding necrotic 
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areas. The SUVmean of each ROI was calculated to determine the intratumoural distribution. 
Similar to the comparison in lung cancer, a negative correlation between 62Cu-ATSM and 
18F-FDG uptake was found in squamous cell carcinomas, suggesting these 2 tracers detect 
different tumour characteristics. However, in the 3 adenocarcinoma cases investigated they 
showed similar and homogeneous tracer accumulation. Nyflot et al410 compared 18F-FDG, 
18F-FLT, and 61Cu-ATSM uptake in 13 patients with locally advanced oropharyngeal 
cancer. CT images were coregistered to corresponding PET images, and GTV and clinical 
target volumes (CTV) were defined on contrast-enhanced CT and 18F-FDG PET/CT 
images. The volumes were used to calculate the SUVmean and SUVmax. There was high 
voxel-based correlation between 18F-FDG and 18F-FLT uptake, but hypoxia was less clearly 
associated with metabolic or proliferative status. Nyflot et al411 recently reported a phase I 
study to assess the use of 18F-FLT and 61Cu-ATSM to monitor early tumour response when 
bevacizumab was combined with radiation and cisplatin in locally advanced HNSCC. Ten 
patients received scans before and after bevacizumab, and during combined therapy, 
which showed measurable decreases in tumour proliferation and hypoxia at each time 
point.  
 
64Cu-ATSM has been used in head and neck cancers to compare early and late 64Cu-
ATSM PET scans in 11 patients, and with 18F-FDG .412 Cu-ATSM PET scans were carried 
out at 1 hour and 16 hours after injection. The SUVmax of the primary tumour was measured 
and a cut off of 42% of the lesion SUVmax was used to delineate a volume defined as the 
biological target volume (BTV). There was no difference in the SUVmax between early and 
late scans, and SUVmax and BTV had high sensitivity but low specificity in predicting 
complete response to therapy. 
 




There have been a large number of studies attempting to validate Cu-ATSM as a hypoxic 
tracer and elucidate the exact mechanisms, with conflicting results. Preclinical studies have 
not been able to consistently demonstrate the hypoxia selectivity, but they have used a 
range of different cell lines, animal models and techniques. It is clear that Cu-ATSM 
accumulation is dependent on the cell or tumour type and would not be suitable as a 
universal tracer of hypoxia, but this is the true for all PET radiopharmaceutical agents. 
Despite the uncertainties regarding the precise mechanism, small clinical studies have 
suggested the potential as an imaging biomarker that warrants further investigation, with 
clear advantages over the nitroimidazole-based hypoxia tracers.  
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Table 1.9 Summary of Cu-ATSM clinical studies in cancer. 
 
Radiotracer Tumour Patient no. PET scan 
acquisition 
 









20 minutes  
62Cu-ATSM TBR 
18F-FDG SUV 
High 62Cu-ATSM uptake in tumours. No correlation between 62Cu-ATSM 
and 18F-FDG. Negative correlation between 62Cu-ATSM and 15O-water in 














Response at 3 months: mean TMR non-responders greater than 
responders. SUVmax no difference.  
TMR and SUVmax no significant correlation. 













Intratumoural distribution in SCC – high 62Cu-ATSM uptake in periphery of 
tumour, high 18F-FDG in centre. 














SUVmax Malignant lesion high SUVmax. 





























60Cu-ATSM uptake inversely related to PFS and OS. 
TMR 3.5 cut-off distinguished likely recurrence and no recurrence. 










TMR 64Cu-ATSM better image quality. 












Median TMR 2.6 cut-off distinguished worse and better prognosis. 
Mean TMR significantly lower for downstaged tumours.  
No correlation between 60Cu-ATSM and18F-FDG uptake. 
 
403 
62Cu-ATSM Glioma 22 Dynamic PET 
over 40 
minutes 
TBR TBR significantly higher in grade 4 compared with grade 3 tumours. 
TBR 1.8 cut-off distinguished HIF1α positivity on IHC. 













62Cu-ATSM uptake significantly higher in GBM. 
TBR 1.9 cut off predictive off GBM with better sensitivity than 11C-MET. 
18F-FDG had no predictive value. 
 
405 





TBR and SUVmax high in primary CNS lymphoma and GBM, low in low 























17 (15 in 
analysis) 
Static PET TMR 
SUVmax 
SUVmax significantly different in patients with and without recurrence. 
SUVmax 5.0 cut off distinguished patients with and without recurrence. 















Intratumoural distribution in SCC - 62Cu-ATSM uptake higher in periphery 
of tumour, high 18F-FDG in centre. 






Oropharynx 13 (11 
analysed) 
Static PET SUVmax 
SUVmean 
 
High voxel-based correlation values between 18F-FLT and 18F-FDG 
uptake. 







11  Static PET at 1 
and 16 hrs 
SUVmax 
 
No significant difference in SUVmax between early and late scans. 
No difference in BTV calculated with 64Cu-ATSM and 18F-FDG. 












Optimal cut off for TMR 3.2, SUVmax 3.6. 
TMR > 3.2 worse PFS and CSS, SUVmax > 3.6 worse PFS. 





















61Cu-ATSM – significant decrease in SUVmean after bevacizumab and 
combined therapy. 
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1.7 Thesis aims 
The development of individualised treatments in oncology requires understanding of the 
molecular biology of cancer and the ability to translate this into therapy. Due to the 
heterogeneity of HNSCCs biomarkers are needed to identify the mechanisms of 
tumourigenesis and treatment resistance to improve outcome. Radioresistance is a major 
cause of treatment failure, and identification of biomarkers at the diagnostic step in the 
patient pathway that can predict the response of tumours to radiotherapy would open up 
the potential to incorporate different strategies to overcome radioresistance.  
 
MicroRNAs represent novel biomarkers. The first part of this thesis aims to investigate the 
characteristics a potential novel biomarker of intrinsic radioresistance, miR-196a, which 
was identified from miRNA expression profiling of a small number of patients with 
differential outcomes after radical treatment. The oncogenic effects and response to 
radiotherapy after alteration of this single miRNA is explored in HNSCC cell lines.  
 
The second part focuses on hypoxia, a well-established biomarker of radioresistance. The 
use of an imaging biomarker, 64Cu-ATSM, in conjunction with gene expression from 
diagnostic FFPE biopsy samples is explored as a method to identify hypoxia as well as 
assess its distribution. A 15 patient pilot study has been conducted as part of a larger 
study, which aims to define a gene signature that can enable the selection of patients who 
would benefit from hypoxia imaging. 
 













The Oncogenic Role of 
MicroRNA-196a in Head and Neck 
Squamous Cell Carcinoma
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 Introduction 2.1
 MicroRNA-196a as a biomarker in HNSCC 2.1.1
Previous work carried out in our lab identified miR-196a as a potential biomarker for poor 
outcome in HNSCC. Briefly, 16 patients with HNSCC were selected based on their long-
term outcome to anti-cancer treatment. All patients were treated with surgery and post-
operative radiotherapy and classified as ‘good’ responders of therapy if they had no 
evidence of recurrent disease within 5 years of follow up, or ‘bad’ responders if they had 
relapsed. Cases were selected as representative stages and sites in each group to include 
the range of oral carcinoma presentations. All carcinomas were from oral sites with surface 
origin; those from posterior tongue or soft palate were not of human papillomavirus type. 
Tissue samples were collected prior to treatment, immediately snap-frozen in liquid 
nitrogen and stored at -80°C until RNA extraction. Ethics approval was covered by an 
existing project (REC reference 04/02/10). The samples were profiled for miRNA gene 
expression using Illumina v2 miRNA Beadchip (Illumina, San Diego, USA) according to 
manufacturer instructions. Differential expression of miRNAs between the two patient 
groups (‘good’ and ‘bad’ responders) was estimated by fitting a linear model and empirical 
Bayes moderated t-tests using the limma package, and log2 fold-change and P-values were 
inspected to define the top-ranked miRNAs for differential expression (Figure 2.1). MiR-
196a was the highest overexpressed miRNA in the ‘bad’ outcome group and therefore 
selected for further investigation.  
 
 
Figure 2.1 Heatmap displaying miRNA expression in tissue samples with differing 
outcomes. 
Sixteen fresh frozen HNSCC samples from patients with ‘good’ (yellow) and ‘bad’ (blue) 
outcome were profiled for miRNA expression. The 41 top-ranked miRNAs for differential 
expression between the two groups are shown. Rows (samples) are ordered by 
expression score. Columns (miRNAs) are ordered by the direction of fold-change then 
alphabetically.  
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Eight HNSCC cell lines were then profiled for the endogenous expression level of miR-




Figure 2.2 MiR-196a gene expression levels in eight HNSCC cell lines. 
Eight HNSCC cell lines were profiled for the expression of miR-196a and displayed as 
expression fold-change compared with HN30. Cell line expression values are shown as 
the mean of two duplicate samples. The cell lines HN5 and HN30, with low and high 




The miRNA-196 gene family is encoded at three locations in the mammalian homeobox 
(HOX) clusters, A, B and C. It has extensive evolutionarily conserved complementarity to 
the mRNA of HOXB8, HOXC8, and HOXD8, with full complementarity to the 3’ UTR of 
HOXB8 mRNA, resulting in cleavage and rapid degradation.415 HOX genes encode 
transcription factors essential for embryonic patterning during embryogenesis, and for 
controlling cell growth, differentiation, identity, and cell-to-cell interaction in adult eukaryotic 
organisms.416 There are two miR-196a genes, miR-196a-1 and miR-196a-2, located on 
different chromosomes but transcribing the same functional mature miRNA sequence. The 
miR-196a-1 gene is located on chromosome 17q21 between HOXB9 and HOXB10 genes, 
and the miR-196a-2 gene is on chromosome 12q13 between HOXC10 and HOXC9. The 
third gene in the miR-196 family is miR-196b, located on chromosome 7p15 between 
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Table 2.1 MiR-196 gene location and mature sequance. 
 
miRNA Location Sequence 
miR-196a-1 Chromosome 17q21.32 3’-GGGUUGUUGUACUUUGAUGGAU-5’ 
miR-196a-2 Chromosome 12q13.13 3’-GGGUUGUUGUACUUUGAUGGAU-5’ 
miR-196b Chromosome 7p.15.2 3’-GGGUUGUUGUCCUUUGAUGGAU-5’ 
 
 
MiRNA-196a is overexpressed in several tumours and increasing evidence indicates that 
abnormal expression contributes to tumourigenesis and tumour progression. Epigenetic 
changes and single nucleotide polymorohisms have been identified in this miRNA, which 
are associated with altered susceptibility to some cancers. For example, a single nucleotide 
polymorphism with a specific homozygous CC genotype in the pre-miRNA-196a, affecting 
the mature miRNA expression and the binding efficiency to target mRNA, has been 
associated with reduced survival in lung cancer in the Chinese population.418 This genotype 
is also associated with increased susceptibility to lung,419 gastric420 and breast cancers421 
in the same population, but a decreased risk of glioma.422 MiR-196a has been shown to act 
both as an oncogenic and TSG miRNA depending on the target and tumour type.  
 
 MiR-196a as oncogenes 2.1.2.1
MiR-196a is significantly upregulated in a variety of cancers compared to normal controls, 
such as pancreas,423 oesophagus,424 gastric,425,426 lung,427 colorectal,428 cervix,429 larynx430 
and oral cancer431, and high levels are associated with worse outcome. MiR-196a has been 
shown to promote cell proliferation, anchorage dependent growth and suppression of 
apoptosis, and act as a potential marker of progression to invasive adenocarcinoma in 
oesophageal cancer.424,432 Annexin A1 (ANXA1), keratin 5 (KT5), S100 calcium-binding 
protein A9 (S100A9) and small proline-rich protein 2C (SPRR2C) were identified as 
potential targets through which miR-196a exerted its effects. Similar studies have been 
carried out in oral SCC and non-small cell lung cancer cell lines, tissues and mouse 
models. MiR-196a overexpression is associated with tumour recurrence, nodal metastasis 
and mortality in oral cancers,431 and, acting through HOXA5, resulted in increased cell 
proliferation, migration and invasion in lung cancer cell lines.427 HOX genes have also been 
found to be associated with miR-196a in colorectal cancer, where high levels of miR-196a 
promoted the AKT signaling pathway, cell detachment, migration, invasion and increased 
lung metastases in mice. HOXA7, HOXB8, HOXC8 and HOXD8 were all inhibited by miR-
196a.433  
 
More recently IκBα, an inhibitor of NF-κB, has been identified as a direct target of miR-
196a. In glioblastoma multiforme miR-196a, which is upregulated and associated with poor 
outcome, directly interacted with IκBα 3’-UTR to suppress IκBα expression and 
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subsequently promote NF-κB activation. This resulted in enhanced proliferation and 
apoptosis suppression.434 Similarly in pancreatic cancer miR-196a downregulation in cell 
lines suppressed proliferation and migration, while silencing of IκBα enhanced cell 
proliferation and migration.435 MiR-196a has also been associated with abnormal apoptosis 
and proliferation in pancreatic cancer cells through downregulation of inhibitor of growth 5 
(ING5).436 In gastric cancer miR-196a overexpression enhanced cellular proliferation and 
p27kip1, a cyclin-dependent kinase inhibitor known to prevent cell cycle progression, was 
identified as a direct target,425 as was radixin, a cytoskeletal protein, in both cells and tissue 
samples where both miR-196a and miR-196b promoted metastases.426 p27kip1 along with 
FOXO1, two important regulators of the PI3K/AKT signaling pathway, were also found to 
be regulated by miR-196a in cervix cancer.429 A further study in cervix cancer confirmed 
the oncogenic potential of miR-196a, this time through netrin-4, which is involved in axon 
guidance and angiogenesis.437 
 
 MiR-196a as TSGs 2.1.2.2
The majority of studies on miR-196a suggest it has an oncogenic role. However a few 
studies have demonstrated that miR-196a can act as a TSG. MiR-196a has been found to 
be downregulated in melanoma438 and breast cancer,439 with overexpression resulting in 
the inhibition of invasion and metastasis by targeting HOXC8, and the suppression of miR-
196a causing increased migration through HOXB7.440 The role of miR-196a is clearly cell 
and tissue specific and the downstream effect dependent on the target gene/or genes 
through which it is acting. 
 
 Summary of targets of miRNA-196a 2.1.2.3
Identification of the mRNA targets of miRNAs is essential in understanding the function of 
each miRNA. Due to the potential multiple targets of a single miRNA and a single mRNA 
being targeted by multiple miRNA, as well as imperfect base pairing to the 3’-UTR of the 
mRNA, this is a huge challenge. Table 2.2 summarises the gene targets of miR-196a 
involved in cancer pathways that have been experimentally verified by functional analysis 
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Table 2.2 Published targets of miR-196a. 
 
Gene Cell type Reference 
HOXB8 Colon cancer cell line SW480 
Leukaemic cell line HL60 
 
415,433,441 
HOXC8 Colon cancer cell line SW480 
Melanoma cell line Mel Im 
Breast cancer cell line MDA-MB-231 
 
415,433,438,439 
HOXD8 Colon cancer cell line SW480 
 
415,433 
HOXA7 Colon cancer cell line SW480 
 
415,433 
HOXB7 Melanoma cell line Mel Im 
 
440 
HOXA5 Lung cancer cell lines A549, SPC-A1 
 
427 
ANXA1 Human umbilical vein endothelial cells 
Oesophageal cancer cell lines BIC-1, OE33, SEG-1 
Breast cancer cell lines MDA-453, MDA-231 
Endometrial cancer cell HEC-1B 
 
424,442 
S100A9 Oesophageal cancer cell line BIC-1 
 
432 
SPRR2C Oesophageal cancer cell line BIC-1 
 
432 
KRT5 Oesophageal cancer cell line BIC-1 
 
432 
ERG Leukaemia cell lines KG1a and MOLT-4 
 
443 
HMGA2 Mouse embryonic fibroblast cell line NIH313 
 
444 
IκBα Glioblastoma cell lines U87MG, T98G 




p27kip1 Gastric cancer cell line SGC-7901 
Cervix cancer cell lines CaSki, C33A 
 
425,429 
ING5 Pancreatic cancer cell line PANC-1 
 
436 
Radixin  Gastric cancer cell line GC 
 
426 











 Annexin A1 2.1.2.4
Annexin A1 (ANXA1) is a member of the annexin family of calcium-dependent 
phospholipid-binding proteins and has been shown to exhibit anti-inflammatory and anti-
proliferative effects.445 However, the molecular mechanisms by which ANXA1 modulates 
these cellular responses have not been fully determined. Due to its anti-proliferative effects 
and role in cellular adhesion and motility,446 ANXA1 protein has been studied in several 
types of cancers, but in vivo studies have demonstrated that the expression pattern of 
ANXA1 in human cancers is not well defined. While ANXA1 has been reported to be 
upregulated in glioma447 and lung adenocarcinoma,448 its expression is reduced or lost in 
other cancer tissues including head and neck,449-451 oesophageal and prostate.452 In 
addition ANXA1 has been found to behave as both an oncogene and TSG in different types 
of cancer. In HNSCC the expression of ANXA1 has been shown to correlate with higher
grades of differentiation, or less aggressive tumours, suggesting a tumour suppressor 
role.449,453 ANXA1 has been shown to be a target of miR-196a in oesophageal and breast 
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cancer cells,424 but the association with miR-196a has not been established in HNSCC and 





The microarray data demonstrated that miR-196a may have a role in the outcome of 
HNSCC. Single miRNAs have been shown to be able to impact on the behaviour of cancer 
cell lines and therefore may represent potential biomarkers of tumour phenotype and 
response to treatment.  
 
This in vitro study aimed to investigate whether miR-196a has a role as a prognostic and/or 
predictive marker in HNSCC by: 
 
• Characterising the behaviour of miR-196a overexpressing cells through functional 
analysis. 
• Assessing whether the opposite behaviour can be induced in miR-196a knockdown 
cells. 
• Determining the effect of miR-196a on the response to irradiation. 
• Elucidating underlying mechanisms for any differential response. 
• Investigating annexin A1 as putative target of miR-196a in HNSCC cell lines. 
• Validating the effect of miRNA-196a in patient samples. 
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 Materials 2.3
Plasticware used in tissue culture were purchased from Grenier Bio-One, Scientific 
Laboratory Supplies or Thermo Scientific. 
 
 Chemicals, reagents and solutions  2.3.1
All chemicals were purchased from Sigma-Aldrich, unless otherwise stated. Solutions were 
stored at room temperature unless otherwise specified. 
 
10% Ammonium persulphate (APS) 
The solution was made up in dH2O and store at 4°C for up to 2 weeks. 
 
Antibiotics 
Carbenicillin was purchased from Bioline, stored at -20°C and used at a working 
concentration of 100 µg/ml. 
Puromycin was purchased from Source Bioscience and stored at -20°C.  The required 
working concentration was determined before use. 
 
BD BioCoat Matrigel Invasion Chamber 
Stored at -20°C and purchased from BD Biosciences with corresponding Control Inserts. 
 
Blocking buffer  
For immunofluorescence: 3% (w/v) bovine serum albumin (BSA, Scientific Laboratory 
Supplies) in PBS. 
For Western blot analysis: 5% (w/v) dry milk powder or 5% BSA in 1x TBS-T.  
 
Calcium chloride (CaCl2) 
0.5 M CaCl2 solution  
Made up in dH2O and sterilised by filtering through a 0.2 µm filter (Fisher Scientific). 
 
Cell lysis buffer 
2 mM MgCl2 
25 mM HEPES KOH pH 7.4 
2 mM EGTA 
Diluted 1:1 in 2% Trition X-100. Protease inhibitors aprotinin and leupeptin at a final 
concentration of 1µg/ml and PMSF at a concentration of 100 µg/ml added before use. 
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Coumaric acid 
90 mM p-coumaric acid made up in dimethyl sulfoxide (DMSO) and stored at -20°C. 
 
Dual-Glo Luciferase Assay System 
Purchased from Promega and stored at -20° 
 
Dubecco’s modified eagle media (DMEM) high glucose  
Purchased from Life Technologies and supplemented with 10% foetal bovine serum (FBS), 
1 ml 100x penicillin/streptomycin to a final concentration of 20 µg/ml penicillin and 10 µg/ml 
streptomycin (PAA Laboratories), and 1mM sodium pyruvate. Media was stored at 4°C. 
 
Enhanced chemiluminescence (ECL) buffer 
100 mM Tris-HCl pH 8.5, stored at 4°C.  
Prior to use 10 ml of ECL buffer mixed with 3 µl hydrogen peroxide, 25 µl 90 mM 
coumaric acid and 50 µl 250 mM luminol. 
 
EDTA solution (pH 8.0) 
0.5 M EDTA solution 




Fermentas PageRuler Prestained Protein Ladder  





50% culture medium 
 
2x HEPES-buffered saline (HEBS) 
50 mM HEPES 
1.5 mM Na2HPO4 
280 mM NaCl 
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3x Lamelli sample buffer (LSB) 




Prepared in dH2O and stored at -20°C. Protease inhibitors aprotinin and leupeptin both at a 
final concentration of 1 µg/ml, PMSF at a final concentration of 100 µg/ml and 5 µl 
saturated bromophenol blue added to 1 ml of LSB prior to use. 
 
Luminol 
250 mM luminol in DMSO, stored at -20°C. 
 
Luria-Bertani (LB) medium  
1% NaCl 
0.5% Bacto-yeast extract 
1% Bacto-tryptone 
Made up in dH2O, pH adjusted to 7.0 with NaOH and sterilised by autoclaving. 
 
LB agar plates 
1.5% (w/v) agar dissolved in LB medium, autoclaved and cooled to 50°C. Plates were 




1% methylene blue 
1% (w/v) made up in dH2O. 
 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
5 mg/ml MTT (Calbiochem) 
Prepared in 1x PBS, sterilised by filtering through a 0.2 µm filter and stored at -20°C 
protected from light. 
 
MTT solubilisation solution 
50% dimethylformamide 
0.2% glacial acetic acid 
20 mM HCl 
20% SDS 
Prepared in dH2O. 
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OptiMEM reduced serum medium 
Purchased from Life Technologies and stored at 4°C. 
 
4% Paraformaldehyde (PFA) 
8 g PFA powder dissolved in 100 ml dH2O and heated to 60°C in fume hood. 3 M NaOH 
added drop-wise until solution turned clear, followed by 20 ml of 10x PBS and dH2O to a 
final volume of 200 ml. Aliquots stored at -20°C. 
 
Phenylmethylsulfonyl fluoride (PMSF) 
10 mM PMSF made up in isopropanol and stored at -20°C. 
 
10x Phosphate-buffered saline (PBS) 
140 mM NaCl 
2.7 mM KCl 
8.0 mM Na2HPO4 
1.5 mM KH2PO4 
Made up in dH2O and sterilised by autoclaving. 
 
Plasmid Midi Kit 
Purchased from Qiagen. 
 
Polybrene 
10 mg/ml, purchased from Santa Cruz Biotechnology and stored at -20°C. Working 
concentration 5 µl/ml. 
 
QRT-PCR reagents 
TaqMan MicroRNA Reverse Transcription Kit 
TaqMan Universal PCR Master Mix II (No UNG) 
TaqMan microRNA assay primers: 
hsa-miR-196a-5p (mature miRNA sequence UAGGUAGUUUCAUGUUGUUGGG) 
RNU48 control miRNA assay  
Purchased from Life Technologies and stored at -20°C. 
 
ReBlot Plus stripping buffer  
Reblot Plus 10x stripping buffer (Millipore) was diluted 1:10 in dH2O and stored at 4°C. 
 
RNeasy formalin fixed paraffin embedded (FFPE) Kit  
Purchased from Qiagen. 
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10x Running/Transfer buffer 
250 mM Tris-base 
2.5 M glycine 
1% SDS 
Made up in dH2O. 
 
1x Running buffer for SDS-PAGE 
10% 10x running/transfer buffer 
90% dH2O 
 
10% Sodium dodecyl sulphate (SDS) 
Made up in dH2O, heated to 68°C to dissolve and pH adjusted to 7.2 using concentrated 
HCl. 
 
SDS polyacrylamide gels 
Protogel 30% Acrylamide Mix (37.5:1 acrylamide to bisacrylamide stabilised solution) was 
purchased from National diagnostics.  
 
Table 2.3 SDS-PAGE gel components for two gels.  
The smaller the size of the protein of interest, the higher the percentage resolving gel 
used. 
 
Stacking gel 4% 
1.0 mM Tris pH 6.8 750 µl 
30% Acrylamide 1.0 ml 
ddH2O 4.1 ml 
10% SDS 60 µl 
10% APS 60 µl 
TEMED 6 µl 
      
 
10x Tris-buffered saline (TBS) 
250 mM Tris-base 
1.5M NaCl 
Made up in dH2O, pH adjusted to 7.4 with concentrated HCl. 
 
1x TBS-Tween (TBS-T) 
0.1% Tween 20 in 1x TBS 
 
Tris-EDTA (TE) buffer 
10 mM Tris-HCl pH 8.0 
1 mM EDTA pH 8.0 
Made up in dH2O. 




1.5 mM Tris pH 8.8 5.0 ml 5.0 ml 5.0 ml 
30% Acrylamide 6.7 ml 8.0 ml 10.0 ml 
ddH2O 7.9 ml 6.6 ml 4.6 ml 
10% SDS 200 µl 200 µl 200 µl 
10% APS 200 µl 200 µl 200 µl 
TEMED 8 µl 8 µl 8 µl 
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1% toluidine blue in 1% borax 
1% (w/v) toluidine blue, 1% (w/v) borax 
Made up in dH2O. 
 
Transfection reagents 
X-tremeGENE HP DNA transfection reagent, purchased from Roche. 
FuGENE HD transfection reagent, purchased from Promega. 
 
1x Transfer buffer for Western blot 




0.2% Triton X-100 
Triton X-100 0.1 ml dissolved in 49.9 ml of 1x PBS. 
 
TRIzol (guanidinium thiocyanate-phenol-chloroform) 
Purchased from Life Technologies. 
 
1x Trypsin 
10% 10x trypsin 
90% versene 
 
VECTASHIELD mounting medium with DAPI 
Purchased from Vector Laboratories and stored at 4°C. 
 
Versene 
0.270 mM EDTA pH 8.0 
Made up in PBS and sterilised by autoclaving. 
 
 Antibodies 2.3.2
 Primary antibodies 2.3.2.1
Annexin A1 
Rabbit monoclonal antibody to annexin A1, MW 38 kDa. 
Dilution: 1:1000 in 5% BSA for Western blotting. 
Purchased from Cell Signaling. 
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β-Actin 
Mouse monoclonal antibody to β-Actin, molecular weight (MW) 42 kDa. 
Dilution: 1:5000 in 5% milk for Western blotting. 
Purchased form Sigma-Aldrich. 
 
Caspase-3 
Rabbit polyclonal antibody to caspase-3 (full length and cleaved), MW 17, 19, 35 kDa. 
Dilution: 1:1000 in 5% milk for Western blotting. 
Purchased from Cell Signaling. 
 
Cleaved PARP 
Mouse monoclonal antibody to cleaved PARP, MW 89 kDa. 
Dilution: 1:1000 in 5% milk for Western blotting. 
Purchased from Cell Signaling. 
 
E-cadherin 
Rabbit monoclonal antibody to E-cadherin, MW 135 kDa. 
Dilution: 1:1000 in 5% BSA for Western blotting, 1:100 in 3% BSA for immunofluorescence. 
Purchased from Cell Signaling. 
 
Phospho-Histone H2AX (gamma H2AX) 
Rabbit polyclonal antibody to gamma H2AX. 
Dilution: 1:100 in 3% BSA for immunofluorescence. 
Purchased from Cell Signaling. 
 
Tubulin 
Mouse monoclonal antibody to tubulin, MW 55 kDa. 
Dilution: 1:2000 in 5% milk for Western blotting. 
Purchased from Sigma-Aldrich. 
 
Vimentin 
Rabbit monoclonal antibody to vimentin, MW 57 kDa. 
Dilution: 1:1000 in 5% BSA for Western blotting, 1:100 in 3% BSA for immunofluorescence. 
Purchased from Cell Signaling. 
 
 Secondary antibodies 2.3.2.2
Mouse-HRP 
Goat anti-mouse IgG conjugated to horseradish peroxidase (HRP). 
Dilution: 1:2000 in 5% milk for Western blotting. 
Purchased from Sigma-Aldrich. 
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Rabbit-HRP 
Donkey anti-rabbit IgG conjugated to HRP. 
Dilution: 1:2000 in 5% milk for Western blotting. 
Purchased from GE Healthcare. 
 
Mouse-FITC 
Goat anti-mouse IgG conjugated to fluorescein isothiocyanate (FITC). 
Dilution 1:100 in 3% BSA for immunofluorescence. 
Purchased from Sigma-Aldrich. 
 
Rabbit-FITC 
Goat anti-rabbit IgG conjugated to FITC. 
Dilution 1:100 in 3% BSA for immunofluorescence. 
Purchased from Sigma-Aldrich. 
 
 Plasmids/viral constructs 2.3.3
pBabe-puro plasmid 
Provided by Dr Joop Gäken, Department of Haemato-Oncology, King’s College London. 
 
miR-196a expression plasmid 
MiR-196a expression plasmid was prepared by Dr Joop Gäken, Department of Haemato-
Oncology, King’s College London, by PCR amplification of a 630 bp genomic DNA 
fragment containing miR-196a using the following forward and reverse primers: 
CAGGCTTGTGCCTGTGTCTA and GTGCCTCGGGAGAGTTGAC. The PCR product was 
sequenced, verified and cloned into the retroviral expression vector pBabe-puro. 
 
Retroviral miR-196a sponge and corresponding empty vector control 
Expresses red fluorescent protein (RFP) and contains puromycin resistance gene. 
Provided by Dr Sebastian Herzog, Division of Developmental Immunology, Medical 
University of Innsbruck, Austria. 
 
Retroviral ANXA1 shRNA and corresponding empty vector control 
Contains puromycin resistance gene. 
Provided by Dr Stéphane Gobeil, CHUL Research Centre, Laval University, Canada. 
 
Retrovirus plasmids 
VSV-G envelope plasmid, HIT60 Gag and Pol expressing plasmid 
Provided by Dr Ulrich Maurer, University of Freiburg, Germany. 
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ANXA1 dual luciferase reporter plasmid 
Expresses green fluorescent protein (GFP). 
Provided by Prof Jacques Huot, Laval University Cancer Research Centre, Canada. 
 
 Cell lines 2.3.4
HEK293T     
Cell line derived from Human Embryonic Kidney 293 cells 
Constitutively express simian virus 40 (SV40) large T antigen involved in viral genome 
replication. 
Provided by Dr Lucas Chan, Rayne Institute, King’s College London. 
 
HN5 
Human tongue SCC cell line 
Provided by Dr Barry Gusterson, Department of Pathology, University of Glasgow. 
 
HN30 
Human pharynx SCC cell line 
Provided by Dr Andrew Yeudall, Department of Craniofacial Development and Stem Cell 
Biology, King’s College London. 
 
MDA-MB-231 
Human metastatic (pleural fluid) breast adenocarcinoma cell line 
Provided by Prof Joy Burchell, Breast Cancer Biology Group, King’s College London. 
 
SCC11B 
Human hypopharynx cell line 
Provided by Dr Thomas Carey, University of Michigan. 
 
SCC22B 
Human metastatic (cervical lymph node) hypopharyngeal cell line 
Provided by Dr Thomas Carey, University of Michigan. 
 
HT-1080  
Human fibrosarcoma cell line 
Purchased from American Type Culture Collection (ATCC). 
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 Methods 2.4
 Cell culture 2.4.1
 Cell maintenance 2.4.1.1
All cell lines were maintained in DMEM high glucose, supplemented with 10% FBS, 20 
µl/ml penicillin, 10 µl/ml streptomycin, and 1 mM sodium pyruvate. HN5 miR-196a 
overexpressing cells and HN5 pBabe-puro empty vector control cells were also 
supplemented with 2 µl/ml puromycin. 
 
Cells were grown in 75 cm2 flasks, incubated in a humidified tissue culture incubator at 
37ºC and 5% CO2, and passaged every 3 to 4 days once 80-90% confluent. The old 
medium was removed, cells were washed with 5 ml versene and incubated with 1 ml 
trypsin at 37ºC. Once the cells had detached they were resuspended in fresh medium to 
neutralise the trypsin and diluted as necessary for further use. 
 
 Counting cells 2.4.1.2
Cells were trypsinised, collected in 5 ml of media and centrifuged at 1000 x g for 5 minutes. 
The resultant pellet was resuspended in 10 ml of media. Ten microlitres of cell suspension 
was pipetted into a haemocytometer and cells in the outer 4 large squares were counted. 
Cell number was calculated as follows: 
Cells/ml = (number of cells in 4 squares/4) x 104. 
 
 Freezing and thawing of cell  2.4.1.3
Cells were collected by trypsinisation and centrifuged for at 1000 x g for 5 minutes. The cell 
pellet was resuspended in 1 ml of freezing medium, transferred into a cryovial and stored at 
-80°C in a container filled with isopropanol to control the freezing speed. The cells were 
transferred to a liquid nitrogen tank for long term storage. For thawing cells, the cryovial 
was placed in a 37°C waterbath, diluted in 10 ml of medium and centrifuged for 5 minutes 
at 1000 x g. The resulting cell pellet was resuspended in fresh medium and placed into a 
flask. 
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 Preparation of plasmid DNA 2.4.2
 Transformation of plasmid DNA into competent bacteria and bacteria 2.4.2.1
culture 
Chemically competent E.Coli (One Shot Mach1-T1, Invitrogen) were used for plasmid 
amplification. One microlitre of plasmid DNA was added to 100 µl of bacteria, incubated on 
ice for 30 minutes, heat shocked at 42°C for 45 seconds in a waterbath, then transferred 
back on ice for 2 minutes. LB medium (250 µl) was added and the bacteria cultured in a 
shaker at 37°C for 1 hour, after which they were spread on a pre-warmed agar plate 
supplemented with the appropriate antibiotic and incubated at 37°C overnight. A single 
colony was selected, placed in 5 ml LB medium supplemented with carbenicillin and 
cultured in a shaker at 37°C for 6-8 hours at 250 rpm. This was transferred into 50 ml LB 
medium with carbenicillin and cultured overnight under the same conditions. 
 
 Plasmid purification and extraction 2.4.2.2
This was carried out using the Plasmid Midi Kit according to the manufacturer’s 
instructions. Briefly, the bacterial cells were harvested by centrifugation at 6000 x g for 15 
minutes at 4°C and the pellet mixed with 4 ml resuspension buffer. Four millilitres of lysis 
buffer was added, incubated at room temperature for 5 minutes followed by the addition of 
4 ml of neutralisation buffer and incubation for 15 minutes on ice. The cells were then 
centrifuged for at 20000 x g for 1 hour at 4°C, during which 4 ml of equilibrium buffer was 
passed through the purification columns. After centrifugation, the supernatant was applied 
to the column and allowed to empty by gravity. The column was washed twice and the 
plasmid DNA eluted using 5 ml of elution buffer, then precipitated by adding 3.5 ml 
isopropanol and centrifuging at 5000 x g for 1 hour at 4°C. The supernatant was removed 
and the pellet air-dried, before dissolving in 150 µl TE buffer. The DNA was stored 
overnight at 4°C and the concentration determined using a NanoDropTM 1000 
Spectrophotometer (Thermo Scientific). DNA was placed in -20°C for long term storage. 
 
 Transfection methods 2.4.3
 Transfection of HN5 cells to overexpress miR-196a using transfection 2.4.3.1
reagent 
For transfection of HN5 cell with miR-196a or pBabe-puro plasmids, cells were seeded in 6 
well-plates to achieve 80% confluency the following day. A transfection mix of 200 µl 
OptiMEM, 2 µg DNA and 4 µl X-tremGENE HP DNA transfection reagent (2:1 transfection 
reagent to DNA ratio), which acts by complexing with and transporting DNA into cells, was 
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prepared and incubated at room temperature for 20 minutes for complex formation. This 
mix was added drop by drop to different areas of the well and the plate was gently rocked 
back and forth and side-to-side for even distribution. The cells were incubated at 37°C and 
5% CO2 for 48 hours, at which point cells were placed under selection or harvested for 
transient transfection experiments.  
 
 Generation of stable HN5 miR-196a overexpressing cell lines 2.4.3.2
The optimum concentration of puromycin was first determined for each cell line by 
incubating cells with medium containing increasing concentrations from 1 to 10 µg/ml. The 
lowest dose to completely kill the parental cell line at 48 hours was 2 µg/ml. Forty eight 
hours after transfection with the plasmid DNA, the medium of the cells was replaced with 
medium supplemented with 2 µg/ml of puromycin alongside untransfected controls. The 
majority of the cells died after 24 to 48 hours, with the remaining single cells and small 
colonies successfully transfected. One hundred percent of the control cells died. The 
medium with puromycin was changed every 3 to 4 days and cells were grown over 6 
weeks. Cells originating from single colonies were selected when they had reached a 
diameter of approximately 5 mm and not coalescing with adjacent colonies. Hole-punched 
pieces of circular filter paper were autoclaved, soaked in trypsin and placed over the 
colonies using autoclaved forceps. After 10 minutes the filter paper was removed and 
placed in conditioned medium supplemented with puromycin in 24-well plates. Conditioned 
medium was prepared by collecting medium from confluent parental cells, passing this 
medium through a 0.45 µm filter (Fisher Scientific) and diluting 1:10 with fresh medium. Of 
the ten colonies suitable for this procedure two colonies survived and were expanded. The 
remainder of the cells after single colony selection were pooled together to form a mixed 
population of cells. The cells were tested for successful modulation by qRT-PCR. 
 
 Virus production  2.4.3.3
HEK293T cells were seeded in 10 cm dishes and grown to 70-80% confluence. A vector 
mix of 10 µg retroviral vector, 3.5 µg VSV-G envelope plasmid and 6.5 µg HIT60 Gag and 
Pol expressing plasmid were prepared in 250 µl sterile dH2O and 250 µl CaCl2 solution for 
transfection by calcium phosphate precipitation. This was added dropwise to 500 µl 2x 
HEBS buffer while vortexing and incubated for 30 minutes at room temperature. This mix 
was adding to the HEK293T cells. The virus-containing supernatant was harvested at 8, 16 
and 24 hours post-transfection, filtered through a 0.45 µm filter and stored at -80°C. Prior to 
use polybrene was added to the supernatant to a final concentration of 5 µg/ml. 
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 Generation of stable virus infected knockdown cell lines 2.4.3.4
The optimum concentration of puromycin was determined as above. Cells were seeded in 
6-well plated to achieve 80% confluency the following day and infected by adding 1 ml of 
virus supernatant supplemented with 5 µg/ml polybrene. Two millilitres of fresh medium 
was added 8 hours after infection. After 48 hours the medium was replaced with medium 
containing puromycin. For the miR-196a sponge or control infected cells successful 
transduction could be confirmed by the expression of RFP. A high proportion of cells 
survived the selection process after virus infection; these cells were expanded and 
knockdown confirmed by qRT-PCR or Western blot analysis. 
 
 RNA methods 2.4.4
 RNA extraction form cells 2.4.4.1
RNA was extracted using the following 3 steps: 
a) Phase separation: Cells were plated in 10 cm dishes and grown until confluent.  One 
millilitre of TRIzol was added directly to the dish and the lysate collected in an eppendorf 
tube. After 5 minutes incubation at room temperature, 0.2 ml chloroform was added and 
the tube shaken vigorously. Samples were incubated at room temperature for 3 minutes 
and centrifuged at 12000 x g for 15 minutes at 4°C to separate the mixture into three 
phases.  
b) RNA precipitation: The top aqueous phase was transferred into a new eppendorf tube, 
without disturbing the interphase. RNA was then precipitated by adding 0.5 ml 
isopropanol per 1 ml TRIzol and incubated at room temperature for 10 minutes. The 
samples were centrifuged again at 12000 x g for 10 minutes at 4°C.  
c) RNA wash and resuspension: The supernatant was removed and the RNA pellet 
washed with 1 ml 75% ethanol per 1 ml TRIzol. The samples were vortexed and 
centrifuged at 7500 x g for 5 minutes at 4°C. The supernatant was removed and the any 
remaining ethanol allowed to air dry. The resultant pellet was dissolved in 30 µl of 
RNAse free water, stored at -20°C overnight and quantified the following day using the 
NanoDrop Spectrophotometer. RNA was placed in -80°C for long term storage. 
 
 RNA extraction from FFPE samples 2.4.4.2
Forty cases of radiosensitive and radioresistant patient tumour samples were selected 
using the Head and Neck clinical database. Patients had stage III or IV primary 
oropharyngeal cancer and were treated radically with concomitant chemoradiation. 
Radioresistance was defined as residual tumour or progressive disease in the radiation 
field after completion of treatment, and radiosensitivity was defined as having a complete 
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response to treatment and remaining disease free for a minimum of 3 years. Tumour slides 
were reviewed by a consultant pathologist and samples containing a minimum tumour 
percentage of 60% were selected for RNA extraction. Ethics approval was covered by an 
existing project (REC reference 10/H0701/27). 
 
Extraction was carried out using the miRNeasy FFPE kit following manufacturer 
instructions. Two 20 µm sections were cut from each selected FFPE block and placed into 
an eppendorf tube. The microtome was cleaned with ethanol and a new blade used for 
each sample. One millilitre of xylene was added for deparaffinisation and the samples 
vortexed and centrifuged at full speed (16000 x g) for 2 minutes. The supernatant was 
removed, 1 ml of 100% ethanol added to the pellet, and the tubes were vortexed and 
centrifuged at full speed again for 2 minutes. The supernatant and residual ethanol were 
removed and the samples incubated at room temperature for 10 minutes. The samples 
were lysed with 150 µl buffer PKD (proteinase K digestion) and 10 µl proteinase K 
(concentration not specified), followed by heat treatment at 56°C for 15 minutes, then 80°C 
for 15 minutes. They were then incubated on ice for 3 minutes, centrifuged for 15 minutes 
at 16000 x g and the supernatant transferred into a new eppendorf. The supernatant was 
treated with 16 µl of DNase booster buffer and 10 µl DNase I and incubated at room 
temperature for 15 minutes. Three hundred and twenty microlitres of Buffer RBC (exact 
composition proprietary) and 720 µl of ethanol were added, the mixture transferred into 
RNeasy MiniElute spin columns placed in collection tubes, and centrifuged at ≥ 8000 x g for 
15 seconds. Buffer RPE (500 µl) was added to the spin columns to wash the samples. The 
columns were centrifuged and the flow-through discarded. This step was repeated. The 
spin columns were placed in new collection tubes, centrifuged with the lid open for 5 
minutes and the flow-through discarded. The spin columns were placed in new eppendorfs 
and 20 µl of RNase free water was added directly to the spin column membranes. The spin 
columns were centrifuged for 1 minute at full speed to elute the RNA. RNA was stored at -
20°C overnight and quantified the following day using the NanoDrop Spectrophotometer. 
RNA was placed in -80°C for long term storage. 
 
 Reverse Transcription Polymerase Chain Reaction (RT-PCR) 2.4.4.3
This technique is used to create complementary DNA (cDNA) transcripts from RNA using 
reverse transcriptase enzymes. The cDNA can then be amplified and quantified by 
quantitative real time PCR (qRT-PCR).  
 
Complementary DNA was created using Taqman miRNA reverse transcription kit. Each 
reaction had a volume of 15 µl and RNA samples were diluted to a concentration of 10 ng/5 
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µl for each reaction. A master mix was prepared containing 0.15 µl of 100 mM dNTP 
(deoxynucleoside triphosphate) building blocks, 1 µl of 50 U/µl MultiScribe reverse 
transcriptase, 1.5 µl reverse transcription buffer, 0.19 µl of 20 U/µl RNase inhibitor, which 
protects RNA during the reverse transcription, and 4.16 µl nuclease-free water for each 
reaction. The reverse transcription reaction was prepared by combing 7 µl of mastermix, 5 
µl (10 ng) total RNA and 3 µl of miR-196a or RNU48 reverse transcription primer. RT 
primers were diluted to a 5x working stock solution using 0.1x TE buffer. The primer is the 
starting point for the reaction and is complementary to the miR-196a or RNU48 sequence. 
The samples were loaded into a thermal cycler (G-Storm) with the following program: 
 








 Quantitative Real Time Polymerase Chain Reaction (qRT-PCR) 2.4.4.4
QRT-PCR simultaneously amplifies and quantifies targeted DNA sequences. During 
amplification, a fluorescent dye binds via a labelled hybridising probe (TaqMan Small RNA 
Assay) to the accumulated DNA molecules. The fluorescence signal is directly proportional 
to the DNA concentration and linear correlation used to calculate the amount of template 
present at the beginning of the reaction. The relative standard curve method was used to 
quantitate the miRNA expression levels, with RNU48 used as the housekeeping or 
reference gene expressed in all cells. The standard curve was optimised for each sample 
set. 
 
Each reaction volume was 10 µl. A master mix was prepared containing 0.5 µl TaqMan 
Small RNA Assay (miR-196a or RNU48), 5 µl TaqMan Universal PCR Master Mix II 
(No UNG) and 3 µl nuclease-free water. The qRT-PCR reaction was prepared by 
combining 8.5 µl of master mix and 1.5 µl of cDNA. Samples were run in triplicate with 
a standard curve, in a Rotor-Gene (Corbett) real time PCR machine. The following 






Step Time Temperature 
Hold 30 minutes 16ºC 
Hold 30 minutes 42ºC 
Hold 5 minutes 85ºC 
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Table 2.5 qRT-PCR thermal cycling conditions. 
 
Step Enzyme activation PCR 
HOLD 
Cycle (40 cycles) 
Denature Anneal/Extend 
Temperature 95ºC 95ºC 60ºC 
Time 10 minutes 15 seconds 60 seconds 
 
 Protein methods 2.4.5
 Protein extraction 2.4.5.1
Cells were trypsinised and collected in cold 1x PBS, centrifuged at 1000 x g for 5 minutes 
and resuspended in 1 ml PBS. This was centrifuged at 4°C and 5000 x g for 5 minutes and 
the resultant cell pellet was stored at -20° until further use. To prepare total cell lysates the 
cell pellet was resuspended in 30-60 µl of cell lysis buffer containing protease inhibitors 
(PMSF, aprotinin/leupeptin), incubated on ice for 10 minutes and centrifuged at 4°C and 
16000 x g for 5 minutes. The solubilised proteins contained within the supernatant were 
transferred into a new eppendorf tube. 
 
 Bradford assay 2.4.5.2
This colorimetric protein assay used to determine protein concentrations and is based on 
the binding of Coomassie blue dye to proteins. When the dye binds to protein, it is 
converted from a doubly pronated red cationic form to a stable unpronated blue form, and 
the increase of absorbance at 595 nm is proportional to the amount of bound dye, and 
therefore the concentration of protein.  
 
Bovine serum albumin (BSA) was serially diluted from 20 µg/ml to 0 for a standard curve, 
and samples diluted between 1:500 to 1:1000. In a 96-well plate 100 µl of Bradford reagent 
was added to 100 µl of sample or standard, and the absorbance of each well was 
measured at 595 nm on a LT-4000 microplate reader (Labtech, Manta software). The 
protein concentration of each sample was calculated via the standard curve. 
 
 Sodium Dodecyl sulphate Polyacrylamide Gel Electrophoresis (SDS-2.4.5.3
PAGE) 
This technique is used to separate proteins according to their molecular weight on a 
polyacrylamide gel. The SDS in the LSB is anionic and both denatures the protein and 
confers a negative charge to them, allowing migration through the gel by molecular weight, 
not intrinsic electric charge. The separation is determined by the relative size of the pores 
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in the gel, which is determined by the amount of acrylamide in the gel. The smaller the size 
of protein of interest, the higher the percentage of acrylamide. 
 
Gels were cast according to the manufacturer’s instructions (BioRad, Mini-PROTEAN 
system) with the stacking gel cast over the resolving gel. The stacking gel has a lower 
concentration of acrylamide, lower pH and ionic content, allowing proteins in a loaded 
sample to be concentrated into a tight band during the start of electropheresis before 
entering the resolving gel. Equal concentrations of protein was resuspended in LSB and 
heated at 95°C for 5 minutes to denature the protein. Gels were placed in an 
electrophoresis tank filled with 1x running buffer and protein samples loaded into the lanes 
in the gel. The first lane was loaded with 4 µl of prestained protein ladder as a molecular 
weight marker. Electrophoresis was carried out at 80 V for protein migration through the 
stacking gel, then the voltage was increased to 100 V for approximately 2 hours.   
 
 Western Blot analysis 2.4.5.4
This method is based on inducing the proteins, which have an electrical charge, to travel in 
an electrical field from the gel onto a nitrocellulose or polyvinylidene membrane, where they 
can be detected by specific antibodies.  
 
Once the proteins were separated by SDS-PAGE, the gel and nitrocellulose membrane 
(Sigma-Aldrich) were sandwiched between sponges and three layers of filter paper on each 
side and clamped together. The sandwich was submerged into a transfer tank (BioRad 
Criterion Blotter) filled with 1x transfer buffer, to which an electrical field was applied with 
the gel closer to the cathode. Negatively-charged proteins travelling towards the anode are 
stopped and bound by the membrane. The transfer was carried out at 400 mA for 90 
minutes.  
 
After the transfer, the membrane was blocked for one hour in 5% milk solution prepared in 
TBS-T, to prevent non-specific background binding of the antibodies to the membrane. The 
membrane was then incubated with the primary antibody of interest overnight at 4°C. After 
incubation the membrane was washed three times for 10 minutes with TBS-T and 
incubated for one hour at room temperature with the corresponding secondary antibody. 
The primary antibody binds directly to the protein of interest on the membrane and the 
secondary antibody, which is linked to an enzyme horseradish peroxidase, detects the 
primary antibody. The membrane was washed again three times for 10 minutes with TBS-T 
and incubated with an enhanced chemoluminescence (ECL) solution for one minute. The 
enzyme in the secondary antibody catalyses oxidation of luminol in the ECL solution, 
resulting in emission of light. This emission can be captured on photographic films which 
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creates an image of the bound antibodies on the membrane. The intensity of the signal is 
proportional to the amount of antibody, which is in turn related to the concentration of 
protein on the membrane. The membranes were exposed to X-ray films (Fujifilm) for 
seconds to 15 minutes depending on the strength of the signal and developed in a JB-33 
X-ray film processor (JPI). Before re-probing with another primary antibody, the membrane 
was stripped with Reblot Plus Strong Buffer for 10 minutes and incubated with blocking 
buffer twice for 5 minutes. 
 
Each western blot was also incubated with tubulin or β-actin as a loading control to check 
the concentration of the protein loaded. The intensity of the bands was compared using 
ImageJ software (National Institutes of Health, USA). 
 
 Radiation assays 2.4.6
 Clonogenic assay  2.4.6.1
This cell survival assay determines the ability of a cell to proliferate and form a colony, and 
is commonly used after an exposure to an insult such as ionising radiation.  
 
Cells were grown in 25 cm2 flasks until 70-80% confluent. They were then irradiated at 0 
(control), 2, 4 and 6 Gy using a Nordion GC-1000S v2.9 cell irradiator, which uses a 
caesium source at a dose rate of 250 +/- 0.59% Gy/hr, and incubated at 37°C overnight. 
The cells were trypsinised and counted and, depending on the behaviour of the cell line, 
600-1000 cells were seeded into 6 cm dishes in triplicate. The optimal seeding density was 
determined using the parental cell lines. The dishes were placed in the incubator, reviewed 
daily and the medium changed every 4 days. They were left for 14-20 days until the cells in 
the control dishes had formed individual colonies that could be counted. At this point the 
cells were washed with versene, fixed with buffered formalin and stained with 1% 
methylene blue. Colonies of greater than 50 cells were counted in triplicate in each dish 
and the plating efficiency (PE) calculated: 
PE = Number of colonies/number of cells plated x 100. 
This was used to calculate the surviving fraction (SF): 
SF = PE of treated sample/PE of control x 100. 
 
 MTT assay 2.4.6.2
The MTT assay is a colorimetric assay, which determines the viable number of cells in 
proliferation and cytotoxicity studies. It measures the reduction of soluble yellow MTT salts 
by mitochondrial enzymes to an insoluble purple formazan product. The cells are then 
solubilised and the intensity of the colour is measured spectrophotometrically. As reduction 
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of MTT can only occur in metabolically active cells the intensity of the colour is proportional 
to cell viability. 
 
Cells were grown and irradiated as in the clonogenic assay. Three thousand cells for each 
cell line and dose were seeded into a 96-well plate, with 6 wells for each dose. In parallel 
cells were seeded in 6 well plates and counted on alternate days. The MTT assay was 
carried out when the control cells became confluent on visualisation under a microscope or 
when the growth plateaued (5-7 days). At this point 20 µl of MTT solution was added to 
each well and incubated for 2 hours at 37°C and 5% CO2, after which 150 µl of MTT 
solubilisation solution was added. After 24 hours of further incubation the optical density 
was measured at 595 nm using an LT-4000 Microplate reader. 
 
 Gamma H2AX immunofluorescence 2.4.6.3
Radiation acts by creating double strand DNA breaks (DSB). Cells react by recruiting a 
number of proteins to the site of damage. One of the earliest events, which occurs within 
minutes, is the phosphorylation of histone H2AX, which becomes gamma H2AX. This is 
necessary for the recruitment of the other proteins involved in the DNA damage response 
pathway. Gamma H2AX foci can be visualised by using a primary antibody against gamma 
H2AX, followed by a secondary antibody labelled with fluorescence. These foci represent 
an accumulation of gamma H2AX, along with the other proteins that have localised to the 
site of damage. Gamma H2AX foci rapidly accumulate and peak 30 minutes after 
irradiation, with foci remaining at 24 hours representing persistent damage and therefore 
increased radiosensitivity. 
 
Forty thousand cells were seeded in duplicate into 8-chamber slides (BD Biosciences) and 
incubated overnight to attach. They were irradiated at 0 (control), 0.5, 1 and 2 Gy and 
incubated for 30 minutes or 24 hours, after which they were processed in the following 3 
steps: 
a) Fixation and permabilisation: Cells were washed three times with PBS and fixed with 
200 µl 4% paraformaldehyade for 15 minutes at 37°C. After further washing with PBS 
cells were permeabilised with 200 µl 0.2% Triron X-100 for 15 minutes and washed 
again. 
b) Antibody staining: Cells were blocked for 30 minutes in 200 µl 3% bovine serum albumin 
in TBS-T (BSA/TBS-T) and then incubated overnight at 4°C with 100 µl of rabbit 
phospho-histone H2AX antibody diluted 1:100 in 3% BSA/TBS-T. Cells were washed 
with PBS and incubated with 100 µl of 1:100 goat anti-rabbit fluorescein isothiocyanate 
(FITC) antibody for 90 minutes.  
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c) Preparation for imaging: The chamber was removed from the slide and 8 µl of 
Vectashield mounting medium was added. The mounting medium contains 4’,6-
diamidino-2-phenylindole (DAPI) which is a fluorescent stain that binds to DNA and 
therefore allows visualisation of the nucleus of the cell. The slide was covered with a 
coverslip and stored at 4°C for at least 10 minutes before imaging or -20°C for long term 
storage. 
 
Images were acquired at 60x magnification using an Olympus BX61 automated 
fluorescence microscope and Cell^F software. BlobFinder image analysis software (Centre 
for Image Analysis, Sweden) was used for automated reproducible foci detection. 
 
 Functional assays 2.4.7
 Cell proliferation 2.4.7.1
This was assessed using 2 methods: daily cell counting and MTT assay. For each cell line 
100000 cells were seeded in triplicate in 6-well plates (day 0). Cells were trypsinised and 
counted from days 1 to 7. For the MTT assay 3000 were seeded in 96 well plates, with 6 
wells per time point and left overnight (day 0). MTT was added and cells processed as 
previously described in section 2.4.6.2 on days 1 to 5. 
 
 Cell migration (Scratch assay) 2.4.7.2
This assay was performed to investigate the migratory ability of the cell lines.  
Perpendicular lines were marked on the bottom surface of 6-well plates as reference points 
for imaging. Four to five hundred thousand cells were seeded in triplicate and grown until 
confluent. Confluent cells were serum starved for 24 hours by replacing the media with 
media without FBS, to synchronise the cells in G0 of the cell cycle. A p200 pipette tip was 
used to create a straight scratch along the diameter of the well, with a minimum of three 
scratched per well. Floating cells were removed by washing the well twice with media and 
the plates were imaged at 4x magnification using an Olympus CKX41 microscope and 
Cell^F software. Cells were incubated at 37ºC and imaged again at various time points 
from 16 to 24 hours. The assay was performed in triplicate and the area between the 
scratch was imaged, analysed using ImageJ, and the percentage of the scratch area 
closed between the two time points calculated. 
 
 Matrigel invasion assay 2.4.7.3
The invasive property of the cell lines was assessed using BD BioCoat Matrigel Invasion 
Chambers. The chambers, or inserts, fit in the wells of a 24-well plate and contain a 
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membrane coated with Matrigel, a protein mixture that resembles extracellular matrix, 
through which cells can invade.  
 
Invasion chambers were placed into the wells of a 24-well plate and warm medium added 
to the chamber and well and incubated for 2 hours to allow rehydration. An equal number 
of control chambers, which do not have Matrigel coating on their membrane, were also 
prepared. The optimal seeding density of the parental cell lines was determined alongside 
the HT-1080 cell line, which is known to be highly invasive, as a control. Between 2x105 to 
4x105 cells/ml in serum free medium were prepared in duplicate and placed in the invasion 
chambers, with chemoattractant (medium containing 5% FBS) added to the wells. Cells 
were incubated for 22 hours, after which the non-invading cells on the upper surface of the 
chamber were scrubbed off with a cotton swab, and the invading cells on the lower surface 
were fixed with 100% methanol and stained with 1% toluidine blue in 1% borax and 
counted. The membrane was then removed using a scalpel, placed gently onto a 
microscope slide and covered with a coverslip. Images of the invasion and control cells 
were taken at 40x magnification using a Zeiss Axioplan microscope with a ColorView Soft 
Imaging System camera. The assay was carried out in duplicate and five random images 
were taken of each membrane. Invasion was expressed as the percent invasion through 
the Matrigel membrane relative to the migration through the control membrane: 
% invasion = Mean number of cells invading through Matrigel insert membrane/mean 
number of cells migrating through control insert membrane x 100. 
 
 Other methods 2.4.8
 E-cadherin and vimentin immunofluorescence 2.4.8.1
Forty thousand cells were seeded in duplicate into 8-chamber slides and allowed to attach 
overnight. Cells were processed as described in section 2.4.6.3 and incubated overnight at 
4°C with rabbit E-cadherin or vimentin antibody (1:100 dilution), followed by secondary 
FITC-conjugated antibody for 90 minutes. Images were acquired at 60x magnification as 
above. 
 
 Luciferase reporter assay 2.4.8.2
Cells were seeded in 96-well plates at a density of 10000 cells per well in triplicate and 
incubated overnight. A transfection mix of 10 µl OptiMEM, 0.1 µg of luciferase plasmid DNA 
and 0.2 µl X-tremeGENE HP DNA transfection reagent or 0.4 µl FuGENE HD transfection 
reagent was prepared and incubated at room temperature for 20 minutes. Ten microlitres 
of this mix was added to each well and incubated for 24 to 48 hours before the luciferase 
assay was performed using the Dual-Glo Luciferase Assay System. Dual-Glo Reagent was 
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added to each well and incubated for 15 minutes to allow cell lysis to occur. The Firefly 
luminescence was then measured in a Veritas Luminometer (Turner Biosystems). Dual-Glo 
Stop & Glo Reagent was then added and left for 15 minutes, after which the Renilla 
luminescence was read in the same order as the Firefly luminescence. Measurements from 
untransfected cells were used as negative controls and the data was normalised by 
dividing the Firefly activity by the Renilla activity.  
 
 Statistical analysis 2.4.9
Data is presented as the mean of independent experiments and the error bars indicate the 
standard deviation unless otherwise stated. Data was assessed for normality using the 
D’Agostino-Pearson normality test. The difference between two groups was compared 
using the unpaired, two-tailed Student’s t-tests if the data was normally distributed, or the 
Mann-Whitney U test if the data was not normally distributed. Data was analysed using 
Microsoft Excel and statistical analysis was performed using GraphPad Prism version 6.0 
(Graphpad Software Inc, La Jolla, CA, USA). P values less than 0.05, indicated by * in the 
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 Results  2.5
 MiR-196a expression level in HN5 and HN30 cell lines 2.5.1
Expression profiling of eight head and neck cell lines showed only the HN5 cell line to have 
low endogenous levels of miR-196a (Figure 2.2). This cell line and HN30, with high 
endogenous levels, were initially selected for further investigation. The expression levels of 
miR-196a were confirmed by qRT-PCR; miR-196a expression was significantly higher in 





Figure 2.3 QRT-PCR of endogenous miR-196a levels in HN5 and HN30 cell lines. 
RNA was extracted from HN5 and HN30 cell lines at 80-90% confluence and miR-196a 
levels compared using qRT-PCR. Data is expressed relative to the housekeeping gene 
RNU48, and is the mean of three independent RNA extractions. Error bars indicate 
standard deviation of the independent experiments. Statistical analysis was performed 




To characterise and compare the behaviour of these two cell lines, the cell proliferation was 
compared by daily counting over 7 days. HN30 demonstrated significantly faster 






























Figure 2.4 Cell proliferation in HN5 versus HN30 cell lines.  
Equal numbers of cells were plated in 6 well plates on day 0. Cells were trypsinised and 
counted every 24 hours for 7 consecutive days. The experiment was performed in 
triplicate and error bars indicate standard deviation. * Student’s t-test P values days 4 to 





 MiR-196a overexpression in HN5 cells 2.5.2
To investigate how miR-196a affects cell behaviour, the miR-196a gene was inserted into 
the retroviral pBabe-puro vector and transfected into HN5 cells. HN5 cells were also 
transfected with empty vector pBabe-puro, as the control cell line, and stable populations 
were selected using puromycin. Two cell populations grown from single colonies survived 
the selection process and were expanded over 6 weeks. The remaining cells were pooled 
together to form a mixed population of miR-196a overexpressing cells, and the levels of 
miR-196a expression were compared (Figure 2.5). The mixed population showed the 
highest level of overexpression of approximately 50-fold and was therefore selected for 
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Figure 2.5 MiR-196a expression in HN5 cells after transfection with miR-196a 
plasmid. 
MiR-196a was transfected into HN5 and stable populations selected using puromycin. 
Two cell populations grown from single colonies, colony 1 and colony 2, and a mixed 
population of overexpressing cells were grown. RNA was extracted once and miR-196a 
levels assessed using qRT-PCR. The levels were compared with HN5 cells and HN5 
cells stably transfected with empty vector pBabe-puro as the control. Data is expressed 
relative to RNU48 and represents the mean of three independent RNA extractions. 
 
 
 Exogenous miR-196a overexpression promotes cell proliferation, 2.5.2.1
migration and invasion 
The functional consequences of increased expression of miR-196a were investigated. The 
effect on cell proliferation was assessed using two methods: daily cell counting over 7 days 
and the MTT cell viability assay over 5 days. Both assays demonstrated significantly 
increased rate of growth in the miR-196a overexpressing cells compared with the control 

















































Figure 2.6 Cell proliferation of miR-196a overexpressing cells compared with 
pBabe-puro empty vector control.  
Left graph: equal numbers of cells were plated in triplicate on day 0 and counted every 
24 hours for 7 consecutive days. Data is the mean of 2 independent experiment and 
error bars indicate standard deviation. Statistical significance determined by Student’s t-
test. Days 3 to 7, P < 0.01. Right graph: cells were plated in 6 wells of a 96-well plate 
and the MTT assay was performed daily over 5 days (right). Data is the mean of 2 




The effect of miR-196a on migration was investigated using the scratch assay. MiR-196a 
significantly enhanced migration after 16 hours, with an average of 78% of the scratch area 
closed in the miR-196a cells versus 28% in the control cells (P < 0.01, Figure 2.7). The 
invasive potential of the cells was tested using the Matrigel invasion assay, which 
demonstrated a clear difference in the behavior of the cells. The mean percentage invasion 
relative to the control membrane was 53% in miR-196a cells compared with 16% in the 
control cells (P = 0.01, Figure 2.8). 
 





















































Figure 2.7 Scratch assay to assess the cell migration of miR-196a ovrexpressing 
cells compared with pBabe-puro control.  
Cells were grown in 6 well plates in triplicate until confluent and a pipette tip used to 
create 3 scratches in each well. Bar graph shows the mean percentage scratch area 
closed after 16 hours from 2 independent experiments. Student’s t-test was used to 
assess statistical significance (P < 0.01). Images show representative examples at 0 
and 16 hours at 4x magnification.  




































Figure 2.8 Invasion assay of miR-196a overexpressing cells compared with 
pBabe-puro control.  
The Matrigel invasion chamber was used to assess the invasive ability of the cells. 
Equal number of cells were seeded into the chamber and incubated for 22 hours, before 
counting the number of cells that have invaded through the Matrigel membrane. Cells 
were also seeded into a control chamber without Matrigel on the membrane. Bar graph 
represents the mean number of cells that have invaded through the membrane, relative 
to the mean number of cells that have migration through the control membrane (P = 
0.01). The assay was carried out in repeated duplicates. Images are representative of 




 MiR-196a overexpression affects vimentin expression 2.5.2.2
The behaviour of the miR-196a overexpressing cells suggested a role for miR-196a in the 
process of epithelial-mesenchymal transition (EMT). EMT is characterised by the loss of 
various cell surface proteins and reorganisation of cytoskeletal proteins. Loss of E-cadherin 
and gain of vimentin are two of the main protein expression alterations associated with 
EMT.454 Western blot analysis was performed to detect changes in expression of E-
cadherin and vimentin. There was no difference in the expression of E-cadherin. Vimentin 
expression was very low in the control cells and further reduced in the miR-196a 



























Figure 2.9 E-cadherin and vimentin protein expression levels in miR-196a 
overexpressing and pBabe-puro control cells.  
Western blot analysis of the EMT markers E-cadherin and vimentin in miR-196a 




To further assess the changes in expression of E-cadherin and vimentin, 
immunofluorescence was performed. Consistent with the Western blot data there was no 
clear difference in the staining pattern of E-cadherin between the miR-196a and control 
cells (Figure 2.10). However the pattern of vimentin expression was significantly altered 
after overexpressing miR-196a (Figure 2.11, upper panel). Vimentin immunofluorescence 
was also carried out using MDA-MB-231 breast cancer cells, a well-established 
mesenchymal cell line, for comparison and the appearances of the miR-196a cells were 
similar (Figure 2.11, lower panel). This suggests miR-196a may contribute to a change in 





Figure 2.10 E-cadherin immunofluorescence of miR-196a overexpressing HN5 
cells compared with pBabe-puro empty vector control.  
Cells were fixed and stained with primary rabbit anti-E-cadherin and secondary FITC-
conjugated anti-rabbit antibody (green). Nuclei were detected by counterstaining with 
DAPI (blue). Representative images were taken at 60x magnification. 






Figure 2.11 Vimentin immunofluoresence of miR-196a cells compared with empty 
vector control and the mesenchymal breast cancer cell line MDA-MB-231.  
Cells were fixed and stained with primary rabbit anti-vimentin and secondary FITC-
conjugated anti-rabbit antibody (green). Nuclei were stained with DAPI (blue) and 
images taken at 60x magnification. 
 
 
 MiR-196a alters the radiosensitivity of head and neck cancer cells 2.5.2.3
The sixteen patients with and without disease recurrence selected for the initial miRNA 
expression profiling received surgery and postoperative radiotherapy. Patients who 
developed disease recurrence had higher levels of pretreatment miR-196a in their tumour 
compared with patients who remained disease free. This observation prompted further 
investigation into whether overexpression of this miRNA had an effect on the sensitivity to 
radiation. 
 
HN5 miR-196a overexpressing cells and empty vector control cells were irradiated at 0, 2, 
4 and 6 Gy and the clonogenic assay performed. After 14 days, miR-196a overexpressing 
cells demonstrated a higher surviving fraction at 2 and 4 Gy compared with the control cells 
(Figure 2.12 and Figure 2.13). Radiosensitivity was further investigated using the MTT cell 
survival assay. This also showed significantly enhanced cell viability 5 days after irradiation 
at 2 and 4 Gy, and also at 6 Gy (Figure 2.14). 




Figure 2.12 Clonogenicity of miR-196a overexpressing cells compared with 
control post-irradiation.  
Cells were irradiated at 0 (control), 2, 4 and 6 Gy and 1000 cells plated in 6 well dishes 
in triplicate the following day. Cell medium was changed every 4 days. Colony formation 
after 14 days was assessed by counting colonies of greater than 50 cells in triplicate. 
The plating efficiency and surviving fraction was calculated and the graph represents 
data from two independent clonogenic assays. Student’s t-test at 2 Gy and 4 Gy P < 






Figure 2.13 Colony formation of miR-196a overexpressing cells compared with 
control.  
Representative images of colony formation 14 days after irradiation with 0, 2, 4 and 6 
Gy in miR-196a overexpressing (upper panel) and pBabe-puro empty vector control 






















Figure 2.14 MTT cell viability assay of miR-196a and pBabe-puro control cells 
post-irradiation.  
Cells were seeded in 96 well plates 24 hours after irradiation and the absorbance at 
wavelength 595nm was measured after 5 days. Data is presented relative to the 
absorbance of the 0 Gy (unirradiated control) cells and represents two independent 
experiments. Error bars indicate standard deviation, Student’s t-test was used to 




The cells were also irradiated at lower doses and stained for the presence of gamma H2AX 
foci within the nucleus at 30 minutes and 24 hours, as a biomarker for double-stranded 
DNA breaks. Gamma H2AX foci rapidly accumulate and peak 30 minutes after irradiation, 
with foci remaining at 24 hours representing persistent damage and therefore increased 
radiosensitivity.455,456  At 30 minutes post-irradiation, miR-196a overexpressing cells 
demonstrated similar numbers of gamma H2AX foci per nucleus compared with the control 
cells. However, after 24 hours significantly fewer foci were detected in the miR-196a cells, 

























































Figure 2.15 Gamma H2Ax staining for double stranded DNA damage in miR-196a 
and pBabe-puro control cells post-irradiation. 
Cells were irradiated with 0 (control), 0.5, 1 and 2 Gy after 30 minutes (upper left graph) 
and 24 hours (upper right graph) post-irradiation. The number of foci was analysed in a 
minimum of 100 cells at each dose point and data is presented as the mean number of 
foci relative to the unirradiated 0 Gy cells. Error bars represent standard error. 
Differences between the mean number of foci in miR-196a and pBabe-puro cells were 
not significant using the Student’s t-test after 30 minutes. After 24 hours at 0.5 Gy P < 
0.01, at 1 Gy P = 0.04, at 2 Gy P = 0.02. Images are representative of cells irradiated at 
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 MiR-196a knockdown in HN30 cells 2.5.3
The cell line HN30, with high endogenous levels of miR-196 (Figure 2.3), was selected for 
miR-196a knockdown experiments. MiRNA sponges are transcripts that contain multiple 
target sites that are complementary to the miRNA under investigation and sequester 
endogenous miRNAs, resulting in functional inhibition of the mature miRNA.457 Red 
fluorescent protein (RFP) expression pre- and post-transduction was checked (Figure 2.16) 
and qRT-PCR demonstrated an approximate 60% reduction in the expression level of miR-
196a in HN30 cells infected with miR-196a sponge plasmid compared with cells infected 




Figure 2.16 HN30 miR-196a sponge cells after puromycin selection. 





Figure 2.17 QRT-PCR of miR-196a knockdown in HN30 cells compared with 
control.  
HN30 cells were stably infected with miR-196a sponge or control and the expression 
relative to the housekeeping gene RNU48 was measured by qRT-PCR. Data shown is 
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 MiR-196a knockdown results in decreased cell proliferation, migration 2.5.3.1
and invasion, and increased radiosensitivity 
Downregulation of miR-196a in HN30 cells resulted in the opposite functional effects seen 
with overexpressing miR-196a in HN5 cells. Cell proliferation was significantly inhibited 
(Figure 2.18). Cell migration was also inhibited, with a mean percent of scratch area closed 
at 24 hours in miR-196a sponge cells of 39% compared with 76% in the sponge control 
cells (P < 0.01, Figure 2.19). The mean percentage invasion relative to the control 






Figure 2.18 Cell proliferation of miR-196a sponge cells compared with control. 
Left graph: equal numbers of cells were plated in triplicate on day 0 and counted every 
24 hours for 7 consecutive days. Data is the mean of 2 independent experiments and 
error bars indicate standard deviation. Statistical significance determined by Student’s t-
test. Days 4 to 7, P < 0.01. Right graph: cells were plated in 6 wells of a 96-well plate 
and the MTT assay was performed daily over 5 days (right). Data is the mean of 2 



















































































Figure 2.19 Cell migration assessed by scratch assay of miR-196a knockdown 
sponge cells compared with control cells.  
Cells were grown in 6 well plates in triplicate until confluent and a pipette tip used to 
create 3 scratches in each well. Bar graph shows the mean percentage scratch area 
closed after 24 hours from 2 independent experiments. Student’s t-test was used to 
assess statistical significance (P < 0.01). Images show representative examples at 0 


































Figure 2.20 Invasion through Matrigel membrane by miR-196a knockdown cells 
compared with control.  
Equal number of cells were seeded into the Matrigel chamber and incubated for 22 
hours, before counting the number of cells that have invaded through the Matrigel 
membrane. Cells were also seeded into a control chamber without Matrigel on the 
membrane. Bar graph represents the mean number of cells that have invaded through 
the membrane, relative to the mean number of cells that have migration through the 
control membrane (P = 0.02). The assay was carried out in repeated duplicates. Images 





The radiosensitivity of miR-196a knockdown cells was planned to be assessed using the 
clonogenic assay. However when the optimal seeding density was being determined using 
a range of cell numbers and incubation times, it became clear that the colonies formed by 
this cell line were small and compact and too difficult to count (Figure 2.21). Similar 


























Figure 2.21 Colony formation of HN30 cells.  





The MTT cell viability assay was performed after irradiating the miR-196a knockdown and 
control cells with 0 (unirradiated control), 2, 4 and 6 Gy. This clearly demonstrated reduced 






Figure 2.22 MTT cell viability assay of miR-196a sponge and control cells.  
Cells were seeded in 96 well plates 24 hours after irradiation and the absorbance at 
wavelength 595nm measured after 5 days. Data is presented relative to the absorbance 
of the 0 Gy (unirradiated control) cells, from two independent experiments. Student’s t-
test was used to determine statistical significance. P = 0.02 at 2 Gy, P = 0.01 at 4 Gy 
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To investigate whether the inhibition in growth and cellular migration was due to the 
induction of apoptosis, HN30 cells were transiently transduced with miR-196a sponge and 
control, and the cell lysates were analysed for apoptotic markers at 48 and 72 hours. 
Cleaved PARP and cleaved caspase-3 protein levels were measured by Western blot 
analysis. There were no clear differences between the miR-196a sponge and control cells 
(Figure 2.23), suggesting that the observed effects of miR-196a downregulation of 




Figure 2.23 Western blot of the pro-apoptotic markers cleaved PARP and cleaved 
caspase-3 in HN30 sponge and control cells. 
HN30 cells were harvested 48 and 72 hours after transient miR-196a knockdown using 




 MiR-196a inhibition in HN30 cells do not affect markers of EMT 2.5.3.2
E-cadherin and vimentin expression was assessed by Western blot analysis. There was no 
clear difference in the expression of these EMT-associated proteins between the miR-196a 
sponge and control cells (Figure 2.24). There was also no change detected using E-
cadherin and vimentin immunofluorescence (Figure 2.25 and Figure 2.26). 
 
 




Figure 2.24 E-cadherin and vimentin protein expression levels in miR-196a 
knockdown cells compared with control cells.  






Figure 2.25 E-cadherin immunofluorescence in miR-196a sponge cells compared 
with control.  
Cells were fixed and stained with primary rabbit anti-E-cadherin and secondary FITC-
conjugated anti-rabbit antibody (green). Nuclei were detected by counterstaining with 





Figure 2.26 Vimentin immunofluorescence in miR-196a sponge and control cells. 
Cells were fixed stained with primary rabbit anti-vimentin and secondary FITC-
conjugated anti-rabbit antibody (green). Nuclei were stained with DAPI (blue) and 
images taken at 60x magnification. 
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 Confirmation in other modulated cells 2.5.4
 MiR-196a overexpressing HN5 cells from single colony 2.5.4.1
There were no other head and neck cell lines with low endogenous levels of miR-196a to 
confirm the effect of overexpressing this miRNA. The HN5 miR-196a overexpressing cell 
line developed from a single colony with the second highest level of miR-196a (single 
colony 2, Figure 2.5) was therefore used to validate some of the results. This colony had an 
approximate 45-fold increase in the level of miR-196a compared with the pBabe-puro 
control cells.  
 
The MTT assay was used as measure of cell proliferation over 5 days. This demonstrated 
significantly increased cell proliferation in the miR-196a overexpression cells compared 




Figure 2.27 MTT assay over 5 days comparing the cell proliferation of miR-196a 
overexpressing cells grown from a single conlony compared with control.  
MTT assay was performed daily over 5 days, 6 wells per day, and repeated in an 




The scratch assay was also performed, which confirmed that miR-196a overexpression 
promoted migration, with an average of 52% of the scratch area closed after 20 hours 


































Figure 2.28 Cell migration assessed by scratch assay of miR-196a 
overexpressing cells (single colony) compared with pBabe-puro control cells.  
Bar graph shows the mean percentage scratch area closed after 20 hours of three 
scratches in triplicate wells in repeated experiments, P < 0.01. The images show 
representative examples at 0 and 20 hours at 4x magnification. 
 
 
 MiR-196a knockdown in SCC11B and SCC22B head and neck cancer 2.5.4.2
cells lines 
MiR-196a sponge was used to knockdown the expression of miR-196a in SCC11B and 
SCC22B cell lines, which both have high endogenous levels of the miRNA. Figure 2.29 
shows the level of knockdown achieved in these two cell lines, compared with the cell lines 
transduced with the empty vector control. In the SCC11B cell line a 42% knockdown was 
achieved and in SCC22B there was a 50% reduction in miR-196a expression. The effect of 
this knockdown on cell proliferation was assessed using the MTT assay. This confirmed the 
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Figure 2.29 QRT-PCR of miR-196a knockdown with miR-196a sponge compared 
with control in SCC11B and SCC22B.  
Expression is expressed relative to the housekeeping gene RNU48 and represents the 
mean of two RNA extractions. Student’s t-test was used to assess statistical 






Figure 2.30 MTT assay comparing the effect of miR-196a knockdown in SCC11B 
cells (left) and SCC22B cells (right) on cell proliferation. 
Cells were seeded in 6 wells of a 96-well plate per time point and the MTT assay 
performed daily over 5 days in two independent experiments. SCC11B days 3 to 5 and 
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MiR-196a knockdown also had a similar effect to HN30 on migration demonstrated by the 
scratch assay. In SCC11B the mean scratch area closed at 14 hours was 14% versus 41% 
in the sponge and control cells respectively (P < 0.01, Figure 2.31). Similarly in SCC22B 
the mean scratch area closed after 12hours was 29% versus 56% in the sponge cells 






Figure 2.31 Cell migration assessed by scratch assay of SCC11B miR-196a 
sponge and control cells.  
Cells were grown in 6 well plates in triplicate until confluent and a pipette tip used to 
create 3 scratches in each well. Bar graph shows the mean percentage scratch area 
closed after 14 hours from 2 independent experiments. Student’s t-test was used to 
assess statistical significance (P < 0.01). Images show representative examples at 0 
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Figure 2.32 Cell migration assessed by scratch assay of SCC22B miR-196a 
knockdown cells versus control.  
Bar graph represents the average percentage scratch area closed after 12 hours of 
three scratches in triplicate wells in repeated independent experiments. P < 0.01. 
Images are examples at 0 and 12 hours at 4x magnification. 
 
 
 Annexin A1 is a direct target of miR-196a 2.5.5
Several cellular genes have been identified as targets of miR-196a. ANXA1 was further 
investigated as a putative target in of miR-196a in head and neck cell lines due to its role 
as a tumour suppressor and potential prognostic marker in this tumour group. MiR-196a 
overexpression in HN5 cells resulted in suppression of ANXA1 protein expression (Figure 
2.33), whereas miR-196a knockdown induced increased ANXA1 protein levels in HN30 
cells, compared with their respective empty control vectors (Figure 2.34). 
 





















    
 
Figure 2.33 ANXA1 protein levels in miR-196a overexpressing and control cells.  
Western blot analysis was carried out in miR-196a overexpressing HN5 cells to detect 
ANXA1 protein expression. Bar graph shows the mean quantification of the intensity of 
bands, normalised to tubulin, from two separate experiments using ImageJ. Statistical 





     
 
Figure 2.34 ANXA1 protein levels in miR-196a knockdown and control cells.  
Western blot of miR-196a knockdown HN30 cells to measure ANXA1 protein 
expression levels. Bar graph shows the mean quantification of the intensity of bands 
using ImageJ of western blots performed on two separate experiments, normalised to 
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A dual luciferase reporter plasmid containing the 3’-UTR of the ANXA1 gene was 
transiently transfected into miR-196a overexpressing and control cells, and miR-196a 
knockdown and control cells. The plasmid contains both Firefly and Renilla (control) 
luciferase activity. Binding of miR-196a to the 3’UTR of ANXA1 leads to a reduction in 
Firefly luciferase protein production resulting in reduced light emission detected by a 
luminometer, whereas the Renilla activity is constitutively expressed at a different 
wavelength. The Firefly activity is then expressed relative to the expression of the Renilla 
control. The assay was initially carried out using X-tremeGENE transfection reagent, which 
showed a small but statistically significant reduction in the relative luciferase activity in the 
miR-196a overexpressing cells compared with controls (P = 0.01) and increased relative 
luciferase activity in the miR-196a knockdown cells compared to their control (P = 0.02, 
Figure 2.35). The luciferase plasmid also contained a GFP marker, which showed that 
there was a high proportion of cell death. This may be due to toxicity to the cell caused by 





Figure 2.35 ANXA1 luciferase assay using X-tremeGENE transfection of miR-196a 
modulated cells and their respective controls.  
Luciferase reporter plasmid containing ANXA1 3’UTR was transiently transfected into 
miR-196a overexpressing HN5 cells and pBabe-puro control cells, and the relative 
luciferase activity measured using the dual luciferase assay, P = 0.01 (left graph). The 
same experiment was carried out on miR-196a knockdown HN30 cells and control cells, 
































































   
 
Figure 2.36 HN5 miR-196a overexpressing cells after transfection with ANXA1 
luciferase plasmid using X-tremeGENE transfection reagent.  
An example of the appearance of cells 24 hours after transient transfection using X-
tremeGENE. Left panel shows appearance of cells at 4x magnification. Right panel 




The experiment was repeated using FuGENE transfection reagent. There were a higher 
proportion of cells surviving after 24 hours and high transfection efficiency (Figure 2.37). 
This resulted in a greater difference in the luciferase activity between the modulated cells 
and their respective controls (P < 0.01, Figure 2.38).  
 
   
 
Figure 2.37 HN5 miR-196a overexpressing cells post-transfection with ANXA1 
luciferase plasmid isung FuGENE transfection reagent. 
Example of the appearance of cells 24 hours after transient transfection using FuGENE. 
Left panel shows higher proportion of surviving cells at 4x magnification. Right panel 
shows GFP transfection efficiency. 
 
 




Figure 2.38 ANXA1 luciferase assay of miR-196a modulated cells and their 
respective controls using FuGENE transfection reagent.  
Luciferase reporter plasmid containing ANXA1 3’UTR was transiently transfected into 
miR-196a overexpressing (left) and knockdown (right) cells with their corresponding 
control cells. Transfection was carried out in triplicate and repeated in an independent 
experiment. Statistical difference was determined by Student’s t-test, P < 0.01.  
 
 
In addition the baseline endogenous levels of ANXA1 in the cell lines investigated 
demonstrate a reverse association with the endogenous levels of miR-196a (Figure 2.39).  
 
        
 
 
Figure 2.39 Endogenous ANXA1 protein expression levels of ANXA1 in the head 
and neck cancer cell lines tested.  
Western blot was carried out to assess the baseline levels of ANXA1. Tubulin was used 
as loading control and the graph represents the mean intensity assessed by ImageJ 
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 Annexin A1 silencing reproduces the oncogenic phenotype of miR-2.5.6
196a overexpression 
To investigate whether the effects seen after modulating miR-196a levels were due to its 
target ANXA1, HN5 cells were stably transfected with ANXA1 shRNA. Western blot 
confirmed successful knockdown (Figure 2.40). 
  
 
Figure 2.40 Western blot of ANXA1 knockdown in HN5 cells.  
HN5 cells were transduced with ANXA1 shRNA or empty vector control and the 
knockdown efficiency was assessed by Western blot. Graph shows the mean intensity 
of the bands using ImageJ, relative to tubulin, from two independent blots. 
 
 
The effect of this knockdown on cell proliferation, migration and invasion were investigated. 
Similar to the behaviour of miR-196a overexpressing HN5 cells, ANXA1 knockdown (KD) 
resulted in increased cell proliferation assessed growth rate over seven days, as well as 
cell survival measured by MTT assay over 5 days (Figure 2.41).  
 
 
Figure 2.41 Cell proliferation in ANXA1 KD and control cells. 
Left graph: equal numbers of cells were plated in triplicate on day 0 and counted every 
24 hours for 7 consecutive days. Data is the mean of 2 independent experiment and 
error bars indicate standard deviation. Statistical significance determined by Student’s t-
test. Days 4 to 7, P < 0.01. Right graph: cells were plated in 6 wells of a 96-well plate 
and the MTT assay was performed daily over 5 days (right). Data is the mean of 2 
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Cell migration was also enhanced after 20 hours, with the mean percentage scratch area 
closed of 59% and 26% (P < 0.01) in the ANXA1 KD cells and the empty vector control 
cells respectively (Figure 2.42). Invasion was significantly increased, with the mean 
percentage invasion relative to control of 41% in the ANXA1 KD cells compared with 20% 
in the control cells (P < 0.01, Figure 2.43). 
        




Figure 2.42 Scratch assay to assess migration in ANXA1 KD cells versus control.  
Data is expressed as mean percentage scratch area closed after 20 hours incubation 
from repeated triplicate wells, with a minimum of three scratches per well. Student’s t-
test was used to assess statistical significance (P < 0.01). Images are representative 
































Figure 2.43 Matrigel invasion assay of ANXA1 KD cells versus control. 
Equal number of cells were seeded into the Matrigel chamber and incubated for 22 
hours, before counting the number of cells that have invaded through the Matrigel 
membrane. Cells were also seeded into a control chamber without Matrigel on the 
membrane. Bar graph represents the mean number of cells that have invaded through 
the membrane, relative to the mean number of cells that have migration through the 
control membrane (P < 0.01). The assay was carried out in repeated duplicates. Images 





Vimentin immunofluorescence of ANXA1 KD cells showed an altered pattern of staining 
compared with the control cells, similar to the vimentin configuration seen in the miR-196a 



























Figure 2.44 Vimentin immunofluorescence staining in ANXA1 KD cells compared 
with empty vector control. 
ANXA1 KD and control cells were fixed and stained with primary rabbit anti-vimentin 
and secondary FITC-conjugated anti-rabbit antibody (green). Nuclei were stained with 





ANXA1 KD cells were also irradiated and cell survival assessed using the MTT assay. 
ANXA1 KD showed some resistance compared to the control cells, but this did not reach 
significance (Figure 2.45). This suggests that miR-196a-induced radioresistance may not 




Figure 2.45 MTT assay post-irradiation in ANXA1 KD and control cells. 
ANXA1 knockdown cells and their control cells were irradiated at 0 (control), 2, 4 and 6 
Gy and cell survival assessed after 5 days. Data is presented relative to the absorbance 
of the unirradiated control cells (0 Gy) from 2 independent experiments. 
  
      




















  Chapter 2  Results 
 140 
 MiR-196a expression in an independent panel of radioresistant 2.5.7
oropharyngeal FFPE samples     
The initial tissue microarray analysis revealed higher levels of miR-196a in patients with 
disease recurrence after radical treatment a five year follow up period. On review of the 
patient samples 14 cases were from the oral cavity, 1 from the base of tongue and 1 from 
the soft palate. Fourteen cases were locally advanced stage III or IV, with one stage I and 
one stage II. All patients were treated with surgery as the primary modality, followed by 
post-operative radiotherapy. In all cases RNA was extracted from fresh frozen samples 
from the primary surgical excision specimen. 
 
Retrospective validation was attempted in tissue samples with selection of a homogeneous 
group of patients and clearer definition of radioresistance. All patients had received primary 
chemoradiation and therefore only small diagnostic FFPE samples were available. Out of 
40 patients initially selected 10 cases were excluded due to insufficient tumour percentage 
in the biopsy specimen. A further sample was excluded due to poor RNA quality and the 
miR-196a level from this sample could not be measured. Therefore a total of 16 
radiosensitive and 13 radioresistant cases were analysed for miR-196a expression relative 
to the housekeeping gene RNU48. The yield of extracted RNA ranged from 57.4 to 1454.6 
ng/µl and the ratio of absorbance at 260 nm and 280 nm to assess purity ranged from 1.83 





Figure 2.46 MiR-196a expression levels in a panel of radiosensitive and 
radioresistance FFPE oropharyngeal samples. 
Dot plot showing the range of miR-196a expression levels, relative to RNU48, in an 
independent panel of FFPE oropharyngeal biopsy samples with known response to 
treatment. Samples with minimum of 60% tumour were selected and the miR-196a 
expression measured by qRT-PCR. There was no significant difference in the 2 groups 
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HPV status is an independent prognostic factor in oropharyngeal cancers and therefore the 
cases were separated into HPV positive and negative cases. However there was still no 
difference in the pattern of miR-196a expression (Figure 2.47). There was a wider 






Figure 2.47 MiR-196a expression in HPV positive and negative radiosensitive and 
radioresistant samples. 
Samples were separated into HPV positive and negative groups and the miR-196a 








• MiR-196a is upregulated in a group of patients with HNSCC with recurrent disease 
after radical treatment.  
• MiR-196a exerts an oncogenic phenotype in HNSCC cell lines, which may be 
exerted through targeting ANXA1. 
• Suppression of ANAX1 results in an oncogenic phenotype in HNSCC, suggesting a 
tumour suppressive role. 
• MiR-196a overexpression exhibits resistance to irradiation in vitro, and may 
represent both a prognostic and predictive biomarker, but requires validation in a 
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 Discussion 2.6
The deregulation of miRNAs has been reported in nearly all cancers and it has become 
clear that they play key roles in cancer development and progression, as well as 
representing potential predictive biomarkers and therapeutic targets. MiRNA expression 
profiling of a small exploratory cohort of HNSCC biopsy samples identified several miRNAs 
that were differentially expressed between patients with and without recurrent disease after 
radical surgery and adjuvant radiotherapy. Amongst these miRNAs, miR-196a was found to 
be significantly upregulated in patients with recurrence.  
 
 Oncogenic role 2.6.1
Functional analysis demonstrated that overexpression of miR-196a in HNSCC cells with 
low endogenous levels significantly promoted cell proliferation, migration and invasion, 
whereas knockdown of miR-196a in cells with high endogenous levels led to the opposite 
effects. Liu et al also reported similar results using the oral SCC cell lines OECM-1 and 
FaDu.431 They demonstrated that modulating these cells to overexpress miR-196a 
enhanced migration and anchorage-dependent colony formation, but without obvious effect 
on cell growth. Knockdown resulted in decreased migration and growth of FaDu cell 
xenografts expressing exogenous miR-196a in nude mice compared to controls. Consistent 
with our initial microarray findings this study also found that high expression of miR-196a 
was associated with tumour recurrence and mortality. The majority of studies in a variety of 
different cancers have found miR-196a to have an oncogenic role. Overexpression of miR-
196a has been demonstrated in several types of tumours and in general is linked with more 
aggressive, metastatic, tumor phenotype. There is a growing body of evidence indicating 
that many reported targets of miR-196a, including Radixin,426 Netrin 4437 and ANXA1,424 
regulate cell motility and migration, further supporting a potential role for miR-196a in 
conferring invasive tumour characteristics.  
 
MiR-196a acts, in part, through ANXA1. However the precise mechanism through which 
miR-196a modulation of ANXA1 contributes to a more aggressive tumour phenotype 
requires further investigation. Western blot analysis for apoptotic markers did not show a 
difference between miR-196a knockdown and control cells, indicating that the anti-
proliferative effect of miR-196a knockdown is unlikely to be due to increased apoptosis, 
further suggesting a role in tumour invasiveness and resistance to therapy. A number of 
miR-196a studies have investigated the effect on cell cycle progression and apoptosis 
through flow cytometry or Hoechst staining, with differing results. Huang et al435 reported 
transiently silencing miR-196a in Panc-1 cells increased the percentage of cells in the 
G0/G1 phase of the cell cycle at 72 hours with downregulation of cyclin D1 and cyclin-
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dependent kinases (CDKs) 4 and 6, suggesting a role in cell cycle arrest. There was no 
significant difference in apoptosis by flow cytometry after miR-196a knockdown at 24, 48 
and 72 hours.435 In contrast Liu et al,436 who also used Panc-1 cells and flow cytometry, 
demonstrated a significant increase in apoptotic fraction after miR-196a inhibitor 
transfection.436 In cervix cancer cells lines ectopic expression of miR-196a decreased the 
percentage of cells in G0/G1 and increased the percentage in S phase, whilst miR-196a 
inhibition had the opposite effects, indicating promotion of G1/S cell cycle transition by miR-
196a. In addition, miR-196a overexpression upregulated cyclin D1 and downregulated the 
CDK inhibitor p21Cip1.429 Similar effects on cell cycle regulation were found in gastric cancer 
cells, with no increase in apoptosis as assessed by Hoechst staining and cleaved caspase-
3 Western blot analysis.425 In NSCLC cell lines miR-196a inhibition also had no significant 
effect on apoptosis.427 However in glioblastoma cell lines ectopic miR-196a inhibited cell 
apoptosis434 and overexpression of miR-196a in SEG-1 oesophageal cancer cell line, in 
which ANXA1 was found to be a target, inhibited apoptosis induction, suggesting an anti-
apoptotic role for miR-196a.424  
 
MiR-196a may act through different mechanisms via different targets and cell types. 
However the contrasting results in the same pancreatic cell line suggests possible 
alternative pathways in the same cell line. Schimanski et al433 transiently transfected 
increasing concentrations of miR-196a into colorectal cancer cell lines and found dose-
dependent inhibition of cellular adhesion and dose-dependent differences in restriction of 
target gene expression. For example only low concentrations of miR-196a were required to 
suppress HOXB8 as assessed by RT-PCR, whereas higher concentrations were required 
to completely restrict HOXC7 and partially restrict HOXA7 and HOXD8.433 MiR-196a may 
therefore have differing, or even opposing effects, in the same cell type at differing levels of 
expression, through the regulation of a diverse range of targets. 
 
 Epithelial-Mesenchymal Transition 2.6.2
EMT is a process of immotile epithelial cell transition to motile mesenchymal cells, resulting 
in increased migratory and invasive ability. Cancer cell migration, invasion and metastases 
involve phenotypic features similar to EMT, such as loss of cell-cell adhesion and increase 
in cell motility, and is characterised by loss of various cell surface proteins and 
reorganisation of cytoskeletal proteins, for example loss of E-cadherin and cytokeratin, and 
gain of vimentin and N-cadherin.458  
 
EMT as a mechanism for altered vimentin expression in miR-196a overexpressing cells 
was therefore investigated. Western blot analysis was initially used to determine the 
expression levels of E-cadherin and vimentin. The control cell lines had high levels of 
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baseline E-cadherin, which was not affected by miR-196a modulation. The HN30 cell line 
did not express vimentin, and the HN5 cell line had very low levels, which was 
downregulated after miR-196a overexpression. Given that miR-196a overexpression 
increased migration and invasion, this was not the expected pattern of expression 
prompting further investigation with immunofluorescence. The change in the pattern of 
vimentin in both the miR-196a overexpressing and ANXA1 knockdown cells suggested a 
change in the configuration of the vimentin expression, and resembled that of MDA-MB-
231 mesenchymal breast cell lines. This suggests that miR-196a through ANXA1 does 
have an effect on EMT, but this may not be as straight forward as the typical loss of E-
cadherin/gain of vimentin expression.  
 
Three classes of EMT with distinct biological processed have been suggested, with EMT 
that occurs in cancer cells as a separate class.454 Cancer cells go through 
genetic/epigenetic changes affecting oncogenes and TSGs to acquire invasive and 
metastatic capabilities, but differ in the extent to which they undergo EMT. The expression 
of the proteins typical for EMT may therefore not be detected. Cancer cells undergoing 
EMT may retain certain epithelial traits and acquire some mesenchymal ones, whilst others 
shed all epithelial traits and become fully mesenchymal.458 EMT markers can identify 
epithelial or mesenchymal cells and are therefore not necessarily identifying cells that are 
specifically undergoing EMT, which may only be a proportion of the cells.459 EMT involves 
multiple complex signalling pathways, which are regulated by transcription factors such as 
transforming growth factor-β (TGF-β) and the zinc finger proteins ZEB1 and ZEB2. MiRNAs 
have been found to be crucial regulators of expression of these factors. For example, the 
miR-200 family targets ZEB1 and ZEB2, which suppress the transcription of E-cadherin,177 
and miR-155, which is associated with TGF-β-induced EMT.460 MiR-196a through ANXA1 
may have a specific role in vimentin remodelling, contributing to the EMT process, however 
the nature of this regulation needs further investigation. 
 
 Sensitivity to irradiation 2.6.3
MiRNAs are important regulators of the DNA damage response (DDR) pathway and can 
alter the sensitivity of cancer cells to irradiation. MiR-196a has not previously been linked to 
radioresistance. The tissue samples initially used for the microarray analysis originated 
from patients who required post-operative radiotherapy, with those developing recurrent 
disease demonstrating higher levels of pretreatment miR-196a. The increased cell viability 
and repair of DNA damage in the miR-196a overexpressing cells compared with the control 
cells raises the possibility of miR-196a as a biomarker of intrinsic radioresistance, and as a 
potential predictive marker of radiation response, identifying patients at diagnosis who are 
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more likely to fail conventional radiation treatments. In addition, the modulation of miR-
196a and/or its target genes could have therapeutic potential as a radiation sensitising 
agent.  
 
Further investigation into the mechanism and pathways through which miR-196a may 
modify the response to radiation damage is required. Ionising radiation damages cells 
mainly through double strand DNA breaks, which lead to direct or indirect cell death unless 
the damage is repaired. The DDR pathway has a key role in determining the sensitivity of 
cells to radiation, but other cell survival and cell cycle checkpoint pathways are also 
involved, which influence the expression of genes involved in cell repair or apoptosis and it 
would therefore be important to examine cell cycle phase and levels of ATM, ATR and 
cyclin-dependent kinases post-irradiation in miR-196a overexpressing cells. The level of 
DNA damage and repair after radiation is also known to influence intrinsic cellular 
radioresistance and miR-196a overexpressing cells showed evidence of fewer gamma 
H2AX foci 24 hours after irradiation, suggesting miR-196a may be necessary for cell cycle 
arrest and repair in this situation.   
 
Cell death after irradiation can be immediate via apoptosis, or after a few cell divisions. 
Improved cell survival 5 days after irradiation suggests the activation of pro-survival 
signals, such as inhibition of apoptosis, in response to DNA damage. ANXA1 has been 
shown to be anti-proliferative and pro-apoptotic,445 and therefore the trend towards 
radioresistance seen in the ANXA1 knockdown cells may be in part due to inhibition of 
apoptosis. Downregulation of ANXA1 has been hypothesised to increase radioresistance in 
nasopharyngeal carcinoma.461 The trend towards radioresistance in our ANXA1 knockdown 
cells, compared with the greater effect on radioresistance in our miR-196a modulated cells, 
suggests that other target proteins of miR-196a also play a role in the response to 
radiation. For example, the recently reported target of miR-196a IκBα is an inhibitor of 
NFκB.434,435 NFκB, in conjunction with ATM, is activated early in response to stresses such 
as ionising radiation and promotes the upregulation of pro-survival and anti-apoptotic 
genes.462 Inhibition of NFκB significantly enhances radiosensitivity,463,464 and therefore 
downregulation of IκBα may be an important target in miR-196a-induced radioresistance. 
FOXO1 and p27kip1 have also been identified as targets of miR-196a, and are both 
negative regulators of the PI3K/AKT signalling pathway.425,429 This pathway is closely 
associated with intrinsic radiosensitivity, and inhibition of PI3K and its downstream effector 
mTOR has been shown to enhance radiation-induced killing in HNSCC cells by persistent 
DNA damage as evidenced by increase number of gamma H2AX foci, and enhanced G2 
cell cycle delay.465  
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De Jong et al195 selected 32 HNSCC cell lines with known radiosensitivity and analysed the 
miRNA expression. They found low expression of miRNAs involved in the inhibition of EMT 
were important in determining radioresistance, and suggested that the acquisition of an 
EMT phenotype is associated with less damage, better repair and less cell death after 
irradiation, resulting in radioresistance. Although miR-196a was not among their miRNA 
panel of radioresistance, our study did find some evidence that miR-196a contributes to 
increased EMT, which would be consistent with their results. Therefore miR-196a could 
represent a new therapeutic target to inhibit multiple pathways involved in both 
oncogenesis and radioresistance.  
 
 ANXA1 as a target of miR-196a 2.6.4
ANXA1 was investigated as a target of miR-196a through luciferase assay, Western blot 
and ANXA1 knockdown studies. Several genes with important roles in proliferation, 
adhesion and apoptosis have been shown to be targets of miR-196a. Of these targets 
there is evidence that ANXA1 expression changes during the development and progression 
of cancer. It is downregulated in oesophagus,466 breast467, prostate,452 larynx468 and 
oropharyngeal cancer469 compared with normal epithelium suggesting that this protein is an 
essential component for maintenance of the normal epithelial phenotype. In oral cancer 
tissues, low ANXA1 expression is associated with poorer differentiation status,449-451 with 
forced ANXA1 overexpression significantly reducing cell proliferation in oral SCC cell lines 
and nude mice, whereas downregulation increased proliferation.451 In nasopharyngeal 
cancer (NPC) ANXA1 was decreased in NPC tissue compared with normal adjacent 
tissue,470 was only positive in well differentiated SCC areas,453 and downregulation of 
ANXA1 in NPC cell lines promoted proliferation, migration and invasion.471 ANXA1 has also 
been shown to have a tumour suppressor role in prostate cancer models, where 
upregulation of ANXA1 blocked EGF-induced proliferation, reduced cell viability, colony 
formation, and induced apoptosis.472 In breast cancer ANXA1 knockdown, in conjunction 
with RAS, induced EMT and metastases in non-metastatic cells.473 These tumour 
suppressor effects are consistent with the phenotypic characteristics of the HN5 miR-196a 
overexpressing cells, prompting further investigation into ANXA1 in HNSCC. An inverse 
correlation between miR-196a and ANXA1 expression has been shown in oesophageal, 
breast and endometrial cancer cell lines, and in oesophageal tumour specimens.424 The 
use of miR-196a mimics in oesophageal and breast cancer cells resulted in decreased 
ANXA1 mRNA and protein expression, inhibited ANXA1 luciferase expression, and 
promoted cell proliferation, anchorage-independent growth and suppressed apoptosis.424  
In agreement with this data ANXA1 is also a direct target of miR-196a in HNSCC, and 
silencing of ANXA1 results in a more aggressive tumour cell phenotype similar to miR-196a 
overexpressing cells. 
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The mechanism of the anti-proliferative effect of ANXA1 is unclear. ANXA1 has been 
shown to stimulate caspase-mediated apoptosis, mainly in cells of the myelo-monocytic 
lineage, neutrophils and in broncho-alveolar epithelial cells.474,475 ANXA1 has been found to 
bind to NF-κB, suppressing its transcriptional activity by preventing NF-κB binding to DNA, 
leading to enhancement of apoptotic death and inhibition of cell growth mediated by 
changes in NF-κB-dependent cell signalling.476,477 In addition, ANXA1 expression is 
strongly induced in thyroid carcinoma cells during tumour necrosis factor-related apoptosis 
inducing ligand (TRAIL)-induced apoptosis.478  Another possible mechanism for the anti-
proliferative action of ANXA1 could be due to its activation of the extracellular signal-
regulated kinase (ERK) signalling cascade, as previously demonstrated in a variety of cell 
types. This results in disruption of the actin cytoskeleton, inhibition of cyclin D1 and 
subsequent suppression of cell proliferation.479,480 Furthermore, ANXA1 is a substrate for 
the tyrosine kinase activity of the epidermal growth factor (EGF) receptor,481 which is 
expressed in over 90% of HNSCC,20 and has been shown to block EGF-induced cell 
proliferation.482 Both activation of EGFR signaling and overexpression of cyclin D1 are 
closely associated with head and neck cancer progression. It would therefore be interesting 
to explore whether miR-196a through its target ANXA1 influences EGFR signaling and the 
cell cycle pathway.  
 
ANXA1 has a diverse range of biological functions. It is a steroid-regulated protein and 
inhibits phospholipase A2 activity, blocking the production of arachidonic acid.  It can be 
found in both subcellular and extracellular locations and has multiple phosphorylation 
sites.445 In addition to EGF it is also a substrate for platelet-derived growth factor (PDGR), 
hepatocyte growth factor and protein kinase C, and can regulate multiple signalling 
pathways including ERK1/2, p38/MAPK, JAK/STAT3 and TGF-β.473 It is therefore 
unsurprising that although ANXA1 appears to have a tumour suppressor role in HNSCC, 
an oncogenic role has also been reported in other cancers such as breast,483 lung448 and 
stomach.484 In contrast to the study by Maschler et al where ANXA1 knockdown induced 
complete EMT and lung metastasis in vivo in breast cancer,473 ANXA1 knockdown in 
invasive basal-like breast cancer cell lines reduced migration and impaired TGF-β 
signalling, as well as decreasing lung metastasis.485 ANXA1 has also been shown to be a 
major regulator of endothelial cell migration, and thereby angiogenesis, in response to 
VEGF.486,487 Furthermore this pathway is targeted by miR-196a. These opposing functions 
of ANXA1, and miR-196a, are clearly cell and tissue type specific and complex in nature.   
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 Validation in FFPE samples 2.6.5
To try to validate the correlation between the pretreatment expression of miR-196a and 
poor outcome, and investigate whether this association is related to radioresistance, an 
independent panel of tumour samples from patients with homogeneous tumour 
characteristics was selected. Patients all received radiotherapy as their primary mode of 
treatment. However this did not reveal a significant difference in the expression levels of 
miR-196a between tumours with and without recurrence; however many factors could have 
contributed to this negative finding. The sample size was small and all samples were from 
the oropharynx, whilst most of the initial samples originated from the oral cavity, as did 
HN5, the main cell line used in the study. Despite stratifying by HPV status, difference in 
subsite may have an impact on the expression levels. Although only samples with over 
60% tumour were selected, the non-malignant tissue component could influence the 
miRNA levels.  
 
Fresh frozen samples were not available and therefore FFPE samples had to be used. 
RNA can undergo degradation during the formalin fixating process, causing a wide 
variation in the quality of RNA isolated. The purity of RNA extracted was measured using 
the NanoDrop spectrophotometer, which measures the optical density at 260 nm and 280 
nm. A 260/280 ratio greater than 1.8 is considered as suitable for gene expression 
measurements,488 which was achieved in all samples used, and the yield of RNA was 
comparable to other studies.489 Many expression profiling studies have used FFPE 
samples to identify a range of gene signatures, as FFPE specimens represent a valuable 
source of data for investigating biomarkers. MiRNA expression profiles between FFPE and 
fresh frozen samples have been directly compared with high correlation, in contrast to 
mRNA expression profiling which shows wider variation.490,491 In addition miRNA 
expression from samples stored over a 10-year period remained stable.490  
 
The lack of correlation was disappointing but will help to design future validation studies. 
For further FFPE work we would need to consider macrodissection or microdissection of 
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 Conclusions 2.6.6
MiR-196a is an oncogene in head and neck cancer and its overexpression is associated 
with increased tumorigenic potential and radioresistance. ANXA1 is a direct target of miR-
196a and acts as a tumour suppressor in these cells. The association between ANXA1 and 
cancer suggests that its suppression by miR-196a may be an important step in the 
oncogenesis of HNSCC. Expression levels of miR-196a may represent a predictive 
biomarker for selecting patients for individualised therapy, and its target ANXA1 could be 
an important focus for future targeted therapy in HNSCC. However, it is also clear that miR-
196a plays different roles in different tumour types. It is known that most miRNAs can 
target multiple genes to exert specific effects and that single genes can be targeted by 
multiple miRNAs, indicating that miRNAs work in a complex network of regulatory 
pathways.  
 
This study highlights the importance of miR-196a and ANXA1 in HNSCC, but confirmation 
in a larger number of patient samples and in vivo studies are required in order to establish 
a clinical application. 
 
 
 Future work 2.6.7
Further work is required to ascertain the mechanism of oncogenesis and radioresistance of 
miR-196a. This would include: 
• Investigating the effect of miR-196a modulation on cell cycle in HNSCC, and further 
study its role in apoptosis. 
• Investigating the role of miR-196a in response to irradiation and identify proteins 
involved in DNA damage response pathway. 
• Identification of new biologically relevant targets using novel functional assays.492 
 
ANXA1 is an interesting target for further investigation in HNSCC. Specific areas include: 
• Assessing whether ANXA1 knockdown has an anti-apoptotic effect in HNSCC. 
• Investigating the association of ANXA1 with EGFR.  
 
Validation of miR-196a as a candidate biomarker in HNSCC is still required by: 
• Animal studies to assess the effect of miR-196a on tumour growth and metastases, 
and response to irradiation. 
• Larger cohort of patient tissue samples to assess the potential of miR-196 as a 
biomarker for prognosis and radiotherapy response. 












Biomarker of Hypoxia Evaluation with 
Molecular and 64Cu-ATSM PET/CT 
Imaging Techniques in Head and Neck 
Squamous Cell Carcinomas 
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3.1 Introduction 
Hypoxia has been extensively investigated in HNSCC and the association with 
radioresistance and poor outcome is well known. There are a number of therapeutic 
interventions that have been developed which can target global or focal hypoxia in 
tumours. However hypoxia is difficult to assess as it is heterogeneous and dynamic due to 
continuing tumour and vessel growth, and constant fluctuations in blood flow. The 
identification of patients with hypoxic tumours who would benefit from hypoxia-targeted 
interventions has been the major limiting factor in applying these potential advantages into 
clinical practice. Accurately detecting and quantifying hypoxic tumours is essential in 
identifying patients who have aggressive, treatment resistant disease. Various methods 
have been investigated but with inconsistent and sometimes conflicting results, lacking the 
sensitivity and specificity needed for clinical utility. 
 
3.1.1 Cu-ATSM PET 
There have been a large number of studies attempting to validate Cu-ATSM as a hypoxic 
tracer and elucidate the exact mechanisms. Preclinical studies have not been able to 
consistently demonstrate hypoxia selectivity, but they have used a range of different cell 
lines, animal models and techniques. It is clear that Cu-ATSM accumulation is dependent 
on the cell or tumour type and would not be suitable as a universal tracer of hypoxia, but 
this is the true for all PET radiopharmaceutical agents. Despite the uncertainties regarding 
the precise mechanism, clinical studies have clearly demonstrated its potential as an 
imaging biomarker that warrants further investigation, with advantages over nitroimidazole-
based hypoxia tracers.  
 
3.1.2 Hypoxia gene expression profiling 
Hypoxia-specific gene expression profiling has been investigated in HNSCC to identify 
tumour hypoxia. Signatures developed from microarrays have demonstrated predictive 
value when applied retrospectively to formalin fixed paraffin embedded (FFPE) samples. 
These methods require no additional biopsies and have the potential to be directly 
translated into clinical practice by applying the gene signatures to pretreatment diagnostic 
biopsy samples to determine hypoxic status. Next generation sequencing has enabled 
improved the accuracy and speed of sequencing tissue samples, with reduced costs 
allowing wider accessibility.  
 
RNA-Seq is next generation sequencing of transcripts, qualitatively and quantitatively 
profiling the gene expression patterns in tissues. RNA is fragmented into millions of short 
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reads of several hundred base pairs and is converted to a library of complementary DNA 
with adaptors attached to one or both ends. Each molecule is amplified and sequenced in a 
high throughput manner to obtain short sequences, which are either aligned to a reference 
genome, available from whole-genome sequencing projects, or can be assembled de novo. 
The amount of mapped reads can then be counted and the gene expression level 
calculated using platform specific algorithms.493 Compared with hybridisation methods such 
as microarrays, RNA-Seq captures a wider range of gene expression, allowing a snapshot 
of the whole transcriptome rather than a predetermined set of genes. It also has a greater 
dynamic range of expression levels over which transcripts can be detected. It is less 
affected by the amount of RNA available and by background noise when detecting low 
expressed genes, and has been shown to be highly reproducible.494  
 
Gene expression profiling, however, does not provide information on the spatial distribution 
of hypoxia within tumours, and therefore there is increasing interest in combining this with 
hypoxia imaging techniques. A single marker of hypoxia is unlikely to be able to adequately 
describe the hypoxia response, and by combining molecular and imaging biomarkers of 
hypoxia a more comprehensive assessment of the pretreatment hypoxic status of tumours 
could be made. Correlating genomic and imaging data is the expanding field of 
radiogenomics, and advances in the technology in both areas of research will improve the 
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3.2 Aims 
64Cu-ATSM PET is currently a research tool to image hypoxia or hypoxia-related regions, 
but it is currently only available in specialist centres and would not be suitable for all 
HNSCC patients. Hypoxia gene signatures from diagnostic biopsies could enable the 
selection of patient who would benefit from hypoxia imaging, which would provide 
information on the level and distribution of hypoxia regions. This would in turn inform 
treatment selection.  
 
In order to achieve this process the aim of the BoHEMIaN study is to investigate whether 
specific gene signatures can predict for the hypoxic uptake on 64Cu-ATSM PET imaging, by 
correlating the gene expression profiles from diagnostic FFPE biopsies with the uptake 
parameters on PET in a homogeneous cohort of patients with locally advanced 
oropharyngeal squamous cell carcinoma. The combination of genetic and functional 
imaging biomarker data could potentially lead to a more robust method for hypoxia 
identification and mapping. 
 
 
3.2.1 Primary objectives 
• To correlate the gene expression profile of oropharyngeal SCC with 64Cu-ATSM 
PET imaging.  
• To investigate whether published hypoxia signatures correlate with 64Cu-ATSM 
PET imaging parameters. 
 
3.2.2 Secondary objectives 
• To investigate whether circulating biomarkers of hypoxia correlates with 64Cu-ATSM 
PET imaging parameters, specifically miR-196a, following on from our in vitro data, 
and miR-210, the hypoximiR. 
• To evaluate the relationship between gene signatures, 64Cu-ATSM PET uptake and 
circulating biomarkers with clinical response at 3 months post-treatment. 
• To design a validation study of any identified biomarkers for subsequent 
incorporation into clinical trials. 
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3.3 Methods 
3.3.1 Patients  
Research Ethics Committee approval was obtained for the study in November 2012 
(reference 12/LO/1123). All patients gave written and voluntary consent to enter the study, 
which included written consent for the use of a blood sample and their diagnostic biopsy 
specimen.  Fifteen patients were prospectively recruited as part of a pilot phase of the 
study.  
 
The initial eligibility criteria included patients with newly diagnosed with histologically 
proven HPV-negative stage III-IV squamous cell carcinoma of the oropharynx to be treated 
with radical concomitant chemoRT, which was expanded in February 2014 to also include 
HPV-positive patients. Patients were greater than 18 years of age with performance status 
0 – 1 and adequate organ function. Patients with a previous history of cancer other than 
skin basal cell carcinoma, patients with faecal or urinary incontinence and pregnant or 
breast feeding women were excluded. Eligible patients were identified from the weekly 
head and neck multidisciplinary meeting at Guy’s and St Thomas’ NHS foundation Trust.  
 
3.3.2 Study procedure 
All patients were evaluated before treatment with a full history and examination, staging 
with CT head, neck and chest. Staging MRI head and neck and whole-body (base of brain 
to mid-thigh) 18F-FDG-PET/CT scans were carried out if clinically indicated. Routine 
investigations as part of the treatment pathway were performed, and included blood tests, 
audiology and dental assessment, EDTA kidney and radiotherapy planning CT scans.  
 
Consented patients received a static 64Cu-ATSM PET/CT scan of the head and neck 
approximately 1 week prior to the start of their treatment and a sample of blood for serum 
and plasma were obtained at this visit.  
 
Treatment was not affected by the study and was in accordance with institutional protocol. 
All patients received IMRT, 65 Gy in 30 fractions to gross disease and high-risk regions, 
and 54 Gy in 30 fractions to low risk prophylactic regions over 6 weeks. Concomitant 
cisplatin 100 mg/m2 was delivered on days 1 and 29 of RT. Patients received induction 
chemotherapy of 2 cycles of cisplatin (80 mg/m2) and 5-fluorouracil (4000 mg/m2 over 4 
days) prior to chemoRT when indicated. Clinical response to treatment was assessed 
routinely with clinical assessment at 6 weeks and clinical assessment and 18F-FDG 
PET/CT scan 3 months after completion of chemoRT. 
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Fifteen eligible patients were recruited in a pilot study, looking specifically at gene/miRNA 
association with 64Cu-ATSM derived imaging parameters and the feasibility of evaluating 
circulating miRNAs. The overall study is planned for 40 patients (Figure 3.1) and also 
includes immunohistochemical staining for hypoxia-related protein expression from the 





Figure 3.1 Flowchart of overall study plan. 
 
 
3.3.3 64Cu-ATSM production 
64Cu-ATSM was produced in a CTI RDS-112 cyclotron by the Clinical PET Centre at St 
Thomas’ Hospital, which accelerates protons to 11 MeV. A 64Ni electroplated gold target 
was bombarded with protons for 5 to 8 hours to produce approximately 1 GBq 64Cu. The 
64Cu was separated from the nickel target and other contaminants by dissolving in 
hydrochloric acid to produce 64CuCl2. H2ATSM was dissolved in dimethyl sulphoxide 
(DMSO) and added to 64CuCl2 to produce 64Cu-ATSM containing solution. This was 
transferred onto a C18 Sep-Pak Light cartridge, washed with water, and the 64Cu-ATSM 
eluted from the cartridge with ethanol and diluted with sodium chloride for injection. Quality 
assurance procedures to check pH, isotope identity and purity were carried out prior to use. 
 
3.3.4 Image acquisition and reconstruction 
Patients were injected with 545 ±27 (range 486 - 577) MBq of 64Cu-ATSM followed by an 
uptake period of 60 minutes, which was based on in-house data. The first patient 
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acquisition was performed on a GE Discovery VCT PET/CT scanner (General Electric 
Medical Systems, Waukesha, Wisconsin, USA). All subsequent patients were imaged on 
the GE Discovery 710 PET/CT scanner (General Electric Medical Systems, Waukesha, 
Wisconsin, USA). Patients were positioned supine with their head in a foam head holder 
and arms down by their sides. First a low dose CT scan was performed from orbits to below 
the clavicles for attenuation correction and localisation (VCT scanner: 140kVp, 130mA, 
0.5s rotation, pitch 1.375:1 and 3.75 mm slice thickness; 710 scanner: 140kVp, 115mA, 
0.5s rotation, pitch 1.375:1 and 2.5mm slice thickness). The CT parameters for the new 
710 scanner were optimised to improve image quality. A 2 bed position (10 minutes/bed) 
PET scan of the same region was then acquired in 3-dimentional mode. The PET data was 
reconstructed using the GE fully 3D OS-EM algorithm (VCT scanner: voxel size 5.47 mm x 
5.47 mm x 3.27 mm 1 iteration and 20 subsets, 6 mm full-width-at-half-maximum Gaussian 
post filter; 710 scanner: 2.73 x 2.73 x 3.27, 2 iterations and 24 subsets, 6.4 mm full-width-
at-half-maximum Gaussian post filter. PET data for the 710 scanner incorporated time-of-
flight information in the reconstruction. 
 
3.3.4.1 Radiation exposure to patient 
The effective dose of radiation was based on a dose of 600 MBq 64Cu-ATSM and was 21.6 
mSv for the PET component and 1.1 mSv for the CT component. A total effective dose per 
scan would expose the patient to 22.7 mSv, with a risk of fatal cancer associated with the 
additional exposure of approximately 1 in 900. Patients were advised to minimise direct 
contact or 12 hours and avoid pregnant women for 24 hours as a precaution.  
 
3.3.4.2 Image analysis 
The 64Cu-ATSM PET/CT images were interpreted by a nuclear medicine physician and the 
student using Hermes Hybrid Viewer version 2.2C (Hermes Medical Solutions). PET uptake 
was assessed semi-quantitatively using standardised uptake values (SUV) normalised to 
patient body weight determined using the following equation: 
 
SUVbw = 64Cu-ATSM activity concentration measured in the tumour (Bq/cc) x (patient body 
weight (kg)/injected activity of 64Cu-ATSM (Bq) decay corrected to the time of injection) x 
1000 g/cc 
 
Visible lesions on PET with higher than background muscle uptake were considered 
hypoxic. Background uptake was evaluated by placing fixed 2.5 cm spheres over bilateral 
posterior neck muscles on the CT images to ensure correct position, transferring the 
spheres onto the PET images and calculating the average SUVmean. Regions of interest 
(ROIs) were outlined in multiple planes using a set zoom, SUV scaling and colour scale. An 
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initial region was drawn using an automatic segmentation seeded region growing tool on 
each scan slice and manually edited. The seeded region growing technique starts with a 
seed pixel with the tumour and then adds pixels to the region in all directions. The operator 
determines the extent of pixel expansion and final region outlined. ROIs were used to 
create a volume of interest (VOI). For the primary tumour SUVmax, tumour to muscle ratio 
(TMR), SUVmean and hypoxic volume (equal to the VOI) were obtained. For cervical lymph 
nodes SUVmax and TMR were assessed. TMR was determined by the ratio of tumour 
SUVmax to the average SUVmean of the posterior neck muscles. 
 
Abnormal lesions on the CT component were delineated with the aid of diagnostic CT, MRI 
and 18F-FDG PET/CT, where available, and the number of lesions compared with VOIs 
outlined on PET.  
 
3.3.5 Blood sample processing 
Blood sample collection and serum/plasma separation procedures were adapted from the 
guidelines from the Early Detection Research Network (edrn.nci.nih.gov). One purple top 
EDTA Vacutainer for plasma and one red top Vacutainer of blood were taken from each 
patient and processed immediately in the PET centre. For plasma separation the tube was 
mixed by inverting gently 8 to 10 times and centrifuged at 1200 x g for 15 minutes. The 
separated plasma was aliquotted into autoclaved Eppendorf tubes and placed on ice. A 
further centrifuge step at 3000 x g for 5 minutes was carried out and the plasma transferred 
into new tubes before storing at -80°C. Serum separation was achieved by mixing the tube 
gently 5 times and left upright for 30-60 minutes to allow a clot to form. The tube was then 
centrifuged at 1200 x g for 20 minutes, aliquotted, and placed on ice until transferring to -
80°C for long term storage. Between 5 and 6 tubes of 250 µl plasma and serum were 
obtained.  
 
3.3.6 Biopsy tissue preparation for RNA extraction  
OPSCC diagnosis and HPV status were assessed as standard protocol. HPV status was 
evaluated by both p16 IHC and in-situ hybridisation for high risk subtype DNA. Diagnostic 
biopsy slides were reviewed by a head and neck pathologist and the tumour outlined on the 
slide. FFPE tumour blocks were scored with a surgical blade to correspond with the tumour 
regions on the slide. Ten micrometre thick sections were then cut of the tumour area on a 
microtome to achieve a minimum of 10 sections with tumour area 100 mm2 for RNA 
extraction. All surfaces and equipment were thoroughly decontaminated with RNase AWAY 
(Thermoscientific) before and in between samples and a new microtome blade was used 
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for each sample. Samples were placed into autoclaved Eppendorf tubes and sent to BGI 
TechSolutions, China, for RNA extraction, RNA-Seq and small RNA-Seq. 
 
3.3.7 Bioinformatics 
BGI TechSolutions performed RNA-Seq and small RNA-Seq (Illumina HiSeq 2000), filtered 
the reads to remove adaptors and low quality reads. Bioinformatic analyses were carried 
out by Dr Katherine Lawler. In brief, RNAseq reads aligned to a reference genome (hg19; 
BWA v0.7.10-r789) were obtained from BGI and read counts per gene were enumerated 
using htseq-count (HTSeq v0.6.1p1495; union of exons). Read count normalisations and 
differential expression analyses were performed using DESeq2 v1.6.3.496 Gene signature 
activities were estimated from normalised read counts using a weighted sum of Z-scores 
for each gene in the respective gene list, with weights (+1,-1) according to the direction of 
expression in the original gene signature. Small RNA reads were obtained from BGI and 
aligned to miRNA mature sequences (MirBase v21 and Rfam v12) using bowtie2 v2.2.5 
and read counts per feature were enumerated using reads which were uniquely mapped 
among reported alignments.  
 
Two published hypoxia signatures were applied to the study samples to assess correlation 
with 64Cu-ATSM imaging parameters (Table 3.1): the 26-gene signature adapted from 
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Table 3.1 Published hypoxia gene signatures. Adapted from Eustace et al323 and 
Toustrup et al.321 
 
Winter Function  Toustrup  Function 
ALDOA Glucose metabolism  ADM Stress response 
ANGPTL4 Lipid and glucose metabolism  ALDOA Glucose metabolism 
ANLN Cytokinesis  ANKRD37 Protein-protein interaction 
BNC1 Keratinocyte proliferation  BNIP3 Apoptosis 
C20orf20 Cellular proliferation  BNIP3L Apoptosis 
CA9 pH regulation  C3orf28 Unknown 
CDKN3 Cellular proliferation  EGLN3 Regulation of HIF-1 activity 
COL4A6 Extracellular matrix metabolism  KCTD11 Apoptosis 
DCBLD1 Unknown  LOX Extracellular matrix metabolism 
ENO1 Glucose metabolism  NDRG1 Stress response 
FAM83B Unknown  P4HA1 Extracellular matrix metabolism 
FOSL1 Cellular proliferation  P4HA2 Extracellular matrix metabolism 
GNAI1 Signal transduction  PDK1 Energy metabolism 
HIG2 Stress response  PFKFB3 Glucose metabolism 
KCTD11 Apoptosis  SLC2A1 Glucose metabolism 
KRT17 Keratin production  
LDHA Glucose metabolism  
MPRS17 Mitochondrial translation  
P4HA1 Extracellular matrix metabolism  
PGAM1 Glucose metabolism  
PGK1 Glucose metabolism  
SDC1 Cellular proliferation  
SLC16A1 Glucose metabolism  
SCL2A1 Glucose metabolism  
TPI1 Glucose metabolism  
VEGFA Angiogenesis  
 
 
3.3.8 RNA extraction from plasma and qRT-PCR 
RNA extraction from plasma samples was carried out using the Exiquon miRCURY RNA 
isolation kit for biofluids following the manufacturer’s instructions. All surfaces and 
equipment were decontaminated with RNAse Away before use. After thawing 200 µl of 
plasma was transferred into a new tube. Five microliters of 5 fmol/µl of synthetic cel-miR-39 
spike in (Life Technologies) was added to 60 µl lysis solution BF and then to each sample. 
The mixture was vortexed and incubated at room temperature for 3 minutes. Twenty 
microlitres of protein precipitation solution BF was added, the solution vortexes, incubated 
for 1 minute and centrifuged for 3 minutes at 11000 x g. The clear supernatant was 
transferred into a new collection tube and 270 µl isopropranol added before loading onto a 
microRNA mini spin column. This was incubated at room temperature for 2 minutes and 
then centrifuged for 30 seconds at 11000 x g. The spin column was washed with wash 
solution containing ethanol and dried by centrifugation 3 times. The RNA was eluted by 
adding 50 µl of RNA free water onto the membrane of the spin column, incubating for 1 
minute and centrifuging for 1 minute at 11000 x g. The RNA was stored overnight and 
quantified the following day using the NanoDrop Spectrophotometer to provide an 
indication of the RNA content.  
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In accordance with the manufacturer’s protocol, as determination of yield is not possible or 
accurate by spectrophotometric reading, the optimum sample input for cDNA production to 
determine the RNA volume that can be used in the cDNA without inhibiting the RT-PCR 
reaction, was determined by performing a dilution curve. Five microlitres of RNA was used 
for assessment of miR-196a and miR-210 (Life Technologies) by qRT-PCR as previously 
described. All qRT-PCR samples were run in triplicate and the threshold for detection of 
cycle threshold (Ct) values fixed across all experiments. The level of the housekeeping 
genes RNU48 and RNU6B were highly variable amongst the plasma samples and 
therefore the spike in cel-miR-39 was used as the control, and the relative miRNA 
expression to cel-miR-39 was calculated using the relative standard curve method.  
 
3.3.9 Study statistics 
The D’Agostino-Pearson normality test was used to check the normality of the distribution 
of imaging and circulating miRNA data, before using the Pearson’s correlation coefficient 
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3.4 Results 
3.4.1 Patient recruitment and characteristics 
Between January 2013 and January 2015, fifteen patients were recruited. Recruitment was 
severely hampered after the first patient in January 2013 due to a flood in the room housing 
the cyclotron, followed by the relocation of the PET department at St Thomas’ Hospital. 
When recruitment recommenced in October 2013 there were no HPV-negative OPSCC 
patients for a number of months and therefore the eligibility criteria was expanded, with 
relevant permissions, to include HPV-positive locally advanced OPSCC. From March to 
June 2014 the cyclotron failed to produce 64Cu due to technical issues for 5 consented 
patients. A further 14 patients were recruited from June 2014 to January 2015 as part of a 
pilot study. Patient characteristics are summarised Table 3.2. 
 
 
Table 3.2 Patient characteristics (n = 15). 
 
Study ID Gender Age T stage N stage HPV status 
1 Female 51 2 2b Negative 
4 Male 60 3 0 Positive 
8 Male 71 4 2b Negative 
9 Male 54 2 2b Positive 
10 Male 46 4 0 Positive 
11 Female 61 2 2a Positive 
12 Male 64 2 2b Positive 
13 Male 59 3 1 Positive 
14 Male 47 3 2b Positive 
15 Male 44 2 2c Negative 
16 Male 66 3 2b Negative 
17 Male 56 2 2a Positive 
18 Male 69 1 2b Negative 
19 Male 64 2 1 Positive 




3.4.2 64Cu-ATSM uptake 
There were no immediate or late adverse reactions after tracer injection. Initial review of the 
scans demonstrated some tracer remaining in the vessels at the time of the scan, tracking 
towards the head and neck region on the side of tracer injection in 2 patients (Figure 3.2). 
This may have resulted in lower tracer delivery to the head and neck region, with reduced 
availability for uptake by the tumour. 
 




Figure 3.2 Example of 64Cu-ATSM in vein at time of scan. 
Viewing axial slices above and below demonstrated the tracer was travelling through the 
vein on the side of injection at the time of the scan. Top panel is the 64Cu-ATSM PET image 





Three patients had asymmetrical uptake in their trapezius muscle, making this region 
unsuitable for background muscle measurements (Figure 3.3). 
 
       
 
 
Figure 3.3 Example of increased 64Cu-ATSM in right trapezius muscle. 
Tracer 
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Eight patients had a staging 18F-FDG-PET/CT scan, which was not part of the study, but 
visual comparison showed different intensities and patterns of uptake consistent with 





Figure 3.4 Comparison of 64Cu-ATSM PET/CT with 18F-FDG PET/CT. 
Top panels demonstrate low 64Cu-ATSM uptake in base on tongue and no uptake in left 
level 2 lymph node on coregistered PET and CT scans (top left). These regions show 
high 18F-FDG uptake in same patient (top right). Bottom left image shows a large right 
lymph node with 64Cu-ATSM uptake in the periphery but more homogeneous 18F-FDG 
uptake (bottom right). Patients were not scanned in the same position for each scan 




3.4.2.1 Uptake in primary tumours and muscle 
Uptake was detected in all 15 primary tumours on 64Cu-ATSM PET scans. Regions of 
interest were outlined around the primary tumour and manually adjusted (Figure 3.5). The 


















Table 3.3 Summary of uptake parameters for all 15 patients. 
The SUVmax and tumour to muscle ratio (TMR) were measured. TMR is the ratio of 
SUVmax to average SUVmean of bilateral posterior neck muscle. 
 
 








1 2.57 1.04 0.91 0.98 2.64 
4 3.61 0.60 0.59 0.60 6.07 
8 3.96 0.43 0.45 0.44 9.00 
9 2.67 0.75 0.72 0.74 3.63 
10 3.14 0.84 0.84 0.84 3.74 
11 2.99 0.78 1.07 0.93 3.23 
12 4.35 0.80 0.75 0.78 5.61 
13 3.83 0.72 0.71 0.72 5.36 
14 3.34 0.55 0.58 0.57 5.91 
15 4.85 0.99 1.07 1.03 4.71 
16 3.75 0.65 0.85 0.75 5.00 
17 2.34 0.97 0.64 0.81 2.91 
18 2.12 0.80 0.70 0.75 2.83 
19 4.21 0.84 0.81 0.83 5.10 




Two patients had diagnostic tonsillectomies at least 4 weeks prior to the 64Cu-ATSM PET 
scan. The tumour region still showed increased uptake on PET and asymmetry of the 
tonsillar fossa on CT (Figure 3.6). 
 
 




Figure 3.6 Uptake in primary tumour region after diagnostic tonsillectomies.  
64Cu-ATSM uptake is seen on PET (left) and asymmetry of the tumour region compared 





Background uptake was assessed by averaging the SUVmean in fixed spheres placed over 





Figure 3.7 Example of spheres placed over posterior neck muscles to measure 
background uptake. 
Spheres were placed on the axial CT images (left), checked on the coronal (right) and 




The mean TMR was 4.51 ± 1.82 (median 4.71, range 1.84 – 9.00) (Table 3.3). SUVmax and 
TMR were not significantly different between HPV-positive and HPV-negative patients. 
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3.4.2.2 Hypoxic volume (HV) 
Tonsillectomy patients were excluded from analyses using HV and SUVmean. The mean HV 
was 12.54 cm3 ± 11.53 (median 7.55, range 0.68 – 36.89) and the mean SUVmean was 2.34 
± 0.45 (median 2.45, range 1.71 – 3.11) (Table 3.4). 
 
Table 3.4 Hypoxic volume and SUVmean.  
Patient in red had tonsillectomies at diagnosis and were excluded from analyses using 
HV and SUVmean. 
 
Study ID Hypoxic volume (cm3) SUVmean 
1 9.78 1.96 
4 29.58 2.45 
8 5.60 2.46 
9 3.28 1.85 
10 6.31 2.02 
11 5.13 2.29 
12 10.76 3.11 
13 36.89 2.61 
14 7.55 2.27 
15 21.66 2.94 
16 23.01 2.58 
17 2.15 1.90 
18 0.68 1.71 
19 7.51 2.68 
20 1.49 1.77 
 
 
3.4.2.3 Uptake in cervical lymph nodes 
Increased uptake was detected in 22 lymph nodes on 64Cu-ATSM PET scans (Table 3.5). 
When reviewing the number of abnormal lymph nodes using the CT component of the 
scan, with guidance from diagnostic imaging, there were 31 lymph nodes in total. Figure 
3.8 shows an example on abnormal lymph node visible on CT only. Lymph node uptake 
was more heterogeneous than uptake in the primary, especially in large nodes which 
showed uptake in the periphery with central regions of no uptake secondary to necrosis 
(Figure 3.9). 
 
The mean SUVmax of the nodes was 2.43 ± 0.93 (median 2.31, range 1.39 – 5.80) and the 
mean TMR 3.29 ± 2.41 (median 2.85, range 1.35 – 13.18). In general the uptake in the 
nodes were lower than the primary. The exception was patient 8, who had a large 
conglomerate lymph node mass (Figure 3.4 lower panel). This is not consistent with the 
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data from Eppendorf oxygen electrodes where lymph nodes were used as surrogates for 
tumour hypoxia.235  
 
Table 3.5 Summary of uptake in regional lymph nodes. 
 
Study ID Lymph node SUVmax Lymph node TMR 





9 3.55 4.83 
3.05 4.15 















16 2.22 2.96 





19 2.36 2.86 





Figure 3.8 Lymph node visible on CT (right) but not on 64Cu-ATSM PET (left). 
 









The uptake in the SUVmax and TMR in the nodes was compared with the uptake in the 
primary. For patients with multiple nodes the average uptake was compared, and for the 2 
patients with N0 disease the primary uptake was plotted against their background uptake. 
There was no pattern observed comparing SUVmax but there was a positive trend with TMR 
(Figure 3.10).  
 
 
Figure 3.10 SUVmax and TMR in primary tumour compared with cervical lymph 
nodes. 
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3.4.2.4 Other uptake 
64Cu-ATSM uptake was seen in the maxilla and mandible, consistent with recent dental 








All patients had uptake in their salivary glands, in particular in the submandibular glands 
(Figure 3.12). The average SUVmax was 2.20 ± 0.43 (range 1.69 – 3.06) for the 
submandibular gland ipsilateral to the primary tumour, and 2.08 ± 0.39 (range 1.53 – 2.87) 
for the contralateral gland. The average SUVmax was 1.41 ± 0.22 (range 0.98 – 1.72) and 




3.4.2.5 Clinical response 
One patient died 2 weeks after completion of treatment of bilateral pneumonia but no 
evidence of cancer. The remaining 14 patients have had a clinical and radiological 
complete response, assessed by 18F-FDG PET/CT, at 3 months post-treatment and there 














Figure 3.12 Uptake in salivary glands. 
All patients showed 64Cu-ATSM uptake in bilateral submandibular glands (top panel) 
and lower grade uptake in parotid glands (lower panel). 
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3.4.3 RNA-Seq 
RNA extraction by BGI TechSolutions from all 15 samples yielded sufficient RNA 
concentration with adequate RNA integrity number (RIN) of ≥ 2.3 for both RNA and small 
RNA sequencing. 
 
As an initial screen to assess gene expression, the differential gene expression between 
the HPV-positive and HPV-negative samples was compared with previously published 
HPV-positive and HPV-negative gene expression patterns (Figure 3.13).497,498 These gene 
expression patterns were obtained using fresh tumour samples and genome-wide 
microarrays. Overall the pattern of gene expression profiles of HPV-positive versus HPV-
negative of our samples were readily distinguishable and consistent with previous studies. 
In particular, HPV-positive tumours expressed high levels of CDKN2A compared with HPV-




Figure 3.13 Differential expression of genes associated with HPV status.  
Volcano plot showing genes differentially expressed between samples from HPV-
positive versus HPV-negative tumours, filtered to show genes with more than 200 reads 
(baseMean > 200). Point labels indicate overlaps with genes previously reported to be 
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3.4.3.1 Comparison with published hypoxia signatures 
Due to the small number of patients recruited, we initially compared the gene expression to 
the two main published hypoxia signatures used to assess hypoxia, the Winter signature 
(Winter2007)112 and the 15-gene hypoxia classifier (Tousrtup2011).321 The samples were 
ranked from low to high expression of the signatures and the level of expression compared 





Figure 3.14 Winter and Toustrup hypoxia gene expression signatures correlated 
in biopsy samples.  
The mean weighted score for each gene in the published hypoxia gene expression 
signatures was assessed in the study samples and ranked from low to high expression. 
There was strong correlation between the expression of the Winter2007 and 
Toustrup2011 signatures in the study samples.  
 
 
The level of expression of the hypoxia gene signatures in our samples was correlated with 
64Cu-ATSM imaging parameters (Figure 3.15, Figure 3.16). There was significant 
correlation between the expression of both signatures and hypoxic volume, but not TMR or 
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Spearman cor, p = 0.00022

















Figure 3.15 Scatterplot of 64Cu-ATSM imaging parameters and Winter hypoxic signature.  
Hypoxic volume, TMR and SUVmax plotted against the 26-gene hypoxia signature. A significant positive correlation is observed between the hypoxia 
score and hypoxic volume, but not TMR or SUVmax. Samples from patients who had diagnostic tonsillectomies (Study IDs 9 and 11) were excluded as 
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Figure 3.16 Scatterplot of 64Cu-ATSM imaging parameters and Toustrup hypoxia classifier. 
Hypoxic volume, TMR and SUVmax plotted against the 15-gene hypoxia classifier. A significant positive correlation is observed between the hypoxia 
score and hypoxic volume, but not TMR or SUVmax. Red points indicate samples with low hypoxia score but high SUVmax. Samples from patients who 
had diagnostic tonsillectomies (Study IDs 9 and 11) were excluded as a hypoxic volume could not be determined. 
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The scatterplots of the hypoxia signatures, particularly the 15-gene classifier, versus 
SUVmax suggest there is a group of samples (n = 4) which have a high SUVmax but are low 
scoring for expression of the hypoxia signatures. A similar effect is seen with TMR in the 
same samples, suggesting there may be two subpopulations. There were no significant 
differences in the baseline characteristics between the ‘subopulation’ and the other 
samples.  
 
3.4.3.2 De novo gene signature for hypoxic volume 
Hypoxic volume was further investigated as it showed a positive correlation with hypoxia 
signatures. If the hypoxic signatures describe a hypoxic phenotype in the study samples, 
looking for genes differentially expressed by hypoxic volume could define more accurate 
64Cu-ATSM-specific hypoxia signature. The samples were ordered by increasing hypoxic 
volume and the gene expression analysed. There were two genes which overlapped with 
the 15-gene hypoxia classifier, LOX and PFKFB3. In addition when the samples were 
ranked using the 15-gene hypoxia classifier, in general, there was concordance between 
the hypoxic volume gene signature and higher hypoxia score (Figure 3.17).  
 
The name and function of the genes in the hypoxic volume gene signature are summarised 
in Table 3.6. A number of the overexpressed genes encode proteins that are involved in 
cytoskeletal and extracellular matrix remodelling (GJB6, LOX, TPM4, CDCP1) suggesting 
increased turnover of cells or enhancing the potential for increased cell motility. Other 
overexpressed genes include those involved in the regulation of inflammatory responses 
(IL20RB, S100A7) and angiogenesis (S100A7). Interestingly there are a few genes with 
specific roles in the glucose metabolism/oxidative phosphorylation pathway (SOD2, 





















Figure 3.17 Gene expression associated with hypoxic volume.  
Samples were ordered by increasing hypoxic volume and the gene expression 
analysed (reads > 200, adjusted P < 0.05; or italicised: adjusted P < 0.1). Two genes 
which overlapped with the 15-gene hypoxia classifier gene list are shown in bold. 
Yellow and blue colour bar shows the hypoxia 15-gene classifier score by rank within 
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Table 3.6 Summary of genes associated with hypoxic volume. 
 
Gene Name Function of protein 
TMPRSS11D Transmembrane protease, serine 
11D 
Integral membrane protein, trypsin-like serine 
protease 
 
GJB6 Gap junction protein beta 6 Connexin protein that is part of gap junctions, 
cell communication 
 
IL20RB Interleukin 20 receptor beta Receptor for interleukin 20, a pro-
inflammatory cytokine 
 
TFRC Transferrin receptor C Cell surface receptor for cellular iron uptake  
 
LOX Lysyl oxidase Copper enzyme that initiates the crosslinking 
of collagens and elastin in extracellular matrix 
 
APOL1 Apolipoprotien 1 Lipid metabolism 
 
FBXO45 F-box protein 45 Protein-ubiquitin ligase 
 
SOD2 Superoxide dismutase Mitochondrial protein, binds to the superoxide 
byproducts of oxidative phosphorylation, 
antiapoptotic role against oxidative stress 
 
S100A7 S100 calcium-binding protein A7 Mediate inflammation, endothelial 
proliferation and angiogenesis 
 
NCOA7 Nuclear receptor coactivator 7 Coactivates nuclear receptors, involved in 
oxidation resistance 
 
TM4SF1 Transmembrane 4 L six family 
member 1 
Mediates signal transduction events in 
regulation of cell development and growth 
 




Catalyses step in the biosynthesis of 




Glucose metabolism, required for cell cycle 
progression and prevention of apoptosis 
 
TPM4 Tropomyosin 4 Actin-binding proteins involved in the 
cytoskeleton  
 
SRPK1 SRSF protein kinase 1 Regulation of constitutive and alternative 
splicing 
 
RUNX3 Runt-related transcription factor 3 Tumour suppressor 
 
SYNGR2 Synaptogyrin 2 Unknown 
 
ORAI2 ORAI calcium release-activated 
calcium modulator 2 
Cellular calcium homeostasis 
 
POU2AF1 POU class 2 associating factor 1 B-cell transcriptional co-activator 
 
LIFR Leukaemia inhibitory factor 
receptor alpha 
Receptor for cytokine leukaemia inhibitory 
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3.4.3.3 SUVmax differential gene expression 
SUVmax is a parameter that is not operator dependent and available for all patients, and has 
been prognostic in previous clinical studies. To further investigate the lack of association 
between this parameter and published hypoxia signatures samples were split into less than 





Figure 3.18 Differential gene expression between low and high SUVmax samples. 
The samples were grouped into low and high SUVmax using the median SUVmax and 
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The function of the proteins encoded by the genes are summarised in Table 3.7. There 
were no clear links with hypoxia in the genes seen, apart from the overexpression of ECM1 
in high SUVmax samples, which is important in endothelial cell proliferation and 
angiogenesis. 
 
Table 3.7 Summary of genes differentially expressed by SUVmax. 
 
Gene Name Function of protein 
FZD5 Frizzled class receptor 5 Receptor for Wnt signalling proteins 
 
LAMB3 Laminin beta 3 Basement membrane protein 
 
SYNGR2 Synaptogyrin 2 Unknown 
 
ABLIM1 Actin-binding LIM protein 1 Cytoskeletal protein, protein binding 
interface 
 
SAMD9 Sterile alpha motif domain-containing 9 IFN-γ responsive inflammatory response 
 
ECM1 Extracellular matrix protein 1 Promotes endothelial cell proliferation and 





There was no obvious trend with the genes differentially expressed in the high versus low 
SUVmax groups. This may have been affected by the presence of the possible 4 patient 
subgroup and high SUVmax samples may include 2 populations; one with high hypoxic 
expression according to the 15-gene classifer and one with low hypoxic expression. To 
look at possible differences in these groups, we compared the gene expression in the 4 
high SUVmax/low hypoxia score samples with 4 low SUVmax/low hypoxia score samples 
(Figure 3.19). 
 
The function of the proteins encoded by these genes are summarised in Table 3.8. In the 
high SUVmax/low hypoxia score group there is downregulation of genes involved in the 


















Figure 3.19 Differential gene expression between 4 samples with high SUVmax/low 
hypoxia score and low SUVmax/low hypoxia score. 
Among biopsy samples with the lowest Tousrup2011 hypoxia score, samples were 
grouped according to high or low SUVmax in the patient’s tumour (defined by 
inspection of scatterplots). The heatmap shows top-ranked genes by evidence of 
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Results: 
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-- Lack of podoplanin and IFITM1 
(both have been associated with 
HNSCC progression).
-- Epithelial, corniﬁed envelope?
-- Epidermal diﬀerentiation complex 
(EDC) has been reported associated 
with some HNC's.
-- Cell metabolism may be 
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Table 3.8 Summary of differentially expressed genes in low and high SUVmax 
groups. 
 
Gene Name Function of protein 
PDPN Popoplanin Transmembrane glycoprotein, roles in 
development, cell motility and immune 
response 
 




CXCL10 Chemokine ligand 10 Chemoattracts monocytes, natural killer and 
T cells, inhibition of angiogenesis 
 
IFITM3 Interferon-induced transmembrane 
protein 3 
Immune response signalling 
PTGES Prostagladin E synthase Inflammation response 
 
IFITM1 Interferon-induced transmembrane 
protein 1 
 
Immune response signalling 




SLC39A1 Solute carrier family 39, member 1 Zinc uptake transporter on cell membrane 
 
FBXW5 F-box and WD repeat domain-
containing 5 
Proteosome-mediated ubiquitin-dependent 
protein, promotes degradation of TSC2 
 
C14orf43 ELM2 and Myb/SANT-like domain-




TPCN1 Two pore segment-containing 
channel 1 
 
Calcium transmembrane transport 
CXCL12 Chemokine ligand 12 Immune surveillance, inflammation 
response, angiogenesis 
 
ECM1 Extracellular matrix protein 1 Promotes endothelial cell proliferation and 





3.4.3.4 MicroRNAs associated with hypoxic volume 
As the hypoxic volume correlated with the hypoxic signatures, the top ranked miRNAs by 
association with increasing hypoxic volume were assessed (Figure 3.20). There was no 
overlap between the miRNAs in our samples and published HIF-1-associated hypoxia 
response miRNAs.230 MiR-210 was not found to be upregulated in samples with increasing 
hypoxic volume defined by 64Cu-ATSM. Samples were also ranked by increasing hypoxia 
score, as defined by the 15-gene classifier, and miR-31-5p and miR-21-5p were top ranked 
in samples with increasing hypoxia score (Figure 3.20). 





Figure 3.20 MiRNAs associated with increasing hypoxic volume and increasing 
15-gene classifier hypoxia score.  
Samples were ordered by increasing hypoxic volume and the top ranked miRNAs by 
association with hypoxic volume are shown (top panel, P < 0.006, adjusted P = 0.99). 
The top ranked miRNAs by association with the 15-gene classifier Toustrup2011 are 




3.4.4 Plasma analysis 
RNA extraction from plasma samples was performed in triplicate once 15 patient samples 
were collected. NanoDrop measurements were taken for each extraction as a broad 
indication of the presence and quantity of RNA. The concentration ranged from 11.2 – 22.7 
ng/µl and the absorbance at 260/280 ranged from 1.29 – 1.79. The expression of the 
commonly used housekeeping genes RNU48 and RNU6B were measured by qRT-PCR 
but the Ct values obtained were high, inconsistent and non-reproducible. The Ct values for 
cel-miR-39 were consistent and reproducible. Two samples were visibly haemolysed and 
not included in further analyses.   
 
MiR-196a showed no correlation with SUVmax and TMR (Figure 3.21). However there was a 
significant correlation between increasing hypoxic volume and increasing miR-196a levels, 
assessed by Spearman’s rank correlation coefficient (Figure 3.22, left). The tumour volume 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.21 Correlation between SUVmax (left) or TMR (right) and plasma miR-196a 
expression relative to cel-miR-39.   
MiR-196a expression levels in plasma were measured in triplicate from 3 separate RNA 
extractions and expressed relative to the expression of an exogenous spike in, cel-miR-








Figure 3.22 Correlation between hypoxic volume (left) or CT volume and plasma 
miR-196a expression relative to cel-miR-39. 
MiR-196a levels were correlated with tumour volumes. The hypoxic volume was 
delineated on PET images, whereas the CT volume was based on outlining the gross 
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Similarly miR-210 was compared with the imaging parameters. There was a non-significant 
positive correlation between increasing SUVmax or TMR with increasing miR-210 levels in 
the plasma (Figure 3.23), but no correlation with hypoxic volume (Figure 3.24, left). There 





Figure 3.23 Relationship between SUVmax (left) or TMR (right) with plasma miR-210 
expression relative to cel-miR-39. 
MiR-210 expression levels were measured in triplicate from 3 separate RNA extractions 
and expressed relative to the expression of an exogenous spike in, cel-miR-39. The 






Figure 3.24 Relationship between hypoxic volume (left) or SUVmean (right) with 
plasma miR-210 expression relative to cel-miR-39. 
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3.5 Discussion  
3.5.1 Patient recruitment 
The recruitment rate was initially slow due to problems with the production of the tracer and 
relocation of the PET centre. A second site for recruitment was set up at University College 
Hospital London, but as 64Cu-ATSM production could not be guaranteed we were unable to 
recruit from this site during the pilot phase of the study. Locally advanced HPV-negative 
OPSCC was initially selected for study eligibility as a homogeneous population that would 
potentially benefit the most from hypoxia-targeted intensification strategies. However, there 
were few eligible HPV-negative OPSCC patients, reflecting the change in aetiology and 
incidence of this group in the Western world. Hypoxia has been demonstrated in both HPV-
positive and negative OPSCC at the same frequency by pO2 measurement, CA9499 and 
HIF-1α IHC,500 hypoxia gene expression signature,324 18F-FMISO501 and 18F-FAZA PET 
imaging.352 HPV-positive oropharyngeal cell lines in vitro have been shown to upregulate 
the same hypoxia-related genes as HPV negative cell lines when exposed to hypoxic 
conditions.502 However HPV-positive OPSCC demonstrates good outcomes after RT 
irrespective of hypoxia or hypoxic modification, despite in vitro data suggesting HPV 
oncoproteins stabilise HIF-1α and contribute to downstream biological effects of hypoxia.503 
Not all HPV-positive tumours have the same good outcome and a subset of these patients 
may benefit from hypoxia-targeted treatment. Cell line data has shown that although HPV-
positive HNSCC have increased intrinsic radiosensitivity compared to HPV-negative cells, 
they also demonstrate a sensitiser effect with nimorazole similar in magnitude to HPV-
negative cell lines.502 Investigation into the role of hypoxia in HPV-positive OPSCC and the 
potential for radiotherapy dose reduction in the presence of a hypoxic modifier is therefore 
warranted as a strategy in these patients. 
 
3.5.2 Cu-ATSM PET as a hypoxia imaging agent 
Preclinical studies of Cu-ATSM have shown the tracer to be selective for hypoxic cancers, 
ischaemic myocardium, and other states of impaired mitochondrial ETC activity, and small 
clinical studies have demonstrated prognostic potential and response prediction to 
radiotherapy. Despite many studies investigating the chemical and biochemical properties 
of Cu-ATSM in vitro an in vivo, the precise mechanism of the pO2 dependence and factors 
that can affect cellular uptake and retention in both normoxic and hypoxic tissues is 
unclear. Emerging evidence suggests that Cu-ATSM may be an indirect marker for 
hypoxia. Hypoxia results in the accumulation of cellular NADH, which is the primary source 
of electrons for the mitochondrial electron transport chain (ETC). Hypoxia reduces the 
availability of oxygen as the terminal electron acceptor in the ETC resulting in the 
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accumulation of NADH, which is then able to reduce Cu(II) to Cu(I) with subsequent 
dissociation from ATSM and cellular trapping. However, this mechanism still provides 
support for Cu-ATSM as a radiotracer to detect hypoxia, although possible other sources of 
uptake need to be taken into consideration when interpreting the images. 
 
Other uncertainties include the optimal time for hypoxia imaging after injection. One clinical 
study in 11 HNSCC patients demonstrated that scans at 1 and 16 hours showed no 
significant difference in the mean SUVmax of the primary lesions between the two time 
points. However they did not report on whether there was any change in the spatial 
distribution of uptake. Canine studies have suggested temporal changes between early and 
late scans, whereas rodent studies demonstrate conflicting results when comparing with 
nitroimidazole-based markers for validation. However, it has been shown that anaesthetic 
and carrier gases influence the uptake of 64Cu-ATSM and 18F-FMISO by murine 
adenocarcinoma bearing mice, with different regimes having varied effects, which may 
have affected animal studies.504 
 
Cu-ATSM has also been criticised for variation in uptake with different cell lines, especially 
prostate cancer cell lines, which may be explained by differences in the extent of trapping 
and retention of Cu-ATSM, and more specifically due to fatty acid synthase in prostate cell 
lines.381 Unreliable uptake is also true for other tracers including 18F-FMISO, which has 
been shown to be a poor tracer in soft tissue sarcomas,505,506 and 18F-FDG PET, which is 
not good for differentiating benign and malignant prostate disease.507 In general Cu-ATSM 
shows consistent uptake kinetics in squamous cell carcinomas, but with variable spatial 
correlation with nitroimidazole-based IHC staining, especially when compared with 18F-
FMISO. However it is not surprising that 18F-FMISO correlates well in these situations as 
the retention mechanism is the same. Unless the differences in uptake and retention of 
both tracers are known, direct comparisons are likely to result in inconsistent results as 
they have different underlying mechanisms. Bowen et al,508 through electrochemical 
modelling, observed that dual tracer imaging which has been used in preclinical studies, 
where both Cu-ATSM and 18F-FMISO are injected at the same time, may lead to 
competition for the cytochrome reductases required for Cu-ATSM reduction by 18F-FMISO, 
as FMISO is reduced by a larger family of nitroreductases that includes the cytochrome 
reductases. This may result in higher 18F-FMISO retention compared with Cu-ATSM when 
imaging at early time points and more equal retention at late time points, which has been 
seen in some preclinical studies.380 They also suggested that cell line dependent uptake of 
Cu-ATSM may be related to variations in enzymatic activity and intracellular pH, and that 
Cu-ATSM uptake may be more sensitive to changes in low pO2, whereas FMISO is more 
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discriminating over larger ranges of oxygen tension. The 2 tracers may therefore both 
provide information on hypoxia and may be complementary to each other.  
 
3.5.3 64Cu-ATSM uptake measurements 
64Cu-ATSM uptake was mainly assessed using SUVs, which is a semi-quantitative 
measure of regional tracer uptake commonly used in 18F-FDG PET interpretation. In a 
region of interest it is the decay corrected tumour activity concentration normalised to 
injected activity per unit body weight at fixed time point.509 In this study it provided a 
simplified surrogate measure of tracer uptake that allowed intra- and inter-patient 
quantification and comparison, as well as correlation with other molecular markers. Full 
quantitative measures require arterial blood sampling, dynamic scanning and kinetic 
modelling, limiting patient recruitment and direct clinical applicability. This has already been 
carried out in a previous in-house study, which showed stable tracer uptake from 
approximately 15 minutes post-injection, and guided the protocol used for static imaging at 
60 minutes post-injection in the current study.  
 
3.5.3.1 SUV 
The SUVmax reflects the highest voxel value within a ROI or VOI, and is the most widely 
used parameter. It is independent of ROI definition, less observer dependent and more 
reproducible.509 The SUVmax ranged from 1.39 to 5.80 in lesions with uptake seen on PET 
images. A study using 64Cu-ATSM in 11 HNSCC reported a higher mean SUVmax in tumour 
(various subsites) and nodes of 16.2 ± 7.9.412 The reported mean SUVmax in the primary 
tumour only in HNSCC studies using 62Cu-ATSM was 5.48 ± 1.69 (range 1.75 – 7.55 in 15 
patients)407 and using 61Cu-ATSM was 4.6 ± 2.3 (range 2.2 – 9.3 in 11 patients),410 which 
again are higher than the mean SUVmax of 3.32 ± 0.85 (range 2.12 – 4.85) in our patient 
population.  
 
Other SUV measurements reported in previous studies include SUVmean and SUVpeak using 
61Cu-ATSM in OPSCC.410 The SUVmean incorporates uptake from multiple voxels but 
changes depending on the definition of the VOI, resulting in intra- and interobserver 
variability.510 The reported SUVmean ranged from 0.7 to 2.8 (average 1.5 ± 0.6), which is 
lower than that seen in our study. However this group defined the gross tumour volume 
(GTV) on CT images, expanded the volume by 2 mm after coregistering the CT and PET 
images. This is not likely to reflect the hypoxic volume of the tumour, which may be a 
subvolume within the GTV, resulting in lower SUVmean values. SUVpeak is the average SUV 
in 8 voxels surrounding the voxel with highest activity and has been suggested to be more 
representative of the tumour uptake than SUVmax, whilst maintaining high reproducibility.511 
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However this parameter requires a minimum size of tumour and was not available in 4 out 
of our 15 patients. 
 
The main limitation of utilising SUV parameters to quantify hypoxia is that a single value is 
used to describe a heterogeneous tumour mass, which does not take into account the 
complex mixture of hypoxic, necrotic and inflammatory cells, blood vessels and 
metabolism. Many factors affect SUV including technical errors, such as inaccurate 
estimation of residual tracer activity in administration system, resulting in lower net 
administered dose and lower SUV.509 This usually refers to the syringe and tubes used, 
which is measured post-injection, but may have also affected the SUV of the 2 patients 
who had uptake in their vascular system at the time of the scan. It is unclear why this 
occurred; no discomfort or signs suggestive of extravasation were apparent during or after 
injection but the tracer may have caused irritation and inflammation of the vein during 
delivery.  
 
The PET image acquisition and reconstruction procedures can have an impact on the SUV, 
as well as interscanner variability.512 After the first patient was scanned there was a delay 
of over a year, and the remaining patients were scanned on a more advanced PET scanner 
with improved image acquisition parameters. Although reconstruction procedures were 
performed to ensure similar interpretation the images from the new scanner were of higher 
resolution (Figure 3.25), which may affect tumour volume outlining.  
 
 
   
 
Figure 3.25 Different image quality between PET scanners. 
The first patient recruited to the study was scanned in a different PET scanner to the 
remaining 14 patients. The images from the old scanner (left) is of slightly lower quality 
than images from the new scanner (right). 
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Other general limitations of PET can affect SUV. The 2 coincident photons travelling in 
opposite directions from the positron decay of 64Cu are detected by scintillation crystals in a 
ring around the patient. They record photon pairs that interact at approximately the same 
time with a pair of detectors, and an image reconstruction algorithm is used to compute the 
image of the tracer distribution from the collected coincidence count data. Corrections are 
required for tissue attenuation, non-uniform detector activity, scattered and random 
coincidence events when photons are deviated from their true path, and dead time when 
the scintillation crystal is unable to record photon counts until the detection process is 
complete. These factors and the finite number of photon detection lead to noise, to which 
SUVmax is more susceptible, due to loss of precision.510 There is limited spatial resolution of 
approximately 4 mm due to factors such as positron range, non-colinearity of the photon 
pair and the detector size, resulting in the spill in or out of activity into adjacent voxels, 
known as partial volume effects.509 The partial volume effect means that a small source of 
radioactivity may show up as a larger less intense source, underestimating SUVs. Two 
patients had T1 tumours, of which one did not have a tumour visible on CT imaging but 
detected on PET imaging and histology, and 2 patients had tonsillectomies, which may 
have significantly reduced the tumour size. Newer scanners have better sensitivity with 
better corrections and image reconstruction, including time of flight data, which records the 
precise time that each of the coincident photons is detected and calculates the difference to 
accurately locate the site of the annihilation reaction along the line of the 2 detectors, and 
therefore imaging analysis and interpretation are constantly improving.  
 
3.5.3.2 TMR 
Kinetic analysis demonstrated that muscle activity is essentially stable after the first 10 
minutes post-60Cu-ATSM injection and parallels the time course of the tracer in blood. The 
muscle activity has therefore been used as an estimation of blood activity, as it avoids 
blood sampling, to estimate the net trapping of radiotracer in a tumour under blood activity 
of constant value.396 TMR performed better as a prognostic indicator in lung and cervix 
cancers in Cu-ATSM PET studies.396,399 In HNSCC one group found a TMR cut off of 3.2 to 
be associated with better outcome,408 whereas another group found no difference in TMR 
between responders and non-responders to treatment.407  Both studies used SUVmax to 
calculate the TMR, but one study used bilateral sternocleidomastoid muscles as the 
background uptake, whilst the other used posterior cervical muscle groups. We 
investigated the sternocleidomastoid muscles as a measure of background uptake, but 
these were in close proximity to metastatic cervical lymph nodes and salivary glands with 
increased uptake. We also looked at using 3 cm fixed spheres over the trapezius muscles 
as they are larger and further away from the primary tumour and lymph nodes, but found 
asymmetrical uptake in some patients. The range of TMRs in the primary tumours and 
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nodes was greater than SUVmax (1.39 – 13.18), which may result in better discrimination 
when determining cut off values for prognostic groups. 
 
3.5.3.3 Hypoxic volume delineation 
The hypoxic primary tumour volume and corresponding SUVmean were also used as 
parameters for assessing 64Cu-ATSM uptake, as it estimates tumour volume based on the 
distribution of hypoxic activity and quantifies the overall tumour volume. The volume was 
determined by visual delineation of the tumour edge, as there is no validated automated 
segmentation method for Cu-ATSM, but this method is highly operator dependent. Chao et 
al used a TMR ≥ 2, or uptake twice that of the contralateral normal neck, to define 60Cu-
ATSM hypoxic volume as no normal tissue in the neck displayed activity at this threshold. 
This was defined to demonstrate RT dose escalation to the hypoxic volume in 1 patient, 
and it is not clear how many patients they assessed overall to determine the threshold. We 
did attempt to use this threshold but, depending on the individual background uptake and 
size of tumour, this resulted in large volumes that required extensive manual editing in a 
large proportion of patients (Figure 3.26). Although the aim was not to determine the 
optimal method for hypoxic volume outlining, we tried applying higher TMR thresholds, 
which resulted in smaller volumes, but there was no single threshold that could be applied 




Figure 3.26 Example of tumour delineation using TMR > 2 automated 
segmentation. 
Tumour delineation using this threshold resulted in overestimation of tumour size 
without extensive manual editing. 
 
 
Grassi et al412 used a cut off of 42% of the lesion SUVmax to delineate a biological target 
volume in 11 HNSCC patients to compare the volumes obtained from 64Cu-ATSM and 18F-
FDG PET images. European guidelines in 18F-FDG PET recommend using a 3D isocontour 
TMR > 2 41% and 50% of SUVmax 
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at 41% of the maximum pixel value in metabolic tumour volume reporting where indicated, 
unless the tumour to background ratio is low or the tumour has heterogeneous uptake. For 
these cases 50% of the maximum uptake should be used consistently when assessing 
response to therapy.513 These cut offs are not validated in Cu-ATSM PET but were also 
attempted in our dataset. However this again resulted in large volumes due the lower 




Figure 3.27 Example of delineation using 41% (red) and 50% (blue) of SUVmax. 
Automated segmentation of primary tumour in this case resulted in extension across 
midline and into submandibular gland seen on coronal imaging. 
 
 
As there is no standard to which these various volumes from different thresholds could be 
compared, we could not conclude if any were superior or more accurate. One difficulty is 
whether the whole visible tumour volume with uptake above background or whether a 
threshold defined hypoxic subvolume represents clinically relevant radioresistant regions. 
TMR or SUVmax cut offs identified by previous studies associated with residual or recurrent 
disease or poorer long-term outcome, may be the thresholds that should be applied to 
define biologically significant hypoxic volumes within tumours. However these cut offs are 
variable between studies. The limited spatial resolution of PET makes defining the edge of 
tumour uptake difficult, but also means that PET imaging does not necessarily show the 
microregional, true heterogeneity of hypoxia within the tumour.330 Clinically relevant cellular 
hypoxia may be present in smaller areas that are not detected by PET, making any of the 
PET parameters used to quantify hypoxia inaccurate. Further studies with larger numbers 
of patients are required be able to investigate a more robust method for defining hypoxic 
volume. 
 
A further volumetric measure that has been explored using 18F-FAZA in HNSCC is the 
fractional hypoxic volume, or the percentage of hypoxic volume within the whole primary 
TMR > 2 41% and 50% of SUVmax 
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tumour, using a fixed TMR threshold to define hypoxic volume and manually delineated 
tumour volume on CT.352 This was also performed using our data but the volumes were 
similar or larger on PET in over half the cases. PET manual delineation may have 
overestimated the hypoxic volume and the CT delineation was performed on images 
without contrast, making tumour edges more difficult to identify. Two patients had 
tonsillectomies, which were not included in hypoxic volume or SUVmean correlations. For 
future recruitment we would need to consider whether these patients, and possibly T1 
tumours, should be excluded. 
 
Lymph node Cu-ATSM uptake in HNSCC has only been reported in one study.412 The 
uptake or distribution has not been associated with outcome or correlated with primary 
tumour uptake in Cu-ATSM studies. 18F-FAZA uptake has been assessed in HNSCC lymph 
nodes, where the TMR of the lymph node with the highest uptake was compared with the 
TMR of the primary tumour.352 Similar to our results a positive correlation was seen 
between the TMR of the primary and lymph nodes. Although in general the uptake was 
lower in lymph nodes compared with primary tumours, this positive correlation and the 
peripheral pattern of hypoxia in lymph nodes may explain why Eppendorf pO2 electrode 
measurements from neck nodes were similar to measurements from primary tumours.235,239 
In addition HPV-positive patients have more cystic nodal metastases,514 which may be why 
the lymph node uptake was lower in our dataset. 
 
3.5.3.4 Other uptake  
The asymmetric uptake seen muscle may be related to sustained muscle contraction just 
prior to injection, during the uptake period or due to patient position during the 20 minute 
scan. This may result in reduced intracellular oxygen levels, which occurs during muscle 
contractile activity, leading to irreversible tracer trapping which is seen on the scan. 64Cu-
ATSM imaging immediately and 1 hour after 10 minutes of calf muscle contractions in rats 
showed a 1.5-fold increase in uptake in the muscles compared with resting conditions.515 
The SUV in muscles correlated with HIF-1α and CA9 mRNA expression. Patients should 
be advised to avoid exercise before the scan, rest once the tracer has been injected, and 
set up on the scanner couch with sufficient time prior to the start of the scan to ensure 
comfortable positioning.  
  
The salivary glands had 64Cu-ATSM uptake above background, which has not been 
reported in previous clinical HNSCC studies. Cu(II) is present in salivary secretions, with 
the majority of saliva in the oral cavity produced by the submandibular glands. The copper 
transporting ATPase ATP7A (Menkes protein) has been localised in the acinar cells in 
parotid glands and is involved in Cu secretion into saliva.516 The uptake may also be due to 
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histatins, which are histidine-rich antimicrobial peptides present in the saliva and secreted 
by the salivary glands. Histatin 5 has Cu(II) binding motif, as well as a Zn(II) binding motif 
which is characteristic of metalloproteases.517 This supports the suggestion that 64Cu-
ATSM may become incorporated into the intracellular copper pool and used in the normal 
Cu metabolism of the salivary glands. The normal parotid gland has been shown to be a 
site of misonidazole binding in mice under conditions of normoxia, which may be due to 
high local nitroreductase activity.518 This may also be a cause of high 64Cu-ATSM retention 
in the salivary glands. 
 
Recent dental extractions were associated with uptake. In feline studies uptake was also 
seen in other inflammatory conditions such as tooth abscess and otitis media. Cu is an 
essential trace element that is involved in the expression and control of inflammation. It is 
transported in the blood mainly by the acute phase protein ceruloplasmin and intracellular 
metallothioneins, which are a family of metalloprotiens with high affinity for Cu and Zn, and 
modulate the binding, exchange and transport of copper.519,520 Both ceruloplasmin and 
metallothioneins are induced by inflammatory stress and increase the transport of copper 
to sites of inflammation. In addition superoxide radicals are released from activated 
neutrophils and macrophages, which stimulate superoxide dismutase, a copper/zinc 
utilising antioxidant enzyme. Therefore 64Cu may be transported and localised to the site of 
active inflammation.  
 
Other physiological or non-malignant uptake does not prevent the use of a tracer, as long 
as this is known. 18F-FDG is well documented to be taken up by inflammatory conditions 
due to increased glycolysis and by physiological mechanisms in various organs.521 For 
example, in the salivary glands 18F-FDG is taken up physiologically and secreted into the 
saliva, and uptake is usually seen bilaterally. Muscle uptake due to straining or contractions 
increases 18F-FDG uptake, generally a linear pattern. Brown adipose fat uptake due to 
increased metabolic activity secondary to sympathetic stimulation is often seen in the lower 
neck, and can lead to misinterpretation in HNSCC, as can physiological uptake in 
Waldeyer’s ring.522 In addition there are malignant lesions that are known to not take up 
18F-FDG significantly, such as certain histological types of gastric cancer.523 A high SUV is 
associated with a higher suspicion of cancer, but the reported cut offs are variable. 
Similarly with 64Cu-ATSM it will be difficult to establish a cut off for clinically significant 
hypoxia that can be applied to all tumours. Further experience in imaging is required to 
confirm physiological and benign causes of 64Cu-ATSM uptake. 
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3.5.4 Gene expression analysis 
The study was initially designed to use microarrays to analyse and quantify gene 
expression. However in the 3 years from set up to recruiting 15 patients, due to the 
development, availability and affordability of next generation sequencing, RNA-Seq has 
become the new standard for transcriptome analysis. The major advantage of using this 
technology, although outsourcing the majority of the work, was that only a limited amount of 
tissue was available from each sample. Each patient only had one or two diagnostic biopsy 
blocks, from which only the tumour region was macrodissected. Microdissection of the 
tumour would have been technically challenging and may not have yielded sufficient RNA 
quantities. Inclusion of stromal cells in macrodissection has been shown to have a minimal 
effect on tumour gene expression, and extra amplification after microdissection to obtain 
sufficient RNA for sequencing actually had a high impact on gene expression profiles.524 
During the development and response of tumours to hypoxia the tumour microenvironment 
has a crucial role and therefore the exclusion of stromal cells may miss important 
information. In addition, for potential future clinical use, macrodissection is a technique that 
can be applied more directly. 
 
FFPE samples were used in this study to increase the potential for clinical translation. 
Formalin fixation can lead to significant fragmentation and cross-linking and chemical 
modification of nucleic acids, potentially creating artificial sequence alterations. Many 
factors can affect the quality of the RNA including specimen size, time and duration of 
fixation and storage time RNA.525 As RNA-Seq can analyse large numbers of short 
sequences, it is potentially the ideal technique to apply to FFPE samples. More studies are 
applying NGS to FFPE samples and high correlation of expression profiles between fresh 
frozen and FFPE tumour sample pairs has been demonstrated using RNA-Seq,526 and 
RNA-Seq provides data of sufficient quality to enable biomarker discovery.527 
 
3.5.4.1 Correlation between hypoxic signatures and hypoxic volume 
The overall study aims to recruit 40 patients to allow an interim sample size calculation. At 
this analysis point if there is supporting evidence for potential discovery of gene-imaging or 
gene-outcome associations the recruitment would extend to 60 patients, as in a previous 
study this sample size was sufficient to identify 4 de novo intrinsic subtypes in HNSCC 
tumours.115 Due to the small number of patients in the pilot study we chose to initially 
investigate whether validated hypoxia signatures were relevant in our study population. The 
Winter hypoxia signature was developed initially from fresh frozen HNSCC samples 
followed by in silico generation of hypoxia co-expression networks, to form a hyopxia 
metagene. This was subsequently applied retrospectively to laryngeal FFPE samples, 
where tumours were scored and categorised into high and low hypoxia groups, and found 
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to be predictive of benefit from ARCON. The 15-gene classifier used 18F-FAZA as an 
endogenous hypoxia radiotracer in xenografts and validated in FFPE HNSCC samples with 
known oxygen electrode measurements. This classifier was used to retrospectively 
categorise HNSCC FFPE samples to more or less hypoxic groups and similarly was found 
to be predictive of benefit from nimorazole. Despite the differences in the way these 2 
signatures were developed, when our samples were ranked according to the expression 
the Winter hypoxia signature and the 15-gene hypoxia classifier, a strong correlation was 
found between the 2 signatures, suggesting both these signatures are able to detect a 
similar tumour phenotype.   
 
When samples were ranked according to each Cu-ATSM imaging parameter, hypoxic 
volume was the only feature to correlate with both hypoxic signatures. A recent publication 
by Lopci et al528 investigated a number of 64Cu-ATSM PET parameters including hypoxic 
tumour volume and hypoxic burden (hypoxic tumour volume x SUVmean), SUVmax, SUVmean 
and SUV ratio to muscle, in 18 patients with lung cancer or HNSCC. After a median follow-
up period of 14.6 months they found that the hypoxic tumour volume and hypoxic burden 
were more robust prognostic parameters for progression free survival. Similarly in 18F-FDG 
PET many studies have demonstrated that metabolic tumour volume and metabolic tumour 
burden may represent better measures for prognosis, but is limited by the difficulties in 
defining this volume.529  
 
Assuming the hypoxia signatures can be used to describe a hypoxic phenotype in our 
samples, as there was a positive correlation with hypoxic volume, we looked at the genes 
differentially expressed by hypoxic volume. There were a number of upregulated genes 
relating to the hypoxia response pathways. S100A7 is expressed in many malignancies 
and is a poor prognostic marker in HNSCC.530 It has been shown to enhance cell growth by 
activating pro-inflammatory pathways, upregulate VEGF and induce endothelial cell 
proliferation.531 SOD2 is an antioxidant enzyme, which prevents redox-mediated damage of 
mitochondrial proteins, and is associated with aggressive cancers with enhanced cell 
migration and metastases. Stress such as hypoxia leads to increased reactive oxygen 
species (ROS) and tumours may increase their expression of SOD2 to prevent ROS-
mediated DNA damage.532 NAMPT tissue expression has also been found to be 
upregulated in tumours and shown to induce cell proliferation and angiogenesis.533 It is the 
rate-limiting enzyme for the biosynthesis of NAD essential for metabolism and energy 
production. Tumour cells have high metabolic rate and NAD consumption and therefore 
depend on the production of NAD, and hypoxia has been shown to result in NAMPT 
induction.534 NAMPT small molecule inhibitors are under investigation as a novel 
therapeutic, which reduce NAD levels resulting in ATP loss and inhibition of tumour cell 
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proliferation.535 PFKFB3, which is also included in the 15-gene classifier, is a key enzyme 
in glycolysis, and activated in cancer cells to increase glycolysis to meet metabolic 
demands. It promotes cell cycle progression, suppressed apoptosis536 and is involved in 
angiogenesis.537 TM4SF1 is expressed on cancer cells and endothelial cells and is a 
potential new vascular therapeutic target in cancer,538 and SRPK1 expression is elevated in 
hypoxic cells, with inhibition suppressing angiogenesis and tumour growth in animal 
models.539  
 
RUNX3 is downregulated in our samples with increasing hypoxic volume. RUNX3 has been 
shown to inhibit HIF-1α stability through enhancing the interaction between HIF-1α and 
PHD2, promoting HIF-1α degradation in gastric cancer cells,540 with resulting inhibition of 
angiogenesis. Its expression has been shown to be downregulated in response to hypoxia 
and is frequently inactivated in gastric cancer, resulting in stimulation of proliferation and 
suppression of apoptosis.541 
 
3.5.4.2 Correlation with SUVmax 
SUVmax and TMR are the main parameters in previous studies reported to have association 
with outcomes. However we did not find a correlation between these parameters and the 
hypoxia signatures, and therefore using these signatures to define low to high hypoxic 
phenotypes in our samples, then looking for genes differentially expressed by SUVmax or 
TMR would not be expected to define a hypoxia-related gene list. We also did not find a 
clear pattern of hypoxia related gene expression in the high versus low SUVmax groups, 
when comparing all samples or just the 4 patient outlying group. However ECM1 was 
consistently upregulated in the high SUVmax groups, which has been reported to induce the 
expression of genes that promote the Warburg effect, such as GLUT1, LDHA and HIF-
1α.542 In the high SUVmax outlying group there were a number of downregulated genes that 
have roles in the immune response, such as IFITM1, IFITM3 and CXCL10. Immune cells, 
especially tumour-associated macrophages, are recruited to the tumour site and can 
stabilise HIF-1α when deprived of oxygen. They stimulate angiogenesis, tumour cell 
growth, motility and invasion,543 and are also immunosuppressive by depressing adaptive 
T-cell responses.544 The pattern of downregulated genes may reflect modulation of the 
immune system in tumours with high Cu-ATSM uptake. 
 
One explanation for the lack of association could be sampling bias. A snapshot of gene 
expression is captured through sequencing and may be highly variable from one region of 
the same tumour to another. The published hypoxia signatures were validated by 
retrospectively applying them to FFPE needle biopsy samples taken from any region of 
tumours and they demonstrated predictive value, suggesting that the specific location from 
Chapter 3  Discussion 
 197 
which a sample is not essential in determining the overall hypoxic status of the tumour. The 
signatures may consist of key genes that are expressed throughout hypoxic tumours. 
However when trying to correlate gene expression with an imaging parameter such as 
SUVmax which is measured from a small region of the tumour, the area from which the 
biopsy is taken may be more relevant. This may also be the case with TMR, as it is 
obtained from the SUVmax. In contrast hypoxic volume may be a better marker as it may 
take into account more of the overall behaviour of the tumour. Long-term follow data could 
help to assess which parameters have the potential to provide prognostic information. 
 
3.5.4.3 MicroRNA 
MiRNAs are better able to withstand the formalin fixation process and demonstrate stability 
win both FFPE and plasma.156 However small RNA-Seq did not lead to a hypoxia-specific 
signature and disappointingly miR-210 and miR-196a we not found to be upregulated. 
When our samples were ranked by the 15-gene classifier, miR-21 and miR-31 were the top 
upregulated genes in more hypoxic samples. MiR-21 is the most frequently dysregulated 
miRNA in HNSCC. Upregulation promotes cell proliferation migration and inhibition of 
apoptosis, and is associated with poor prognosis.166 MiR-31 is also known to be oncogenic 
and upregulated in HNSCC, where it targets factor-inhibiting hypoxia-inducible factor (FIH) 
resulting in increased HIF activity.167 Ranking by hypoxic volume demonstrated miR-21 to 
be consistently upregulated in samples with greater hypoxic volume, along with miR-10b. 
There are conflicting studies regarding the role of miR-10b in HNSCC, and no reported 
associations with hypoxia. However in breast cancer, miR-10b is highly expressed in 
metastatic breast cancer cells and is induced by TWIST, which is involved in EMT, which in 
turn is regulated by HIF-1α.545 
 
3.5.5 Circulating miRNAs 
Reports on circulating miRNAs were first published in 2008. Lawrie et al546 demonstrated 
that miR-155, miR-21 and miR-210 were higher in the serum of patients with diffuse large B 
cell lymphoma compared with healthy controls, and miR-21 levels are associated with 
relapse free survival. Mitchell et al547 found that plasma miR-141 was able to distinguish 
patients with prostate cancer from healthy controls, and Chen et al155 systematically 
characterised miRNAs in serum of healthy subjects and patients with lung cancer, 
colorectal cancer and diabetes, identifying a unique expression profile for each. In addition 
they demonstrated that circulating miRNAs are stable and reproducible, and are resistance 
to pH extremes, extended storage, boiling temperatures and multiple freeze thaw cycles. 
MiRNAs are released into the circulation as a result of cell damage, death and active 
secretion. They are released in microvesicles such as exosomes and apoptotic bodies, and 
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can also form complexes with RNA-binding proteins such as argonaute 2 (AGO2). These 
mechanisms protect them from RNAse degradation and make them highly stable in a 
variety of conditions.548 Circulating miRNAs act as a mode of cell-cell communication. They 
are taken up by recipient cells by endocytosis or fusion with the plasma membrane and 
function in signalling events that can trigger tumourigenesis and metastasis in recipient 
cells.549,550 In addition they can trigger a paracrine effect on tumour growth by binding to 
Toll-like receptor 8 (TLR8) on surrounding immune cells, resulting in the release of 
cytokines that promote cell proliferation and metastases.551 Circulating miRNAs have been 
matched to the miRNAs expression in tumour tissue, and may therefore be representative 
of the primary tumour expression, providing a less invasive way to measure miRNAs.552 
 
The sample size in our study was too small to make any conclusions about the clinical 
significance of circulating miR-196a and miR-210, but a few hypothesis-generating 
observations can potentially be made. MiR-196a correlated with increasing primary tumour 
size measured by both hypoxic volume and gross tumour volume, but not with 64Cu-ATSM 
SUVmax or TMR. Our in vitro data demonstrated increased cell proliferation in miR-196a 
overexpressing HNSCC cell lines and the increased circulating miR-196a expression may 
reflect the proliferative characteristics of the primary tumour, representing tumours with 
faster growth. Clinical stage and change in tumour volume has been linked to the quantity 
of circulating miRNAs in other cancers. Larger, more advanced tumours were associated 
with higher levels of miR-21 in gastric cancers.553 Pre-operative serum miR-21 was 
increased in HNSCC patients compared with normal volunteers, which significantly 
decreased 1 month after surgery. This remained low in patients with good prognosis, 
potentially representing a biomarker that could be used to monitor for recurrence.552 Lu et 
al554 recently found both miR-196a and miR-196b to be upregulated in plasma samples of 
patients with pre-cancerous oral lesions and oral squamous cell carcinoma compared with 
healthy controls, with higher fold increases in carcinoma, suggesting that they could serve 
as biomarkers for the early detection of oral cancer.  
 
There was a trend towards increasing miR-210 expression and the hypoxia uptake 
parameters SUVmax, TMR and SUVmean, suggesting a link between tumour hypoxia and 
circulating miR-210 levels. Circulating miR-210 has been investigated in various tumour 
types as a biomarker as high tissue expression correlates with hypoxia and poor prognosis. 
However it has not previously been correlated with other markers of hypoxia, such as 
hypoxia imaging measures. Hale et al555 demonstrated that miR-210 is released from cells 
in culture during hypoxia, using human pulmonary arterial endothelial cells and HT-29 
adenocarcinoma cells, under the control of AGO2 to facilitate hypoxic communication 
between cells. Higher levels of plasma miR-210 under conditions of hypoxia or ischaemia 
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were also demonstrated in vivo in pregnant Andean women living at high altitude and 
humans with intermittent claudication secondary to peripheral artery disease compared 
with their respective controls.555 This suggests that circulating miR-210 could reflect the 
level of hypoxia of the primary tumour and may represent a potential screening tool for 
patients who would benefit from hypoxia imaging. However as other non-malignant 
conditions, such as peripheral vascular disease and aortic stenosis, can elevate circulating 
miR-210 release, further investigation into whether the level can distinguish between 
malignant and benign disease is required.556 
 
Since the initial discovery there have been numerous studies investigating the diagnostic, 
prognostic and predictive potential of circulating miRNAs in cancer, including HNSCC.557,558 
However there has been a lack of consistent expression in the same malignancies due the 
many different methods in sample collection, isolation and analysis. Some studies have 
used serum samples, whilst others used plasma samples, and direct comparisons have 
resulted in conflicting results. No differences have been reported, with strong correlation of 
miRNA measurements between plasma and serum, indicating both would be suitable for 
investigation as blood-based biomarkers.547 However others have shown that using serum 
samples result in higher RNA concentrations and have suggested that additional RNA 
could be released from cell lysis or platelets during the coagulation process.559 We 
therefore opted to use plasma samples for miRNA analysis. Different methods for obtaining 
serum and plasma have been reported and may groups recommend a second 
centrifugation step with plasma samples to reduce platelet contamination, although a 
variety of different speeds and times have been used.560,561 We used guidance from the 
NCI protocol and performed a second centrifugation step in accordance with the 
recommendation of the RNA extraction kit used. 
 
Haemolysis of the blood during collection may release miRNAs from white and red blood 
cells, which contaminates the overall miRNA population.562 Unfortunately 2 of our samples 
had obvious haemolysis and were excluded from analysis. Future improvements to the 
study could include a different time point for blood collection. Blood was collected through a 
vacutainer when patients were cannulated for tracer injection, to prevent further 
unnecessary discomfort. However blood could be collected at the pretreatment stage when 
routine bloods are checked and collected through a larger needle. Methods to identify 
haemolysis have been investigated such as spectrophotometric measurements of 
oxyhaemoglobin, but other factors such as lipaemia interferes with haemoglobin 
absorbance.562 More recently, a lipaemia-independent NanoDrop-based method using a 
small volume of sample has been reported, which could be tested in future samples.563  
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Commercially available RNA extraction kits have been compared with differing RNA yields. 
Commercial column-based kits have shown better yield than TRIzol extraction and the 
biofluid-specific miRCURY kit from Exiquon outperformed other kits for isolation of miRNAs 
from plasma.564,565 In addition it was easier to use, with shorter processing time, and 
therefore the Exiquon kit was used in our study. Quantification of extracted RNA is not 
accurate using measures such as NanoDrop.566 RNA was normalised for concentration and 
technical variation by using fixed volume of starting plasma rather than mass and the same 
volume of eluted RNA was used for the RT-PCR reaction. Internal controls used to 
normalise miRNA expression in cells or tissue, such as RNU6B, are not stably expressed in 
blood.567 MiR-16 has been shown to be stable and used as an internal control in certain 
cancers, but has also been shown to be dysregulated in others and sensitive to 
haemolysis.547,562 As miR-16 has not been investigated as a control in HNSCC we used an 
exogenous miRNA, cel-miR-39, of known concentration which has no effect on human 
miRNA detection to normalise our data.  
 
Further work is required to ascertain the optimal method to process and interpret circulating 
miRNA data and there is a need to standardise protocols. However, despite the very small 
sample size, the potential correlations seen with miR-196a and miR-210 are worth 
investigating. It is tempting to speculate that miR-196a is a potential biomarker of tumour 
proliferation and aggressiveness, whereas increasing miR-210 is a potential indicator of 
hypoxia in the primary tumour.    
 
3.5.6 Conclusions 
Although the sample size was small this exploratory pilot study has generated hypotheses 
to guide future recruitment and data analyses. Static 64Cu-ATSM PET is well tolerated and 
demonstrates a spectrum of hypoxic imaging phenotypes in oropharyngeal squamous cell 
carcinomas. 64Cu-ATSM as a radiotracer provides hypoxic-to-normoxic contrast of 
sufficient quality to define a hypoxic volume, but the optimal method for hypoxic volume 
delineation requires further investigation. RNA-Seq can assess the expression of published 
hypoxia gene signatures in FFPE biopsy samples. These signatures are significantly 
associated with increasing hypoxic volume as defined by 64Cu-ATSM PET, and a hypoxic 
volume-specific gene expression signature has been derived. Using SUV parameters to 
quantify hypoxia may not be the optimal method for reporting Cu-ATSM PET scans as this 
does not take into account tumour heterogeneity. Circulating miR-196a may be associated 
with increasing tumour volume and warrants further investigation.  
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Combing molecular and imaging biomarkers of hypoxia is a feasible strategy to identify 
HNSCC patients with hypoxia and subsequently alter their management to improve 
outcome. 
 
3.5.7 Future work 
The BoHEMIaN study is currently open for ongoing recruitment. Given the finding that 
hypoxic volume is an important parameter, patients who have received diagnostic 
tonsillectomies will be excluded.  Further analysis would include: 
• Immunohistochemical staining with a panel of hypoxia-related antibodies, including 
HIF-1, CA9, VEGF, GLUT1, FIH and PHD, and correlation with imaging parameters 
and gene expression. Sections have already been prepared from the 15 patients 
recruited.  
• Applying the Cu-ATSM hypoxic volume gene signature to further samples and 
comparing with imaging parameters. 
• Hypoxia-induced serum protein measurements, such as osteopontin and VEGF, 
using multiplex Luminex assays. 
• Correlation with long term outcome data. 
• Validation of the hypoxic volume gene signature in an independent publically 
available dataset to assess the potential as a prognostic biomarker. 
 
Continuing on from this study, future studies could look at comparing the gene expression 
from tumour samples from high Cu-ASTM uptake regions and low uptake regions to 
provide more information on tumour heterogenity. A recently completed study at our centre 
has mapped and compared preoperative Cu-ATSM scans with postoperative laryngectomy 
specimens. Patients received pimonidazole infusion before surgery and aim of this study 
was to validate Cu-ATSM as a hypoxic tracer by correlating pimonidazole staining with Cu-
ATSM uptake. Using this data, regions of tumours with different SUVs could be sampled 
and differential gene expression assessed. 
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Forty percent of patients cured of their cancer receive radiotherapy as part of their curative 
treatment and 16% of all cures can be attributed to radiotherapy alone.3 Despite advances 
in tumour voluming, radiation dose coverage and delivery techniques, the majority of 
recurrences occur within the high dose irradiated volume.568 Radioresistance is a major 
cause of treatment failure in HNSCC and biomarkers to identify and geographically map 
these regions could direct strategies to overcome radioresistance and improve outcome.  
 
Locally advanced HNSCC represents tumours with multiple genetic aberrations and is 
characterised by tumour heterogeneity. A wide range of biomarkers are under investigation 
with the aim of improving the identification and stratification of this heterogeneity. This 
would enable the tailoring of treatments based on prognosis and prediction of response to 
radiation, optimising the therapeutic ratio. Established biomarkers in HNSCC, such as HPV 
and 18F-FDG, currently have a clear prognostic role and this is now translating into the 
development of studies which use these biomarkers to alter management. A current phase 
I study recruiting at our centre utilises both these biomarkers to overcome radioresistance; 
18F-FDG avid regions of HPV-negative OPSCC primary tumours are selectively dose-
escalated using intensity modulated radiotherapy. If radioresistance can be reliably and 
easily identified, standard treatment techniques can be modified to target resistance, as 
well as guiding the direction of the development of newer therapeutics. However the lack of 
robust biomarkers for early detection and response prediction represents one of the current 
challenges in the management of HNSCC. 
 
Genome-wide sequencing studies have improved the understanding of the molecular 
mechanisms of tumourigenesis and treatment resistance in HNSCC, and identified the 
major mutations involved. In addition gene expression profiling has improved the 
categorisation of HNSCC into different phenotypes, identifying specific characteristics 
associated with differing outcomes. Advances in molecular biology has led to the discovery 
of miRNAs, which are now known to be major players in the pathogenesis of cancer and 
treatment resistance. They represent a huge bank for novel biomarker discovery, not just 
from tissues but also blood and saliva.548 Developments in imaging have led to the 
investigation of new radiotracers and scanning techniques to identify established and new 
biomarkers of radioresistance and to achieve non-invasive patient stratification. All these 
research strategies have allowed the discovery of potential new biomarkers as well as the 
advancement of investigation of known biomarkers of radioresistance, creating 
opportunities for personalised medicine.  
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4.1 MiR-196a 
MiRNAs are involved in the response to ionising radiation and many studies have 
demonstrated that their expression significantly changes in response to radiation. However 
to investigate miRNAs that underlie the mechanisms of intrinsic radioresistance, 
pretreatment alterations need to be identified. Our study identified miR-196a and the 
alteration of this single miRNA resulted in significant changes in the proliferation, migration, 
invasion and radiosensitivity of head and neck cell lines. This suggests that miR-196a 
potentially represents a novel prognostic and predictive biomarker. 
 
However, the path from biomarker discovery in in vitro exploratory studies to use in clinical 
trials requires rigorous preclinical and clinical validation. The behaviour of miR-196a 
overexpressing cells was confirmed in head and neck cancer cell lines from different 
subsite origins, and the opposite effects demonstrated in miR-196a knockdown studies. 
However, the negative correlation of miR-196a in a small independent group of 
radioresistant patient samples suggests that further in vitro or animal work is required to 
establish patterns of behaviour and mechanisms before planning a clinical validation study. 
The number of samples, sample handling and preparation, number of replicates and 
methods for analyses need careful consideration before limited patient samples are used.  
 
MiRNAs work in a complex interactive network, utilising the imperfect matching between 
the seed region of the miRNA with the 3’-UTR of the target mRNA to potentially interact 
with multiple mRNA target sites.127 Although ANXA1 was identified as a direct target of 
miR-196a this did not fully explain the effects of miR-196a modulation, in particular the 
effects on radiosensitivity, suggesting that other targets of miR-196a may be involved. 
When investigating miRNA function, multiple downstream targets should be considered 
rather than focusing on one gene target or pathway to gain an accurate insight into the 
biological effects.   
 
MiRNAs have been shown to be stable in plasma and serum,155 and the ease of collection 
of blood makes it an attractive source for identifying biomarkers. The level of miRNA-196a 
measured in the plasma samples of patients in the BoHEMIaN pilot study was significantly 
associated with the tumour volumes of the primary tumour, correlating with the in vitro 
behaviour of increased cell proliferation. However there are many uncertainties in the 
processing and analysis of circulating miRNAs, especially in relation to quantification and 
internal normalisation methods. Unlike cells and tissues where normalisation with 
housekeeping genes is generally reliable, these controls in serum or plasma are easily 
degraded and not reliably detected.567 Levels of the commonly used housekeeping genes 
RNU48 and RNU6B were measured in our samples but with wide variations and lack of 
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reproducibility. MiR-196a was not found to be a miRNA of interest on small RNA 
sequencing of the RNA extracted from the tissue samples, but it would be interesting to 
separately measure the level of miR-196a using the RNA extracted from the tissue 
samples. Combined miR-196a assessment from the tumour and blood to identify more 
aggressive radioresistant tumours could increase the sensitivity and specificity of 
diagnosis.  
 
Although thousands of miRNAs have been discovered, targeting a single miRNA could be 
an effective strategy as they affect the expression of multiple genes and their pathways. 
Further knowledge of the critical pathways involved in radioresistance and the interplay 
with miRNAs is required, but encouragingly early phase studies are currently underway 
using miRNA inhibitors or mimics, confirming their potential as treatment targets. MiRNA-
targeting therapeutics could have a future role in combination with conventional and other 
targeted treatments, enhancing their effects as well as inhibiting specific pathways via more 




Hypoxia has been extensively investigated, both at a molecular and clinical levels, and it is 
clear that it is a major cause of radioresistance and recurrence in HNSCC. Much of the 
research has focused on therapeutic approaches to overcome hypoxia-associated 
radioresistance, but this has not led to changes in routine management. Due to the 
heterogeneity of hypoxia in HNSCC the identification, and therefore stratification, of 
patients who would benefit from these modifications in treatment has been a major issue. 
Investigations into the detection of hypoxia using molecular and imaging biomarkers have 
shown some promise, each having their own advantages and disadvantages. However 
results have been inconsistent, which may reflect the heterogeneous nature of both 
HNSCC and hypoxia, and have not led to the translation of these methods into clinical 
practice.  
 
Hypoxia imaging is a challenging area of research, as hypoxia is spatially and temporally 
heterogeneous. It has the potential to identify and quantify hypoxia, which can be used as a 
prognostic or predictive biomarker, as well as provide information on the distribution of 
hypoxia within primary tumours and metastatic lesions. The distribution of hypoxia would 
then inform decisions on possible localised targeted versus systemic treatment strategies. 
64Cu-ATSM is the hypoxia radiotracer under investigation at our centre and separate 
studies are being carried out to further analyse the mechanism and to validate its use in 
cancer. Previous clinical studies have shown associations between different Cu-ATSM 
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imaging parameters and outcomes.399,408 However there have been no consistency in the 
results, as studies have used different cohorts of patients, a range of Cu-ATSM uptake 
times and PET image acquisition and analysis methods, and all have only a limited number 
of patients. We used the main reported parameters of SUVmax and TMR, but also included 
hypoxic volume as an alternative measure. Hypoxia is not well defined, with no threshold, 
and can have variable consequences in different situations. All of our patients showed 
some uptake in their primary tumours, but not in all metastastic lymph nodes. It is unclear 
whether any level of uptake or above a certain threshold represents clinically relevant 
hypoxia. Radioresistance has been reported to start at pO2 levels < 25-30 mmHg.197 There 
have not been any clinical studies comparing Eppendorf electrode measurements and Cu-
ATSM uptake, but studies using FMISO and pimonidazole show retention at O2 levels 
lower than 25 mmHg.569 In head and neck cancer patients FMISO TMR correlated with pO2 
readings of ≤ 5 mmHg,338 suggesting that a large fraction of radioresistant cells are not 
hypoxic enough to take up the tracer. Many large lymph nodes and primary tumours 
showed reduced uptake centrally, which may be secondary to tumour necrosis. However 
an alternative explanation could be due to disordered tumour vasculature affecting tracer 
uptake and retention, which would result in inaccuracies in image interpretation.  
 
A lot more work needs to be carried out before Cu-ATSM can be used in the clinical setting 
to assess the optimal tracer uptake time, reproducibility and repeatability, and 
spatiotemporal stability of the tracer. Test-retest repeatability studies are limited by the 
radiation dose associated with 64Cu-ATSM and therefore 62Cu can be used as an 
alternative, especially as it is not reliant on a cyclotron for production. Repeated FMISO 
data suggests that there are significant intratumoural changes in hypoxia distribution 
between scans carried out a few days apart,335 and hypoxia imaging during RT may be a 
better method to identify clinically relevant radioresistance within tumours, as this may be 
indicative of incomplete reoxygenation with increased hypoxic fraction. Validation of Cu-
ATSM as a reliable hypoxic tracer is also a major area of research that is required, which 
may be difficult, as the gold standard for measuring hypoxia remains the Eppendorf 
polargraphic needle electrode with its sampling limitations. Other methods would be to 
compare uptake with FMISO or pimonidazole, but as the mechanism of uptake is different 
lack of correlation does not necessarily exclude Cu-ATSM as a clinically useful tracer to 
detect hypoxia. Due to the dynamic nature of hypoxia in different situations, it is unlikely 
that one hypoxia tracer could have universal application. The cost and availability of Cu-
ATSM PET scans will also be a factor in the clinical setting and further investigation into 
which group of patients whose management could potentially be changed through the 
knowledge of hypoxia distribution needs to be determined.  
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Hypoxia gene expression signatures have shown encouraging results as a biomarker for 
identifying hypoxia, using multiple genes rather than a single marker to detect hypoxia. 
Advancements in gene sequencing have enabled more accurate gene expression analysis 
using smaller RNA samples and FFPE samples that have been archived for a number of 
years. FFPE samples represent a huge bank of data and retrospective analyses have 
enabled the validation of gene expression signatures, as well as demonstrate predictive 
potential.324,570 When two published hypoxia signatures were applied to our samples, there 
was a significant correlation with increasing Cu-ATSM defined hypoxic volume, but not 
SUVmax or TMR, suggesting that hypoxic volume may be an important marker for hypoxia. 
A larger hypoxic volume could represent a more aggressive, rapidly growing tumour or 
represent of sampling bias, as there is a greater chance of sampling a region of hypoxia 
from a tumour with a larger hypoxic volume. It is unclear whether the gene signature from a 
small part of a tumour could be representative of the phenotype of the whole tumour. 
Although retrospective stratification of FFPE biopsy samples into low or high hypoxia 
groups using hypoxia gene signatures could identify subgroups of patients with poorer 
outcome and predict benefit from hypoxic modification,324,570 comparison of gene 
signatures from multiple biopsies from the same tumour would be required to further clarify 
the issue of sampling bias.  
 
The aim of the BoHEMIaN study is to identify a gene signature that would predict for a 
64Cu-ATSM hypoxic phenotype, to enable the selection of patients who would benefit from 
64Cu-ATSM imaging, which would in turn inform treatment. The use of two methods to 
identify hypoxia before altering management would enhance the accuracy of hypoxia 
diagnosis and assessment. The combined use of imaging and molecular biomarkers to 
improve tumour characterisation is a relatively new field of radiogenomics.571 Studies such 
as the Cancer Genome Atlas have described distinct molecular gene expression profiles 
within tumours originating from the same site, leading to the development of radiogenomic 
maps that associate imaging features with underlying molecular data. Gene expression 
data only allows analysis of small regions of tumour tissue, whereas imaging can provide a 
more comprehensive view of the entire tumour and then be used on an ongoing basis to 
monitor disease response or progression. This pilot study has suggested that hypoxic 
volume is important and a novel gene signature associated with hypoxic volume has been 
developed which will need further investigation with the recruitment of more patients and 
correlation with long term outcome data. However this has raised the question of how the 
hypoxic volume should be defined. PET-based tumour volume delineation for dose 
escalation has been investigated in 18F-FDG PET, without a consensus on the optimal 
method, despite higher tumour to background contrast compared with hypoxia tracers. 
Methods include manual delineation, fixed percentage of SUVmax thresholds, gradient 
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based methods and fully automated segmentation algorithms.529 The edge of the tumour is 
difficult to determine due to the limited spatial resolution of PET. Cellular hypoxia in the 
edges of tumours may not be detected on the scan but clinically relevant at the microscopic 
level. We used manual delineation with supervision from an experienced nuclear medicine 
physician, but the level of accuracy required to define the overall hypoxic volume requires 




The aim of this thesis was to further explore biomarkers of radioresistance in HNSCC, from 
initial discovery and experimentation at the molecular level, and the early process for 
translation of an established biomarker into clinical practice. MiRNA-196a and tumour 
hypoxia in HNSCC promote aggressive, radioresistant tumour phenotypes associated with 
poorer outcomes. We have found that: 
 
• MiR-196a promotes an oncogenic phenotype in head and neck cancer cells in vitro 
and confers radioresistance, partly through targeting ANXA1. 
• Circulating miR-196a is associated with increasing tumour volume in patients from 
a limited cohort. 
• 64Cu-ATSM PET defined tumour volume correlates with hypoxia gene signatures 
and may be an important parameter to report on scan analysis. 
• A gene signature associated with 64Cu-ATSM PET defined tumour volume has 
been developed for future application. 
 
Studies are continuing to further investigate both miR-196a and the combination of 64Cu-
ATSM PET and gene expression signatures as biomarkers of radioresistance.
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Clinical update on cancer: molecular oncology of head
and neck cancer
Y Suh1, I Amelio2, T Guerrero Urbano3 and M Tavassoli*,1
Head and neck cancers encompass a heterogeneous group of tumours that, in general, are biologically aggressive in nature.
These cancers remain difficult to treat and treatment can cause severe, long-term side effects. For patients who are not cured by
surgery and/or (chemo)radiotherapy, there are few effective treatment options. Targeted therapies and predictive biomarkers are
urgently needed in order to improve the management and minimise the treatment toxicity, and to allow selection of patients who
are likely to benefit from both nonselective and targeted therapies. This clinical update aims to provide an insight into the current
understanding of the molecular pathogenesis of the disease, and explores the novel therapies under development and in clinical
trials.
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Facts
! Head and neck squamous cell carcinoma (HNSCC) is the
sixth leading cause of cancer worldwide. Exposure to
carcinogens (tobacco and alcohol) and infection with
human papillomavirus (HPV) are the most common risk
factors.
! The main molecular determinants in HNSCC are the
abrogation of p53 and retinoblastoma (pRb) pathways that
lead to uncontrolled cell replication.
! Mutations in EGFR-MEK, NOTCH, PI3K, PTEN and AKT
pathways are frequently observed in HNSCC. These
mutations cooperate to create aberrant mitogenic/survival
signalling.
! Changes in metabolism and tumour hypoxia contri-
bute to resistance to current therapies and tumour
recurrence.
Open Questions
! Although HNSCC is a heterogeneous disease, the current
molecular classification distinguishes only HPV-positive
and HPV-negative tumours: further investigation to geneti-
cally classify HNSCC subgroups is needed.
! HNSCC metastasises primarily and frequently to regional
lymph nodes (more rarely to other organs via haemato-
genous spread): genetic profiles should aid the identifica-
tion of causative genes of metastasis.
! Radioresistance has been identified as an important cause
of locoregional treatment failure, and identification of
molecular mechanisms underpinning this could contribute
to better treatment selection and outcome.
! The genetics of HNSCC is complex, especially of HPV-
negative cancers: a detailed understanding of the mole-
cular basis and identification of driving mutations and
drugable targets should lead to personalised therapies.
Head and neck cancer accounts forB4% of all malignancies
worldwide and 5% mortality of all cancers,1 and includes the
following subsites: oral cavity, nasopharynx, oropharynx,
hypopharynx, larynx, paranasal sinuses, nasal cavity and
salivary glands. Over 90% are squamous cell carcinomas
(head and neck squamous cell carcinoma (HNSCC)), arising
from the epithelial cells that line the mucosal surfaces of the
head and neck.
More than 75% of cases of HNSCC are attributable to
smoking and alcohol consumption. Smoking increases the
risk by B10-fold compared with never smokers, and heavy
alcohol intake is an independent risk factor.2 The combined
effect of tobacco and alcohol causes a greater than multi-
plicative risk.3 Public health measures have been successful
in reducing the use of tobacco, and therefore the incidence of
HNSCC overall has been decreasing over the past 30 years in
developed countries. However, there has been a dramatic
increase in the incidence rates of oropharyngeal (tonsil and
base of tongue) cancers because of infection with high-risk
human papillomavirus (HPV).4,5
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At present, treatment of an individual cancer is typically
determined in a multidisciplinary setting, with the histological
subtype, subsite, staging information, patient fitness, baseline
swallow and airway function guiding management decisions.
Approximately one-third of patients present with early-stage
disease and these patients are treated with either surgery or
radiotherapy depending on the primary tumour site, with cure
rates of 70–90%.6 The majority of patients, however, present
with locally advanced stage disease. Radical treatment in this
situation requires multimodality therapy with surgery, com-
monly followed by postoperative radiotherapy or chemora-
diotherapy, or organ preserving primary radiotherapy, with or
without chemotherapy, with reduced cosmetic compromise.7
These treatments are intensive and associated with severe
acute toxicity, such as mucositis, dermatitis and dysphagia,
and long-term sequelae, for example, sensorineural hearing
loss, permanent xerostomia and altered swallowing function.
Despite recent advances in both surgical and radiotherapy
delivery techniques, up to 50% of locally advanced tumours
relapse usually within the first 2 years after treatment, with
limited options for salvage surgery or reirradiation.6,7 Several
chemotherapy agents can be used for inoperable recurrences
or metastatic disease, with response rates of only 10–35%
and median survival of 6–12 months.8
Beyond HPV status, no validated molecular characterisa-
tion of the disease has been established. However, pre-
liminary work suggests the existence of several different
molecular classes of HNSCC (basal, mesenchymal, atypical
and classical), based on the biological characteristics of
differentially expressed genes in each subtype.9 Genetic and
molecular advances have revealed new genes and pathways
involved in the development and progression of HNSCC,
creating opportunities to explore novel therapeutic targets.
HNSCC research has shifted to focus on biomarker discovery
for diagnosis, prognosis and prediction of treatment response,
alongside the development of targeted therapies, with the
ultimate goal of personalising therapy for each individual
patient.
TP53/RB Pathway
Tumour suppressor protein p53 plays a key role in the
regulation of genes involved in cell cycle and growth arrest,
DNA repair or apoptosis, thereby maintaining genomic
stability.10 In response to DNA damage, p53 can arrest the
cell cycle and activate repair or initiate apoptosis. p53 controls
a significant spectrum of genes involved in various path-
ways;11 these include recently discovered biochemical path-
ways, such as the connection of IL-7Ra to telomere erosion,12
the metabolism of the cell13 and the silencing of repeats and
noncoding RNA.14 This intense gene expression results in a
very fine regulation of life, death or senescence.15,16 p53 level
is regulated by mouse double minute 2 homolog (MDM2), an
E3 ubiquitin protein ligase that binds to p53 and causes its
degradation. MDM2 is inhibited by p14ARF that is encoded by
the gene CDKN2A, protecting p53 from degradation.10,17
Ataxia telangiectasia mutated (ATM) and ataxia telangiecta-
sia and Rad3-related (ATR) pathways sense DNA damage
and phosphorylate the cell cycle checkpoint kinases CHK1
and CHK2, resulting in p53 activation. p53 transactivates a
number of proteins with roles in cell cycle arrest and
apoptosis. Together with p53, its more recently discovered
family members, p63 and p73, have also been shown to play
important roles in cell cycle regulation and apoptosis, and their
link to various types of cancer including HNSCC is being
investigated.18
The tumour suppressor protein retinoblastoma (pRb)
controls the expression of genes involved in cell cycle
progression through the G1 restriction point. pRb binds and
inhibits E2F transcription factors that induce expression of
S-phase genes and cell proliferation. Mitogenic signals
activate cyclin D1/CDK4/CDK6 complexes that phosphorylate
pRb, resulting in the release of E2F. The cyclin D1-CDK4/6
complexes are inhibited by p16INK4A that is encoded by the
gene CDKN2A, and also p21 ((cyclin-dependent kinase
inhibitor 1 (CDKN1)) that binds to the complexes and prevents
them from phosphorylating pRb, thereby halting progression
into S phase.17
Mutations in p53 and pRb pathways result in limitless
replicative potential and immortalisation. TP53mutations can
occur throughout the entire gene but the majority are because
of a missense mutation in the DNA-binding domain. These
mutations can result in a number of consequences including
inhibition of function, tumour suppressor loss or occasionally
gain of function.19 Mutation of the TP53 tumour suppressor
gene is one of the earliest and most frequently detectable
genetic alterations in HNSCC reported in 50–80% of
cases,20,21 and can also be detected in premalignant
dysplastic lesions and in histopathologically negative tumour
surgical margins.22,23 A recent mutational screening in 12
types of cancer has revealed mutations of p53 in 69.8% of
HNSCC (Figure 1). From this analysis, HNSCC appears the
most common p53 mutation-carrying cancer type after
ovarian cancer and lung squamous cell carcinoma.24
Increased TP53 mutation rate is associated with tobacco
and alcohol use in HNSCC and also with increased risk of
progression to cancer.25,26 In p53 wild-type tumours, p53
function may be inactivated by other mechanisms, such as
HPV infection, overexpression or amplification of MDM2 and
deletion of the p14ARF gene.10
pRb is targeted early in the carcinogenesis of HNSCC
through inactivation of the tumour-suppressive CDKN2A
gene, with mutations seen in 7–9% and copy number losses
in a further 20–30% of cases.20,27 The CCND1 gene, which
encodes cyclin D1 on chromosome 11q13, is amplified or
overexpressed in over 80% of HNSCC.28 TP53mutation, loss
of p16INK4A and overexpression of cyclin D1 are all associated
with reduced survival.21,29 In addition, TP53 mutation is
predictive of poor response to chemotherapy and locoregional
recurrence following radiotherapy.30,31
Restoring or modulating p53 as targeted therapy has been
an area of intensive research for decades, with limited
success. Only one phase III study has been completed using
adenoviral p53 gene therapy in HNSCC. This showed that
patients with wild-type p53 had better response to Ad-p53
gene therapy, whereas mutant p53 patients responded better
to methotrexate chemotherapy, suggesting a potential of p53
profile as predictive biomarker of response to specific type of
therapy.32 p53-reactivating small molecules are currently
under investigation in HNSCC cell lines,33 and other
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strategies include targeting CDKN2A to reactivate p16INK4A
and CDK inhibitors. A phase I study of a CDK inhibitor in
combination with radiation has recently completed recruit-
ment (NCT00899054, Table 1).
Epidermal Growth Factor Receptor (EGFR) Pathway
EGFR (ErbB1) is a member of the ErbB/HER2 family of
transmembrane receptor tyrosine kinases. Other members
include HER2 (ErbB2), ErbB3 and ErbB4 and they play a
major role in cell proliferation, differentiation, survival and
migration. EGFR is composed of an extracellular ligand-
binding domain, a transmembrane segment and a cytoplasmic
domain with tyrosine kinase activity. It is activated by a
number of ligands including EGF, transforming growth factor-a
and amphiregulin. Ligand binding results in a conformational
change in EGFR and homo- or hetero-dimerisation with other
ErbB family members, leading to autophosphorylation and
receptor activation. This results in the activation of down-
stream signal transduction cascades including the Ras/Raf/
mitogen-activated protein kinase (MAPK), phosphoinositide
3-kinase (PI3K)/AKT and Janus kinase (JAK)/signal transdu-
cer and activator of transcription 3 (STAT3) pathways.34 The
EGF-bound EGFR can also translocate to the nucleus to
function as a transcription factor. One of the nuclear targets is
CCND1 that encodes cyclin D1 protein involved in cell cycle
progression (Figure 2).35
EGFR protein is detected by immunohistochemistry in over
90% of HNSCC cases. EGFR overexpression is mainly at the
transcriptional level as there are few EGFR-activating muta-
tions in HNSCC.36 Approximately 10–30% of HNSCC display
EGFR gene amplification, and EGFR point mutations are
reported in only 1–7% of patients.37,38 A mutant form of
EGFR, EGFRvIII, resulting from an in-frame deletion of exons
2–7 in the extracellular domain, has been reported in 42% of
HNSCC.39 The intensity of expression, as assessed by
immunohistochemistry, has been shown to indicate poor
prognosis, as has EGFR gene copy number.40,41 However,
the gene copy number has not been found to be a predictive
biomarker of efficacy with EGFR-directed therapy,41 unlike
specific mutations in non-small-cell lung cancer.
EGFR can be targeted either by inhibition of the extra-
cellular ligand binding using monoclonal antibodies (mAbs),
such as cetuximab, or by inhibition of the tyrosine kinase
domain with a small molecule (TKIs), such as gefitinib,
erlotinib and lapatinib. Cetuximab is a chimeric human–
murine IgG1 mAb directed specifically against EGFR, result-
ing in inhibition of cell cycle progression, angiogenesis and
metastasis, induction of apoptosis and synergy with radio-
therapy and chemotherapy. It remains the only FDA-approved
and European Medicines Agency-approved targeted therapy
in HNSCC and its use is not dependent on EGFR status. It is
used in combination with radiotherapy in locally advanced
HNSCC, in combination with platinum-based chemotherapy
and 5-fluorouracil for first-line treatment of recurrent/meta-
static disease, and as a single agent in recurrent/metastatic
disease after failure of platinum-based chemotherapy.42,43
Skin toxicity is a common side effect with cetuximab treatment
and this clinical feature has been suggested as a biomarker
for response to cetuximab, with response rates of 33%
observed in patients with skin rash compared with 7% in those
who do not develop skin toxicities.44 Panitumumab is a fully
humanised mAb against EGFR in use in colorectal cancer.
In HNSCC, a phase III trial of panitumumab in combination
with chemotherapy did not show an improvement in survival,
although retrospective analysis showed that median overall
survival in p16 (surrogate marker for HPV)-negative patients
was longer in the panitumumab group than in the control
group.45 Other promising mAbs currently in phase III trials
include zalutumumab and nimotuzumab (NTC00496652 and
NTC00957086). Despite the high expression of EGFR in
HNSCC, EGFR inhibition with mAbs has only a modest effect.
Preclinical studies investigating resistance to EGFR inhibition
have suggested mechanisms such as increased nuclear
localisation of EGFR, cross-talk of EGFR with other receptor
tyrosine kinases, such as HER2 and ErbB3, as well as
upregulation of these receptors and their ligands.46
TKIs block the activation and phosphorylation of EGFR, and
these drugs are given orally as they are well absorbed across
the gastrointestinal tract. Gefitinib and erlotinib, currently used
in lung cancer, inhibit only EGFR and have not been shown to
be efficacious in HNSCC to date. Because of the potential
resistance mechanisms, TKIs that have action against multi-
ple ErbB family receptors are under investigation. Lapatinib
has dual specificity for EGFR and HER2 and is in use in
breast cancer. In HNSCC trials, it has shown activity in
p16-negative tumours in combination with chemoradiation,47
and is currently being evaluated in the recurrent/metastatic
setting in combination with capecitabine chemotherapy
(NCT01044433), and in a phase III adjuvant trial (NCT
00424255). Afatinib irreversibly blocks EGFR, HER2 and
ErbB4 and is being investigated in the recurrent/metastatic,
neoadjuvant and adjuvant settings (NCT 01856478,
NCT01538381 and NCT01345669).
NOTCH Pathway
NOTCH1 signalling is involved in a number of biological




















Figure 1 The p53 structure with different protein domains (transactivation
domain, proline-rich domain, DNA-binding domain, oligomerisation domain and
regulation domain). Vertical lines indicate the occurrence of mutation of the amino
acid residues in HNSCC (data from COSMIC website: cancer.sanger.ac.uk/
cancergenome/projects/cosmic)
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survival and promoting terminal differentiation. The NOTCH
pathways consist of four receptors bound to the cell
membrane, NOTCH 1–4, and two families of ligands, Delta-
like (1, 3 and 4) and Jagged (1 and 2). Ligand binding leads to
two cleavages of NOTCH1 by TNFa-converting enzyme
(TACE) and g-secretase, resulting in the release of NOTCH1
intracellular domain (NCID). NCID translocates to the nucleus
to promote transcription of its target genes, including the HRT
and HES families. NOTCH1 is regulated partly by ubiquitina-
tion and degradation that involves FBXW7.48
One of the novel findings generated from whole-exome
sequencing was the discovery that the second most common
mutation in HNSCC is in the NOTCH1 gene, accounting for
14–15%, with mutations in the other NOTCH family members
occurring in 3–5% of HNSCC.20,27 Mutations in the FBXW7
gene were also identified in 5% of cases that have not been
previously observed in HNSCC.20 Recent integrated analysis
has identified the NOTCH pathway to be defective in 66% of
HNSCC patients. Along with the mutations in NOTCH itself,
chromosomal aberrations were frequent in JAG1, JAG2,
MUMB and MAML1, all of which are involved in modulating
NOTCH signalling.49 NOTCH1 signalling has been reported to
be oncogenic, as activating mutations and translocations
were found in NOTCH receptor genes in haematological
malignancies.50 However, in HNSCC, the majority were
nonsensemutations, predicted to result in truncated NOTCH1
proteins lacking the transcriptional activation domains, there-
fore suggesting a tumour-suppressor role for this pathway in
HNSCC.
NOTCH1 signalling promotes terminal differentiation in
keratinocytes and skin SCC, and this is negatively regulated
by EGFR. Inhibition of EGFR blockade induces keratinocyte
Table 1 Targeted therapies in HNSCC
Type of drug Drug Target Stage of development NCT number
Adenovirus gene therapy Advexin p53 Phase III NCT00064103
ONYX-015 p53 Approved in China N/A
CDK inhibitor P276-00 pRb Phase II NCT0089954
Monoclonal antibody Cetuximab EGFR In clinical use N/A
Panitumumab Phase II NCT00756444
NCT00454779
NCT00820248
Zalutumumab Phase III NCT00496652
Nimotuzumab Phase III NCT00957086
Bevacizumab VEGFR Phase II NCT01588431
Tyrosine kinase inhibitor Gefitinib EGFR Phase III NCT00206219
NCT00684385
Erlotinib EGFR Phase II NCT01064479
Lapatinib EGFR, HER2 Phase III NCT00424255
Afatinib EGFR, HER2, ErbB4 Phase III NCT01856478
NCT01345669
NCT01345682
Sorafenib VEGFR-2, VEGFR-3, Raf, PDGFR Phase II NCT00939627
Sunitinib VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, RET, c-KIT Phase II NCT00387335
Vandetanib EGFR, VEGFR, RET Phase II NCT00459043
Pazopanib VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, c-KIT Phase II NCT01377298
Axitinib VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, c-KIT Phase II NCT01469546
Nilotinib BCR-ABL, c-KIT, PDGFR Phase I NCT01871311
MEK inhibitor Trametinib MEK Phase I NCT01725100
PI3K inhibitor PX866 PI3K Phase II NCT01204099
BKM120 PI3K Phase II NCT01527877
BYL719 PI3K Phase II NCT01602315
Rigosertib PI3K, PLK Phase II NCT01807546
AKT inhibitor MK2206 AKT Phase II NCT01349933
mTOR inhibitor Rapamycin mTOR Phase II NCT01195922
Everolimus mTOR Phase II NCT01133678
Temsirolimus mTOR Phase II NCT01172769
CC-115 mTOR, DNA-PK Phase I NCT01353625
JAK inhibitor Ruxolitinib JAK Phase I NCT04822756
MET/VEGFR inhibitor Foretinib MET, VEGFR-2 Phase II NCT00725764
E7050/Golvatinib MET, VEGFR-2 Phase II NCT01332266
MET inhibitor LY2801653 MET Phase I NCT01285037
PDK inhibitor Dichloroacetate PDK Phase I NCT01386632
AMPK activator Metformin AMPK Phase II NCT01333852
Data source: www.clinicaltrials.gov
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differentiation.51 NOTCH1 has also been found to be inhibited
in basal epithelial cells by the p53-related transcription factor
p63 that becomes downregulated during terminal differentia-
tion coinciding with NOTCH1 upregulation. Overexpression
and amplification of TP63 have been observed in the majority
of HNSCC.52 However, as p63 encodes several isoforms with
opposing functions, the precise role of p63 in NOTCH1
signalling and malignant transformation of oral epithelial cells
remains to be elucidated.
NOTCH1 signalling has also been linked to suppression of
HPV E6 and E7 protein expression in cervical carcinoma cell
lines; expression of activated NOTCH1 causes growth
inhibition of HPV-positive but not HPV-negative cervical
carcinoma cell lines, and results in the downmodulation of
HPV-driven transcription of the E6 and E7 viral genes.53 The
role of NOTCH1 in the complex signalling pathway of HNSCC
tumourigenesis needs to be further investigated, but could
potentially represent another therapeutic target. Both
NOTCH1 pathway inhibitors that inhibit g-secretase and
NOTCH1 pathway activators, via inhibition of histone deace-
tylase, are currently in clinical development.
PI3K/AKT/mTOR Pathway
PI3Ks are a family of enzymes that phosphorylate the 30OH
position of phosphatidylinositols and have important roles in
promoting cell growth, differentiation and survival. There are
three classes of PI3Ks, each with its own substrate specificity,
and class 1A is most frequently associated with cancer. Class
1A PI3Ks are heterodimers and composed of a 110-kDa
catalytic subunit and an 85-kDa regulatory subunit, both of
which exist in several isoforms. PI3Ks are activated by RTKs,
such as EGFR, and the catalytic subunit phosphorylates
phosphatidylinositol1,4-bisphosphate (PIP2) to form phos-
phatidylinositol1,4,5-triphosphate (PIP3). PIP3 recruits pleck-
strin-homology domain-containing proteins including
phosphoinositide-dependent protein-kinase 1 (PDK1) and
AKT to the plasma membrane. Interaction of PIP3 with the PH
(Pleckstrin Homology) domain of AKT results in a conforma-
tional change causing phosphorylation of AKT by PKD1 and
mammalian target of rapamycin complex 2 (mTORC2). This
activates AKT that then phosphorylates proteins involved in
cell growth and survival. The tumour-suppressor phosphatase
and tensin homology (PTEN) mediates the conversion of PIP3
to PIP2, counteracting the activation of AKT.
54 mTOR is a
protein kinase that acts downstream of PI3K and AKT and
plays an important role in cell growth, survival and protein
synthesis regulation. There are two mTOR complexes:
mTORC1 activates ribosomal protein S6 kinase 1 (SK6) and
inactivates eukaryotic translation initiation factor 4E-binding
protein 1 (4E-BP1), resulting in protein translation and cell
growth, whereas mTORC2 activates AKT.
Genetic aberrations of the PI3K pathway are common in
HNSCC. One of the isoforms of the 110 kDa catalytic subunit,
p110a, is encoded by the PIK3CA gene. This gene is mutated
in 6–20% of HNSCC, especially through the mechanisms of
gene amplification and low-level copy number increase.20,27
It has been found to be particularly common in HPV-positive
HNSCC cases, and specific mutations, such as H1047R in
exon 20, may predict higher response rates to treatment with
PI3K pathway inhibitors.55,56 In addition, PTEN mutations
have been reported in 7% of HNSCC, and themTOR pathway
is frequently activated, independent from activation of EGFR
or the presence of mutant p53, particularly in HPV-positive
tumours.27,57
PI3K pathway is an important therapeutic target for cancers
and its therapeutic modulation has been assessed in a number
of tumour types. The mTOR inhibitor everolimus is in clinical
use in renal cell carcinoma, pancreatic neuroendocrine
tumours, breast cancer and subependymal giant cell astro-
cytoma, and temsirolimus can be used in renal cell carcinoma.
PI3K inhibitors are being investigated in phase II trials in
HNSCC in conjunction with chemotherapy or cetuximab
(NCT01252628); AKT inhibitors are being tested in recurrent
ormetastatic nasopharyngeal cancer (NCT01349933); and the
mTOR inhibitors rapamycin, everolimus and temsirolimus are
being assessed for HNSCC at the phase II stage in
neoadjuvant and recurrent/metastatic settings.
Ras/Raf/MEK/MAPK Pathway
Ras is a guanosine nucleotide binding protein localised on the
plasma membrane. There are three Ras genes: HRAS, KRAS
and NRAS. In the inactivated state, Ras is bound to guanosine
diphosphate (GDP) and activation converts Ras to the
guanosine triphosphate (GTP)-bound form; Ras-GTP binds to
and activates Raf-1. The targets for phosphorylation of Raf-1
include the kinases MEK1 and MEK2 that in turn activate the
MAPkinasesERK1andERK2. These translocate to the nucleus
and target genes involved in cell growth, proliferation and
survival. Ras can also activate the PI3K signalling cascade.58
Mutations in the Ras proto-oncogenes are implicated in
20–30% of all cancers.58 Activating HRAS mutations have
been found in 4–5% of HNSCC cases.20,27 KRAS mutations
occur in 30–50% of colorectal cancers and are predictive















Figure 2 Schematic representation of the major molecular pathways affected in
HNSCC. Stars indicate possible mutations in the molecule. EGFR, MET and
NOTCH activation can promote molecular signalling through RAS/ERK, PI3K/AKT
or JAK/STAT pathways. Aberrant activation of these pathways promotes survival,
proliferation and motility of cancer cells, favouring HNSCC tumourigenesis
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The predictive value of KRAS in HNSCC remains unclear and
requires further investigation.
Sorafenib is a tyrosine kinase inhibitor that has multiple
targets including Raf, VEGF (vascular endothelial growth
factor receptor) and PDGFR (platelet-derived growth factor
receptor).60 It is in use in renal cell carcinoma and
hepatocellular carcinoma, but has poor results as a single
agent in HNSCC. Sorafenib in combination with chemother-
apy has shown a response rate of 55% and median overall
survival of 22.6 months in a phase II trial in HNSCC.61 The
MEK inhibitor trametinib has recently been approved for use in
metastatic melanoma and is under investigation in combina-
tion with AKT inhibition in solid tumours including HNSCC
(NCT01725100).
MET Pathway
The proto-oncogene c-MET encodes mesenchymal–
epithelial transition factor (MET), an RTK activated by
hepatocyte growth factor (HGF). Ligand binging activates
signalling cascades including the RAS, PI3K, STAT3 and
NOTCH pathways, resulting in cell morphogenesis, motility,
growth and survival. MET and HGF have been found to be
overexpressed in over 80% of HNSCC and increased MET
copy numbers in 13% of HNSCC tumour samples.62,63 MET
expression has been suggested to be a prognostic biomarker
in HPV-negative HNSCCwith overexpression correlating with
reduced disease-free and overall survival.64,65 It has also
been implicated in resistance to radiation, cisplatin and
cetuximab.66–68
MET overexpression results in enhanced cell motility,
angiogenesis and invasion/metastases, and therefore is an
important potential therapeutic target. Foretinib is a multi-
tyrosine kinase inhibitor that binds to the adenosine tripho-
sphate (ATP) pocket of the receptor. It has been tested in a
phase II study in recurrent/metastatic HNSCC but showed
disease stabilisation and only minor tumour shrinkage as a
single agent.69 There are several RTK inhibitors and mAbs
against MET and HGF in early phase clinical trials.
JAK/STAT Pathway
The JAKs are part of a family of nonreceptor tyrosine kinases.
They interact with the cell surface cytokine receptors and
activate them by transphosphorylation. Activated cytokine
receptors recruit STAT that is phosphorylated by JAKs,
mediating dimerisation and translocation to the nucleus to
activate transcription of their target genes. JAKs can also be
phosphorylated directly by RTKs such as EGFR, activating
the RAS and PI3K pathways. The JAK/STAT pathway has a
role in promoting cell growth and survival, angiogenesis and
suppression of immune surveillance.70
STAT proteins are important in mediating EGFR signalling
and STAT3 is overexpressed in HNSCC.71 Ruxolitinib is a
JAK inhibitor approved for use in myelofibrosis and is in phase
I studies in combination with chemotherapy in advanced solid
tumours. A phase 0 trial of a STAT decoy oligonucleotide
injected into HNSCC tumours before surgery demonstrated
downregulation of STAT3 target gene expression, warranting
further investigation of this target in HNSCC.72
HPV-Mediated Pathogenesis
HPVs are small, nonenveloped, double-stranded DNA
viruses. The genome encodes for early genes (E1–7) and
late structural genes (L1, L2). E1 and E2 encode regulatory
proteins and E5–7 encode oncoproteins. Over 100 human
HPV genotypes have been isolated, and mucosal HPVs can
be classified into high and low risk based on their potential to
induce malignant transformation. High-risk HPVs include
types 16, 18, 31 and 33, with HPV type 16 accounting for
over 90% of cases in HNSCC.73 HPVs enter the host via
wounds or abrasions in the mucosa and infect basal epithelial
cells, where the host cell DNA replication machinery is used
for viral replication. The basal cell nuclei maintain low copy
numbers of viral DNA, whereas the virus replicates to high
copy numbers in terminally differentiated cells.74 The E6
protein interacts with E6-associated protein (E6-AP), resulting
in a rapid degradation of tumour suppressor p53 via the
ubiquitin–proteosome pathway (Figure 3). This leads to
inhibition of the proapoptotic functions of p53 and bypassing
of the p53-mediated checkpoints.75 The E7 protein competes
with E2F transcription factor for binding to the pRb tumour
suppressor, displacing E2F. E2F activates genes responsible
for cell cycle progression through the G1 to S phase, including
cyclin A, E and DNA polymerase, causing inactivation of
checkpoints and regulatory pathways, and ultimately promot-
ing cellular proliferation and transformation (Figure 3).76 pRb
is a negative regulator of the cyclin-dependent kinase inhibitor
p16, and therefore inactivation of pRb results in p16
upregulation. This can be detected using immunohistochem-
istry in HPV-associated tumour samples and represents a


























Figure 3 Mechanism of action of the human papillomavirus (HPV) on cell cycle
regulation. To progress from G1 to S cell cycle phase, cells have to pass the G1
restriction point that is under the control of the retinoblastoma protein (pRb). pRb
binds and represses E2F transcriptional factors. Mitogenic signalling through
CyclinD1/CDK4 or CyclinD1/CDK6 phosphorylates pRb, promoting E2F release.
CyclinE/CDK2 completes pRb phosphorylation, allowing S-phase entry. HPV
affects the cell cycle by using two viral oncoproteins, E6 and E7. The E6 protein
binds p53 and promotes its degradation, whereas E7 protein binds and inactivates
pRb. These viral oncoproteins determine cell cycle entry and inhibition of p53-
mediated apoptosis. HPV-dependent inhibition of pRb promotes p16 accumulation.
p16 represents a surrogate marker of HPV-positive HNSCC
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HPV infection in oropharyngeal cancer is now recognised
as an aetiological agent, responsible for the significant
increase in incidence in Western countries (Table 2).5,78
These cancers represent a distinct subgroup characterised by
specific biological and clinical profiles and improved out-
comes. Patients with HPV-associated oropharyngeal squa-
mous cell carcinoma (OPSCC) tend to be white males, on
average 5 years younger than HPV-negative patients, have
higher socioeconomic status and are less likely to smoke or
drink alcohol.4 Risk factors for HPV-positive HNSCC are
related to sexual behaviour, including young age at first
intercourse and high number of sexual partners, in particular
oral sex partners, and antibodies against HPV16 viral capsid
protein and E6 oncoprotein.79–82 Clinically, these tumours
have been found to be present at an earlier stage of the
primary cancer but with cystic, multilevel nodal metas-
tases.83,84 Histologically, the tumours tend to be poorly
differentiated basaloid (or nonkeratinising squamous cell)
carcinomas.85 HPV is detected in other subsites such as
larynx and nasopharynx but no causal relationship or
association with outcome has been established, and therefore
the significance in nonoropharyngeal head and neck tumours
remains unclear.86
HPV-associated OPSCC has a favourable prognosis.
Compared with HPV-negative OPSCC, patients have a
60–80% reduction in the risk of death from their cancer after
controlling for other factors, highlighting the need for different
treatment strategies to reduce the morbidity associated with
current treatment.77,78 The reasons for the improved outcome
are unclear but possibilities include host factors such as
younger age, fewer smoking-related comorbidities and
tumour factors such as increased sensitivity to radiotherapy,
absence of field cancerisation mainly seen in smokers,
differing response of the host immune system to viral
infection, and the presence of wild-type p53 that may become
activated in response to radiotherapy and chemotherapy.
However, not all HPV-positive patients have the same
excellent outcome and they can be further classified into low
and intermediate risk of death categories depending on their
smoking history.87 HPV-negative HNSCC are typically char-
acterised by TP53 and RB genetic alterations resulting in
genomic instability and resistance to apoptosis. No TP53
mutations were seen in HPV-positive HNSCC on exome
sequencing, and the overall mutation rate was approximately
half of that seen in HPV-negative samples. In addition, in
contrast to HPV-negative tumours, the expression of
CDKN2A, encoding p16INK4A, is highly upregulated and
amplification of cyclin D is infrequent.88
At present, treatment is the same regardless of HPV status
outside the context of a clinical trial. Two phase III studies
currently recruiting (De-ESCaLATE HPV and RTOG 1016)
are investigating the replacement of standard cisplatin in
concomitant chemoradiation with cetuximab, on the basis that
cetuximab may be less toxic with comparable results in
retrospective analyses.89 The results of two studies treating
HPV-positive patients with induction chemotherapy followed
by reduced dose radiation in responders are awaited. HPV
vaccines are under development and investigation, as both
preventative and therapeutic applications. Gardasil and
Cervarix are HPV vaccines in use for the prevention of
cervical cancer, but could afford protection against oral
HPV16/18 infection. Reduced prevalence of oral HPV
infection was found in women recruited to investigate the
efficacy of HPV vaccination against cervical cancer.90 These
vaccines may also cause induction of cell-mediated immunity
against HPV-positive tumours, and phase I studies are
ongoing investigating the use of HPV16 peptide epitopes in
recurrent disease.91
Hypoxia and Angiogenesis
Tumour hypoxia is common in HNSCC and is associated with
treatment resistance and reduced survival.92 Under normoxia,
the hypoxia-inducible factors HIF1-a and HIF2-a are rapidly
degraded by the Von Hippel–Lindau protein (VHL). Hypoxia
leads to stabilisation of HIFs that heterodimerise with
constitutively expressed HIF2b and translocate to the
nucleus. Genes that promote survival in hypoxia, including
carbonic anhydrase 9 (CA9), glucose transporter 1 (GLUT1)
and vascular endothelial growth factor (VEGF), are upregu-
lated. HIF2-amediates activation of EGFR, and HIF activation
is partly regulated by mTOR signalling.93 Hypoxia can also
drive genomic instability in tumour cells and select for cell
populations with a more aggressive phenotype, reduced
apoptotic and increased metastatic potential.94
Oxygen is required for effective radiation-induced cell
damage, as oxygen stabilises the free radicals produced by
ionising radiation that causes DNA damage and cell death.95
To improve their nutrient and oxygen supply, tumours produce
angiogenic factors that induce the proliferation of endothelial
cells and form new blood vessels. VEGF is the strongest inducer
of angiogenesis, and immunohistochemical expression in
tumour samples is associated with an increased risk of death.96
Strategies to improve tumour oxygenation have included
the use of hyperbaric oxygen, carbogen and nicotinamide,
radiosensitisation using nitroimidazoles and the hypoxic
cytotoxin tirapazamine. However, because of the difficulties
in measuring and stratifying for hypoxia, these techniques
have not translated into regular clinical practice.95 There is
therefore interest in developing methods to diagnose hypoxia
and predict the response to hypoxia-modifying treatments.
For example, a 15-gene hypoxia classifier applied retro-
spectively to HNSCC tissue samples was found to predict for
hypoxic modification of radiotherapy with the radiosensitiser
nimorazole.97 More recently, a 26-gene hypoxia signature
showed predictive benefit from hypoxia-modifying agents
carbogen and nicotinamide in combination with accelerated
radiotherapy.98 Prospective application and validation of
these signatures are awaited. The VEGFR-targeting thera-
pies are currently under investigation in HNSCC.
Table 2 Clinical features of HPV-positive and -negative HNSCC
HPV negative HPV positive References
Aetiology Tobacco/alcohol HPV infection 2,5,78
Age Above 60 years Below 60 years 5
p53 mutations Highly frequent Infrequent 20,27
Site Not predictable Oropharynx 78
Prognosis Poor Favourable 77,87
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Bevacizumab, a monocloncal antibody against VEGFR, is in
clinical use in metastatic colorectal and breast cancer,
NSCLC, glioblastoma and renal cell carcinoma. Phase II
studies in HNSCC using bevacizumab in combination with
pemetrexed, erlotinib or cetuximab have shown response
rates of 15–30%.99–101 The multiple tyrosine kinase inhibitors
sunitinib, sorafenib and vandetanib are in clinical use, and
sorafenib has shown promise in combination with chemother-
apy in recurrent/metastatic HNSCC (Table 1).
Metabolism
Energy in the form of ATP is generated in normal cells via
glycolysis or the tricarboxylic acid (TCA) cycle. In glycolysis,
glucose is metabolised to pyruvate in the cytosol to produce
two ATPs from each molecule of glucose. The TCA cycle
utilises pyruvate from glycolysis to produce acetyl-CoA that is
catalysed by pyruvate dehydrogenase (PDH) in the mitochon-
dria. Acetyl-CoA is metabolised by oxidative phosphorylation,
consuming oxygen and generating 36 ATPs per glucose. In
anaerobic conditions, pyruvate is not used in the TCA cycle
and is converted to lactate in the cytosol by lactate
dehydrogenase (LDH).102
Metabolic alterations are common in cancer. The best-
characterised metabolic phenotype was originally described by
Warburg et al.103 in the 1920s. The Warburg effect is the
increase in glycolysis to generate ATP, even in the presence of
normal oxygen concentrations. ATP production via glycolysis is
much faster but less efficient than oxidative phosphorylation,
and cancer cells avidly consume glucose to meet their
increased energy and biosynthesis needs.104 Aerobic glyco-
lysis in tumour cells is regulated by aberrant signalling
pathways, including p53, PI3K, HIF1, MYC105–107 and liver
kinase B1 (LKB1)/AMP-activated protein kinase (AMPK) path-
ways,108 as well as alterations in metabolic enzymes, such as
pyruvate kinase and pyruvate dehydrogenase kinase (PDK).109
Aberrant metabolism can be targeted by inhibiting the AKT
and mTOR pathways as previously discussed. PDK inhibition
with dichloroacetate is being explored in a phase I trial of
metabolic reprogramming therapy in recurrent HNSCC
(NCT01163487). Metformin is currently used in type II
diabetes but also acts as an AMPK activator. Diabetic patients
treated with metformin were found to be at lower risk of
developing cancer than those on other treatments.110
Metformin in combination with paclitaxel is being investi-
gated in a phase II trial in metastatic/recurrent HNSCC
(NCT01333852).
HNSCC Cancer Stem Cells
HNSCC is highly heterogeneous. This heterogeneity was
originally thought to be because of the step-wise accumulation
of specific genetic and epigenetic alterations in response to
carcinogens, resulting in preneoplastic fields. Clonal diver-
gence and selection within these fields leads to the develop-
ment of cancer, and the incomplete eradication of these areas
are the source of recurrence and secondary tumours after
treatment.111 However, accumulating evidence supports an
alternative model for the development and progression of
HNSCC involving cancer stem cells (CSCs). This model
describes the existence of a hierarchy of cells, where CSCs
are a subpopulation within the tumour, capable of initiating
and propagating tumourigenesis. These cells have the ability
of self-renewal, maintaining the CSC reservoir and differenti-
ate into the heterogeneous progeny.112 CSCs have been
implicated in resistance to treatment, as they are nondividing
or slowly dividing, evading the conventional chemotherapy
and radiotherapy strategies that target rapidly diving cells.113
However, they have the potential to become activated
resulting in recurrences or metastases.
CD44 is a transmembrane glycoprotein that acts as a receptor
for hyaluronic acid and other extracellularmatrixmolecules, and is
involved in cell adhesion andmigration. Alternative splicing results
in multiple different CD44 variants with a diverse functional
repertoire.114 HNSCCCSCswere first described based on CD44
expression.115 CD44þ HNSCC cells, but not CD44" cells,
initiated tumourigenesis in mice, reproduced the original tumour
heterogeneity and demonstrated self-renewal after serial
passaging in vivo.115 CD44þ cells were also found to
differentially express the BMI-1 gene,115 encoding a self-renewal
protein found in embryonic stem cells.116 However, expression of
CD44 has also been observed diffusely in normal, benign and
malignant epithelia of the head and neck, suggesting CD44 alone
cannot identify CSCs.117
Aldehyde dehydrogenase (ALDH) is an enzyme involved in
detoxifying intracellular aldehydes by oxidation, and convert-
ing retinol to retinoic acid.118 It has been shown that ALDHþ
and CD44þ cells form a subpopulation of cells that are highly
tumourigenic in immunodeficient mice at very low cell
numbers, as well as the ability to self-renew.119 Therefore,
the combination of these two markers are more selective for
CSCs. ALDH1þCD44þ cells have also demonstrated
increased expression of BMI-1,119 resistance to chemoradia-
tion and involvement in epithelial–mesenchymal transition.120
CSCs represent potential novel diagnostic and therapeutic
targets. The concentration of CD44 in the peripheral blood of
HNSCC patients has been shown to be significantly higher
than healthy controls,121 and increased CD44þ cell popula-
tion in the primary tumour correlates with higher rates of
recurrence.122 In addition, CD44 gene expression levels have
been found to correlate with response to radiotherapy in
laryngeal SCC, suggesting its role as a predictive marker.123
Targeted elimination of cancer stem cells directly or via their
niche, for example, with antiangiogenic agents, are potential
treatment strategies under development. Bivatuzumab mer-
tansine, an anti-microtubule agent coupled to a monoclonal
antibody against CD44 variant 6, has been tested in
metastatic HNSCC. However, two parallel phase I studies
were terminated early after a fatal case of toxic epidermal
necrolysis.124 Further investigation is required to fully under-
stand the potential effects of targeting CSCs in HNSCC.
Gene and MicroRNA Expression in HNSCC
There has been a multitude of published studies investigating
gene expression profiling to diagnose HNSCC and predict
behaviour and sensitivity to treatment.125–127 The detailed
analysis of such studies is beyond the scope of this review; in
general, because of tumour heterogeneity and low case
numbers in some studies, these studies have not been
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conclusive. Larger and heterogeneous patient cohorts are
therefore needed to obtain an mRNA signature that can be
utilised in a clinical setting.
MicroRNAs (miRNAs) are endogenous, small, non-coding
RNAs of 18–25 nucleotides that regulate and refine gene
expression at both transcriptional and translational levels.
Over 1000 miRNAs have so far been identified, with each
miRNA influencing the expression of multiple genes and a
single mRNA being targeted by several miRNAs. They are
involved in the fine-tuning of the expression of many genes
involved in a variety of critical biological processes, including
cell cycle regulation, differentiation, metabolism and death
(Table 3).128 Consistently altered miRNAs in HNSCC include
miR-21 that is negatively correlated with PTEN and the
programmed cell death 4 (PDCD4) gene and implicated in cell
proliferation, invasion and metastases;129 the miR-106b
family that negatively regulates the p21 CDK inhibitor;130
and miR-205 that targets PTEN and is suggested as a
potential maker for diagnosis, lymph mode metastasis and
outcome.131,132 The ratio of miR-221 to miR-375 can
distinguish between normal and malignant tissue,133 and high
expression of miR-181 and miR-211 in oral SCC has been
found to be associated with lymph node metastases, vascular
invasion and poor outcome.134,135 Tumour-suppressive miR-
NAs include let-7 that negatively regulates KRAS, and
reduced expression is associated with poor prognosis.131,136
MiR-133a/b is repeatedly reported to be downregulated in
HNSCC and targets pyruvate kinase M2, a key regulator of
cancer metabolism.137 MiR-133a also directly regulates the
actin-related protein complex 5 (ARPC5) with inhibition of cell
migration and invasion when miR-133a is restored or ARPC5
is repressed.138 Downregulation of the tumour-suppressive
miR-200a is seen in both saliva and tissue samples of HNSCC
patients and is known to target ZEB1 and ZEB2 that repress
the transcription of E-cadherin and mediate epithelial–
mesenchymal transition and tumour cell migration.139 MiRNAs
are also implicated in chemoresistance, with different patterns
of expression in resistant HNSCC.140 Modulation of miRNAs
can alter the sensitivity of HNSCC to both drugs and radiation,
highlighting the potential for miRNAs in predicting response to
treatment and as a therapeutic target.
Conclusion
HNSCC is a group of highly heterogeneous tumours. Their
management is likely to change in the near future, moving
from treatment as a single disease to tailoring the therapy
based on both patient and tumour characteristics. Identifica-
tion of specific genetic, epigenetic and metabolic aberrations,
together with the more traditional techniques in diagnosis,
staging and prognostication, will need to inform the individual
treatment strategy. It has the potential to provide the clinician
with a comprehensive set of diagnostic, prognostic and
predictive tools. The paucity of driver mutations in HNSCC
and frequent tumour suppressor loss represents a pharma-
cological challenge, but increased understanding of the
molecular biology through the developments in high-through-
put technology heralds a future of personalised medicine.
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MicroRNA-196a promotes an oncogenic effect in head and neck
cancer cells by suppressing annexin A1 and enhancing
radioresistance
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Radiotherapy is a major treatment modality for head and neck squamous cell carcinoma (HNSCC). Up to 50% of patients with
locally advanced disease relapse after radical treatment and there is therefore a need to develop predictive bomarkers for clin-
ical use that allow the selection of patients who are likely to respond. MicroRNA (miRNA) expression profiling of a panel of
HNSCC tumours with and without recurrent disease after surgery and radiotherapy detected miR-196a as one of the highest
upregulated miRNAs in the poor prognostic group. To further study the role of miR-196a, its expression was determined in
eight head and neck cancer cell lines. Overexpression of miR-196a in HNSCC cells, with low endogenous miR-196a expression,
significantly increased cell proliferation, migration and invasion, and induced epithelial to mesenchymal transition. Conversely,
miR-196a knockdown in cells with high endogenous expression levels significantly reduced oncogenic behaviour. Importantly,
overexpression of miR-196a increased radioresistance of cells as measured by gamma H2AX staining and MTT survival assay.
Annexin A1 (ANXA1), a known target of miR-196a, was found to be directly modulated by miR-196a as measured by luciferase
assay and confirmed by Western blot analysis. ANXA1 knockdown in HNSCC exhibited similar phenotypic effects to miR-196a
overexpression, suggesting the oncogenic effect of miR-196a may at least be partly regulated through suppression of ANXA1.
In conclusion, this study identifies miR-196a as a potential important biomarker of prognosis and response of HNSCC to radio-
therapy. Furthermore, our data suggest that miR-196a and/or its target gene ANXA1 could represent important therapeutic tar-
gets in HNSCC.
Introduction
Head and neck squamous cell carcinoma (HNSCC) encompass
a group of heterogeneous tumours, the majority of which pres-
ent with locally advanced disease. Despite recent advances in
both surgical and radiotherapy techniques, which are associ-
ated with long-term side effects, up to 50% of locally advanced
cases relapse after radical therapy. Treatment options at this
stage with salvage surgery, re-irradiation or palliative chemo-
therapy are limited.1 Therefore, predictive biomarkers and tar-
geted therapies to enable individualisation of treatment are
needed to improve outcomes and minimise morbidity.
MicroRNAs (miRNAs) are small non-coding RNAs that
regulate and refine gene expression by base pairing with the
3’-untranslated region (3’-UTR) of mRNA targets, resulting
in mRNA degradation or inhibition of translation. They
function within a complex interactive network, with a single
miRNA influencing the expression of multiple genes and a
single mRNA being targeted by multiple miRNAs.2,3 Altered
miRNA expression has been reported in almost all types of
Key words: MicroRNA-196a, annexin A1, head and neck squamous
cell carcinoma, biomarkers, radiosensitivity
Abbreviations: MiRNA: microRNA; ANXA1: annexin A1;
HNSCC: head and neck squamous cell carcinoma; OSCC: oral
squamous cell carcinoma; 3’-UTR: 3’ untranslated region; QRT-
PCR: quantitative real-time polymerase chain reaction; MTT: 3-(4:
5-dimethylthiazol-2-yl)-2: 5-diphenyltetrazolium bromide; IjBa:
nuclear factor kappa-B-inhibitor alpha; NF-jB: nuclear factor
kappa-B
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cancers.4 MiRNAs can act as oncogenes or tumour suppres-
sor genes and are involved in a variety of pathways in cancer
development and progression, such as proliferation, apopto-
sis, metastasis and resistance to therapy.5
MiRNAs have potential roles as biomarkers in HNSCC in
tumour diagnosis and prognosis, and as predictors of
response to treatment such as radiotherapy.1,6 Recently, there
has been increasing interest in miR-196a as an oncogene in
different solid tumours, including oral squamous cell carci-
noma (OSCC),7 glioblastoma,8 cervical,9 pancreatic,10 and
gastric cancers.11 The first identified targets of miR-196a
were HOXA and HOXB genes in primary adult acute mye-
loid leukaemia,12 and HOXC8 and HOXB7 in malignant
melanoma.13,14 However, HOX genes have not been shown
to be regulated by miR-196a in head and neck cancer cell
lines such as SCC25 and FaDu.15 Other validated targets of
miR-196a include annexin A1 (ANXA1),16 S100A9, SPRR2C
and KRT5 in oesophageal cancer cells,17 and ERG in leukae-
mia,18 but the precise roles of these targets in regulating the
oncogenic effects of miR-196a so far remain unclear.
Here, we studied the miR-196a target ANXA1. A member
of the annexin family of calcium-dependent phospholipid-
binding proteins, ANXA1 has been shown to exhibit anti-
inflammatory and anti-proliferative effects.19 However, the
molecular mechanisms by which ANXA1 modulates these
cellular responses have not been fully determined. Due to its
anti-proliferative effects, ANXA1 protein has been studied in
several types of cancers, but in vivo studies have demon-
strated that the expression pattern of ANXA1 in human can-
cers is not well defined. While ANXA1 has been reported to
be upregulated in glioma20 and lung adenocarcinoma,21 its
expression is reduced or lost in other cancer tissues including
head and neck,22–24 oesophageal and prostate.25 In general,
suppression of ANXA1 has been associated with cell line
transformation, tumour progression and metastasis. In
HNSCC, the expression of ANXA1 has been shown to corre-
late with higher grades of differentiation, or less aggressive
tumours, suggesting a tumour suppressor role.22,26 ANXA1
has been shown to be a target of miR-196a in oesophageal
and breast cancer cells,16 but the association with miR-196a
has not been established in HNSCC.
MiRNA expression profiling of a panel of HNSCC
tumours identified miR-196a to be upregulated in a group of
patients with HNSCC with recurrent disease after radical
treatment. Functional studies demonstrated that miR-196a
overexpression induced resistance to irradiation, suggesting an
important potential of miR-196a as both a prognostic and pre-
dictive biomarker in HNSCC. Amongst the known target genes
of miR-196a we studied ANXA1, as it has been shown to have
a tumour suppressor role in different tumours including
OSCC.22–24 Here, we show that ANXA1 is a direct target of
miR-196a in HNSCC. The overexpression of miR-196a or sup-
pression of ANXA1 in HNSCC cells resulted in similar effects
including increased proliferation, migration and invasion. This
study suggests that the oncogenic effects of miR-196a in
HNSCC are at least partly exerted through targeting ANXA1.
Material and Methods
Tissue samples and miRNA microarray
Sixteen patients with head and neck squamous cell carcinoma
were selected based on their long-term outcome to anticancer
treatment. All patients were treated with surgery and postop-
erative radiotherapy and classified as ‘good’ responders of
therapy if they had no evidence of recurrent disease within 5
years of follow up, or ‘bad’ responders if they had relapsed.
Cases were selected as representative stages and sites in each
group to include the range of oral carcinoma presentations.
All carcinomas were from oral sites with surface origin; those
from posterior tongue or soft palate were not of human pap-
illomavirus type. Tissue samples were collected prior to
receiving treatment and immediately snap-frozen in liquid
nitrogen and stored at -80 !C until RNA extraction. Ethics
approval was covered by an existing project (REC reference
04/02/10). The samples were profiled for miRNA gene
expression using Illumina v2 miRNA Beadchip (Illumina,
Inc., San Diego, CA, USA) according to manufacturer’s
instructions. Bead summary data were exported from
GenomeStudio (GSGX V1.9.0; no background subtraction, no
normalisation) and imported into R/Bioconductor. Arrays
were log2-transformed and quantile normalized using the
beadarray package.27 Differential expression of miRNAs
between the two patient groups (‘good’ and ‘bad’ responders)
was estimated by fitting a linear model and empirical Bayes mod-
erated t-tests using the limma package for R/Bioconductor.28
Log2 fold-change, unadjusted and adjusted p-values were
inspected.29 There was insufficient power to detect signifi-
cantly differentially expressed genes after adjustment for mul-
tiple testing (p< 0.05, adjusted), which may be due to the
biopsy origin of samples. Therefore the unadjusted p -values
(p< 0.05) were used to define the top-ranked miRNAs for
What’s new?
There is accumulating evidence that miR-196a plays an important role in the pathogenesis of a number of cancers. Through
functional studies, here the authors demonstrate that miR-196a confers an oncogenic phenotype in head and neck cancer
cells, through the targeting of ANXA1. The results also show that MiR-196a modulation is associated with response to radia-
tion. MiR-196a may therefore represent both a prognostic and a predictive biomarker in head and neck cancer. Furthermore,
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differential expression (Fig. 1A) and the fold-change between
“good” and “bad” responders was inspected (Fig. 1B).
Cell lines and culture
Eight head and neck cancer cell lines were profiled for
expression of miR-196a. HN5, HN30, SCC11B and SCC22B
were selected to further investigate the effects of miR-196a
modulation. HN5 was obtained from Professor Barry Guster-
son, Department of Pathology, University of Glasgow, UK
and HN30 from Dr Andrew Yeudall, Department of Cranio-
facial Development, King’s College London, UK. SCC11B
and 22B were obtained from Dr Thomas Carey, University of
Michigan, USA. HEK293T cells were provided by Dr Lucas
Chan, Rayne Institute, King’s College London, UK and
MDA-MB-231 were obtained from Prof Joy Burchell, Breast
Cancer Biology Group, King’s College London, UK. All cells
were maintained in Dulbecco’s Modified Eagle’s Medium
(DMEM; GE Healthcare, Chalfont St. Giles, UK) supple-
mented with 10% fetal bovine serum (FBS), 20 ll/ml penicil-
lin and 10 ll/ml streptomycin, and 1 mM sodium pyruvate.
RNA extraction and quantitative real-time RT-PCR (qRT-
PCR)
Total RNA was extracted from tissue samples using the miR-
Neasy kit (Qiagen, Hilden, Germany) and from cells using
TRIzol (Life Technologies, Paisley, UK) according to the
manufacturer’s instructions. Complementary DNA was cre-
ated from 10 ng of RNA using TaqMan miRNA reverse tran-
scription kit (Life Technologies, Paisley, UK). Quantitative
RT-PCR was performed using TaqMan Small RNA Assay
(Life Technologies, Paisley, UK), with each 10ll reaction con-
sisting of 1.5ll cDNA, 0.5ll miRNA primer, 5 ll of TaqMan
mastermix and 3 ll RNA free water. Samples were run in
triplicate according to the manufacturer’s recommendations,
and the standard curve method was used to quantitate
miRNA expression levels relative to the level of the house-
keeping gene RNU48. All mature miRNA primers were pur-
chased from Life Technologies. QRT-PCR analysis was
carried out on three independent RNA samples.
Plasmids and transfection
MiR-196a expression plasmids were prepared by PCR ampli-
fication of a 630 bp genomic DNA fragment containing mir-
196a using the following forward and reverse primers;
CAGGCTTGTGCCTGTGTCTA and GTGCCTCGGGA-
GAGTTGAC. The PCR product was sequence verified and
cloned into the retroviral expression vector pBabe-puro. HN5
cells at 70–80% confluency were transfected with miR-196a
or empty vector pBabe-puro using X-tremeGENE DNA
transfection reagent (Roche Applied Science, West Sussex,
UK) and stable populations were selected using puromycin.
A mixed population of cells and a population grown from a
single surviving colony after selection were used. MiR-196a
sponge and sponge control were gifts from Dr Sebastian Her-
zog, Division of Developmental Immunology, Medical Uni-
versity of Innsbruck, Austria. The sponge plasmid was
produced using HEK293T cells as the packaging cell line and
the retrovirus-containing supernatant was harvested at 24
and 48 hrs. HN30 cells were infected with the supernatant
and stable cells selected using puromycin. This was repeated
using SCC11B and SCC22B cells. Lentiviral ANXA1 shRNA
and control were gifts from Dr St!ephane Gobeil, CHUL
Research Centre, Laval University, Canada. ANXA1 shRNA
was produced using HEK293T cells as the packaging cell line.
HN5 cells were infected and a stable population selected with
puromycin.
Cell proliferation assays
Stably transfected cells were seeded in triplicate in 6-well
plates (105 cells per well) and left for 24 hrs. Cells were tryp-
sinized and counted over the next 7 days. Cell proliferation
was also assessed using the 3–(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) cell viability assay. Cells
were seeded in 96-well plates (3000 cells per well), 6 wells
per time point, and left overnight. On days 1 to 5, 20ll of
MTT (5 mg/ml, Calbiochem, Watford, UK) solution was
added to each well and incubated for 2 hrs, after which
150ll of solubilisation solution (50% dimethylformamide,
0.2% glacial acetic acid, 20 mM HCl, 20% SDS) was added.
After further incubation for 24 hrs, the optical density was
measured at a wavelength of 595 nm on a LT-4000 micro-
plate reader.
Scratch assay
To investigate the migratory ability of the modulated cells,
cells were seeded to confluence in 6-well plates with perpen-
dicular markings on the bottom surface as reference points
for imaging. Confluent cells were serum starved for 24 hrs,
before creating a straight scratch along the diameter of the
well using a p200 pipette tip. Floating cells were removed by
washing the well twice with media. Images were taken at 0
and 16 to 24 hrs. The assay was performed in triplicate in
two independent experiments and the area between the
scratch was imaged, analyzed using ImageJ (NIH, Bethesda,
MD, USA) and the percentage of the scratch area closed
between the two time points calculated.
Invasion assay
The invasion potential of the cells was assessed using Matri-
gel invasion chambers (BD Biosciences, San Jose, CA, USA),
according to the manufacturer’s instructions. Briefly, the opti-
mal seeding density of the parental cell lines was determined
before the 2x105/ml and 4x105/ml cells were prepared for
HN5 and HN30 modulated cells respectively. Cells were
placed in the invasion chambers, which were placed in a 24-
well plate, and chemoattractant (medium containing 5% FBS)
was added to the wells. Cells were incubated for 22 hrs, after
which the non-invading cells on the upper surface of the
chamber were scrubbed off with a cotton swab, and the
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counted. Five random images from each membrane were
counted and invasion expressed as the percent invasion
through the Matrigel membrane relative to the migration
through the control membrane. Invasion assays were per-
formed in duplicate and repeated in an independent
experiment.
Vimentin immunofluorescence
Forty thousand cells were seeded in duplicate into 8-chamber
slides (BD Biosciences, San Jose, CA, USA) and allowed to
attach overnight. Cells were then washed with PBS, fixed
with 4% paraformaldehyde for 15 min, washed and permeab-
ilized with 0.2% Triton X-100 for 15 min, washed and
blocked for 30 min with 3% bovine serum albumin in TBS-
tween. Cells were then incubated overnight at 4 !C with rab-
bit anti-vimentin antibody (Cell Signaling, Danvers, MA,
USA; 1:100 dilution). Cells were washed again and incubated
for 90 min with secondary fluorescein isothiocyanate (FITC)-
conjugated goat anti-rabbit antibody (Sigma-Aldrich, Poole,
UK; 1:100 dilution). The chambers were removed from the
slide and cells mounted in Vectashield mounting medium
containing 4’,6-diamidin-2-phenylindole (DAPI; Vector Labo-
ratories, Burlingame, CA, USA). Images were acquired at
603 magnification using a fluorescence microscope.
Radiation assays
Radiosensitivity of the miR-196a overexpressing cells was
assessed using gamma H2AX immunofluorescence. Forty
thousand cells were seeded into 8-chamber slides in duplicate
and incubated overnight prior to irradiation with 0 (control),
0.5 Gy, 1 Gy and 2 Gy using a Noridon GC-1000S v2.9 cell
irradiator, which contains a caesium source at a dose rate of
2506 0.59% Gy/hour. Cells were fixed, permeabilized and
blocked as above at 30 min or 24 hrs post-irradiation, and
incubated overnight with rabbit phospho-histone H2AX
(Ser139) antibody (Cell Signaling, Danvers, MA, USA; 1:100
dilution), followed by secondary anti-rabbit FITC antibody.
The number of gamma H2AX foci in each nucleus was ana-
lyzed using BlobFinder software (Center for Image Analysis,
Uppsala University, Sweden) and expressed relative to the
control cells. A minimum of 100 cells were imaged and ana-
lyzed for each dose and time point. Radiosensitivity of the
miR-196a cells and the other modulated cells was also
assessed by MTT cell viability assay. Cells were irradiated in
25 cm2 flasks when 70–80% confluent, irradiated at 0 (con-
trol), 2, 4, and 6 Gy, and incubated overnight. Cells were
seeded in a 96-well plate (3000 cells per well, 6 wells per
dose, two independent experiments) and incubated for five
days, at which point the control cells were confluent. The
MTT assay was then carried out as above and measurements
expressed relative to the control cells.
Western blot analysis
The concentration of proteins extracted was determined
using the Bradford assay (Bio-Rad, Hercules, CA). Equal
amounts of protein were separated by 10% SDS-PAGE and
transferred to a nitrocellulose membrane (Sigma-Aldrich,
Poole, UK). The membrane was blocked in 5% milk and
incubated with rabbit anti-ANXA1 (Cell Signaling, Danvers,
MA, USA; 1:1000), rabbit anti-cleaved PARP (Cell Signaling;
1:1000), mouse anti-caspase-3 (Cell Signaling; 1:1000), or
mouse anti-tubulin (Sigma-Aldrich; 1:2000) as a loading con-
trol. Primary antibody binding was detected using secondary
anti-rabbit (GE Healthcare, Chalfont St. Giles, UK; 1:2000) or
anti-mouse (Sigma-Aldrich; 1:2000) antibodies linked to
horseradish peroxidase and enhanced chemoluminescence.
Luciferase reporter assay
The ANXA1 luciferase reporter construct was a gift from
Professor Jacques Huot, Laval University Cancer Research
Centre, Canada. Cells were seeded in 96-well plates at a den-
sity of 104 cells per well and transfected with 0.1 mg of
ANXA1 luciferase construct the following day using FuGENE
HD transfection reagent (Promega, Madison, WI, USA). The
cells were incubated for 48 hrs before the luciferase assay was
performed using the Dual-Glo Luciferase Assay System
according to the manufacturer’s instructions (Promega).
Measurements from untransfected cells were used as negative
controls and the data was normalized by dividing the Firefly
activity by the Renilla activity. Each experiment was carried
out in repeated triplicates.
Statistical analysis
The data is presented as the mean6 standard deviation
unless otherwise stated, and compared using one-way
ANOVA or unpaired student’s t-test. Statistical analysis was
performed using GraphPad Prism version 6.0 (Graphpad
Software Inc, La Jolla, CA, USA). p values less than 0.05 were
considered statistically significant.
Results
MiR-196a is overexpressed in patients with worse
outcome
Gene expression profiling of the sixteen patient samples with
differing outcomes identified 41 miRNAs to be differentially
expressed between the patients with “good” and “bad” out-
comes (threshold p< 0.05; limma, unadjusted p; Fig. 1A).
MiR-196a was selected as being highly upregulated in the
“bad” responders group compared with the “good” respond-
ers group (log2 fold-change521.8; p5 0.014; limma, unad-
justed P; Fig. 1B). To investigate the function of miR-196a,
eight HNSCC cell lines were evaluated for the expression of
miR-196a (Fig. 1C). Only the cell line HN5 was found to
have low endogenous expression of miR-196a and was there-
fore selected for ectopic overexpression functional studies,
while HN30, SCC11B and SCC22B, with high miR-196a lev-
els, were selected for miR-196a suppression experiments. The
cell proliferation rate of representative cell lines with low
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daily cell counting over seven days. HN30 showed a signifi-
cantly faster proliferation rate (Fig. 1D).
Exogenous miR-196a overexpression promotes cell
proliferation, migration and invasion
MiR-196a overexpression plasmid was transfected into HN5
cells and a stable population selected using puromycin. QRT-
PCR analysis demonstrated successful upregulation, with an
approximate 50-fold increase in the expression in the mixed
population of miR-196a overexpressing cells (Fig. 2A). The
effect of this modulation on cell proliferation was assessed
using two different methods: daily cell counting and MTT
cell viability assay. Both methods demonstrated significant
enhancement in the rate of growth in the miR-196a overex-
pressing cells compared with control vector transfected cells
(Fig. 2B). The impact of miR-196a on cell migration and
invasion was analyzed using the scratch and Matrigel inva-
sion assays, respectively. MiR-196a overexpression clearly
increased cell migration when the scratch assay was analyzed
at 16 hrs, with an average of 78% of the scratch area closed
in the miR-196a cells versus 28% in the control cells
(p< 0.01, Fig. 2C). Invasion was also enhanced with the
upregulation of miR-196a, with the mean percentage invasion
relative to the control membrane of 53% compared with 16%
in the empty vector control cells (p5 0.01, Fig. 2D). Vimen-
tin immunofluorescence was used as a marker for epithelial-
mesenchymal transition (EMT). The pattern of vimentin
expression was significantly altered after overexpressing miR-
196a, with appearances resembling the known mesenchymal
breast cancer cell line MDA-MB-231 (Fig. 2E), suggesting
miR-196a contributes to the change in vimentin configura-
tion in preparation for transition into the mesenchymal phe-
notype. To validate the functional effect of miR-196a
overexpression, single colonies were selected and expanded.
The miR-196a level was approximately 45-fold higher, shown
in a representative clone, compared to control cells (Support-
ing Information Fig. S1A). Importantly, cell cultures derived
from single miR-196a overexpressing clones or a mixed pop-
ulation of cells showed similar oncogenic characteristics.
These results confirm that the phenotypic changes induced
by miR-196a are unlikely to be due to clonal effects (Sup-
porting Information Fig. S1B–C).
MiR-196a alters radiosensitivity of head and neck cancer
cells
The patients with disease recurrence after treatment had
higher levels of miR-196a than patients who remained disease
free after treatment. This observation prompted further inves-
tigation into whether this miRNA could alter the sensitivity
of HNSCC to radiation. First, the miR-196a overexpressing
cells and empty vector transfected control cells were irradi-
ated at low doses and stained for the presence of gamma
H2AX foci within the nucleus as a biomarker for double-
stranded DNA breaks. Gamma H2AX foci rapidly accumu-
lated and peaked at 30 min after irradiation, with foci
remaining at 24 hr representing persistent damage and there-
fore increased radiosensitivity.30 The miR-196a overexpress-
ing cells demonstrated similar numbers of gamma H2AX foci
per nucleus (relative to the unirradiated cells, Supporting
Information Fig. S2) compared with empty vector control
cells at 30 min. However, at 24 hr significantly fewer foci
were detected in miR-196a overexpressing cells, indicating
more efficient repair and increased radioresistance (Fig. 3A).
This was confirmed by MTT assay, where the cells were irra-
diated at higher doses and enhanced cell viability was dem-
onstrated after five days in the miR-196a overexpressing cells
(Fig. 3B).
MiR-196a knockdown results in decreased cell
proliferation, migration and invasion
MiRNA sponges are transcripts that contain multiple target
sites complementary to the miRNA under investigation and
sequester endogenous miRNAs, resulting in functional inhibi-
tion of the mature miRNA.31 MiR-196a sponge infection in
HN30 cell lines resulted in approximately 60% suppression of
the expression level measured by qRT-PCR (Fig. 4A). The
effect of this downregulation led to the opposite functional
consequence of miR-196a overexpression on cell proliferation
(Fig. 4B), migration (Fig. 4C) and invasion (Fig. 4D). The
mean percentage of the scratch closed at 24 hrs was 39% in
the knockdown cells compared with 76% in the sponge con-
trol cells (p< 0.01). The mean percentage invasion relative to
the control membrane was 18% in the knockdown cells ver-
sus 46% in the control cells (p5 0.02). Response to radiation
was assessed using the MTT assay, which showed reduced
cell viability at 2, 4 and 6 Gy, suggesting increased radiosen-
sitivity in the miR-196a knockdown cells (Fig. 4E). MTT and
scratch assays were also performed on two other cell lines
with high miR-196a levels, SCC11B and SCC22B. Inhibition
of miR-196a using miR-196a sponge induced similar effects
observed with HN30 miR-196a knockdown cells, with con-
sistent inhibition of cell proliferation and migration (Support-
ing Information Fig. S3A–E). To investigate whether the
inhibition of growth and cellular migration was due to induc-
tion of apoptosis, HN30 cells were transiently transduced
with miR-196a sponge or control vector, and cell lysates were
analyzed for apoptotic markers at 48 and 72 hr. Western blot
analysis confirmed similar levels of cleaved PARP and
cleaved caspase-3 between miR-196a knockdown and vector
control cells suggesting that the observed effects of miR-196a
downregulation on suppressing proliferation and migration
are unlikely to be due to increased apoptosis (Fig. 4F).
ANXA1 is a direct target of miR-196a in HNSCC
We explored the mechanisms by which miR-196a exerts its
oncogenic effect in HNSCC cell lines. As described several
cellular genes have been shown to be targeted by miR-196a.
In this study, ANXA1 was further analyzed due to its role as
a tumour suppressor and potential prognostic marker in
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HN5 cells induced suppression of ANXA1 protein (Fig. 5A),
while its knockdown induced increased ANXA1 protein
expression in HN30 cells, compared with their respective
empty vector controls. Using a luciferase reporter plasmid
containing the 3’-UTR of the ANXA1 gene demonstrated
that there was direct interaction between ANXA1 and miR-
196a, with a clear reduction in relative luciferase activity in
the miR-196a overexpressing cells compared with controls
(p< 0.01, Fig. 5C). Similarly, increased relative luciferase
activity was observed in the miR-196a knockdown cells com-
pared with their empty vector control (p< 0.01, Fig. 5D).
Importantly, a reverse association between the endogenous
levels of miR-196a and ANXA1 in the HNSCC cell lines
tested was observed (Supporting Information Fig. S4).
ANXA1 silencing reproduces the oncogenic phenotype of
mir-196a overexpression
The role of ANXA1 in HNSCC cell lines was further investi-
gated by stably downregulating ANXA1 expression in the
HN5 cell line with ANXA1 shRNA (Fig. 6A). Similar to the
behaviour of the miR-196a overexpressing HN5 cells,
ANXA1 knockdown resulted in enhanced cell proliferation
assessed by growth rate over seven days, as well as cell sur-
vival measured by MTT assay over five days (Fig. 6B). Cell
Figure 1. MiRNA expression pattern in head and neck cancers. (a) heatmap displaying miRNA expression in samples with “good” (yellow)
and “bad” (blue) survival following anticancer therapy from a panel of 16 fresh tissue specimens. The 41 top-ranked miRNAs for differential
expression between “good” and “bad” survival groups are shown (threshold p<0.05; limma, unadjusted p). Rows (samples) are ordered
by expression score (sum of expression weighted by the sign of the fold-change,
P
probes,g[expressiong x sign of fold-changeg]). Columns
(miRNAs) are ordered by the direction of fold-change then alphabetically. (B) volcano plot for ‘good’ versus ‘bad’ survival showing log2
fold-change versus significance (2log10 p; limma, unadjusted p) for all probes. The arrow indicates miR-196a, which shows increased
expression in the “bad” survival group compared with the “good” survival group (log2FC521.8, p50.014; limma, unadjusted p). Red
points: p<0.05 (limma, unadjusted p). (C) MiR-196a gene expression levels in eight head and neck cancer cell lines, displayed as expres-
sion fold-change compared with HN30. Cell line expression values are shown as the mean of two duplicate samples. The cell lines HN5
and HN30, with low and high endogenous levels of miR-196a respectively, were selected for further investigation. (D) cell proliferation in
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Figure 2. Overexpression of miR-196a increases cell proliferation, migration and invasion. (a) Mir-196a expression level by qRT-PCR after
stable transfection of HN5 cells with miR-196a plasmid. (B) cell proliferation of miR-196a overexpressing cells was assessed by daily count-
ing (left) and MTT cell viability assay (right). (C) cell migration by scratch assay at 16 hrs of miR-196a overexpressing cells compared with
empty vector pBabe-puro, with representative images at 0 and 16 hrs at 43 magnification. Data shown as mean percentage scratch area
closed after 16 hr. (D) invasion through matrigel in the miR-196a cells compared with control. Data represents mean number of invaded
cells through the matrigel membrane relative to migration through the control membrane. Images are representative of cells fixed and
stained on the invasion membrane at 103 magnification. (E) vimentin immunofluorescence of miR-196a cells compared with empty vector
pBabe-puro and the mesenchymal breast cancer cell line MDA-MB-231. Images taken at 603 magnification. * p<0.05. [Color figure can be












Suh et al. 1027
Int. J. Cancer: 137, 1021–1034 (2015) VC 2014 UICC































migration was also significantly increased after 20 hr, with a
mean percentage scratch area closed by 59% in the ANXA1
knockdown compared with 26% in control cells (p< 0.01,
Fig. 6C). The mean percentage invasion relative to control
was 41% in the ANXA1 knockdown cells and 20% in the
ANXA1 empty vector control cells (p< 0.01, Fig 6D). Immu-
nofluorescence analysis of ANXA1 knockdown cells also
revealed similar changes in vimentin configuration to that of
miR-196a overexpressing cells (Fig. 6E). ANXA1 silencing
resulted in some resistance to irradiation (Fig. 6F). However,
this was lower than that observed with miR-196a overexpres-
sion, suggesting that the miR-196a-induced radioresistance in
HNSCC cells may not be entirely through ANXA1 suppres-
sion, and additional targets are likely to be involved.
Discussion
It has become clear that miRNAs play important roles in
cancer development and metastasis and are potential predic-
tive biomarkers and therapeutic targets. Expression profiling
of a small exploratory cohort of HNSCC biopsy samples
identified several miRNAs, which were differentially
expressed, amongst which miR-196a was found to be highly
upregulated in patients with poor outcome. Functional analy-
sis demonstrated that overexpression of miR-196a in HNSCC
cells with low endogenous levels significantly promoted cell
proliferation, migration, invasion, and radioresistance,
whereas knockdown of miR-196a in cells with high endoge-
nous levels led to the opposite effects. Moreover, the anti-
proliferative effect of miR-196a is unlikely to be due to
Figure 3. MiR-196a overexpression and response to irradiation. (a) MiR-196a overexpressing HN5 cells were irradiated at 0.5, 1 and 2 gy
and stained for gamma H2AX foci at 30 min (top) and 24 hrs (bottom) post irradiation. The number of foci was analyzed in a minimum of
100 cells at each dose point and data is presented as the mean number of foci relative to unirradiated cells. Error bars represent standard
error. Images are representative of cells irradiated at 0.5 gy at 603 magnification. (B) MTT cell viability of miR-196a and empty vector con-
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Figure 4. MiR-196a knockdown with miRNA sponge inhibits cell proliferation, migration, invasion and increases sensitivity to radiation com-
pared with control. (a) HN30 cells were stably infected with miR-196a sponge to inhibit the expression of miR-196a and assessed by qRT-
PCR. (B) cell proliferation of miR-196a downregulated HN30 cells was assessed by daily counting (left) and MTT cell viability assay (right).
(C) cell migration by scratch assay of miR-196a sponge cells compared with empty vector control. Bar graph shows mean percentage of
scratch area closed after 24 hrs incubation. Representative images are shown at 0 and 24 hrs, at 43 magnification. (D) invasion through
matrigel in the miR-196a sponge cells compared with empty vector control. Bar graph represents the mean number of invaded cells through
the matrigel membrane relative to migration through the control membrane. Images are representative of cells fixed and stained on the
invasion membrane at 103 magnification. (E) assessment of response to radiation by MTT cell viability assay. Cells were irradiated at 2, 4
and 6 gy and data are expressed relative to unirradiated control cells. (F) western blot of proapoptotic markers cleaved PARP and caspase-
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increased apoptosis, further suggesting a role for this miRNA
in tumour invasiveness and resistance to therapy. However
this requires further investigation.
Although overexpression of miR-196a has been demon-
strated in several types of tumours, and in general is linked
with a more aggressive, metastatic, tumour phenotype,10,32 it
has not previously been linked to radioresistance. The patient
samples in this study were derived from cases that required
radiotherapy, with patients developing recurrent disease dem-
onstrating higher levels of pretreatment miR-196a. One of
the important findings of our study was the significant effect
of miR-196a overexpression on reducing radiation-induced
gamma H2AX foci after 24 hrs, indicating more efficient
repair of radiation-induced DNA damage, as well as
Figure 5. ANXA1 is a direct target of miR-196a. (a) western blot of ANXA1 protein levels in miR-196a overexpressing cells and pBabe-puro
control, with tubulin as loading control. Bar graph shows mean quantification of the intensity of the bands by ImageJ. (B) western blot of
ANXA1 protein level in miR-196a knockdown sponge and empty vector control. (C) luciferase reporter plasmid containing ANXA1 3’UTR was
transfected into HN5 miR-196a overexpressing cells and the relative luciferase activity measured using the dual luciferase assay. (D) lucifer-
ase reporter plasmid containing ANXA1 3’UTR was transfected into HN30 miR-196a knockdown cells and the relative luciferase activity
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Figure 6. ANXA1 knockdown (ANXA1 KD) with shRNA increases cell proliferation, migration, invasion and alters vimentin immunofluores-
cence. (a) western blot of ANXA1 KD with shRNA in HN5 cells compared with empty vector control. (B) cell proliferation in ANXA1 KD meas-
ured by daily counting and MTT cell viability. (C) scratch assay to assess the effect of ANXA1 KD on migration. Data is expressed as mean
percentage scratch area closed after 20 hrs of incubation and representative images at 0 and 20 hrs at 43 magnification are shown. (D)
matrigel invasion assay. Data shown as mean percentage invasion relative to control membrane without matrigel. Images of the invasion
membrane in ANXA1 KD and empty vector control cells, taken at 10x magnification. (E) vimentin immunofluorescence staining in ANXA1 KD
cells compared with empty vector control. Images at 60x magnification. (F) analysis of response to radiation of ANXA1 knockdown HN5 cells
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increased cell viability after irradiation. These data suggest
that miR-196a could have potential value as a predictive bio-
marker of radiation response, identifying patients at diagnosis
who are more likely to fail conventional radiation treatments.
In addition, the modulation of miR-196a and/or its target
genes could have a therapeutic potential as a radiation sensi-
tising agent. In agreement with our data Liu et al.also dem-
onstrated an association between higher miR-196a expression
in tumours and worse disease free survival in patients with
OSCC.7 However, it is unclear how many patients in the Liu
et al. study received radiotherapy, and whether the worse
survival could be due to increased radioresistance.
Several cellular genes with important roles in proliferation,
adhesion and apoptosis have been shown to be targets of
miR-196a.33 Of these targets there is strong evidence that
ANXA1 expression decreases during the development and
progression of cancer. In oral cancer tissues, low ANXA1
expression is associated with poorer differentiation sta-
tus,22–24 with forced ANXA1 overexpression significantly
reducing cell proliferation in oral squamous cell carcinoma
lines and nude mice, whereas downregulation increased pro-
liferation.24 These effects are consistent with the phenotypic
characteristics of our miR-196a overexpressing cells, prompt-
ing further investigation into ANXA1 as a target of interest
in this study. An inverse correlation between miR-196a and
ANXA1 expression has been previously shown in oesopha-
geal, breast and endometrial cancer cell lines, but not in
HNSCC.16 Here, we show that ANXA1 is a direct target of
miR-196a in head and neck cancer cell lines, and that knock-
down of ANXA1 resulted in a more aggressive tumour cell
phenotype. Interestingly, we observed that overexpression of
miR-196a in HNSCC cell lines had a clear effect on the
expression pattern of vimentin, a known marker of EMT.
ANXA1 downregulation by shRNA reproduced similar changes
in vimentin expression as observed by miR-196a upregulation.
ANXA1 overexpression has been shown to attenuate EMT and
metastasis in breast cancer, with knockdown resulting in
stimulation of EMT.34 We demonstrate a similar role of EMT
promotion by ANXA1 knockdown in HNSCC, which may
occur through suppression mediated by miR-196a.
Several mechanisms for the anti-proliferative function of
ANXA1 have been suggested. In myelo-monocytic cells and
broncho-alveolar epithelial cells ANXA1 has been shown to
stimulate apoptosis.35,36 ANXA1 can bind to NF-jB, sup-
pressing its transcriptional activity, leading to enhancement
of apoptotic cell death and inhibition of cell growth.37,38
In addition, ANXA1 expression is strongly induced in thy-
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apoptosis inducing ligand (TRAIL)-induced apoptosis.39
Another possible mechanism for the anti-proliferative action
of ANXA1 could be due to the activation of the extracellular
receptor kinase (ERK) signalling cascade, as demonstrated in
a variety of cell types. This results in disruption of the actin
cytoskeleton, inhibition of cyclin D1 and subsequent suppres-
sion of cell proliferation.40,41 Furthermore, ANXA1 is a sub-
strate for the tyrosine kinase activity of the epidermal growth
factor (EGF) receptor,42 which is expressed in over 90% of
HNSCC,43 and has been shown to block EGF-induced cell
proliferation.44 Interestingly, both activation of EGFR signal-
ling and overexpression of cyclin D1 are strongly implicated
in head and neck cancer progression. It would therefore be
interesting to explore whether miR-196a through its target
ANXA1 influences EGFR signalling and the cell cycle path-
way on HNSCC tumour behaviour. It is important to men-
tion that although the majority of evidence indicates a
tumour suppressor role for ANXA1, an oncogenic role has
also been reported in cancers such as lung21 and stomach.45
ANXA1 has also been shown to be a major regulator of
endothelial cell migration, and thereby angiogenesis in
response to vascular endothelial growth factor (VEGF).46,47
Additionally, apoptosis-induced externalization of endoge-
nous cytosolic ANXA1 was found to initiate an anti-
inflammatory effector mechanism that suppressed the
immune response against antigens of apoptotic cells.48 The
opposing functions of ANXA1 are likely to be cell type spe-
cific and may also depend on other factors including tissue
microenvironment and immune response.
Downregulation of ANXA1 has been hypothesised to
increase radioresistance in nasopharyngeal carcinoma.49 We
observed a trend towards radioresistance in ANXA1 knock-
down cells, whereas miR-196a modulation had a more pro-
found effect on radioresistance. MiR-196a has several cellular
targets, and it is likely that other target proteins play roles in
the response to radiation. Recent reported targets of miR-
196a include IjBa, an inhibitor of NF-jB. In glioblastoma
multiforme miR-196a, which is upregulated and associated
with poor outcome, has been shown to directly interact with
IjBa 3’-UTR to suppress IjBa expression and subsequently
promote NF-jB activation, enhance proliferation and sup-
press apoptosis.8 Similar results have also been demonstrated
in pancreatic cancer.10 In cervix and gastric cancers increased
miR-196a expression has shown to be associated with
advanced tumour stage and poor outcome,9,11 and p27kip1, a
cyclin-dependent kinase inhibitor known to prevent cell cycle
progression, was identified as a direct target. These findings
highlight that there are multiple targets of miR-196a which
may contribute to the behaviour and response to therapy,
and these targets may depend on the tumour type.
In conclusion, miR-196a is an oncogene in HNSCC and
its overexpression is associated with increased tumourigenic
potential and radioresistance. ANXA1 is a direct target of
miR-196a and acts as a tumour suppressor in these cells.
The clear association between ANXA1 and cancer suggests
that its suppression by miR-196a may be an important step
in the oncogenesis of HNSCC. Expression levels of miR-196a
may represent a predictive biomarker for selecting patients
for individualized therapy, and its target ANXA1 could be
an important focus for future targeted therapy in HNSCC.
Confirmation in a larger number of patient samples and in vivo
studies are required in order to establish a clinical application
for miR-196a and ANXA1 in cancers of head and neck.
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